WO2009130481A1 - Pyrrole antifungal agents - Google Patents

Pyrrole antifungal agents Download PDF

Info

Publication number
WO2009130481A1
WO2009130481A1 PCT/GB2009/001058 GB2009001058W WO2009130481A1 WO 2009130481 A1 WO2009130481 A1 WO 2009130481A1 GB 2009001058 W GB2009001058 W GB 2009001058W WO 2009130481 A1 WO2009130481 A1 WO 2009130481A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
pyrrol
oxo
dimethyl
acetamide
Prior art date
Application number
PCT/GB2009/001058
Other languages
French (fr)
Inventor
Graham Edward Morris Sibley
Robert Downham
Lloyd James Payne
Derek Law
Jason David Oliver
Mike Birch
Gareth Morse Davies
Original Assignee
F2G Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0807532A external-priority patent/GB0807532D0/en
Priority claimed from GB0819696A external-priority patent/GB0819696D0/en
Priority to US12/989,410 priority Critical patent/US8993574B2/en
Priority to DK09734928.6T priority patent/DK2283006T3/en
Priority to AU2009239778A priority patent/AU2009239778B2/en
Priority to JP2011505591A priority patent/JP5657524B2/en
Application filed by F2G Ltd filed Critical F2G Ltd
Priority to ES09734928.6T priority patent/ES2535516T3/en
Priority to NZ589010A priority patent/NZ589010A/en
Priority to CA2721944A priority patent/CA2721944C/en
Priority to EP09734928.6A priority patent/EP2283006B1/en
Priority to PL09734928T priority patent/PL2283006T3/en
Publication of WO2009130481A1 publication Critical patent/WO2009130481A1/en
Priority to US14/625,532 priority patent/US9452168B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/76—1,3-Oxazoles; Hydrogenated 1,3-oxazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/84—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,4
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • This invention relates to pyrrole compounds, combinations and compositions comprising the pyrrole compounds and known antifungal agents, and their therapeutic use in prevention or treatment of fungal diseases. It also relates to the use of the compounds, combinations and compositions as agricultural fungicides.
  • fungal infection occurs at high frequency; lung transplant recipients have a frequency of up to 20% colonisation and infection with a fungal organism and fungal infection in allogenic haemopoetic stem cell transplant recipients is as high as 15% (Ribaud et al., 1999, Clin Infect Dis. 28:322-30).
  • polyenes e.g., amphotericin B
  • azoles e.g., ketoconazole or itraconazole
  • echinocandins e.g., caspofungin
  • flucytosine e.g., flucytosine
  • amphotericin B interacts with membrane sterols to produce pores allowing leakage of cytoplasmic components and subsequent cell death. Azoles work by inhibition of the 14 ⁇ -demethylase via a cytochrome P450- dependent mechanism. This leads to a depletion of the membrane sterol ergosterol and the accumulation of sterol precursors resulting in a plasma membrane with altered fluidity and structure.
  • Echinocandins work by the inhibition of the cell wall synthetic eri2yme ⁇ -glucan synthase. This leads to abnormal cell wall formation, osmotic sensitivity and cell lysis. Flucytosine is a pyrimidine analogue interfering with cellular pyrimidine metabolism as well DNA 5 RNA and protein synthesis. However widespread resistance to flucyotosine limits its therapeutic use.
  • pyrrole compounds and combinations of these pyrrole compounds with known antifungal agents, are antifungal.
  • the compounds inhibit the growth of human pathogenic fungi such as Aspergillus and therefore may be used to treat fungal infection and disease.
  • the present invention provides a pyrrole derivative of formula (I) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of a fungal disease:
  • Rl represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4;
  • Al represents a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6- ClO aryl or 5- to 12-membered heterocyclyl group;
  • A2 and A3 are the same or different and represent C3-C6 cycloalkyl or an unsubstituted or substituted C6-C 10 aryl or 5- to 12-membered heterocyclyl group;
  • Ll represents a bond, a C1-C6 alkylene group in which none, one, two or three -CH 2 - groups are independently replaced by -O-, -S- or -NR'-, or a 5- to 12-membered heterocyclyl group;
  • L2 represents -NR'-, -O-, -CO-, -OCO-, -OCONR'R"-, -CONR'R"- or -SO 2 -;
  • L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH 2 - groups are independently replaced by -O-, -S- or -NR'-; n is 1 or 2;
  • R6 represents hydrogen or C1-C4 alkyl
  • R5 represents an unsubstituted or substituted group selected from C6-C10 aryl, a
  • Bl represents an unsubstituted or substituted C6-C10 aryl group
  • B2 represents an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group
  • Y represents C1-C8 alkylene, C2-C8 alkenylene or C2-C8 alkynylene;
  • Al represents a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group.
  • the present inventors have further found that a number of the compounds of formula (I) have particular activity in inhibiting the growth of a wide variety of fungi such as those of the Aspergillus and Candida genera.
  • the present invention accordingly also provides a pyrrole derivative of formula (IB) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of a fungal disease:
  • R2 is a group of formula -AIk 1 -X-R', wherein AIk 1 is an unsubstituted or substituted C1-C6 alkylene group, X is a group -O-, -S-, -NR"-, -CO 2 -, -CONR"-, -OCO-, -OCONR"- or -SO 2 -, and R' and R" are independently selected from hydrogen and unsubstituted or substituted C1-C4 alkyl.
  • the invention also provides the use of a derivative or pharmaceutically acceptable salt of formula (I) or (IB) as defined above for the manufacture of a medicament for the prevention or treatment of a fungal disease.
  • the invention also provides an agent for the treatment of a fungal disease comprising a derivative or pharmaceutically acceptable salt of formula (I) or (IB) as defined above.
  • a method of treating a subject suffering from or susceptible to a fungal disease comprises administering to said subject an effective amount of a derivative or pharmaceutically acceptable salt of formula (I) or (IB) as defined above.
  • the invention also provides a method of controlling a fungal disease in a plant, which method comprises applying to the locus of the plant a derivative of formula (I) or (IB) as defined above or an agriculturally acceptable salt thereof, optionally in combination with a second antifungal agent.
  • the invention also provides the use of a derivative of formula (I) or (IB) as defined above or an agriculturally acceptable salt thereof, optionally in combination with a second antifungal agent, as an agricultural fungicide.
  • the invention also provides a pharmaceutical combination comprising a combination of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof with a second antifungal agent. Also provided is a pharmaceutical composition comprising a combination of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof with a second antifungal agent.
  • the pyrrole derivative of formula (I) or (IB) or pharmaceutically acceptable salt thereof has an antifungal effect and is sometimes referred to as the "first antifungal agent", to distinguish it from the second antifungal agent described later, hi the combinations, compositions and products of the invention, the first antifungal agent is different from the second antifungal agent.
  • the pyrrole derivative of formula (I) or (IB) or pharmaceutically acceptable salt thereof and the second antifungal agent are formulated for simultaneous or successive administration.
  • the combination of the pyrrole derivative of formula (I) or (IB) or pharmaceutically acceptable salt thereof and the second antifungal agent are for use in the treatment or prevention of a fungal disease.
  • the invention further provides a product comprising a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent for separate, simultaneous or sequential use in the prevention or treatment of a fungal disease.
  • a pharmaceutical composition comprising (i) a pyrrole of formula (I) or (IB) or a pharmaceutically acceptable salt thereof, (ii) a second antifungal agent, and (iii) a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutical composition is for use in the treatment or prevention of a fungal disease.
  • the invention also provides the use of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent in the manufacture of a medicament for use in the treatment or prevention of fungal disease.
  • the invention also provides the use of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration with a second antifungal agent in the treatment or prevention of fungal disease.
  • a second antifungal agent in the treatment or prevention of fungal disease.
  • the invention provides the use of an antifungal agent
  • a method of treating a fungal disease which comprises administering a therapeutically effective amount of a first antifungal agent which is a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent.
  • a kit comprising, in admixture or in separate containers, a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent.
  • the invention also provides a compound, which is a pyrrole derivative of formula (I) or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a human or animal body by therapy.
  • R6 is hydrogen; Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group;
  • R2 is as defined above with the exception that when R2 is cycloalkyl it is an unsubstituted cycloalkyl group;
  • R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -OR', -CONR'R", -COR', -CN, -NO 2 , -NR'R", CF 3 , -Y-Z, C6-C10 aryl,
  • Rl, Ll, n, R3 and R5 are as defined above;
  • Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl,
  • R6 represents hydrogen
  • R2 represents C6-C10 aryl, a 5- to 12-membered heterocyclyl group other than benzothiophene, unsubstituted C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2- C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO 2 R', -
  • R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted benzyl or substituted phenethyl;
  • the invention also provides a compound of formula (IB) as defined above or a pharmaceutically or agriculturally acceptable salt thereof, provided that the compound is not 3-[2-(4-fluoro-phenylaminooxalyl)-pyrrol-l-yl]-propionic acid or 3- ⁇ 2-[2-(3,4- Dimethoxy-phenyl)-ethylaminooxalyl]-pyrrol-l-yl ⁇ -propionic acid.
  • compositions comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent, optionally together with a second antifungal agent, are also provided.
  • compositions comprising a compound of the invention and an agriculturally acceptable carrier or diluent, optionally together with a second antifungal agent, are also provided.
  • a C1-C8 alkyl group or moiety can be linear, branched or cyclic but is preferably linear. It is preferably a C1-C6 alkyl group, more preferably a C1-C4 alkyl group, most preferably a C1-C3 alkyl group. Suitable such alkyl groups and moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl and tert-butyl, as well as pentyl, e.g. CH 2 C(CH 3 ) 3 , hexyl, heptyl and octyl and isomers thereof.
  • a C1-C8 alkylene group or moiety is a divalent alkyl group or moiety as defined above, for example a C1-C4 alkylene group or moiety such as methylene, ethylene or propylene.
  • a C2-C8 alkynyl group or moiety can be linear or branched but is preferably linear. It contains one or more carbon-carbon triple bonds. It is preferably a C2-C6 alkynyl group, more preferably a C2-C4 alkynyl group, most preferably a C2- C3 alkynyl group. Suitable such alkynyl groups and moieties include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl and isomers thereof. An alkyl, alkenyl or alkynyl group or moiety can be substituted or unsubstituted.
  • substituents typically themselves unsubstituted and include halogen such as fluorine, hydroxy, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy such as methoxy, ethoxy and propoxy, -S(C1-C4 alkyl) such as -SMe 5 -CO 2 H, -CO 2 (C 1-C4 alkyl), phenyl, 5- or 6-membered heterocyclyl such as pyridinyl,
  • R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl.
  • R' and R" are the same or different and represent hydrogen or methyl. More preferably R' represents hydrogen and R" represents methyl.
  • substituents include unsubstituted substituents such as halogen (for example fluorine), hydroxy, amino, -S(C1-C4 alkyl) (for example -SMe), phenyl, pyridinyl, -COO(C 1-C4 alkyl) (for example -COOMe, -COOEt and -COOPr), -CONR'R' ' (for example -CONHMe) 5 -NR'C0(C 1 -C4 alkyl) (for example -NHCOMe), (C1-C4 alkyl)amino and di(Cl-C4 alkyl)amino, and C1-C4 alkoxy such as methoxy, ethoxy or propoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or ethoxy.
  • substituents such as halogen (for example fluorine), hydroxy, amino, -S(C1-C4 al
  • C1-C4 alkoxy such as methoxy or ethoxy, halogen, such as fluorine, and hydroxy are preferred.
  • Other preferred groups include unsubstituted phenyl or pyridinyl, -NMe 2 , -COOR' where R' is C1-C3 alkyl, -CONHMe and -NHCOMe.
  • suitable substituents on an alkyl, alkenyl or alkynyl group or moiety are preferably themselves unsubstituted and include halogen such as fluorine, hydroxy, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy such as methoxy or ethoxy, -CO 2 H and -CO 2 (C 1-C4 alkyl).
  • substituents include unsubstituted substituents such as halogen (for example fluorine), hydroxy, amino, (C1-C4 alkyl)amino and di(Cl-C4 alkyl)amino, and C1-C4 alkoxy such as methoxy or ethoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or ethoxy.
  • substituents such as halogen (for example fluorine), hydroxy, amino, (C1-C4 alkyl)amino and di(Cl-C4 alkyl)amino
  • C1-C4 alkoxy such as methoxy or ethoxy
  • fluorine for example fluorine
  • hydroxy amino
  • amino amino
  • C1-C4 alkoxy such as methoxy or ethoxy which are themselves unsubstituted or
  • a C3-C6 cycloalkyl group is typically a C4, C5 or C6 cycloalkyl group, more preferably a C5 or C6 cycloalkyl group.
  • a cycloalkyl group is unsubstituted or substituted with up to three substituents, e.g. one or two substituents.
  • Suitable substituents include C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Z and -Y-Z wherein Y and Z are as hereinbefore defined. Where present, preferably the substituents are themselves unsubstituted.
  • a cycloalkyl group is unsubstituted.
  • Y is C1-C8 alkylene, it is preferably C1-C4 alkylene, more preferably methylene or ethylene.
  • Y is C2-C8 alkenylene, it is preferably C2-C4 alkenylene, more preferably ethenylene.
  • Y is C2-C8 alkynylene, it is preferably C2-C4 alkynylene, more preferably ethynylene.
  • R' or R" is C1-C8 alkyl, it is preferably C1-C4 alkyl, more preferably methyl or ethyl.
  • R' or R" is C2-C8 alkenyl, it is preferably C2-C4 alkenyl, more preferably ethenyl.
  • R' or R" is C2-C8 alkynyl, it is preferably C2-C4 alkynyl, more preferably ethynyl.
  • an aryl group or moiety is typically phenyl or naphthyl, more preferably phenyl.
  • a heterocyclyl group or moiety is a saturated or unsaturated, 5- to 12-membered ring system in which the ring contains at least one heteroatom.
  • the ring contains up to three or four heteroatoms, e.g. one or two heteroatoms, selected from O, S and N.
  • a heterocyclyl group or moiety is typically a 5- to 12-membered ring containing one, two or three heteroatoms selected from O, S and N.
  • heterocyclyl groups and moieties include, for example, monocyclic saturated 5- to 8-membered rings, more preferably 5- to 7- membered rings, such as tetrahydrofuranyl, piperidinyl, oxazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, dioxolanyl, piperidonyl, azepanyl, piperazinyl, tetrahydropyranyl and 1,4-diazepanyl, more preferably pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, piperidinyl, azepanyl and 1,4-diazepanyl, more preferably still more preferably pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, piperidinyl, azepanyl and 1,4-diazepanyl,
  • oxazolyl isoxazolyl, imidazolyl, furanyl, thiophenyl, pyrimidinyl or pyridinyl; bicyclic 8- to 10-membered ring systems such as indolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzotriazolyl, quinolinyl, quinazolinyl (including isomers thereof, e.g.
  • heterocyclyl groups and moieties include monocyclic saturated 5- to 8-membered rings, more preferably monocyclic saturated 5- to 7-membered rings such as pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, piperidinyl and 1,4- diazepanyl; and monocyclic at least partially unsaturated 5- to 8-membered rings, more preferably monocyclic unsaturated 5- to 6-membered rings such as oxazolyl, isoxazolyl, imidazolyl, furanyl, thiophenyl, pyrimidinyl or pyridinyl.
  • bicyclic 8- to 10-membered ring systems include indolyl, benzofuranyl, quinolinyl and isoquinolinyl, for example benzofuranyl, quinolinyl and isoquinolinyl.
  • a heterocyclyl or aryl group or moiety may be substituted or unsubstituted.
  • Each ring atom may be unsubstituted or may carry one or two substituents. If desired, a nitrogen atom may be disubstituted and a sulphur atom may be substituted, providing a charged heteroatom.
  • a heterocyclyl or aryl group or moiety carries up to three substituents, e.g. one or two substituents.
  • the heterocycle may be connected to the remainder of the molecule by a bond to any of its available ring positions.
  • Suitable substituents include C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Z and -Y-Z wherein Y and Z are as hereinbefore defined.
  • Substituents on Al when Al is other than a bond can also include substituents of formula -(C1-C2 alkyl)-0-(Cl-C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups.
  • Preferred such substituents which are specific to the Al group are those of formula
  • aryl and heterocyclyl groups axe not substituted with further aryl or heterocyclyl groups or with substituents containing further aryl or heterocyclyl groups.
  • Examples of more preferred substituents on an aryl or heterocyclyl group or moiety are unsubstituted substituents selected from halogen, -NR'R", -CO 2 R', -CONR'R", -OCONR'R", -OCOR', -COCF 3, hydroxyl and cyano, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl, unsubstituted Cl- C4 alkoxy or unsubstituted -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl) group; wherein R' and R" are independently selected from hydrogen, unsubstituted C 1 -C4 alkyl and C 1 -C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. Typically none or one cyano substituent is present.
  • a halogen is typically chlorine, fluorine, bromine or iodine, and is preferably chlorine, fluorine or bromine, more preferably chlorine or fluorine.
  • Al preferably represents a bond, a phenyl, naphthyl, a 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group, e.g. an unsaturated 8- to 10-membered bicyclic heterocyclyl group. More preferably Al represents a bond or a phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl group.
  • Al is other than a bond.
  • Al is typically other than a penicillin derivative, e.g. other than an oxo-thiaazabicyclo-heptane or -octane group.
  • Al represents phenyl or a 5- or 6-membered heterocyclyl group, more preferably Al represents phenyl, pyridyl or piperidinyl. Most preferably Al represents phenyl.
  • Al may also be substituted with a group of formula -(C1-C2 alkyl)-0-(Cl-C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups.
  • R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R" together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups.
  • a substituent of formula -(C1-C2 alkyl)-O-(Cl-C4 alkyl)-NR'R" is present, preferably there are no
  • Preferred substituents are unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, - CO 2 H and halogen, and a group of formula -(C1-C2 alkyl)-O-(Cl-C4 alkyl)-NR'R". More preferred substituents are unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO 2 H and halogen.
  • n is one or two, preferably one.
  • n is 2, preferably Al is phenyl, each Ll is the same or different and represents piperazinyl or methylene, and each Rl is the same or different and represents pyridinyl or morpholinyl.
  • Ll preferably represents a bond, a 5 -to 7-membered heterocyclyl group or a C1-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group.
  • Ll represents a 5- to 7-membered heterocyclyl group
  • it may be linked to Al and Rl via a carbon atom or a heteroatom.
  • Preferred 5- to 7-membered heterocyclyl groups are saturated groups which contains at least one nitrogen atom, for example one or two nitrogen atoms, wherein the heterocyclyl group is linked to at least one of Al and Rl, preferably both of Al and Rl, via a nitrogen atom.
  • suitable heterocycles for Ll include piperazinyl, pyrrolidinyl, oxazolyL morpholinyl, piperidinyl and 1,4-diazepanyl.
  • suitable heterocycles for Ll include piperazinyl and 1,4-diazepanyl, especially piperazinyl.
  • Ll represents a 5- to 7- membered heterocyclyl group, it is typically unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen. Hydroxy substituents are preferred.
  • Ll represents a 5- to 7-membered heterocyclyl group, it is unsubstituted.
  • Ll is most preferably a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C1-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group.
  • Ll is a saturated 5- to 7- membered heterocyclyl group, preferably a piperazinyl or 1,4-diazepanyl group.
  • suitable groups include C4 or C5 alkylene groups where two -CH 2 - moieties (preferably one or both terminal -CH 2 - moieties) are replaced by -O- or -NR'- where R' is hydrogen or unsubstituted C1-C2 alkyl.
  • preferred Ll groups in this category include -NMe-CH 2 -CH 2 -NMe-, -NH-CH 2 -CH 2 -O-, -0-CH 2 -CH 2 -NMe-, -0-CH 2 -CH 2 -O-, -NMe-CH 2 -CH 2 -NH-, -NH-CH 2 -CH 2 -NH-, -NH-CH 2 -CH 2 -NMe-, -CH 2 -CH 2 -CH 2 -NMe- and -NMe-CH 2 -CH 2 -CH 2 -NMe-.
  • Ll is piperazinyl.
  • Rl preferably represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (Cl -C4 alkyl), or a group -A2, -L2-A2, - L3-A2, -A2-L3-A3 or -A4.
  • Rl represents hydrogen, an unsubstituted group selected from C 1 -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C 1 -C4 alkyl) and -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Ll is a bond
  • Rl preferably represents hydrogen or a group -A2, L2-A2, A2-L3-A3 or A4.
  • Rl is preferably hydrogen, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, unsubstituted -CO-(C l-C4-alkyl), unsubstituted -SO 2 (C 1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or -A2-L3-A3.
  • Rl is preferably a group -A2, -L2-A2, -L3-A2 or -A2-L3-A3, more preferably a group -A2.
  • Rl represents unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Ll is a bond
  • Rl preferably represents A2, L2-A2, A2-L3-A3 or A4.
  • Rl is preferably a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, unsubstituted -SO 2 (C1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or -A2-L3-A3.
  • Rl represents an alkyl, alkenyl or alkynyl group it is preferably C1-C6 alkyl, C2-C6 alkenyl or C3-C6 alkynyl, more preferably C1-C6 alkyl (e.g. C3 or C4 alkyl), C3-C6 alkenyl or C3-C6 alkynyl.
  • the alkyl, alkenyl and alkynyl groups are unsubstituted or substituted with 1, 2 or 3 substituents selected from halogen (e.g. fluorine), hydroxyl, amino, C1-C4 alkoxy, CO 2 H and C ⁇ 2 (Cl-C4 alkyl). Halogen, e.g. fluorine, is preferred.
  • the substituents are themselves unsubstituted.
  • Rl represents an alkyl, alkenyl or alkynyl group it is unsubstituted.
  • A2 preferably represents C3-C6 cycloalkyl, phenyl or a 5- to 12-membered heterocyclyl group.
  • A2 represents phenyl or a 5- or 6-membered heterocyclyl group.
  • Preferred heterocyclyl groups include monocyclic, saturated or unsaturated, 5- to 6-membered rings, each of which may contain one, two or three, e.g. one or two, heteroatoms selected from N, O and S.
  • Unsaturated 5- or 6-membered rings include oxazolyl, isoxazolyl, imidazolyl, furanyl, thiophenyl, pyrimidinyl and pyridinyl, preferably pyridinyl.
  • Saturated rings are preferably 6-membered rings, for example piperidinyl, morpholinyl and tetrahydropyranyl, e.g. morpholinyl or tetrahydropyranyl.
  • A2 represents phenyl or pyridinyl, especially pyridinyl. A2 may be unsubstituted or substituted by one, two or three substituents.
  • Preferred substituents on A2 are unsubstituted substituents selected from halogen, -NR'R", -CO 2 R', -CONR'R", -OCONR'R", -OCOR', -COCF 3, hydroxyl and cyano, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl, unsubstituted C1-C4 alkoxy or unsubstituted -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl) group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. Typically none or one cyano substituent is present.
  • substituents on A2 are halogen, -COCF 3 , -OCONR'R" and -NR'R", and C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-O(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group.
  • Most preferred substituents are C1-C2 alkyl and C1-C2 alkoxy, especially methyl.
  • L2 represents -SO 2 -.
  • L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH 2 - moieties are independently replaced with -O- or -NR'- wherein R' represents hydrogen or unsubstituted C1-C4 alkyl.
  • L3 represents a bond or an unsubstituted C1-C4 alkylene group.
  • L3 represents a bond or unsubstituted methylene, ethylene or propylene, e.g. unsubstituted methylene or ethylene, more preferably unsubstituted methylene.
  • L3 preferably represents unsubstituted methylene, ethylene or propylene, e.g. unsubstituted methylene or ethylene, more preferably unsubstituted methylene.
  • A3 represents phenyl or a 5- to 12-membered heterocyclyl group.
  • Preferred heterocyclyl groups include monocyclic, unsaturated or saturated 5- to 6-membered rings, each of which may contain one, two or three, e.g. one or two, heteroatoms selected from N 5 O and S.
  • Saturated 5- or 6-membered rings are preferred, e.g. morpholinyl, tetrahydropyranyl, piperidinyl or piperazinyl, in particular morpholinyl and piperazinyl.
  • Preferred substituents are C1-C4 alkyl, C1-C4 alkoxy and halogen.
  • Preferred A4 groups include unsubstituted or substituted dioxothiomorpholinyl, methoxyiminopiperidinyl, memoxyiminopyrrolidinyl, methylenepiperidinyl, dioxoazaspirodecyl and oxadihydropyrazolyl groups.
  • the A9 groups can be unsubstituted or substituted; more preferably they are unsubstituted. Unsubstituted methylenepiperidinyl is preferred.
  • R6 is hydrogen or methyl, more preferably R6 is hydrogen.
  • R5 is hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, a C3-C6 cycloalkyl group, an unsubstituted C1-C8 alkyl or a C1-C8 alkyl substituted with a C1-C4 alkoxy group.
  • R5 is C1-C8 alkyl substituted with C1-C4 alkoxy, preferably it is -(C1-C2 alkyl)-O(Cl-C2 alkoxy), more preferably -CH 2 -CH 2 -OMe.
  • R5 is hydrogen, phenyl, a monocyclic 5- to 8- membered heterocyclyl ring, a C3 -C6 cycloalkyl group or unsubstituted C1-C8 alkyl.
  • the heterocyclyl ring is typically pyridinyl, thiophenyl, furanyl, tetrahydropyranyl or piperidinyl.
  • the cycloalkyl group is typically cyclobutyl, which is itself preferably unsubstituted.
  • the phenyl and heterocyclyl groups are unsubstituted or substituted with one, two or three unsubstituted substituents selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, -CO 2 R', -CONR'R", -OCOR' or cyano, wherein R' and R" are independently selected from hydrogen and C1-C4 alkyl. Typically only one cyano substituent is present. Most preferably R5 is hydrogen or an unsubstituted phenyl.
  • R5 is hydrogen, unsubstituted or substituted phenyl, unsubstituted C3-C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or cyano, e.g. halogen, unsubstituted C1-C4 alkyl or unsubstituted C1-C4 alkoxy.
  • R5 is, for example, hydrogen, unsubstituted or substituted phenyl or unsubstituted pyridinyl, thiophenyl or furanyl.
  • R5 is hydrogen, unsubstituted or substituted phenyl, unsubstituted C3-C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or cyano, e.g.
  • R5 is a C1-C8 alkyl group substituted with a C1-C4 alkoxy group.
  • R5 is, for example, hydrogen, unsubstituted or substituted phenyl or unsubstituted pyridinyl, thiophenyl or furanyl, or is a group -CH 2 -CH 2 -OMe.
  • R5 is a group -B1-B2 or -B3.
  • Bl is typically an unsubstituted or substituted phenyl group.
  • Bl is an unsubstituted phenyl group.
  • B2 is typically an unsubstituted or substituted phenyl or 5- to 6-membered heterocyclyl group, more preferably an unsubstituted or substituted phenyl, piperazinyl or morpholinyl group, e.g. an unsubstituted or substituted phenyl or piperazinyl group.
  • preferred substituents are 1 or 2 groups selected from halogen atoms and C1-C4 alkyl and C1-C4 alkoxy groups, more preferably halogen atoms or C1-C2 alkyl or C1-C2 alkoxy groups, more preferably C1-C2 alkyl groups such as methyl.
  • Rl 1 is hydrogen or C1-C2 alkyl, more preferably hydrogen or methyl.
  • a preferred B3 group is oxo-dihydropyridinyl.
  • R5 is B3, B3 can be unsubstituted or substituted. Preferably it is unsubstituted.
  • R2 and R3 independently represent C6-C10 aryl, a 5- to 12- membered heterocyclyl group, C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2- C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO 2 R', -SO 2 NR 5 R", -SO 3 H, -NR'R", -NR' COR', -CO 2 R', -CONR'R", -COR', -OCOR', -CF 3 , -NSO 2 R' or -OCONR'R", or a group (Cl -4) alkyl-A5, wherein none, one or two -CH 2 - groups are independently replaced by -0-,-S- or -NR'- and wherein A5 represents C6-10 aryl or a 5-
  • R2 and R3 represent or contain C6-C10 aryl or a 5- to 12-membered heterocyclyl group
  • the aryl or heterocyclyl group is typically phenyl or a 5- or 6- membered, saturated or unsaturated heterocyclyl group.
  • none or one of R2 and R3 represents or contains an aryl or heterocyclyl group.
  • suitable heterocyclyl groups include saturated rings such as pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl and piperidinyl, and unsaturated rings such as oxazolyl, furanyl, thiophenyl, pyridinyl and pyrimidinyl, e.g.
  • Bicyclic 8- to 10-membered rings may also be present at R2 and R3, for example indolyl, benzofuranyl and benzothiophenyl rings.
  • R2 or R3 may be unsubstituted or substituted on any ring atom. Typically it is unsubstituted or substituted with one, two or three substituents.
  • Preferred substituents are unsubstituted substituents selected from halogen, -NR'R", -CO 2 R', -CONR'R", -OCONR'R", -OCOR', -COCF 3 and hydroxyl, or Cl- C6 alkyl or Cl -C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. More preferred substituents are halogen, unsubstituted C1-C4 alkyl (e.g. methyl) and unsubstituted C1-C4 alkoxy groups, in particular methyl.
  • R2 preferably represents phenyl, hydrogen, -COO(C 1-C4 alkyl), halogen, unsubstituted C3-C6 cycloalkyl, or a C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkoxy group which is unsubstituted or substituted with -SMe, -SEt, hydroxyl, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R", -NR'CO(C1-C4 alkyl), unsubstituted C1-C4 alkoxy or C1-C4 alkoxy substituted with -OMe or -OEt, where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH 2 - groups
  • R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C2-C4 alkenyl, unsubstituted C1-C4 alkyl, or C1-C4 alkyl or C2-C4 alkenyl substituted with -OMe, -OEt, -OPr, -OBu, -OCH 2 CH 2 OMe 5 -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl- A5, wherein none or one -CH 2 - groups are independently replaced by -O- and wherein A5
  • R2 represents phenyl, hydrogen, halogen, unsubstituted C2-C4 alkenyl, unsubstituted C3-C6 cycloalkyl, or a C1-C4 alkyl or Cl- C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt. More preferably, R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt. Most preferably, R2 represents unsubstituted C1-C4 alkyl, e.g. methyl.
  • R3 preferably represents hydrogen, halogen, unsubstituted phenyl, unsubstituted C2-C4 alkenyl, or a C1-C4 alkyl or C1-C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt. More preferably, R3 represents hydrogen, halogen, unsubstituted phenyl, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt.
  • R3 represents hydrogen, halogen, unsubstituted C2-C4 alkenyl, or a C1-C4 alkyl or C1-C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt. More preferably, R3 represents hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt. Most preferably R3 represents hydrogen or unsubstituted C1-C4 alkyl, e.g. methyl.
  • R2 and R3 together with the ring atoms to which they are bonded form a 5- to 7-membered, at least partially saturated ring containing a nitrogen atom from the adjacent pyrrole ring, and optionally one or two further heteroatoms selected from N, O and S, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring.
  • Preferred heterocyclyl rings are at least partially saturated 5- or 6-membered rings containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O.
  • preferred rings are piperazinyl, morpholinyl and pyrrolidinyl.
  • Alternative preferred heterocyclyl rings include saturated 5- to 7-membered rings containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O, for example azepanyl.
  • the heterocyclyl ring formed by R2 and R3 may be unsubstituted or substituted on any ring atom. Typically, none, one or two substituents are present.
  • Preferred substituents are unsubstituted substituents selected from halogen, -NR'R", -CO 2 R', -CONR'R", -OCONR'R", -OCOR', -COCF 3 and hydroxyl, or Cl- C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. More preferred substituents are halogen, unsubstituted C1-C4 alkyl (e.g. methyl) and unsubstituted C1-C4 alkoxy groups, in particular methyl.
  • R4 is or contains an aryl or heterocyclyl group
  • the aryl or heterocyclyl group is phenyl, benzyl or pyridyl.
  • the aryl or heterocyclyl group may be unsubstituted or substituted on any ring atom, for example with one, two or three substituents.
  • Preferred substituents are unsubstituted substituents selected from halogen, -NR'R", -CO 2 R', -CONR'R", -OCONR'R", -OCOR', -COCF 3 and hydroxyl, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group.
  • substituents are halogen, unsubstituted C1-C4 alkyl (e.g. methyl) and unsubstituted C1-C4 alkoxy groups, in particular methyl or methoxy. More preferably, the aryl or heterocyclyl ring is unsubstituted.
  • R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2- C4 alkenyl, C2-C4 alkynyl, -OR', -CO 2 R', CONR'R", -COR', -CN, -NO 2 , -NR'R” or -CF3 wherein R' and R" are independently hydrogen or C1-C4 alkyl, more preferably R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', -CO 2 R', CONR'R", -COR', -CN, -NO 2 , -NR'R” or -CF 3 wherein R' and R" are independently hydrogen or C1-C4 alkyl.
  • R4 represents hydrogen, halogen or C1-C4 alkyl, preferably hydrogen. Where R4 is capable of being substituted,, it is typically unsubstituted or substituted with one halogen atom, more preferably it is unsubstituted.
  • R4 when R5 is phenyl or thienyl then preferably R4 is hydrogen. In another embodiment when R4 is phenyl preferably R5 is hydrogen.
  • Z is halogen, OR', SR', -NR'R', -CO 2 R', -CONR'R", -COR', -OCOR' or CN, wherein R' and R' ' are independently hydrogen or C 1 -C4 alkyl.
  • Rl represents hydrogen, unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4;
  • Al represents a bond, phenyl, naphthyl, a 5- or 6-membered monocyclic heterocyclyl group, or an 8- to 10-membered bicyclic heterocyclyl group;
  • A2 and A3 are the same or different and represent phenyl or a 5- to 12- membered heterocyclyl group
  • Ll represents a bond, a 5-to 7-membered heterocyclyl group which is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, Cl- C4 alkoxy, hydroxy and halogen, or a C1-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C 1 -C4 alkyl or C 1 -C4 alkyl substituted with an unsubstituted C 1 -C4 alkoxy group;
  • L2 is as defined above;
  • L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH 2 - moieties are independently replaced with -O- or -NR'-, wherein R' represents hydrogen or unsubstituted C1-C4 alkyl; n is as defined above; R6 represents hydrogen or unsubstituted C1-C4 alkyl;
  • R5 represents hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, an unsubstituted C3-C6 cycloalkyl group, an unsubstituted Cl -C 8 alkyl or a Cl- C8 alkyl substituted with a C1-C4 alkoxy; either (i) R2 represents phenyl, hydrogen, -COO(C 1-C4 alkyl), halogen, unsubstituted C3 -C6 cycloalkyl, or a C 1 -C4 alkyl, C2-C4 alkenyl or C 1 -C4 alkoxy group which is unsubstituted or substituted with -SMe, -SEt, hydroxyl, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R", -NR'CO(C1-C4 alkyl), unsubstituted C
  • R4 represents hydrogen, halogen, phenyl, or an unsubstituted group selected from C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', -CO 2 R', CONR'R", -COR', - CN, -NO 2 , -NR'R” or -CF 3 , wherein R' and R" are independently hydrogen or C1-C4 alkyl; wherein the aryl and heterocyclyl rings formed by Al, A2, A3, A4, R5, R2 or R2 and R3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted groups halogen, -CO 2 R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO 2 R', -O(C2-C4 alkenyl), C2-C4 alkenyl,
  • Rl represents unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (Cl -C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Al represents phenyl or a 5- or 6- membered heterocyclyl group.
  • R5 represents hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, an unsubstituted C3-C6 cycloalkyl group or unsubstituted C1-C8 alkyl.
  • R4 represents hydrogen, halogen, or an unsubstituted group selected from C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', -CO 2 R' , CONR'R' ' , -COR' , -CN, -NO 2 , -NR'R' ' or -CF 3 , wherein R' and R' ' are independently hydrogen or C1-C4 alkyl.
  • the aryl and heterocyclyl rings formed by Al, A2, A3, A4, R5, R2 or R2 and R3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted groups halogen, -CO 2 R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO 2 R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO 2 R', -OCONR'R' ' and
  • C1-C6 alkyl and C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four unsubstituted groups selected from hydroxyl, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl).
  • Particularly preferred compounds for use in the invention are pyrrole derivatives of formula (Ia) and pharmaceutically or agriculturally acceptable salts thereof:
  • Al represents a bond, phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl, each of which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, - CO 2 H and halogen, or from a group of formula -(C 1 -C2 alkyl)-O-(C 1 -C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsub
  • Ll represents a bond, a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C1-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, and wherein the heterocyclyl group is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen; when Ll is a bond, Rl represents hydrogen, -A2, -SO 2 -A2, A2-L3-A3 or A4; and when Ll is other than a bond, Rl represents hydrogen or an unsubstituted group selected from C1-C6 alkyl,
  • A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF 3 , -OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; L3 represents a bond or unsubstituted methylene, ethylene or propylene; A4 represents unsubstitute
  • R5 represents hydrogen, unsubstituted or substituted phenyl, unsubstituted C3- C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or R5 is a C1-C8 alkyl group which is unsubstituted or substituted with a C1-C4 alkoxy group; and either (i) R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C 1 -C4 alkoxy, unsubstituted C2-C4 alkenyl, unsubstituted C 1 -C4 alkyl, or C 1 -C4 alkyl or C2-C4 al
  • Al is other than a bond. More preferably Al represents phenyl, pyridyl or piperidinyl, each of which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO 2 H and halogen.
  • Rl represents -A2, -SO 2 -A2, A2-L3-A3 or A4; and when Ll is other than a bond, Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO 2 (C1-C4 alkyl), or a group -A2, -SO 2 -A2, -L3-A2 or -A2-L3-A3.
  • R5 represents hydrogen, unsubstituted or substituted phenyl, unsubstituted C3-C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl or unsubstituted C1-C4 alkoxy.
  • R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt 3 and R3 represents hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt; or R2 and R3 together with the ring atoms to which they are bonded form a substituted or unsubstituted at least partially saturated 5- or 6-membered ring containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O 5 the substituents being selected from unsubstituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy groups.
  • a further preferred embodiment provides pyrrole derivatives of formula (Ia) and pharmaceutically or agriculturally acceptable salts thereof, wherein: Al represents phenyl, which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO 2 H and halogen, preferably Al is unsubstituted or substituted with one group selected from F, Cl and methyl, most preferably Al is unsubstituted; n represents one;
  • Ll represents an unsubstituted, saturated 5- to 7-membered heterocyclyl group containing two nitrogen atoms, the heterocycle being attached to Al and to Rl via a nitrogen atom, preferably Ll represents piperazinyl;
  • Rl represents unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or a group -A2, -CH 2 -A2 or - A2-CH 2 -A3 ;
  • A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF 3 , - OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe 5 -OEt or -0(Cl -C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group;
  • R5 represents unsubstituted phenyl
  • R2 represents hydrogen, or C1-C4 alkyl or C2-C4 alkenyl, each of which may be unsubstituted or substituted with -OMe, -OEt 5 -OPr 5 -OBu, -OCH 2 CH 2 OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH 2 - groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C
  • R3 represents hydrogen or C1-C4 alkyl which is unsubstituted or substituted with -OMe or -OEt.
  • Al is a phenyl group which is unsubstituted or substituted with F, Cl or methyl, preferably Al is unsubstituted phenyl; Ll is piperazinyl and is linked to Al and Rl via a nitrogen atom; and Rl is unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or piperidinyl, wherein the piperidinyl group is unsubstituted or substituted with one, two or three substituents selected from unsubstituted C1-C4 alkyl groups. More preferably, Rl is piperidinyl which is substituted with two methyl groups.
  • R2 and R3 are independently selected from hydrogen and unsubstituted C1-C4 alkyl groups, preferably methyl.
  • a particular embodiment of the invention relates to pyrrole derivatives of formula (I) and pharmaceutically acceptable salts thereof, for use in a method of treatment of a human or animal body by therapy.
  • R6 is hydrogen and Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group.
  • Al represents a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or unsaturated 8- to 10-membered bicyclic heterocyclyl group.
  • Al represents a phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl group. Possible substituents on Al are as defined above.
  • Al is a bond
  • -Ll-Rl is other than hydrogen, unsubstituted or substituted benzyl, substituted phenethyl or unsubstituted or substituted C2-C4 alkyl. More preferably, Al is not a bond.
  • R4 preferably represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO 2 , -NR'R" or -CF 3 wherein R' and R' ' are independently hydrogen or C1-C4 alkyl.
  • R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO 2 , -NR'R" or -CF 3 wherein R' and R" are independently hydrogen or C1-C4 alkyl.
  • R4 represents hydrogen, halogen or C1-C4 alkyl, preferably hydrogen. Where R4 is capable of being substituted, it is typically unsubstituted or substituted with one halogen atom, more preferably it is unsubstituted.
  • R2 when R2 is cycloalkyl it is an unsubstituted cycloalkyl group.
  • the present invention provides novel pyrrole derivatives of formula (I) and pharmaceutically or agriculturally acceptable salts thereof.
  • Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group.
  • Al represents a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or unsaturated 8- to 10- membered bicyclic heterocyclyl group.
  • Al represents a phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl group. Possible substituents on Al are as defined above.
  • Al is a bond
  • -Ll-Rl is other than hydrogen, unsubstituted or substituted benzyl, substituted phenethyl or unsubstituted or substituted C2-C4 alkyl. More preferably, Al is not a bond.
  • Rl when Al and Ll are both a bond, Rl preferably represents unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2 or -A2-L3-A3.
  • Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C1-C4 alkyl) and -SO 2 (C1-C4 alkyl) or a group -A2, -L2-A2, -L3-A2 or -A2-L3-A3. More preferably, Rl represents a group -A2, -L2-A2, -L3-A2 or -A2-L3- A3. Preferred alkyl, alkenyl and alkynyl groups and substituents on these groups are described above. A2, A3, L2 and L3 are as defined above.
  • R6 is hydrogen
  • R2 when R2 is heterocyclyl, it is not substituted with an aryl or further heterocyclyl group.
  • Preferred substituents on an R2 heterocyclyl group are defined above.
  • R2 when R2 is heterocyclyl it is not thienyl or benzothienyl, more preferably it is not thienyl, benzothienyl or pyrazolyl.
  • R2 when R2 is heterocyclyl, it is an unsubstituted 5- or 6-membered heterocyclyl ring other than thienyl. More preferably, R2 is not heterocyclyl.
  • Most preferred R2 groups are defined above.
  • R2 is a substituted C1-C8 alkyl group
  • the substituent(s) do not include -CN or -CO 2 H.
  • Preferred substituents on an R2 C1-C8 alkyl group are defined above.
  • R2 is substituted phenyl
  • the substituent(s) do not include nitro.
  • Preferred substituents on an R2 phenyl group are defined above.
  • R4 represents an aryl or heterocyclyl group it is typically phenyl, benzyl or pyridyl.
  • the aryl or heterocyclyl group may be unsubstituted or substituted as defined above.
  • R4 preferably represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO 2 , -NR'R" or -CF 3 wherein R' and R" are independently hydrogen or C1-C4 alkyl.
  • R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO 2 , -NR'R" or -CF 3 wherein R' and R" are independently hydrogen or Cl -C4 alkyl.
  • R4 represents hydrogen, halogen or C1-C4 alkyl, preferably hydrogen. Where R4 is capable of being substituted, it is typically unsubstituted or substituted with one halogen atom, more preferably it is unsubstituted.
  • Rl when Ll is a bond, Rl preferably represents hydrogen, unsubstituted or substituted C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents hydrogen, an unsubstituted group selected from C2-C6 alkenyl, C2-C6 alkynyl and -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, - L3-A2, -A2-L3-A3 or -A4.
  • Rl represents hydrogen or a group -A2, -L2-A2, A2-L3-A3 or A4.
  • Rl when Ll is a bond, Rl preferably represents unsubstituted or substituted C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents an unsubstituted group selected from C2- C6 alkenyl, C2-C6 alkynyl and -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents -A2, -L2-A2, -A2-L3-A3 or A4.
  • Rl represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents hydrogen, an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C1-C4 alkyl)and -SO 2 (C1-C4 alkyl), C1-C6 alkyl substituted with -OMe or -OEt, or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents hydrogen, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, unsubstituted -CO(Cl -C4 alkyl), unsubstituted -SO 2 (C1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or -A2-L3-A3.
  • Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO 2 (C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4.
  • Rl represents a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2- C6 alkynyl group, unsubstituted -SO 2 (C 1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or - A2-L3-A3.
  • Ll is a bond, -CH 2 -, -NR'-, a C2-C6 alkylene group in which none, one, two or three -CH 2 - groups are independently replaced by -0-, -S- or -NR'-, or a 5- to 12-membered heterocyclyl group, wherein R' is as defined above.
  • Ll preferably represents a bond, -CH 2 -, -NR'-, a 5-to 7-membered heterocyclyl group or a C2-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group.
  • Ll represents a 5- to 7-membered heterocyclyl group, it is preferably as defined above.
  • Ll is most preferably -CH 2 -, -NR'-, a saturated 5- to 7- membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C2-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or Cl- C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group.
  • Preferred compounds of this embodiment are compounds of formula (IA) as defined above, or pharmaceutically or agriculturally acceptable salts thereof, wherein when Al is a bond, (i) -Ll-Rl is not hydrogen, (ii) when R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted ben ⁇ yl or substituted phenethyl, and (iii) when R6 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll 5 L3 and Ll-Rl represents an unsubstituted or substituted C1-C4 alkyl group and (iv) when Ll is a bond, Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,
  • Ll represents a bond, -CH 2 -, -NR'- a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C2-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, and wherein the heterocyclyl group is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen.
  • Ll represents an unsubstituted C2-C6 alkylene group wherein none, one or two -CH 2 - groups are independently replaced with -O- or -NR'-, preferably it is a C4 or C5 alkylene group wherein none, one or two, more preferably one or two, -CH 2 - groups are independently replaced with -O- or -NR'- wherein R' is hydrogen or unsubstituted Cl-
  • Preferred examples of compounds of formula (I) include: 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N- ⁇ 4-[4-(4 5 6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -phenyl ⁇ -2-oxo-acetamide,
  • One embodiment of the invention relates to pyrrole derivatives of formula (IB), which are particularly active against fungi from both the Aspergillus and Candida genera and may therefore find use as broad spectrum anti-fungal agents.
  • the pyrrole derivatives of this embodiment are of formula (IB):
  • R2 is a group of formula -AIk 1 -X-R', wherein AIk 1 is an unsubstituted or substituted C1-C6 alkylene group, X is a group -O-, -S-, -NR"-, -CO 2 -, -CONR"-, -OCO-, -OCONR"- or -SO 2 -, and R' and R" are independently selected from hydrogen and unsubstituted or substituted C1-C4 alkyl, for example unsubstituted or substituted C1-C4 alkyl.
  • AIk 1 is typically an unsubstituted or substituted C1-C4 alkylene group, for example methylene or ethylene. Where AIk 1 is substituted, it typically carries one or two, preferably one, substituent selected from halogen and further groups of formula -XR' as defined herein. Preferably AIk 1 is unsubstituted.
  • X is typically selected from -0-, -NR"-, -CO 2 - and -CONR"-. When X is
  • R' is typically a C1-C4 alkyl group.
  • R' and R" typically represent hydrogen or unsubtituted or substituted methyl or ethyl.
  • R' is typically a methyl or ethyl group.
  • R' and R" are independently unsubstituted or substituted, typically with one or two, preferably one, substituent.
  • Suitable susbtituents are selected from unsubstituted substituents such as halogen (for example fluorine), hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, -CO 2 H and -CO 2 (C1-C4 alkyl) and from C1-C4 alkoxy such as methoxy or ethoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or ethoxy.
  • substituents such as halogen (for example fluorine), hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, -CO 2 H and -CO 2 (C1-C4 alkyl) and from C1-C4 alkoxy such as methoxy or ethoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or
  • substituerits are hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino and unsubstituted C1-C4 alkoxy.
  • R' and R" are unsubstituted.
  • Specific examples of compounds of formula (IB) include:
  • Compounds of the invention containing one or more chiral centre may be used in enantiomerically or diastereoisomerically pure form, or in the form of a mixture of isomers.
  • the compounds of the invention can, if desired, be used in the form of solvates. Further, for the avoidance of doubt, the compounds of the invention may be used in any tautomeric form.
  • a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
  • Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic, hydroiodic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic, p-toluenesulphonic acid, formic, acetic, propionic, glycolic, lactic, pyruvic, oxalic, salicylic, trichloroacetic, picric, trifluoroacetic, cinnamic, pamoic, malonic, mandelic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA,
  • compositions include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan.
  • Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines and heterocyclic amines, lysine, guanidine, diethanolamine and choline.
  • alkali metal e.g. sodium or potassium
  • alkali earth metal e.g. calcium or magnesium
  • organic bases such as alkyl amines, aralkyl amines and heterocyclic amines, lysine, guanidine, diethanolamine and choline.
  • Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form.
  • the acid addition salts may be obtained as the direct products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • the present invention also provides prodrugs of the compounds of the invention.
  • a prodrug is an analogue of a compound of the invention which will be converted in vivo to the desired active compound.
  • suitable prodrugs include compounds of formula (I) which have been modified at a carboxylic acid group to form an ester, or at hydroxy! group to form an ester or carbamate. Other suitable methods will be known to those skilled in the art.
  • Further suitable prodrugs include those in which a nitrogen atom of a compound of formula (I) is quaternised by addition of an ester or alkyl ester group.
  • the nitrogen atom of an amine group or heterocyclyl ring on a substituent Rl or R5 may be quaternised by addition of a -CH 2 -O-COR group, wherein R is typically methyl or tert-butyl.
  • Suitable salts of the compounds of the invention include those mentioned herein as examples of pharmaceutically and agriculturally acceptable salts.
  • the compounds of the invention may be synthesised by reacting a compound of formula (II), wherein R2, R3, R4 and R5 are as hereinbefore defined, with a compound of formula (III), wherein R6, Al, n, Ll and Rl are as hereinbefore defined.
  • the reaction takes place in the presence of an organic solvent and a base.
  • the solvent is dichloromethane or tetrahydrofuran and the base is triethylamine or pyridine.
  • the reaction is carried out at 0°C initially while the reagents are added and then stirred at room temperature until the reaction is complete.
  • Compounds of formula (III) are typically available from commercial sources or can be prepared by known methods. Details of the synthesis of certain compounds of formula (III) are provided hereinafter.
  • a compound of formula (II) may be prepared by reacting a compound of formula (IV) 5 wherein R2, R3, R4 and R5 are as hereinbefore defined, with preferably oxalyl chloride.
  • the reaction takes place in an organic solvent.
  • the solvent is dichloromethane.
  • the reaction is carried out at 0 °C initially while the reagents are added and then stirred at room temperature until the reaction is complete.
  • Reagents/solvents sodium hydride, THF, O °C to room temperature; sodium hydride, DMF, O 0 C to 90 0 C; potassium carbonate, acetonitrile, reflux.
  • Reagents sodium or potassium hydroxide, water/ethanol or water/methanol mixtures, reflux temperature.
  • iV-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethyl]-benzene-l,4-diamine From 2-chloro-4,6-dimethylpyridine by treatment with ethanolamine and sodium hydroxide in a mixture of water and dioxane to afford 2-(4,6-dimethyl-pyridin- 2-yloxy)-ethylamine, followed by heating with l-fiuoro-4-nitrobenzene in ethanol to give [2-(4,6-dimethyl-pyridin-2-yloxy)-ethyl]-(4-nitro-phenyl)-amine.
  • the free amine is protected as a trifluoroacetamide by treatment with trifluoroacetic anhydride and sodium hydride in THF then the nitro group is reduced with zinc powder in the presence of ammonium chloride in ethanol. Following coupling with the appropriately-selected acid chloride, a final treatment with lithium hydroxide in methanol removes the trifluoroacetamide to give the final compound described.
  • N-[2-(4,6-Dimemyl-pyrid ⁇ -2-ylamino)-emyl]-N-memyl-benzene-l,4-diamine From l-fluoro-4-nitrobenzene by heating with glycine at reflux in a mixture of aqueous sodium bicarbonate and dioxane to give (4-r ⁇ 1ro-phenylamino)-acetic acid, followed by treatment with formaldehyde and formic acid at reflux to give [methyl-(4- nitro-phenyl)-amino] -acetic acid.
  • the amides are then reduced with borane- dimethylsulfide in THF at reflux, the free amine is protected as a trifluoroacetamide by treatment with trifluroacetic anhydride and sodium hydride in THF then the nitro group is reduced with zinc powder in the presence of ammonium chloride in ethanol.
  • a final treatment with lithium hydroxide in methanol removes the trifluoroacetamide to give the final compound described.
  • iV- ⁇ 2-[(4,6-Dimethyl- ⁇ yridin-2-yl)-methyl-amino]-ethyl ⁇ -benzene-l,4-diamine From (4-nitro-phenylamino)-acetic acid (prepared as described above) by treatment with trifluroacetic anhydride and sodium hydride in THF to give [(4-nitro- phenyl)-(2,2 5 2-trifluoro-acetyl)-amino]-acetic acid followed by acid chloride formation with thionyl chloride in chloroform and coupling with (4,6-dimethyl-pyridin-2-yl)- methyl-amine to yield iV- ⁇ [(4,6-dimethyl-pyridin-2-yl)-methyl-carbamoyl]-methyl ⁇ - 2 ; 2,2-trifluoro-N-(4-nitro-phenyl)-acetamide.
  • [3-(4-Amino-phenyl)-propyl]-(4,6-dimethyl-pyridin-2-yl)-methyl-amine Alkylation of diethyl malonate with 4-nitrobenzyl bromide using sodium hydride in THF, followed by ester hydrolysis with sodium hydroxide in water and ethanol, then heating the resulting diacid to its melting point causing decarboxylation gives 3-(4-nitro-phenyl)-propionic acid.
  • the present invention provides combinations of the pyrrole derivative of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof, with a further antifungal agent.
  • a further antifungal agent e.g., the pyrrole derivative of formula (I) 5 (IA), (IB) or pharmaceutically acceptable salt thereof (also referred to herein as the first antifungal agent) is present in the combinations, compositions and products of the invention with a second antifungal agent
  • the second antifungal agent used in the invention can be any suitable antifungal agent that the skilled person would judge to be useful in the circumstances.
  • antifungal agents include azoles, polyenes, purine nucleotide inhibitors, pyrimidine nucleotide inhibitors, mannan inhibitors, protein elongation factor inhibitors, chitin synthase inhibitors, Beta-glucan synthase inhibitors, echinocandins, allylamines, anti-HSP90 antibodies, bactericidal/permeability inducing protein products and polyoxins.
  • suitable antifungal agents which do not fall within the classes above include the compounds AN2690, AN2718 and icofungipen.
  • Preferred azoles are clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, fluconazole, isoconazole, itraconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, isavuconazole, ravuconazole, posaconazole, terconazole and voriconazole.
  • Preferred echinocandins are anidulafungin, caspofungin and micafungin.
  • Preferred allylamines are terbinafine, butenafine, amorolfine and naftifme.
  • Preferred polyenes are amphotericin B and nystatin.
  • a preferred example of a purine or pyrimidine nucleotide inhibitor is flucytosine.
  • a preferred mannan inhibitor is pradamicin.
  • a preferred protein elongation factor inhibitor is sordarin and analogues thereof.
  • a preferred polyoxin is nikkomycin Z.
  • Particularly preferred second antifungal agents are caspofungin, micafungin, amphotericin B, voriconazole, posaconazole, fluconazole and itraconazole.
  • Examples of preferred combinations of the invention are compounds of formula (IA) and their pharmaceutically acceptable salts as defined above with a second antifungal agent selected from caspofungin, micafungin, amphotericin B, voriconazole, posaconazole, fluconazole and itraconazole.
  • Further preferred combinations of the invention are combinations of (i) compounds of formula (Ia) and pharmaceutically acceptable salts thereof wherein:
  • Al represents phenyl, which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO 2 H and halogen, preferably Al is unsubstituted or substituted with one group selected from F, Cl and methyl, most preferably Al is unsubstituted; n represents one;
  • Ll represents an unsubstituted, saturated 5- to 7-membered heterocyclyl group containing two nitrogen atoms, the heterocycle being attached to Al and to Rl via a nitrogen atom, preferably Ll represents piperazinyl;
  • Rl represents unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or a group -A2, -CH 2 - A2 or -A2-CH 2 -A3;
  • A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF 3 , - OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group;
  • R5 represents unsubstituted phenyl
  • R2 represents hydrogen, or C1-C4 alkyl or C2-C4 alkenyl, each of which may be unsubstituted or substituted with -OMe, -OEt, -OPr, -OBu 3 -OCH 2 CH 2 OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH 2 - groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C
  • R3 represents hydrogen or C1-C4 alkyl which is unsubstituted or substituted with -OMe or -OEt; with (ii) a second antifungal agent selected from caspofungin, micafungin, amphotericin B 5 voriconazole, posaconazole, fluconazole and itraconazole.
  • Al is a phenyl group which is unsubstituted or substituted with F, Cl or methyl, preferably Al is unsubstituted phenyl; Ll is piperazinyl and is linked to Al and Rl via a nitrogen atom; and Rl is unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or piperidinyl, wherein the piperidinyl group is unsubstituted or substituted with one, two or three substituents selected from unsubstituted C1-C4 alkyl groups. More preferably, Rl is piperidinyl which is substituted with two methyl groups.
  • in the compounds of formula (IA) is a phenyl group which is unsubstituted or substituted with F, Cl or methyl, preferably Al is unsubstituted phenyl; Ll is piperazinyl and is linked to Al and Rl via a nitrogen atom; and Rl
  • R2 and R3 are independently selected from hydrogen and unsubstituted C1-C4 alkyl groups, preferably methyl.
  • the compound of formula (IA) is 2-(l,5-Dimethyl-3-phenyl-lH " -pyrrol-2-yl)-iV- ⁇ 4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -phenyl ⁇ -2-oxo-acetamide,
  • the most preferred combinations of the invention include combinations of 2- (l,5-Dimethyl-3-phenyl-lH ' -pyrrol-2-yl)-iV ' - ⁇ 4-[4-(4 5 6-dimethyl-pyridin-2-yl)-piperazm-
  • a second antifungal agent selected from caspofungin, micafungin, amphotericin B, voriconazole, posaconazole, fluconazole and itraconazole.
  • the compounds of the invention have antifungal activity. Accordingly, they may be used in a method of treating a subject suffering from or susceptible to a fungal disease, which method comprises administering to said subject an effective amount of a pyrrole derivative of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof.
  • the compounds may be used in combination with a second antifungal agent, as desired.
  • the fungal disease comprises an infection by a fungus, for example an Ascomycete.
  • the fungal disease comprises an infection by an organism selected from the genera Absidia; Acremonium; Alternaria; Aspergillus; Bipola ⁇ s;
  • Cryptococcus Curvularia; Encephalitozoon; Epicoccum; Epidermophyton; Exophiala; Exserohilum; Fusarium; Histoplasma; Leptosphaeria; Microsporum; Mycosphaerella;
  • Neurospora Paecilomyces; Penicillium; Phytophthora; Plasmopara; Pneumocystis;
  • Scopulariopsis Trichophyton; Trichosporon; and Ustilago.
  • the fungal disease comprises an infection by an organism of the genus Aspergillus or Candida.
  • the fungal disease comprises an infection by an organism selected from the species Absidia corymbifera; Acremonium spp; Alternaria alternata;
  • Aspergillus parasiticus; Aspergillus terreus; Bipolar is spp; Blastomyces dermatitidis; Blumeria graminis; Candida albicans; Candida glabrata; Candida krusei; Candida parapsilosis; Candida ti'opicalis; Cladosporium cladosporoides; Cladosporium herbarium; Coccidioides immitis; Coccidioides posadasii; Curvularia lunata; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi; Epicoccum nigrum; Epidermophyton ⁇ occosum; Exophiala spp; Exserohilum rostratum; Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Histoplasma capsulation; Leptosphaeria nodorum; Microsporum canis; Mycos
  • the fungal disease comprises an infection by Aspergillus fumigatus.
  • fungal diseases which can be prevented or treated using the compounds of the invention, include both systemic and superficial infections.
  • the fungal diseases include invasive fungal diseases caused by Aspergillus and Candida species such as aspergillosis or candidiasis, but also local forms of these infections.
  • the compounds of the invention are particularly useful against diseases caused by Aspergillus species, for which a fungicidal drug is required which has lower toxicity than amphotericin.
  • the invention also provides for the treatment of dermatological infections.
  • the compounds of the invention are for use in the prevention or treatment of a disease caused by Aspergillus species.
  • the compounds of the invention are pyrrole derivatives of formula (IB) or pharmaceutically acceptable salts thereof, these compounds being for use in preventing or treating diseases caused by Candida species.
  • the compounds of formula (IB) or pharmaceutically acceptable salts thereof are therefore particularly useful in the prevention or treatment of diseases caused by Aspergillus species and diseases caused by Candida species.
  • the diseases caused by Aspergillus species include diseases caused by A. fumigatus, A. flavus, A. terreus and A. niger.
  • the diseases cause by Candida species include diseases caused by C. albicans, C. glabrata, C. krusei, C. tropicalis and C. parapsillosis.
  • Examples of systemic infections which might be prevented or treated using the compounds of the invention include: systemic candidiasis; pulmonary aspergillosis, e.g.
  • immunosuppressed patients such as bone marrow recipients or AIDS patients; systemic aspergillosis; cryptococcal meningitis; rhinocerebral mucomycosis; blastomycosis; histoplasmosis; coccidiomycosis; paracoccidiomycosis; lobomycosis; sporotrichosis; chromoblastomycosis; phaeohyphomycosis; zygomycosis; cryptococcosis and disseminated sporotrichosis.
  • Examples of superficial infections which can be prevented or treated using the compounds of the invention, include: ring worm; athlete's foot; tinea unguium (nail infection); candidiasis of skin, mouth or vagina; and chronic mucocutaneous candidiasis.
  • ABPA allergic bronchopulmonary asthma
  • asthma examples of diseases or conditions which are caused by fungi or where fungi exacerbate an allergic response, and which can be prevented or treated using the compounds of the invention, include allergic bronchopulmonary asthma (ABPA); asthma, rhinosinusitis and sinusitis.
  • ABPA allergic bronchopulmonary asthma
  • the present invention includes a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to the invention and a pharmaceutically acceptable carrier or diluent.
  • Said pharmaceutical composition typically contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention.
  • Preferred pharmaceutical compositions are sterile and pyrogen free.
  • the pharmaceutical compositions provided by the invention typically contain a substantially pure optical isomer.
  • the composition additionally comprises a second antifungal agent.
  • the pyrrole and second antifungal agent need not be present in admixture in a single composition.
  • the pyrrole and second antifungal agent are preferably formulated for simultaneous or successive administration.
  • the compounds, combinations, compositions and products of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the compounds, combinations, compositions and products of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
  • the compounds, combinations, compositions and products may also be administered as suppositories.
  • the compounds, combinations, compositions and products may be administered by inhalation in the form of an aerosol via an inhaler or nebuliser.
  • a compound of the invention, and optionally a second antifungal agent is typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
  • solid oral forms may contain, together with the active compound, solubilising agents, e.g. cyclodextrins or modified cyclodextrins; diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g.
  • starches arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
  • Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
  • Liquid dispersions for oral administration may be solutions, syrups, emulsions and suspensions.
  • the solutions may contain solubilising agents e.g. cyclodextrins or modified cyclodextrins.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol; solubilising agents, e.g. cyclodextrins or modified cyclodextrins, and if desired, a suitable amount of lidocaine hydrochloride.
  • a pharmaceutically acceptable carrier e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol
  • solubilising agents e.g. cyclodextrins or modified cyclodextrins, and if desired, a suitable amount of
  • Solutions for intravenous or infusions may contain as carrier, for example, sterile water and solubilising agents, e.g. cyclodextrins or modified cyclodextrins or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. Nanoformulations are also envisaged.
  • a therapeutically effective amount of a compound of the invention is administered to a patient.
  • a typical daily dose is up to 200 mg, e.g.
  • daily dosage levels are up to 200mg, e.g. up to 150mg, up to lOOmg, up to 50 mg or up to 40mg per kg of body weight.
  • Daily dosage levels are for example at least lmg, at least 2 mg or at least 5 mg per kg of body weight. In one embodiment the daily dosage level is from 0.05 mg to 2 g, preferably from 0.1 mg to 10 mg.
  • the compound of the invention is typically administered in an amount of at least 0.05 mg, preferably at least 0.1 mg, 2 mg or at least 5 mg.
  • a preferred upper limit on the amount of compound of the invention administered is typically 200mg, e.g. 100 mg, 50 mg or 25 mg.
  • the second antifungal agent is typically administered at or below the standard dose used for that drug.
  • An advantage of the combinations of the present invention is that known antifungal agents may be administered in lower doses than are currently used, resulting in a reduction in toxic effects.
  • the compound, combination or composition of the invention is typically administered to the patient in a non-toxic amount.
  • the present invention also provides a method of controlling a fungal disease of a plant, which comprises applying to the locus of the plant a pyrrole derivative of formula (I), (IA) or (IB) or an agriculturally acceptable salt thereof, and optionally a second antifungal agent.
  • the compounds, combinations, compositions and products of the invention may, for example, be applied to the seeds of the plants, to the medium (e.g. soil or water) in which the plants are grown, or to the foliage of the plants.
  • the medium e.g. soil or water
  • the compounds, combinations, compositions and products of the invention are preferably used in the treatment or prevention of fungal diseases.
  • fungal diseases of plants which can be controlled using the compounds of the invention include fungal diseases caused by the following plant pathogens: Blumeria graminis; Colletotrichium trifolii; Fusarium gramimarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Neurospora crassa; Phytophthora capsic ⁇ , Phytophthora infestans; Plasmopara viticola; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani; Trichophyton rubrum; and Ustilago maydis.
  • the present invention includes a composition comprising a compound of the invention, or an agriculturally acceptable salt thereof, and an agriculturally acceptable carrier or diluent.
  • the composition further comprises a second antifungal agent.
  • Said agricultural composition typically contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention.
  • the antifungal agent(s) can be used at a level of from 5g to 10kg per hectare, for example from 1Og to 5kg per hectare, for example from lOOg to 2kg per hectare.
  • Suitable agriculturally acceptable salts include salts with agriculturally acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with agriculturally acceptable bases such as alkali metal (e.g. sodium or potassium) and alkaline earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
  • a preferred agriculturally acceptable salt is the hydrochloride salt.
  • the compounds of the invention, and optional second antifungal agents may be applied in combination with inert carriers or diluents, as in aqueous sprays, granules and dust formulations in accordance with established practice in the art.
  • An aqueous spray is usually prepared by mixing a wettable powder or emulsifiable concentrate formulation of a compound of the invention with a relatively large amount of water to form a dispersion.
  • Wettable powders may comprise an intimate, finely divided mixture of a compound of the invention, an inert solid carrier and a surface-active agent.
  • the inert solid carrier is usually chosen from among the attapulgite clays, the kaolin clays, the montmorillonite clays, the diatomaceous earths, finely divided silica and purified silicates.
  • Effective surfactants which have wetting, penetrating and dispersing ability are usually present in a wettable powder formulation in proportions of from 0.5 to 10 percent by weight.
  • the surface active agents commonly used for this purpose are the sulfonated lignins, naphthalenesulfonates and condensed naphthalenesulfonates, alkylbenzenesulfonates, alkyl sulfates and non-ionic surfactants such as products of condensation of ethylene oxide with alkylphenols.
  • Emulsifiable concentrates may comprise a solution of a compound of the invention in a liquid carrier which is a mixture of a water-immiscible solvent and a surfactant, including an emulsifier.
  • a surfactant including an emulsifier.
  • Useful solvents include aromatic hydrocarbon solvents such as the xylenes, alkylnaphthalenes, petroleum distillates, terpene solvents, ether-alcohols and organic ester solvents.
  • Suitable emulsifiers, dispersing and wetting agents may be selected from the same classes of products which are employed in formulating wettable powders.
  • the fungicide formulations desirably contain from 0.1 percent to 95 percent by weight of the compound of the invention, or in the case of a combination of antifungal agents the total weight of antifungal agent, and from 0.1 to 75 percent of an inert carrier or surfactant.
  • the direct application to plant seeds prior to planting may be accomplished in some instances by mixing either a powdered solid compound of the invention or a dust formulation with seed to obtain a substantially uniform coating which is very thin and represents only one or two percent by weight or less, based on the weight of the seed.
  • a non-phytotoxic solvent such as methanol is conveniently employed as a carrier to facilitate the uniform distribution of the compound of the invention on the surface of the seed.
  • a typical granular formulation comprises a compound of the invention dispersed on an inert carrier such as coarsely ground clay, or clay which has been converted to granules by treatment of a rolling bed of the powdered material with a small amount of liquid in a granulating drum.
  • Dust formulations customarily employ essentially the same inert diluents as wettable powders and granules, but are well-mixed in powder form and do not usually contain emulsifiers. Dusts may contain some surface active agents to facilitate uniform distribution of the active ingredient in the formulation and to improve the uniformity and adhesion of the dust coating on seeds and plants.
  • the colloidal dispersion of dust formulations in the air is usually prevented by incorporation of a minor amount of an oily or waxy material in the formulation to cause agglomeration of colloidal size particles. In this way the dust may be applied to seeds or plants without generation of an air-polluting aerosol.
  • Triethylamine (11.7 mL, 84.3 mmol) was added drop wise to a suspension of potassium ethyl malonate (13.4 g, 78.5 mmol) in acetonitrile (80 mL) at 10 0 C, followed by portionwise addition of anhydrous magnesium chloride (9.12 g, 95.8 mmol).
  • the reaction mixture was warmed to room temperature and stirred for 2.5 h.
  • the resulting white slurry was cooled to 0 0 C and furan-2-carbonyl chloride (5.0 g, 38.3 mmol) in acetonitrile (20 mL) was added dropwise over a period of 20 min. The mixture was allowed to stir at ambient temperature overnight.
  • the mixture was quenched with ice- water (100 mL) and concentrated in vacuo to remove volatile organics.
  • the aqueous phase was decanted off and the residual solid was extracted with dichloromethane (350 mL).
  • the aqueous phase was extracted with dichloromethane (2 x 100 mL) and the combined extracts were washed successively with water (2 x 200 mL), brine (2 * 100 mL), dried over anhydrous sodium sulfate and concentrated to afford diethyl 1,5- dimethyl-3-phenyl-pyrrole-2,4-dicarboxylate (80 g, 90%) as a yellow solid.
  • Toluene-4-sulfonic acid 2-ethoxy-ethyl ester (prepared according to Crowley et. al, J. Chem. Soc, 1957, 2931-2934; 3.5 g, 14.3 mmol) was added to a solution of sodium iodide (4.30 g, 28.7 mmol) in acetone (30 mL) and heated at reflux overnight. Acetone was evaporated from the reaction mixture and ether was added. The mixture was filtered and the filtrate was concentrated in vacuo to afford l-ethoxy-2-iodo-ethane (1.5 g, 52%).
  • Potassium fert-butoxide (780 mg, 6.96 mmol) was added in three portions over a period of 10 minto a stirred solution of ethyl 4-phenyl-lH ' ⁇ pyrrole-2-carboxylate (1.0 g, 4.63 mmol) in dimethylsulfoxide (10 mL) at 10 0 C and maintained at this temperature for 30 min.
  • a solution of l-bromo-2-methoxy-ethane (770 mg, 5.50 mmol) in dimethylsulfoxide (2 mL) was added drop wise to the reaction mixture at 10 °C and then stirred for 2 h at room temperature.
  • reaction mixture was poured into ice water (25 mL) and the aqueous layer extracted with diethyl ether (3 x 20 mL). The combined organic layer was washed with water, brine (2 x 20 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford ethyl l-(2-methoxyethyl)-4- phenyl- ⁇ yrrole-2-carboxylate (1.15 g, 91%) as an oil.
  • silica gel (60-120 mesh) using 0% to 15% of ethyl acetate in pet ether as eluent to afford ethyl 3-cyclobutylprop-2-enoate (2.10 g, 15%) as a liquid.
  • Toluenesulfonylmethyl isocyanide (3.04 g, 15.59 mmol) was added to the stirred solution of ethyl 3-cyclobutylprop-2-enoate (2.00 g, 12.99 mmol) in a mixture of dimethylsulfoxide (2 mL) and diethyl ether (30 mL) and stirred for 45 min.
  • the resulting mixture was added to a slurry of sodium hydride (675 mg, 38.14 mmol, 60% in mineral oil) in diethyl ether (10 mL) over a period of 30 min then stirred for a further 1 h.
  • a solution of sodium hydroxide (101 g, 2.53 mol) in water (340 mL) was added to a solution of diethyl l,5-dimethyl-3-phenyl-pyrrole-2,4-dicarboxylate (80 g, 0.25 mol) in ethanol (340 mL) and heated at reflux for 15 h. Ethanol was removed under reduced pressure and the residue diluted with water (200 mL) and chilled to 0 °C. Concentrated hydrochloric acid ( ⁇ 150 mL) was slowly added to adjust pH to ⁇ 2 5 while maintaining temperature below 10 °C and the mixture was stirred for 30 min.
  • Reference Example 151 & 152 Dimethyl l-(3-methoxypropyD-5-methyI-3-phenyI- pyrroIe-2,4-dicarboxyIate (151) & 4-methoxycarbonvI-l-(3-methoxypropyI)-5- methyI-3-phenyi-pyrroIe-2-carboxyIic acid (152)
  • the organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford dimethyl l-(3-methoxypropyl)-5-methyl-3-phenyl-pyrrole-2;,4-dicarboxylate (330 mg, 33%) as a yellow oil.
  • the aqueous layer was acidified with 2N hydrochloric acid to pH 2 and extracted with ethyl acetate.
  • the combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated to afford 4- methoxycarbonyl-1 -(3-methoxypropyl)-5-methyl-3-phenyl-pyrrole-2-carboxylic acid (170 mg, 18%) as a pink oil.
  • N-Bromo succinimide (1.40 g, 7.87 mmol) was added to a solution of ethyl 5- methyl-3 -phenyl- l//-pyrrole-2-carboxylate (1.5g, 6.55 mmol) in a mixture of dioxane (10 mL) and acetic acid (20 niL) at 0 0 C. The reaction mixture was stirred at 0 0 C for 15 min. The reaction mixture was warmed to room temperature and stirred for another 15 min.
  • Dry hydrogen chloride gas was bubbled into a stirred solution of 5-(3-phenyl ⁇ pyrrol- l-yl)pentanenitrile (1.45 g, 6.47 mmol) in dry diethyl ether (50 mL) and boron trifluoride etherate (2 mL) at -5 to 0 0 C.
  • the mixture became saturated with the hydrogen chloride gas, it was allowed to stand for 24 h.
  • Excess diethyl ether was removed in vacuo and the residue hydrolyzed by adding dilute ammonium hydroxide (20 mL) and chloroform (30 mL). The reaction mixture was refluxed for 12 h and the chloroform layer separated.
  • the chloroform layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford a mixture of 2-phenyl- 5,6,7,8-tetrahydro-pyrrolo[l 5 2-a]azepin-9-one & l-phenyl-5,6,7,8-tetrahydro- pyrrolo[l,2-a]azepin-9-one (1.50 g, 99%) as a gummy solid.
  • Phosphorus oxychloride (6.8 g, 44.4 mmol) was added to anhydrous dimethylformamide (16 g, 220 mmol) over a period of 15 min at 0-5 0 C, then warmed to room temperature and stirred for 1 h. Phenylacetic acid (2.0 g, 14.7 mmol) was added and the reaction mixture stirred at 90-100 0 C for 16 h. The reaction mixture was quenched by pouring into ice water with vigorous stirring. A solution of 70% perchloric acid (1.88 mL, 2.2 g, 22.0 mmol) in water (5 mL) was added dropwise with vigorous stirring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

Description

PYRROLE ANTIFUNGAL AGENTS
Field of the invention
This invention relates to pyrrole compounds, combinations and compositions comprising the pyrrole compounds and known antifungal agents, and their therapeutic use in prevention or treatment of fungal diseases. It also relates to the use of the compounds, combinations and compositions as agricultural fungicides.
Background of the invention Invasive fungal infections are well recognised as diseases of the immunocompromised host. Over the last twenty years there have been significant rises in the number of recorded instances of fungal infection (Groll et al., 1996. J Infect 33, 23-32). In part this is due to increased awareness and improved diagnosis of fungal , infection. However, the primary cause of this increased incidence is the vast rise in the number of susceptible individuals. This is due to a number of factors including new and aggressive immunosuppressive therapies, increased survival in intensive care, increased numbers of transplant procedures and the greater use of antibiotics worldwide.
In certain patient groups, fungal infection occurs at high frequency; lung transplant recipients have a frequency of up to 20% colonisation and infection with a fungal organism and fungal infection in allogenic haemopoetic stem cell transplant recipients is as high as 15% (Ribaud et al., 1999, Clin Infect Dis. 28:322-30).
Currently only four classes of antifungal drug are available to treat systemic fungal infections. These are the polyenes (e.g., amphotericin B), the azoles (e.g., ketoconazole or itraconazole), the echinocandins (e.g., caspofungin) and flucytosine. The polyenes are the oldest class of antifungal agent being first introduced in the
1950's. The exact mode of action remains unclear but polyenes are only effective against organisms that contain sterols in their outer membranes. It has been proposed that amphotericin B interacts with membrane sterols to produce pores allowing leakage of cytoplasmic components and subsequent cell death. Azoles work by inhibition of the 14α-demethylase via a cytochrome P450- dependent mechanism. This leads to a depletion of the membrane sterol ergosterol and the accumulation of sterol precursors resulting in a plasma membrane with altered fluidity and structure.
Echinocandins work by the inhibition of the cell wall synthetic eri2yme β-glucan synthase. This leads to abnormal cell wall formation, osmotic sensitivity and cell lysis. Flucytosine is a pyrimidine analogue interfering with cellular pyrimidine metabolism as well DNA5 RNA and protein synthesis. However widespread resistance to flucyotosine limits its therapeutic use.
It can be seen that to date the currently available antifungal agents act primarily against only two cellular targets; membrane sterols (polyenes and azoles) and β-glucan synthase (echinocandins).
Resistance to both azoles and polyenes has been widely reported leaving only the recently introduced echinocandins to combat invasive fungal infections. As the use of echinocandins increases, resistance by fungi will inevitably occur.
The identification of new classes of antifungal agent is required to give the promise of positive therapeutic outcomes to patients.
Summary of the invention
The present inventors have found that certain pyrrole compounds, and combinations of these pyrrole compounds with known antifungal agents, are antifungal. In particular, the compounds inhibit the growth of human pathogenic fungi such as Aspergillus and therefore may be used to treat fungal infection and disease.
Accordingly, the present invention provides a pyrrole derivative of formula (I) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of a fungal disease:
Figure imgf000003_0001
wherein: Rl represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4;
Al represents a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6- ClO aryl or 5- to 12-membered heterocyclyl group;
A2 and A3 are the same or different and represent C3-C6 cycloalkyl or an unsubstituted or substituted C6-C 10 aryl or 5- to 12-membered heterocyclyl group;
A4 is an unsubstituted or substituted 5- to 12-membered heterocyclyl group wherein 1 or 2 ring carbon atoms are replaced with a group selected from >C(=O), >S(=O)2, >C(=NOR7) where R7 is hydrogen or a C 1 -C4 alkyl group, >C=CH2 or >C(-OCH2CH2O-);
Ll represents a bond, a C1-C6 alkylene group in which none, one, two or three -CH2- groups are independently replaced by -O-, -S- or -NR'-, or a 5- to 12-membered heterocyclyl group; L2 represents -NR'-, -O-, -CO-, -OCO-, -OCONR'R"-, -CONR'R"- or -SO2-;
L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH2- groups are independently replaced by -O-, -S- or -NR'-; n is 1 or 2;
R6 represents hydrogen or C1-C4 alkyl; R5 represents an unsubstituted or substituted group selected from C6-C10 aryl, a
5- to 12-membered heterocyclyl group, C1-C8 alkyl and C3-C6 cycloalkyl, hydrogen, halogen or a group of formula -B1-B2 or -B3;
Bl represents an unsubstituted or substituted C6-C10 aryl group;
B2 represents an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group;
B3 is an unsubstituted or substituted 5- to 12-membered heterocyclyl group where 1 or 2 ring carbon atoms are replaced with a group selected from >C(=O), >S(=O)2, >C(=NOR11) where Rl 1 is hydrogen or a C1-C4 alkyl group, >C=CH2 or >C(-OCH2CH2O-); R2 and R3 independently represent C6-C10 aryl, a 5- to 12-membered heterocyclyl group, C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', -SO2NR5R", -SO3H, -NR'R", -NR'COR', -CO2R', -CONR'R", -COR', -OCOR', -CF3, -NSO2R' or -OCONR'R", or a group (Cl-4) alkyl-A5, wherein none, one or two -CH2- groups are independently replaced by -0-,-S- or -NR'- and wherein A5 represents C6-10 aryl or a 5- to 12-membered heterocyclyl group; or R2 and R3 together with the ring atoms to which they are bonded form a 5- to 7-membered, at least partially saturated ring containing a nitrogen atom from the adjacent pyrrole ring, and optionally one or two further heteroatoms selected from N, O and S, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring; R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl,
-OR', -CO2R', -CONR'R", -COR', -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12-membered heterocyclyl group, or a group of formula -Alk6-L5-A12, where AIk6 is a C1-C4 alkylene group, L5 is a group of formula -0-C(=0)-, -C(=0)- or -NR13-C(=0)- and R13 is hydrogen or C1-C4 alkyl, and A12 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group;
Y represents C1-C8 alkylene, C2-C8 alkenylene or C2-C8 alkynylene; Z represents halogen, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', -SO2NR5R", -SO3H, -NR'R", -NR'COR', - NO2, -CO2R', -CONR'R", -COR', -OCOR', -CN, -CF3, -NSO2R', -OCONR'R" or -CR'=N0R"; and R' and R" independently represent hydrogen, C1-C8 alkyl, C2-C8 alkenyl or
C2-C8 alkynyl.
Preferably Al represents a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group.
The present inventors have further found that a number of the compounds of formula (I) have particular activity in inhibiting the growth of a wide variety of fungi such as those of the Aspergillus and Candida genera. The present invention accordingly also provides a pyrrole derivative of formula (IB) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of a fungal disease:
Figure imgf000006_0001
wherein Al, Ll, n, Rl and R3 to R5 are as defined for formula (I) above, and R2 is a group of formula -AIk1-X-R', wherein AIk1 is an unsubstituted or substituted C1-C6 alkylene group, X is a group -O-, -S-, -NR"-, -CO2-, -CONR"-, -OCO-, -OCONR"- or -SO2-, and R' and R" are independently selected from hydrogen and unsubstituted or substituted C1-C4 alkyl.
The invention also provides the use of a derivative or pharmaceutically acceptable salt of formula (I) or (IB) as defined above for the manufacture of a medicament for the prevention or treatment of a fungal disease. The invention also provides an agent for the treatment of a fungal disease comprising a derivative or pharmaceutically acceptable salt of formula (I) or (IB) as defined above. There is further provided a method of treating a subject suffering from or susceptible to a fungal disease, which method comprises administering to said subject an effective amount of a derivative or pharmaceutically acceptable salt of formula (I) or (IB) as defined above. The invention also provides a method of controlling a fungal disease in a plant, which method comprises applying to the locus of the plant a derivative of formula (I) or (IB) as defined above or an agriculturally acceptable salt thereof, optionally in combination with a second antifungal agent. The invention also provides the use of a derivative of formula (I) or (IB) as defined above or an agriculturally acceptable salt thereof, optionally in combination with a second antifungal agent, as an agricultural fungicide.
The invention also provides a pharmaceutical combination comprising a combination of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof with a second antifungal agent. Also provided is a pharmaceutical composition comprising a combination of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof with a second antifungal agent.
In the combinations of the invention the pyrrole derivative of formula (I) or (IB) or pharmaceutically acceptable salt thereof has an antifungal effect and is sometimes referred to as the "first antifungal agent", to distinguish it from the second antifungal agent described later, hi the combinations, compositions and products of the invention, the first antifungal agent is different from the second antifungal agent.
In the combination therapies of the invention, preferably the pyrrole derivative of formula (I) or (IB) or pharmaceutically acceptable salt thereof and the second antifungal agent are formulated for simultaneous or successive administration.
Preferably the combination of the pyrrole derivative of formula (I) or (IB) or pharmaceutically acceptable salt thereof and the second antifungal agent are for use in the treatment or prevention of a fungal disease.
The invention further provides a product comprising a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent for separate, simultaneous or sequential use in the prevention or treatment of a fungal disease.
There is also provided a pharmaceutical composition comprising (i) a pyrrole of formula (I) or (IB) or a pharmaceutically acceptable salt thereof, (ii) a second antifungal agent, and (iii) a pharmaceutically acceptable carrier or diluent. Preferably the pharmaceutical composition is for use in the treatment or prevention of a fungal disease. The invention also provides the use of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent in the manufacture of a medicament for use in the treatment or prevention of fungal disease. The invention also provides the use of a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for administration with a second antifungal agent in the treatment or prevention of fungal disease. Alternatively the invention provides the use of an antifungal agent
(corresponding to the second antifungal agent mentioned above) in the manufacture of a medicament for administration with a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof in the treatment or prevention of fungal disease. There is also disclosed a method of treating a fungal disease which comprises administering a therapeutically effective amount of a first antifungal agent which is a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent. Furthermore, the invention relates to a kit comprising, in admixture or in separate containers, a pyrrole derivative of formula (I) or (IB) or a pharmaceutically acceptable salt thereof and a second antifungal agent.
The invention also provides a compound, which is a pyrrole derivative of formula (I) or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a human or animal body by therapy. In this embodiment, R6 is hydrogen; Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group; R2 is as defined above with the exception that when R2 is cycloalkyl it is an unsubstituted cycloalkyl group; R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -OR', -CONR'R", -COR', -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12-membered heterocyclyl group, or a group of formula -Alk6-L5-A12, where AIk6 is a C1-C4 alkylene group, L5 is a group of formula -O-C(=O)-, -C(=O)- or -NR13-C(=O)- and R13 is hydrogen or C1-C4 alkyl, A12 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group and R', R", Y and Z are as defined above; with the provisos that (i) when Al is a bond, -Ll-Rl is not hydrogen, (ii) when Al is a bond, R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted benzyl or substituted phenethyl, (iii) when Al is a bond, R6 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll, L3 and Ll-Rl represents an unsubstituted or substituted Cl- C4 alkyl group; and (iv) the compound is not: N-[I -(4-methyl-3 -penten- 1 -yl)-4-piperidinyl]- 1 H-pyrrole-2-acetamide,
5-Thia-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 3 -(hydroxymethyl)-8 -oxo-7- [2-(2- pyrrolyl)glyoxylamido]-, acetate ester,
2-Oxo-N-[2-(5-piperidin-l-ylmethyl-lH-ρyrrol-2-yl)-ethyl]-2-[5-(lH-pyrrol-2- ylmethyl)- 1 H-pyrrol-2-yl] -acetamide, 2-Oxo-N-[2-(lH-pyrrol-2-yl)-ethyl]-2-[5-(lH-pyrrol-2-ylmethyl)-lH-pyrrol-2-yl]- acetamide, 5-Arninooxalyl-3 -(2-methoxycarbonyl-ethyl)-4-methoxycarbonylmethyl- 1 H-pyrrole-2- carboxylic acid tert-butyl ester,
(2S,5R,6R)-353-Dimethyl-6-[2-(l-methyl-lH-ρyrrol-2-yl)-2-oxo-acetylamino]-7-oxo-4- thia- 1 -aza-bicyclo [3.2.0]heptane-2-carboxylic acid, (2S,5R,6R)-3 ,3-Dimethyl-7-oxo-6-[2-oxo-2-(l -phenyl- 1 H-ρyrrol-2-yl)-acetylamino] -4- thia- 1 -aza-bicyclo [3.2.0]heptane-2-carboxylic acid,
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[2-oxo-2-(lH-pyrrol-2-yl)-acetylamino]-4-tbia-l- aza-bicyclo[3.2.0]heptane-2-carboxylic acid,
Potassium; (2S,5R,6R)-353-dimethyl-7-oxo-6-[2-oxo-2-(l-ρb.enyl-lH-ρyrrol-2-yl)- acetylamino] -4-thia- 1 -aza-bicyclo [3.2.0]heptane~2-carboxylate,
Potassium; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[2-oxo-2-(lH-pyrrol-2-yl)-acetylamino]-
4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate, or
Potassium; (2S,5R,6R)-3,3-dimethyl-6-[2-(l-methyl-lH-pyrrol-2-yl)-2-oxo- acetylamino]-7-oxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate. The invention also provides a compound, which is a pyrrole derivative of formula (I) or a pharmaceutically or agriculturally acceptable salt thereof:
Figure imgf000009_0001
(I) wherein Rl, Ll, n, R3 and R5 are as defined above; Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl,
5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group; R6 represents hydrogen;
R2 represents C6-C10 aryl, a 5- to 12-membered heterocyclyl group other than benzothiophene, unsubstituted C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2- C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', -
SO2NR5R", -SO3H, -NR'R", -NR' COR', -CO2R', -CONR'R", -COR', -OCOR', -CF3, -NSO2R' or -OCONR'R", or a group (C 1-4) alkyl-A5, wherein none, one or two -CH2- groups are independently replaced by -O-,-S- or -NR'- and wherein A5 represents C6- 10 aryl or a 5- to 12-membered heterocyclyl group; or R2 together with R3 and the ring atoms to which they are bonded form a 5- to 7-membered, at least partially saturated ring containing a nitrogen atom from the adjacent pyrrole ring, and optionally one or two further heteroatoms selected from N, O and S, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring; wherein when R2 represents aryl or heterocyclyl it is unsubstituted or substituted with one or more unsubstituted substituents selected from halogen, -NR'R", -CO2R', - CONR'R", -OCONR'R", -OCOR', -COCF3 and hydroxyl, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl,
-OR', -CO2R', -CONR'R", -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12- membered heterocyclyl group, or a group of formula -Alk6-L5-A12, where AIk6 is a Cl- C4 alkylene group, L5 is a group of formula -O-C(=O)-, -C(=O)- or -NRl 3 -C(O)- and Rl 3 is hydrogen or C1-C4 alkyl, and Al 2 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group; wherein Y, Z and, unless otherwise specified, R' and R' ' are as defined above; with the provisos that
- when Al is a bond, Ll-Rl is not hydrogen;
- when Al is a bond, R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted benzyl or substituted phenethyl;
- when Al is a bond, R2 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll, L3 and Ll-Rl represents an unsubstituted or substituted C1-C4 alkyl group; and - the compound is not
N-(4-Bromo-phenyl)-2-[l-(2-chloro-4-nitro-phenyl)-lH-pyrrol-2-yl]-2-oxo-acetamide, 2-[l-(2-chloro-4-nitro-phenyl)-lH-pyrrol-2-yl-N-(4-chloro-phenyl)-2-oxo-acetamide, 3-[2-(4-Fluoro-phenylaminooxalyl)-pyrrol-l-yl]-propionic acid, N-Benzo [1,3] dioxol-5 -yl-2- [ 1 -(2-cy ano-ethyl)- 1 H-pyrrol-2-yl] -2-oxo-acetamide, 2-[l-(2-Cyano-ethyl)-lH-pyrrol-2-yl]-N-(4-fluoro-phenyl)-2-oxo-acetamide, N-(2,4-Difluoro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 5 N-(2,3-Difluoro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 2-(l -Methyl- lH-pyrrol-2-yl)-2-oxo-N-(4-phenoxy-phenyl)-acetamide, N-(2-Methoxy-4-nitro-phenyl)-2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-(2,3-Dichloro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 4-[2-(l-Methyl-lH-pyrrol-2-yl)-2-oxo-acetylamino]-benzoic acid methyl ester,
0 2-( 1 -Methyl- 1 H-pyrrol-2-yl)-2-oxo-N-(2-trifluoromethyl-phenyl)-acetamide, 2-( 1 -Methyl- 1 H-pyrrol-2-yl)-2-oxo-N-(3 -trifluoromethyl-phenyl)-acetamide, N-(3 ,5-Dichloro-phenyl)-2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-(2,4-Dichloro-phenyl)-2-(l -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-( 1 -Methyl- 1 H-pyrrol-2-yl)-2-oxo-N-phenyl-acetamide,
5 N-(4-Chloro-phenyl)-2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
3-[2-(4-Bromo-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
3-[2-(4-Chloro-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
!0 3-[2-(2-trifluorcmethyl-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
3 - [2-(4-trifluoromethyl-phenylaminooxalyl)-pyrrol- 1 -yl] -thiophene-2-carboxylic acid methyl ester, 3-[2-(3-trifluoromethyl-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid
!5 methyl ester,
3-[2-(4-Fluoro-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
N-[I -(4-methyl-3 -penten- 1 -yl)-4-piperidinyl] - 1 H-pyrrole-2-acetamide,
3-(2-Allylaminooxalyl-pyrrol-l-yl)-thiophene-2-carboxylic acid methyl ester,
10 3-(2-Propylaminooxalyl-pyrrol-l-yl)-thiophene-2-carboxylic acid methyl ester,
5-TMa-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-(hyάroxymethyl)-8-oxo-7-[2-(2- pyrrolyl)glyoxylamido]-, acetate ester
3 - { 2- [2-(3 ,4-Dimethoxy-phenyl)-ethylaminooxalyl]-pyrrol- 1 -yl } -propionic acid 2- [ 1 -(2-Cyano-ethyl)- 1 H-pyrrol-2-yl] -N-fαran-2-ylmethyl-2-oxo-acetamide
2-[ 1 -(2-Cyano-ethyl)- 1 H-ρyrrol-2-yl]-N- [2-(3 ,4-dimemoxy-phenyl)-ethyl]-2-oxo- acetamide
2-Oxo-N-[2-(5-ρiperidin-l-ylmethyl-lH-ρyrrol-2-yl)-ethyl]-2-[5-(lH-pyrrol-2- ylmethyl)- 1 H-pyrrol-2-yl]-acetamide 2-Oxo-N-[2-(lH-pyrrol-2-yl)-ethyl]-2-[5-(lH-pyrrol-2-ylmethyl)-lH-pyrrol-2-yl]- acetamide
5- Aminooxalyl-3 -(2-methoxycarbonyl-ethyl)-4-methoxycarbonylmethyl- 1 H-pyrrole-2- carboxylic acid tert-butyl ester
N-(3-Nitro-biphenyl-4-yl)-2-oxo-2-(lH-pyrrol-2-yl)-acetamide (2S55R,6R)-3,3-Dime%l-6-[2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetylamino]-7-oxo-4- tbia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5RJ6R)-33-Dimethyl-7-oxo-6-[2-oxo-2-(l-phenyl-lH-pyrrol-2-yl)-acetylamino]-4- thia- 1 -aza-bicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-33-Dimethyl-7-oxo-6-[2-oxo-2-(lH-pyrrol-2-yl)-acetylamino]-4-tbia-l- aza-bicyclo[3.2.0]heptane-2-carboxylic acid
Potassium; (2S35R,6R)-353-dimethyl-7-oxo-6-[2-oxo-2-(l-phenyl-lH-pyrrol-2-yl)- acetylamino]-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate
Potassium; (2S55R,6R)-3,3-dimethyl-7-oxo-6-[2-oxo-2-(lH-pyrrol-2-yl)-acetylamino]-
4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate or Potassium; (2S,5R,6R)-3,3-dimethyl-6-[2-(l-methyl-lH-pyrrol-2-yl)-2-oxo- acetylamino]-7-oxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate.
The invention also provides a compound of formula (IB) as defined above or a pharmaceutically or agriculturally acceptable salt thereof, provided that the compound is not 3-[2-(4-fluoro-phenylaminooxalyl)-pyrrol-l-yl]-propionic acid or 3-{2-[2-(3,4- Dimethoxy-phenyl)-ethylaminooxalyl]-pyrrol-l-yl}-propionic acid.
Pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent, optionally together with a second antifungal agent, are also provided. Compositions comprising a compound of the invention and an agriculturally acceptable carrier or diluent, optionally together with a second antifungal agent, are also provided.
Detailed description of the invention
As used herein, a C1-C8 alkyl group or moiety can be linear, branched or cyclic but is preferably linear. It is preferably a C1-C6 alkyl group, more preferably a C1-C4 alkyl group, most preferably a C1-C3 alkyl group. Suitable such alkyl groups and moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl and tert-butyl, as well as pentyl, e.g. CH2C(CH3)3, hexyl, heptyl and octyl and isomers thereof. As used herein, a C1-C8 alkylene group or moiety is a divalent alkyl group or moiety as defined above, for example a C1-C4 alkylene group or moiety such as methylene, ethylene or propylene.
As used herein, a C2-C8 alkenyl group or moiety can be linear, branched or cyclic but is preferably linear. It contains one or more carbon-carbon double bonds. It is preferably a C2-C6 alkenyl group, more preferably a C2-C4 alkenyl group, most preferably a C2-C3 alkenyl group. Suitable such alkenyl groups and moieties include vinyl, allyl, propenyl, butenyl, e.g. CH2C(Me)=CH2, pentenyl, hexenyl, heptenyl and octenyl and isomers thereof. As used herein, a C2-C8 alkynyl group or moiety can be linear or branched but is preferably linear. It contains one or more carbon-carbon triple bonds. It is preferably a C2-C6 alkynyl group, more preferably a C2-C4 alkynyl group, most preferably a C2- C3 alkynyl group. Suitable such alkynyl groups and moieties include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl and octynyl and isomers thereof. An alkyl, alkenyl or alkynyl group or moiety can be substituted or unsubstituted.
Typically, it carries up to three substituents, e.g. one or two substituents. Suitable substituents are preferably themselves unsubstituted and include halogen such as fluorine, hydroxy, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy such as methoxy, ethoxy and propoxy, -S(C1-C4 alkyl) such as -SMe5-CO2H, -CO2(C 1-C4 alkyl), phenyl, 5- or 6-membered heterocyclyl such as pyridinyl,
-CONR'R" and -NRZCO(C 1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl. Preferably R' and R" are the same or different and represent hydrogen or methyl. More preferably R' represents hydrogen and R" represents methyl. Examples of these substituents include unsubstituted substituents such as halogen (for example fluorine), hydroxy, amino, -S(C1-C4 alkyl) (for example -SMe), phenyl, pyridinyl, -COO(C 1-C4 alkyl) (for example -COOMe, -COOEt and -COOPr), -CONR'R' ' (for example -CONHMe)5 -NR'C0(C 1 -C4 alkyl) (for example -NHCOMe), (C1-C4 alkyl)amino and di(Cl-C4 alkyl)amino, and C1-C4 alkoxy such as methoxy, ethoxy or propoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or ethoxy. C1-C4 alkoxy, such as methoxy or ethoxy, halogen, such as fluorine, and hydroxy are preferred. Other preferred groups include unsubstituted phenyl or pyridinyl, -NMe2, -COOR' where R' is C1-C3 alkyl, -CONHMe and -NHCOMe.
In a preferred embodiment, suitable substituents on an alkyl, alkenyl or alkynyl group or moiety are preferably themselves unsubstituted and include halogen such as fluorine, hydroxy, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy such as methoxy or ethoxy, -CO2H and -CO2(C 1-C4 alkyl). Preferred examples of these substituents include unsubstituted substituents such as halogen (for example fluorine), hydroxy, amino, (C1-C4 alkyl)amino and di(Cl-C4 alkyl)amino, and C1-C4 alkoxy such as methoxy or ethoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or ethoxy. Most preferred are C1-C4 alkoxy, such as methoxy or ethoxy, halogen, such as fluorine, and hydroxy.
As used herein, a C3-C6 cycloalkyl group is typically a C4, C5 or C6 cycloalkyl group, more preferably a C5 or C6 cycloalkyl group. Typically a cycloalkyl group is unsubstituted or substituted with up to three substituents, e.g. one or two substituents. Suitable substituents include C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Z and -Y-Z wherein Y and Z are as hereinbefore defined. Where present, preferably the substituents are themselves unsubstituted. Typically, a cycloalkyl group is unsubstituted.
When Y is C1-C8 alkylene, it is preferably C1-C4 alkylene, more preferably methylene or ethylene. When Y is C2-C8 alkenylene, it is preferably C2-C4 alkenylene, more preferably ethenylene. When Y is C2-C8 alkynylene, it is preferably C2-C4 alkynylene, more preferably ethynylene.
When R' or R" is C1-C8 alkyl, it is preferably C1-C4 alkyl, more preferably methyl or ethyl. When R' or R" is C2-C8 alkenyl, it is preferably C2-C4 alkenyl, more preferably ethenyl.
When R' or R" is C2-C8 alkynyl, it is preferably C2-C4 alkynyl, more preferably ethynyl.
As used herein, an aryl group or moiety is typically phenyl or naphthyl, more preferably phenyl.
As used herein and unless otherwise stated, a heterocyclyl group or moiety is a saturated or unsaturated, 5- to 12-membered ring system in which the ring contains at least one heteroatom. Typically, the ring contains up to three or four heteroatoms, e.g. one or two heteroatoms, selected from O, S and N. Thus, a heterocyclyl group or moiety is typically a 5- to 12-membered ring containing one, two or three heteroatoms selected from O, S and N. Suitable such heterocyclyl groups and moieties include, for example, monocyclic saturated 5- to 8-membered rings, more preferably 5- to 7- membered rings, such as tetrahydrofuranyl, piperidinyl, oxazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, dioxolanyl, piperidonyl, azepanyl, piperazinyl, tetrahydropyranyl and 1,4-diazepanyl, more preferably pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, piperidinyl, azepanyl and 1,4-diazepanyl, more preferably still more preferably pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, piperidinyl, azepanyl and 1,4-diazepanyl; monocyclic at least partially unsaturated 5- to 8-membered rings, more preferably 5- to 6-membered rings, such as furanyl, pyrrolyl, thiophenyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and di- and tetrahydropyridinyl, e.g. oxazolyl, isoxazolyl, imidazolyl, furanyl, thiophenyl, pyrimidinyl or pyridinyl; bicyclic 8- to 10-membered ring systems such as indolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzopyrazolyl, benzothiazolyl, benzotriazolyl, quinolinyl, quinazolinyl (including isomers thereof, e.g. isoquinolinyl), quinoxalinyl, cinnolinyl, purinyl and cyclopentapyridines which may optionally be partially unsaturated, for example dihydroindolyl; and tricyclic 11- or 12- membered ring systems such as acridinyl, pteridinyl and benzathiazinyl. Particular examples of such heterocyclyl groups and moieties include monocyclic saturated 5- to 8-membered rings, more preferably monocyclic saturated 5- to 7-membered rings such as pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl, piperidinyl and 1,4- diazepanyl; and monocyclic at least partially unsaturated 5- to 8-membered rings, more preferably monocyclic unsaturated 5- to 6-membered rings such as oxazolyl, isoxazolyl, imidazolyl, furanyl, thiophenyl, pyrimidinyl or pyridinyl. Particular examples of bicyclic 8- to 10-membered ring systems include indolyl, benzofuranyl, quinolinyl and isoquinolinyl, for example benzofuranyl, quinolinyl and isoquinolinyl. A heterocyclyl or aryl group or moiety may be substituted or unsubstituted.
Each ring atom may be unsubstituted or may carry one or two substituents. If desired, a nitrogen atom may be disubstituted and a sulphur atom may be substituted, providing a charged heteroatom. Typically, a heterocyclyl or aryl group or moiety carries up to three substituents, e.g. one or two substituents. The heterocycle may be connected to the remainder of the molecule by a bond to any of its available ring positions.
Suitable substituents include C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, Z and -Y-Z wherein Y and Z are as hereinbefore defined. Preferred substituents on an aryl or heterocyclyl group or moiety are unsubstituted substituents selected from halogen, -CO2R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO2R', -OCONR'R" and -CR'=N0R", or C1-C6 alkyl or C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four, for example one, two, or three, for example one, unsubstituted group selected from halogen, hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C4 alkyl), preferably hydroxyl, C1-C4 alkoxy and -0-(Cl- C4 alkyl)-0-(Cl-C2 alkyl). Substituents on Al when Al is other than a bond can also include substituents of formula -(C1-C2 alkyl)-0-(Cl-C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups. Preferred such substituents which are specific to the Al group are those of formula
-CH2-O-(C2-C3 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or methyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with one methyl group. Unless otherwise specified, aryl and heterocyclyl groups axe not substituted with further aryl or heterocyclyl groups or with substituents containing further aryl or heterocyclyl groups. Examples of more preferred substituents on an aryl or heterocyclyl group or moiety are unsubstituted substituents selected from halogen, -NR'R", -CO2R', -CONR'R", -OCONR'R", -OCOR', -COCF3, hydroxyl and cyano, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl, unsubstituted Cl- C4 alkoxy or unsubstituted -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl) group; wherein R' and R" are independently selected from hydrogen, unsubstituted C 1 -C4 alkyl and C 1 -C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. Typically none or one cyano substituent is present.
As used herein, a halogen is typically chlorine, fluorine, bromine or iodine, and is preferably chlorine, fluorine or bromine, more preferably chlorine or fluorine. Al preferably represents a bond, a phenyl, naphthyl, a 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group, e.g. an unsaturated 8- to 10-membered bicyclic heterocyclyl group. More preferably Al represents a bond or a phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl group. Preferably Al is other than a bond. Al is typically other than a penicillin derivative, e.g. other than an oxo-thiaazabicyclo-heptane or -octane group. In a preferred embodiment Al represents phenyl or a 5- or 6-membered heterocyclyl group, more preferably Al represents phenyl, pyridyl or piperidinyl. Most preferably Al represents phenyl.
Al may be unsubstituted or substituted with one, two or three substituents selected from the unsubstituted groups halogen, -CO2R', -CONR'R", -OCOR', hydroxyl, cyano, -NR'R", -COR', NSO2R', -O(C2-C4 alkenyl), -C2-C4 alkenyl, -SO2R', -OCONR'R" and -CR'=N0R", and from C1-C6 alkyl and C1-C4 alkoxy which are unsubstituted or substituted with a further unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently hydrogen or C1-C4 alkyl. Al may also be substituted with a group of formula -(C1-C2 alkyl)-0-(Cl-C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups. When a substituent of formula -(C1-C2 alkyl)-O-(Cl-C4 alkyl)-NR'R" is present, preferably there are no other substituents on the Al group. Typically only one cyano group is present. Preferred substituents are unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, - CO2H and halogen, and a group of formula -(C1-C2 alkyl)-O-(Cl-C4 alkyl)-NR'R". More preferred substituents are unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO2H and halogen. In one embodiment, Al is unsubstituted. n is one or two, preferably one. When n is 2, preferably Al is phenyl, each Ll is the same or different and represents piperazinyl or methylene, and each Rl is the same or different and represents pyridinyl or morpholinyl.
Ll preferably represents a bond, a 5 -to 7-membered heterocyclyl group or a C1-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group.
When Ll represents a 5- to 7-membered heterocyclyl group, it may be linked to Al and Rl via a carbon atom or a heteroatom. Preferred 5- to 7-membered heterocyclyl groups are saturated groups which contains at least one nitrogen atom, for example one or two nitrogen atoms, wherein the heterocyclyl group is linked to at least one of Al and Rl, preferably both of Al and Rl, via a nitrogen atom. Examples of suitable heterocycles for Ll include piperazinyl, pyrrolidinyl, oxazolyL morpholinyl, piperidinyl and 1,4-diazepanyl. Preferred examples of suitable heterocycles for Ll include piperazinyl and 1,4-diazepanyl, especially piperazinyl. When Ll represents a 5- to 7- membered heterocyclyl group, it is typically unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen. Hydroxy substituents are preferred. Preferably, when Ll represents a 5- to 7-membered heterocyclyl group, it is unsubstituted.
Ll is most preferably a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C1-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group. In one embodiment, Ll is a saturated 5- to 7- membered heterocyclyl group, preferably a piperazinyl or 1,4-diazepanyl group.
When Ll is an unsubstituted C1-C6 alkylene group wherein none, one or two - CH2- groups are independently replaced with -O- or -NR'-, suitable groups include C4 or C5 alkylene groups where two -CH2- moieties (preferably one or both terminal -CH2- moieties) are replaced by -O- or -NR'- where R' is hydrogen or unsubstituted C1-C2 alkyl. For example, preferred Ll groups in this category include -NMe-CH2-CH2-NMe-, -NH-CH2-CH2-O-, -0-CH2-CH2-NMe-, -0-CH2-CH2-O-, -NMe-CH2-CH2-NH-, -NH-CH2-CH2-NH-, -NH-CH2-CH2-NMe-, -CH2-CH2-CH2-NMe- and -NMe-CH2-CH2-CH2-NMe-. Most preferably Ll is piperazinyl.
Rl preferably represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(Cl -C4 alkyl), or a group -A2, -L2-A2, - L3-A2, -A2-L3-A3 or -A4. More preferably Rl represents hydrogen, an unsubstituted group selected from C 1 -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C 1 -C4 alkyl) and -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. When Ll is a bond, Rl preferably represents hydrogen or a group -A2, L2-A2, A2-L3-A3 or A4. When Ll is other than a bond, Rl is preferably hydrogen, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, unsubstituted -CO-(C l-C4-alkyl), unsubstituted -SO2(C 1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or -A2-L3-A3. In one embodiment, Rl is preferably a group -A2, -L2-A2, -L3-A2 or -A2-L3-A3, more preferably a group -A2.
In a preferred embodiment Rl represents unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. More preferably Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. When Ll is a bond, Rl preferably represents A2, L2-A2, A2-L3-A3 or A4. When Ll is other than a bond, Rl is preferably a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, unsubstituted -SO2(C1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or -A2-L3-A3.
When Rl represents an alkyl, alkenyl or alkynyl group it is preferably C1-C6 alkyl, C2-C6 alkenyl or C3-C6 alkynyl, more preferably C1-C6 alkyl (e.g. C3 or C4 alkyl), C3-C6 alkenyl or C3-C6 alkynyl. The alkyl, alkenyl and alkynyl groups are unsubstituted or substituted with 1, 2 or 3 substituents selected from halogen (e.g. fluorine), hydroxyl, amino, C1-C4 alkoxy, CO2H and Cθ2(Cl-C4 alkyl). Halogen, e.g. fluorine, is preferred. The substituents are themselves unsubstituted. Preferably, when Rl represents an alkyl, alkenyl or alkynyl group it is unsubstituted.
A2 preferably represents C3-C6 cycloalkyl, phenyl or a 5- to 12-membered heterocyclyl group. Preferably A2 represents phenyl or a 5- or 6-membered heterocyclyl group. Preferred heterocyclyl groups include monocyclic, saturated or unsaturated, 5- to 6-membered rings, each of which may contain one, two or three, e.g. one or two, heteroatoms selected from N, O and S. Unsaturated 5- or 6-membered rings include oxazolyl, isoxazolyl, imidazolyl, furanyl, thiophenyl, pyrimidinyl and pyridinyl, preferably pyridinyl. Saturated rings are preferably 6-membered rings, for example piperidinyl, morpholinyl and tetrahydropyranyl, e.g. morpholinyl or tetrahydropyranyl. In one embodiment, A2 represents phenyl or pyridinyl, especially pyridinyl. A2 may be unsubstituted or substituted by one, two or three substituents.
Examples of suitable substituents are unsubstituted substituents selected from halogen, -CO2R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO2R', -OCONR'R" and -CR'=N0R", or C1-C6 alkyl or C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four, for example one, two, or three, for example one, unsubstituted group selected from halogen, hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C4 alkyl), preferably hydroxyl, C1-C4 alkoxy and -0-(Cl- C4 alkyl)-0-(Cl-C2 alkyl).
Preferred substituents on A2 are unsubstituted substituents selected from halogen, -NR'R", -CO2R', -CONR'R", -OCONR'R", -OCOR', -COCF3, hydroxyl and cyano, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl, unsubstituted C1-C4 alkoxy or unsubstituted -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl) group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. Typically none or one cyano substituent is present.
Particularly preferred substituents on A2 are halogen, -COCF3, -OCONR'R" and -NR'R", and C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-O(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. Most preferred substituents are C1-C2 alkyl and C1-C2 alkoxy, especially methyl. In one embodiment, L2 represents -SO2-.
In one embodiment, L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH2- moieties are independently replaced with -O- or -NR'- wherein R' represents hydrogen or unsubstituted C1-C4 alkyl. In another embodiment, L3 represents a bond or an unsubstituted C1-C4 alkylene group. Preferably, L3 represents a bond or unsubstituted methylene, ethylene or propylene, e.g. unsubstituted methylene or ethylene, more preferably unsubstituted methylene. In the group -L3-A2, L3 preferably represents unsubstituted methylene, ethylene or propylene, e.g. unsubstituted methylene or ethylene, more preferably unsubstituted methylene.
In one embodiment, A3 represents phenyl or a 5- to 12-membered heterocyclyl group. Preferred heterocyclyl groups include monocyclic, unsaturated or saturated 5- to 6-membered rings, each of which may contain one, two or three, e.g. one or two, heteroatoms selected from N5 O and S. Saturated 5- or 6-membered rings are preferred, e.g. morpholinyl, tetrahydropyranyl, piperidinyl or piperazinyl, in particular morpholinyl and piperazinyl. A3 may be unsubstituted or substituted by one, two or three unsubstituted groups selected from C1-C4 alkyl, C1-C4 alkoxy, halogen, -CO2R', -CONR'R", -OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), -C2-C4 alkenyl, -SO2R', -OCONR'R" and-CR'=N0R", wherein R' and R" are independently hydrogen or C1-C4 alkyl. Typically only one cyano group is present. Preferred substituents are C1-C4 alkyl, C1-C4 alkoxy and halogen.
A4 is preferably an unsubstituted or substituted 5- to 6-membered heterocyclyl group wherein 1 ring carbon atom has been replaced with a group selected from >C(=0), >S(=0)2, >C(=N0R7) where R7 is hydrogen or a C1-C4 alkyl group, >C=CH2 or >C(-OCH2CH2O-). Preferably A4 is an unsubstituted or substituted 5- to 6- membered heterocyclyl group wherein 1 ring carbon atom has been replaced with >C=CH2. Preferred A4 groups include unsubstituted or substituted dioxothiomorpholinyl, methoxyiminopiperidinyl, memoxyiminopyrrolidinyl, methylenepiperidinyl, dioxoazaspirodecyl and oxadihydropyrazolyl groups. The A9 groups can be unsubstituted or substituted; more preferably they are unsubstituted. Unsubstituted methylenepiperidinyl is preferred.
In one embodiment, R6 is hydrogen or methyl, more preferably R6 is hydrogen. In one embodiment, R5 is hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, a C3-C6 cycloalkyl group, an unsubstituted C1-C8 alkyl or a C1-C8 alkyl substituted with a C1-C4 alkoxy group. When R5 is C1-C8 alkyl substituted with C1-C4 alkoxy, preferably it is -(C1-C2 alkyl)-O(Cl-C2 alkoxy), more preferably -CH2-CH2-OMe. More preferably R5 is hydrogen, phenyl, a monocyclic 5- to 8- membered heterocyclyl ring, a C3 -C6 cycloalkyl group or unsubstituted C1-C8 alkyl. The heterocyclyl ring is typically pyridinyl, thiophenyl, furanyl, tetrahydropyranyl or piperidinyl. The cycloalkyl group is typically cyclobutyl, which is itself preferably unsubstituted. The phenyl and heterocyclyl groups are unsubstituted or substituted with one, two or three unsubstituted substituents selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, -CO2R', -CONR'R", -OCOR' or cyano, wherein R' and R" are independently selected from hydrogen and C1-C4 alkyl. Typically only one cyano substituent is present. Most preferably R5 is hydrogen or an unsubstituted phenyl.
In another embodiment, R5 is hydrogen, unsubstituted or substituted phenyl, unsubstituted C3-C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or cyano, e.g. halogen, unsubstituted C1-C4 alkyl or unsubstituted C1-C4 alkoxy. In this embodiment R5 is, for example, hydrogen, unsubstituted or substituted phenyl or unsubstituted pyridinyl, thiophenyl or furanyl. Preferably in this embodiment, R5 is hydrogen, unsubstituted or substituted phenyl, unsubstituted C3-C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or cyano, e.g. halogen, unsubstituted C1-C4 alkyl or unsubstituted C1-C4 alkoxy, or R5 is a C1-C8 alkyl group substituted with a C1-C4 alkoxy group. In this embodiment R5 is, for example, hydrogen, unsubstituted or substituted phenyl or unsubstituted pyridinyl, thiophenyl or furanyl, or is a group -CH2-CH2-OMe. In another embodiment, R5 is a group -B1-B2 or -B3. When R2 is -B1-B2, Bl is typically an unsubstituted or substituted phenyl group. More preferably Bl is an unsubstituted phenyl group. When R5 is -B1-B2, B2 is typically an unsubstituted or substituted phenyl or 5- to 6-membered heterocyclyl group, more preferably an unsubstituted or substituted phenyl, piperazinyl or morpholinyl group, e.g. an unsubstituted or substituted phenyl or piperazinyl group. When substituted, preferred substituents are 1 or 2 groups selected from halogen atoms and C1-C4 alkyl and C1-C4 alkoxy groups, more preferably halogen atoms or C1-C2 alkyl or C1-C2 alkoxy groups, more preferably C1-C2 alkyl groups such as methyl. When R5 is B3, typically B3 is a 5- to 6-membered heterocyclyl group where 1 or 2 ring carbon atoms are replaced with >C(O>, >S(=O)2-, >C(=NOR11)5 >C(NR11), >C(=CH2) or >C(-OCH2CH2O-), where Rl 1 is hydrogen or C1-C4 alkyl. Preferably Rl 1 is hydrogen or C1-C2 alkyl, more preferably hydrogen or methyl. When R5 is B3, more preferably B3 is a 5- to 6-membered heterocyclyl group where 1 ring carbon atom is replaced with >C(=O)-, >S(=O)2-, >C(=NOR11), >C(NR11), >C(=CH2) or
>C(~0CH2CH2O), where RIl is hydrogen or C1-C2 alkyl, more preferably 1 ring carbon atom is replaced with >C(=O). A preferred B3 group is oxo-dihydropyridinyl. When R5 is B3, B3 can be unsubstituted or substituted. Preferably it is unsubstituted. In one embodiment, R2 and R3 independently represent C6-C10 aryl, a 5- to 12- membered heterocyclyl group, C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2- C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', -SO2NR5R", -SO3H, -NR'R", -NR' COR', -CO2R', -CONR'R", -COR', -OCOR', -CF3, -NSO2R' or -OCONR'R", or a group (Cl -4) alkyl-A5, wherein none, one or two -CH2- groups are independently replaced by -0-,-S- or -NR'- and wherein A5 represents C6-10 aryl or a 5- to 12-membered heterocyclyl group;
When R2 and R3 represent or contain C6-C10 aryl or a 5- to 12-membered heterocyclyl group, the aryl or heterocyclyl group is typically phenyl or a 5- or 6- membered, saturated or unsaturated heterocyclyl group. Typically none or one of R2 and R3 represents or contains an aryl or heterocyclyl group. Examples of suitable heterocyclyl groups include saturated rings such as pyrrolidinyl, morpholinyl, piperazinyl, tetrahydropyranyl and piperidinyl, and unsaturated rings such as oxazolyl, furanyl, thiophenyl, pyridinyl and pyrimidinyl, e.g. furanyl, thiphenyl, pyridinyl and pyrimidinyl. Bicyclic 8- to 10-membered rings may also be present at R2 and R3, for example indolyl, benzofuranyl and benzothiophenyl rings.
An aryl or heterocyclyl group or moiety on R2 or R3 may be unsubstituted or substituted on any ring atom. Typically it is unsubstituted or substituted with one, two or three substituents. Examples of suitable substituents are unsubstituted substituents selected from halogen, -CO2R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO2R', -OCONR'R" and -CR'=NOR", or C1-C6 alkyl or C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four, for example one, two, or three, for example one, unsubstituted group selected from halogen, hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C4 alkyl), preferably hydroxyl, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl).
Preferred substituents are unsubstituted substituents selected from halogen, -NR'R", -CO2R', -CONR'R", -OCONR'R", -OCOR', -COCF3 and hydroxyl, or Cl- C6 alkyl or Cl -C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. More preferred substituents are halogen, unsubstituted C1-C4 alkyl (e.g. methyl) and unsubstituted C1-C4 alkoxy groups, in particular methyl.
In this embodiment, R2 preferably represents phenyl, hydrogen, -COO(C 1-C4 alkyl), halogen, unsubstituted C3-C6 cycloalkyl, or a C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkoxy group which is unsubstituted or substituted with -SMe, -SEt, hydroxyl, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R", -NR'CO(C1-C4 alkyl), unsubstituted C1-C4 alkoxy or C1-C4 alkoxy substituted with -OMe or -OEt, where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -0-, -S- or -NR'- and wherein A5 represents phenyl, pyridinyl or oxazolyl. More preferably, R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C2-C4 alkenyl, unsubstituted C1-C4 alkyl, or C1-C4 alkyl or C2-C4 alkenyl substituted with -OMe, -OEt, -OPr, -OBu, -OCH2CH2OMe5 -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl- A5, wherein none or one -CH2- groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C4 alkyl and C1-C4 alkoxy.
In this embodiment, more preferably R2 represents phenyl, hydrogen, halogen, unsubstituted C2-C4 alkenyl, unsubstituted C3-C6 cycloalkyl, or a C1-C4 alkyl or Cl- C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt. More preferably, R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt. Most preferably, R2 represents unsubstituted C1-C4 alkyl, e.g. methyl.
In this embodiment, R3 preferably represents hydrogen, halogen, unsubstituted phenyl, unsubstituted C2-C4 alkenyl, or a C1-C4 alkyl or C1-C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt. More preferably, R3 represents hydrogen, halogen, unsubstituted phenyl, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt. In this embodiment, still more preferably R3 represents hydrogen, halogen, unsubstituted C2-C4 alkenyl, or a C1-C4 alkyl or C1-C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt. More preferably, R3 represents hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt. Most preferably R3 represents hydrogen or unsubstituted C1-C4 alkyl, e.g. methyl.
In an alternative embodiment, R2 and R3 together with the ring atoms to which they are bonded form a 5- to 7-membered, at least partially saturated ring containing a nitrogen atom from the adjacent pyrrole ring, and optionally one or two further heteroatoms selected from N, O and S, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring. Preferred heterocyclyl rings are at least partially saturated 5- or 6-membered rings containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O. Examples of preferred rings are piperazinyl, morpholinyl and pyrrolidinyl. Alternative preferred heterocyclyl rings include saturated 5- to 7-membered rings containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O, for example azepanyl.
The heterocyclyl ring formed by R2 and R3 may be unsubstituted or substituted on any ring atom. Typically, none, one or two substituents are present. Examples of suitable substituents on the R2/R3 ring are unsubstituted substituents selected from halogen, -CO2R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO2R', -OCONR'R" and ~CR'=N0R", or C1-C6 alkyl or C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four, for example one, two, or three, for example one, unsubstituted group selected from halogen, hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C4 alkyl), preferably hydroxyl, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl).
Preferred substituents are unsubstituted substituents selected from halogen, -NR'R", -CO2R', -CONR'R", -OCONR'R", -OCOR', -COCF3 and hydroxyl, or Cl- C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. More preferred substituents are halogen, unsubstituted C1-C4 alkyl (e.g. methyl) and unsubstituted C1-C4 alkoxy groups, in particular methyl.
Typically, when R4 is or contains an aryl or heterocyclyl group, the aryl or heterocyclyl group is phenyl, benzyl or pyridyl. The aryl or heterocyclyl group may be unsubstituted or substituted on any ring atom, for example with one, two or three substituents. Preferred substituents are unsubstituted substituents selected from halogen, -NR'R", -CO2R', -CONR'R", -OCONR'R", -OCOR', -COCF3 and hydroxyl, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group. More preferred substituents are halogen, unsubstituted C1-C4 alkyl (e.g. methyl) and unsubstituted C1-C4 alkoxy groups, in particular methyl or methoxy. More preferably, the aryl or heterocyclyl ring is unsubstituted.
In one embodiment, R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2- C4 alkenyl, C2-C4 alkynyl, -OR', -CO2R', CONR'R", -COR', -CN, -NO2, -NR'R" or -CF3 wherein R' and R" are independently hydrogen or C1-C4 alkyl, more preferably R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', -CO2R', CONR'R", -COR', -CN, -NO2, -NR'R" or -CF3 wherein R' and R" are independently hydrogen or C1-C4 alkyl. In another embodiment R4 represents hydrogen, halogen or C1-C4 alkyl, preferably hydrogen. Where R4 is capable of being substituted,, it is typically unsubstituted or substituted with one halogen atom, more preferably it is unsubstituted.
In one embodiment, when R5 is phenyl or thienyl then preferably R4 is hydrogen. In another embodiment when R4 is phenyl preferably R5 is hydrogen. Typically, Z is halogen, OR', SR', -NR'R', -CO2R', -CONR'R", -COR', -OCOR' or CN, wherein R' and R' ' are independently hydrogen or C 1 -C4 alkyl.
In a preferred embodiment of the invention, Rl represents hydrogen, unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4;
Al represents a bond, phenyl, naphthyl, a 5- or 6-membered monocyclic heterocyclyl group, or an 8- to 10-membered bicyclic heterocyclyl group;
A2 and A3 are the same or different and represent phenyl or a 5- to 12- membered heterocyclyl group;
A4 represents a 5- to 6-membered heterocyclyl group wherein 1 ring carbon atom has been replaced with a group selected from >C(=0)5 >S(=0)2, >C(=:N0R7) where R7 is hydrogen or a Cl -C4 alkyl group, >C=CH2 or >C(-OCH2CH2O-);
Ll represents a bond, a 5-to 7-membered heterocyclyl group which is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, Cl- C4 alkoxy, hydroxy and halogen, or a C1-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C 1 -C4 alkyl or C 1 -C4 alkyl substituted with an unsubstituted C 1 -C4 alkoxy group;
L2 is as defined above; L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH2- moieties are independently replaced with -O- or -NR'-, wherein R' represents hydrogen or unsubstituted C1-C4 alkyl; n is as defined above; R6 represents hydrogen or unsubstituted C1-C4 alkyl;
R5 represents hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, an unsubstituted C3-C6 cycloalkyl group, an unsubstituted Cl -C 8 alkyl or a Cl- C8 alkyl substituted with a C1-C4 alkoxy; either (i) R2 represents phenyl, hydrogen, -COO(C 1-C4 alkyl), halogen, unsubstituted C3 -C6 cycloalkyl, or a C 1 -C4 alkyl, C2-C4 alkenyl or C 1 -C4 alkoxy group which is unsubstituted or substituted with -SMe, -SEt, hydroxyl, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R", -NR'CO(C1-C4 alkyl), unsubstituted C1-C4 alkoxy or C1-C4 alkoxy substituted with -OMe or -OEt, where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -0-, -S- or -NR'- and wherein A5 represents phenyl, pyridinyl or oxazolyl; and R3 represents hydrogen, halogen, unsubstituted C2-C4 alkenyl, or a C1-C4 alkyl or C1-C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt; or (ii) R2 and R3 together with the ring atoms to which they are bonded form an at least partially saturated 5- or 6-membered ring containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring; and
R4 represents hydrogen, halogen, phenyl, or an unsubstituted group selected from C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', -CO2R', CONR'R", -COR', - CN, -NO2, -NR'R" or -CF3, wherein R' and R" are independently hydrogen or C1-C4 alkyl; wherein the aryl and heterocyclyl rings formed by Al, A2, A3, A4, R5, R2 or R2 and R3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted groups halogen, -CO2R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO2R', -OCONR'R" and -CR'=N0R", and from C1-C6 alkyl and C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four unsubstituted groups selected from hydroxyl, C1-C4 alkoxy and -O-(C1-C4 alkyl)-O-(Cl-C2 alkyl), and wherein the group Al can additionally or alternatively be substituted by a group of formula -(C1-C2 alkyl)-O-(Cl-C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R' ', together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups.
In this preferred embodiment more preferably Rl represents unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(Cl -C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. Preferably Al represents phenyl or a 5- or 6- membered heterocyclyl group. Preferably R5 represents hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, an unsubstituted C3-C6 cycloalkyl group or unsubstituted C1-C8 alkyl. Preferably R4 represents hydrogen, halogen, or an unsubstituted group selected from C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', -CO2R' , CONR'R' ' , -COR' , -CN, -NO2, -NR'R' ' or -CF3, wherein R' and R' ' are independently hydrogen or C1-C4 alkyl. In this preferred embodiment preferably the aryl and heterocyclyl rings formed by Al, A2, A3, A4, R5, R2 or R2 and R3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted groups halogen, -CO2R', -CONR'R", OCOR', hydroxyl, cyano, -NR'R", -COR', -NSO2R', -O(C2-C4 alkenyl), C2-C4 alkenyl, -SO2R', -OCONR'R' ' and
-CR'=N0R", and from C1-C6 alkyl and C1-C6 alkoxy groups which are unsubstituted or substituted with one, two, three or four unsubstituted groups selected from hydroxyl, C1-C4 alkoxy and -O-(C1-C4 alkyl)-0-(Cl-C2 alkyl).
Particularly preferred compounds for use in the invention are pyrrole derivatives of formula (Ia) and pharmaceutically or agriculturally acceptable salts thereof:
Figure imgf000029_0001
(IA) wherein: Al represents a bond, phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl, each of which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, - CO2H and halogen, or from a group of formula -(C 1 -C2 alkyl)-O-(C 1 -C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 Cl- C4 alkyl groups; n represents one or two, preferably one;
Ll represents a bond, a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C1-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, and wherein the heterocyclyl group is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen; when Ll is a bond, Rl represents hydrogen, -A2, -SO2-A2, A2-L3-A3 or A4; and when Ll is other than a bond, Rl represents hydrogen or an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C1-C4 alkyl) and -SO2(C1-C4 alkyl), or a group -A2, -SO2-A2, -L3-A2 or -A2-L3-A3;
A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF3, -OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; L3 represents a bond or unsubstituted methylene, ethylene or propylene; A4 represents unsubstituted dioxothiomorpholinyl, methoxyiminopiperidinyl, methoxyiminopyrrolidinyl, methylenepiperidinyl, dioxoazaspirodecyl or oxadihydropyrazolyl;
R5 represents hydrogen, unsubstituted or substituted phenyl, unsubstituted C3- C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or R5 is a C1-C8 alkyl group which is unsubstituted or substituted with a C1-C4 alkoxy group; and either (i) R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C 1 -C4 alkoxy, unsubstituted C2-C4 alkenyl, unsubstituted C 1 -C4 alkyl, or C 1 -C4 alkyl or C2-C4 alkenyl substituted with -OMe, -OEt, -OPr, -OBu, -OCH2CH2OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C 1-C4 alkyl), -CONR'R" or -NROO(C 1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C4 alkyl and C1-C4 alkoxy; and R3 represents hydrogen, halogen, unsubstituted phenyl, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt; or (iϊ) R2 and R3 together with the ring atoms to which they are bonded form a substituted or unsubstituted at least partially saturated 5- or 6-membered ring containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O, the substituents being selected from unsubstituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy groups. IQ this more preferred embodiment, preferably Al is other than a bond. More preferably Al represents phenyl, pyridyl or piperidinyl, each of which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO2H and halogen. Preferably when Ll is a bond, Rl represents -A2, -SO2-A2, A2-L3-A3 or A4; and when Ll is other than a bond, Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO2(C1-C4 alkyl), or a group -A2, -SO2-A2, -L3-A2 or -A2-L3-A3. Preferably R5 represents hydrogen, unsubstituted or substituted phenyl, unsubstituted C3-C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl or unsubstituted C1-C4 alkoxy. Preferably either R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt3 and R3 represents hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt; or R2 and R3 together with the ring atoms to which they are bonded form a substituted or unsubstituted at least partially saturated 5- or 6-membered ring containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O5 the substituents being selected from unsubstituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy groups.
A further preferred embodiment provides pyrrole derivatives of formula (Ia) and pharmaceutically or agriculturally acceptable salts thereof, wherein: Al represents phenyl, which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO2H and halogen, preferably Al is unsubstituted or substituted with one group selected from F, Cl and methyl, most preferably Al is unsubstituted; n represents one;
Ll represents an unsubstituted, saturated 5- to 7-membered heterocyclyl group containing two nitrogen atoms, the heterocycle being attached to Al and to Rl via a nitrogen atom, preferably Ll represents piperazinyl;
Rl represents unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or a group -A2, -CH2-A2 or - A2-CH2-A3 ;
A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF3, - OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe5 -OEt or -0(Cl -C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group;
R5 represents unsubstituted phenyl;
R2 represents hydrogen, or C1-C4 alkyl or C2-C4 alkenyl, each of which may be unsubstituted or substituted with -OMe, -OEt5 -OPr5 -OBu, -OCH2CH2OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C4 alkyl and C1-C4 alkoxy; and
R3 represents hydrogen or C1-C4 alkyl which is unsubstituted or substituted with -OMe or -OEt.
In a preferred aspect of this embodiment, Al is a phenyl group which is unsubstituted or substituted with F, Cl or methyl, preferably Al is unsubstituted phenyl; Ll is piperazinyl and is linked to Al and Rl via a nitrogen atom; and Rl is unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or piperidinyl, wherein the piperidinyl group is unsubstituted or substituted with one, two or three substituents selected from unsubstituted C1-C4 alkyl groups. More preferably, Rl is piperidinyl which is substituted with two methyl groups.
In a further preferred aspect of this embodiment, R2 and R3 are independently selected from hydrogen and unsubstituted C1-C4 alkyl groups, preferably methyl.
A particular embodiment of the invention relates to pyrrole derivatives of formula (I) and pharmaceutically acceptable salts thereof, for use in a method of treatment of a human or animal body by therapy. In this embodiment, R6 is hydrogen and Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group. Preferably, Al represents a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or unsaturated 8- to 10-membered bicyclic heterocyclyl group. More preferably, Al represents a phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl group. Possible substituents on Al are as defined above. In this embodiment, when Al is a bond, (i) -Ll-Rl is not hydrogen, (ii) when R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted benzyl or substituted phenethyl, and (iii) when R6 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll, L3 and Ll-Rl represents an unsubstituted or substituted C1-C4 alkyl group. Preferably, when Al is a bond, -Ll-Rl is other than hydrogen, unsubstituted or substituted benzyl, substituted phenethyl or unsubstituted or substituted C2-C4 alkyl. More preferably, Al is not a bond.
In this embodiment, R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -OR', -CONR'R", -COR', -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12-membered heterocyclyl group, or a group of formula -Alk6-L5-A12, where AIk6 is a C1-C4 alkylene group, L5 is a group of formula -O-C(=O>, -C(=O> or -NR13-C(=O)- and R13 is hydrogen or C1-C4 alkyl, A12 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group and R', R", Y and Z are as defined above. Where R4 represents an aryl or heterocyclyl group it is typically phenyl, benzyl or pyridyl. The aryl or heterocyclyl group may be unsubstituted or substituted as defined above.
R4 preferably represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO2, -NR'R" or -CF3 wherein R' and R' ' are independently hydrogen or C1-C4 alkyl. More preferably R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO2, -NR'R" or -CF3 wherein R' and R" are independently hydrogen or C1-C4 alkyl. In another embodiment R4 represents hydrogen, halogen or C1-C4 alkyl, preferably hydrogen. Where R4 is capable of being substituted, it is typically unsubstituted or substituted with one halogen atom, more preferably it is unsubstituted.
In this embodiment, when R2 is cycloalkyl it is an unsubstituted cycloalkyl group.
In a further particular embodiment, the present invention provides novel pyrrole derivatives of formula (I) and pharmaceutically or agriculturally acceptable salts thereof. In this embodiment, Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group. Preferably, Al represents a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or unsaturated 8- to 10- membered bicyclic heterocyclyl group. More preferably, Al represents a phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, indolyl, isoquinolinyl or quinolinyl group. Possible substituents on Al are as defined above.
When Al is a bond, (i) -Ll-Rl is not hydrogen, (ii) when R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted benzyl or substituted phenethyl, and (iii) when R6 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll, L3 and Ll-Rl represents an unsubstituted or substituted C1-C4 alkyl group. Preferably, when Al is a bond, -Ll-Rl is other than hydrogen, unsubstituted or substituted benzyl, substituted phenethyl or unsubstituted or substituted C2-C4 alkyl. More preferably, Al is not a bond.
In this embodiment, when Al and Ll are both a bond, Rl preferably represents unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2 or -A2-L3-A3. More preferably, Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C1-C4 alkyl) and -SO2(C1-C4 alkyl) or a group -A2, -L2-A2, -L3-A2 or -A2-L3-A3. More preferably, Rl represents a group -A2, -L2-A2, -L3-A2 or -A2-L3- A3. Preferred alkyl, alkenyl and alkynyl groups and substituents on these groups are described above. A2, A3, L2 and L3 are as defined above.
In this embodiment, R6 is hydrogen.
In this embodiment, when R2 is heterocyclyl, it is not substituted with an aryl or further heterocyclyl group. Preferred substituents on an R2 heterocyclyl group are defined above. Preferably, when R2 is heterocyclyl it is not thienyl or benzothienyl, more preferably it is not thienyl, benzothienyl or pyrazolyl. More preferably, when R2 is heterocyclyl, it is an unsubstituted 5- or 6-membered heterocyclyl ring other than thienyl. More preferably, R2 is not heterocyclyl. Most preferred R2 groups are defined above.
When R2 is a substituted C1-C8 alkyl group, the substituent(s) do not include -CN or -CO2H. Preferred substituents on an R2 C1-C8 alkyl group are defined above. When R2 is substituted phenyl, the substituent(s) do not include nitro. Preferred substituents on an R2 phenyl group are defined above. In this embodiment, R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -OR', -CONR'R", -COR', -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12-membered heterocyclyl group, or a group of formula -Alk6-L5~A12, where AIk6 is a C1-C4 alkylene group, L5 is a group of formula -O-C(=O>, -C(=O)- or -NR13-C(=0)- and R13 is hydrogen or C1-C4 alkyl, A12 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group and R\ R", Y and Z are as defined above. Where R4 represents an aryl or heterocyclyl group it is typically phenyl, benzyl or pyridyl. The aryl or heterocyclyl group may be unsubstituted or substituted as defined above. R4 preferably represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO2, -NR'R" or -CF3 wherein R' and R" are independently hydrogen or C1-C4 alkyl. More preferably R4 represents hydrogen, halogen, phenyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, -OR', CONR'R", -COR', -CN, -NO2, -NR'R" or -CF3 wherein R' and R" are independently hydrogen or Cl -C4 alkyl. In another embodiment R4 represents hydrogen, halogen or C1-C4 alkyl, preferably hydrogen. Where R4 is capable of being substituted, it is typically unsubstituted or substituted with one halogen atom, more preferably it is unsubstituted.
In a further aspect of this embodiment, when Ll is a bond, Rl preferably represents hydrogen, unsubstituted or substituted C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. More preferably, when Ll is a bond, Rl represents hydrogen, an unsubstituted group selected from C2-C6 alkenyl, C2-C6 alkynyl and -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, - L3-A2, -A2-L3-A3 or -A4. Most preferably, when Ll is a bond, Rl represents hydrogen or a group -A2, -L2-A2, A2-L3-A3 or A4.
In a preferred aspect of this particular embodiment, when Ll is a bond, Rl preferably represents unsubstituted or substituted C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. More preferably, when Ll is a bond, Rl represents an unsubstituted group selected from C2- C6 alkenyl, C2-C6 alkynyl and -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. Most preferably, when Ll is a bond, Rl represents -A2, -L2-A2, -A2-L3-A3 or A4. When Ll is other than a bond, Rl represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. More preferably, when Ll is other than a bond, Rl represents hydrogen, an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C1-C4 alkyl)and -SO2(C1-C4 alkyl), C1-C6 alkyl substituted with -OMe or -OEt, or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. Most preferably, when Ll is other than a bond, Rl represents hydrogen, a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, unsubstituted -CO(Cl -C4 alkyl), unsubstituted -SO2(C1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or -A2-L3-A3. Alternatively, when Ll is other than a bond, Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO2(C1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4. Most preferably, when Ll is other than a bond, Rl represents a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2- C6 alkynyl group, unsubstituted -SO2(C 1-C4 alkyl) or a group -A2, L2-A2, -L3-A2 or - A2-L3-A3.
In a further preferred aspect of this embodiment, Ll is a bond, -CH2-, -NR'-, a C2-C6 alkylene group in which none, one, two or three -CH2- groups are independently replaced by -0-, -S- or -NR'-, or a 5- to 12-membered heterocyclyl group, wherein R' is as defined above. Ll preferably represents a bond, -CH2-, -NR'-, a 5-to 7-membered heterocyclyl group or a C2-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group. When Ll represents a 5- to 7-membered heterocyclyl group, it is preferably as defined above. In this embodiment, Ll is most preferably -CH2-, -NR'-, a saturated 5- to 7- membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C2-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or Cl- C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group. Preferred compounds of this embodiment are compounds of formula (IA) as defined above, or pharmaceutically or agriculturally acceptable salts thereof, wherein when Al is a bond, (i) -Ll-Rl is not hydrogen, (ii) when R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted ben∑yl or substituted phenethyl, and (iii) when R6 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll5 L3 and Ll-Rl represents an unsubstituted or substituted C1-C4 alkyl group and (iv) when Ll is a bond, Rl represents an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,
-CO(C1-C4 alkyl) and ~SO2(C1-C4 alkyl) or a group -A2,-L2-A2, -L3-A2 or -A2-L3-
A3.
Typically in this embodiment, Ll represents a bond, -CH2-, -NR'- a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C2-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, and wherein the heterocyclyl group is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen. When Ll represents an unsubstituted C2-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced with -O- or -NR'-, preferably it is a C4 or C5 alkylene group wherein none, one or two, more preferably one or two, -CH2- groups are independently replaced with -O- or -NR'- wherein R' is hydrogen or unsubstituted Cl-
C4 alkyl. Specific examples of compounds of formula (I) include:
2-(l,5-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-Λ''-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-oxo-2-(l -phenyl- IH- pyrrol-2-yl)-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-l-phenyl-lH:- pyrrol-2-yl)-2-oxo-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-lH-pyrrol-2- yl)-2-oxo-acetamide,
Λr-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(2-methyl-7-phenyl- l,2,3,4-tetraliydro-pyrrolo[l,2-a]pyrazin-6-yl)-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-oxo-2-(2-phenyl-6,7- dihydro-5H"-pyrrolizin-3-yl)-acetamide, Λr-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-ρiperazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3,4- dihydro-lH"-pyrrolo[2,l-c][l,4]oxazin-6-yl)-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-ρiperazin- 1 -yl] -phenyl } -2-( 1 -isopropyl-5-methyl-
3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3~phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
2-(l,5-Dimethyl-3-ρhenyl-lH'-pyrrol-2-yl)-iV-[4-[4-(4,6-diinethyl-pyridin-2-yl)- piperazin-l-yl]-3-(3-morpholin-4-yl-propoxymethyl)-phenyl]-2-oxo-acetamide5
N-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl- 3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide, jV-{4-[4-(436-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(3-furan-2-yl-l;>5- dimethyl- 1 H"-ρyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-3- thiophen-2-yl-lH-pyrrol-2-yl)-2-oxo-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl] -phenyl }-2-(3-isopropyl-l ,5- dimethyl-lH'-pyrrol-2-yl)-2-oxo-acetamide5
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 ,5 -dimethyl-3 -
(tetrahydro-pyran-4-yl)-lH-pyrrol-2-yl]-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH"-pyrrol-2~yl)-7V-naphthalen-l-yl-2-oxo-acetamide5 N-{3-(2-Dimethylamino-ethoxymethyl)-4-[4-(4,6-dimethyl-ρyridin-2-yl)-piperazin-l- yl]-phenyl}-2-(l,5-dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
2-(l54-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iVr-{4-[4-(4,6-dimethyl-pyridin-2-yl)- ρiperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-l/i"-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 - [3 -(4-methyl-piperazin- 1 -yl)-propoxymethyl] -phenyl} -2-oxo- acetamide,
JV- {4_ [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-(5 -isopropyl- 1 -methyl-
3-phenyl-l/f-pyrrol-2-yl)-2-oxo-acetamide,
N- {2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-(l ,5-dimethyl- 3-phenyl-lH-pyrrol-2-yl)-2~oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-ljy-pyrrol-2-yl)-iV-{4-[4-(456-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3-hydroxy-phenyl} -2-oxo-acetamide, iVr-(2,3-Dihydro-benzoforan-4-yl)-2-(l35-dimethyl-3-phenyl-li7-pyrrol-2-yl)-2-oxo- acetamide, iV-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piρerazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, N- {4- [4-(4.6-DimethyI-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [3 -isopropyl- 1 -(2- methoxy-ethyl)-5-methyl- 1 /i-pyrrol-2-yl] -2-oxo-acetamide,
JV- {2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-[l -(2- methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [1 -(2-ethoxy-ethyl)-5- methyl-3-phenyl-l/f-pyrrol-2-yl]-2-oxo-acetamide,
2-(l,5-Dimethyl-3-ρhenyl-lH"-pyrrol-2-yl)-2-oxo-iV-[4-(4-pyridin-2-yl-piperazin-l-yl)- phenyl] -acetamide,
2-(l,5-Dimethyl-3-phenyl-li/-pyrrol-2-yl)-iV-{4-[4-(4-methyl-pyridin-2-yl)-piperazin-
1 -yl]-phenyl} -2-oxo-acetamide, 2-(l55-Dimet]iyl-3-phenyl-liy-pyrrol-2-yl)-7V-{4-[4-(6-methyl-pyridin-2-yl)-piperazin-
1 -yl]-phenyl} -2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N"-{4-[4-(5-methyl-pyridin-2-yl)-piperazm-
1 -yl]-phenyl} -2-oxo-acetamide,
2- [ 1 -(2-Methoxy-ethyl)-5-methyl-3 -phenyl- l/f-ρyrrol-2-yl]-2-oxo-iV-[4-(4-ρyridin-2-yl- piperazin- 1 -yl)-phenyl] -acetamide,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-li:f-pyrrol-2-yl]-iV-{4-[4-(4-methyl-pyridin-
2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-iV-{4-[4-(6-methyl-pyridin-
2-yl)-piperazin- 1 -yl]-phenyl } -2-oxo-acetamide, 2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-N-{4-[4-(5-methyl-pyridin-
2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-Oxo-2-(2-phenyl-6,7-dihydro-5H-pyrrolizin-3-yl)-iV-[4-(4-pyridin-2-yl-piperazin-l- yl)-pheny 1] -acetamide, iV-{4-[4-(4-Methyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-6,7- dihydro-5H-pyrrolizm-3-yl)-acetamide,
N- {4- [4-(6-Methyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-2-(2-phenyl-6,7- dihydro-SH-pyrrolizin-S-yO-acetamide, iV-{4-[4-(5-Methyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-6,7- dihydro-5H-pyrrolizm-3-yl)-acetarnide,
N-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2- phenyl-6,7-dmydro-5if-pyrrolizm-3-yl)-acetarrήde, iV-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2- phenyl-6, 7-dihydro-5iJ-pyrrolizin-3 -yl)-acetamide,
2-Oxo-2-(7-phenyl-3 ,4-dihydro- 1 i?-ρyrrolo [2, 1 -c] [1 ,4] oxazin-6-yl)-.V- [4-(4-pyridin-2- yl-piperazin-l-yl)-phenyl]-acetamide, jV-{4-[4-(4-Methyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3;,4- dihydro-lH"-pyrrolo[2,l-c][l,4]oxazin-6-yl)-acetamide5
N- { 4- [4-(6-Methyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-2-(7-phenyl-3 ,4- dihydro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4]oxazin-6-yl)-acetamide,
7V-{4-[4-(5-Methyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3,4- dihydro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide, N-{3-Chloro-4-[4-(436-dimethyl-ρyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-oxo-2-(7- phenyl-3 ,4-dihydro- lH-pyrrolo [2, 1 -c] [1 ,4]oxazin-6-yl)-acetamide, iy-{2-Chloro-4-[4-(456-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(7- phenyl-354-dihydro-l/f-ρyrrolo[2,l-c][l,4]oxazin-6-yl)-acetamide,
2-( 1 ,5-Dimethyl-3-thiophen-2-yl- 1 #~pyrrol-2-yl)-2-oxo-JV- [4-(4-pyridin-2-yl-piρerazin- l-yl)-phenyl]-acetamide,
2-(l55-Dimethyl-3-thiophen-2-yl-lH'-pyrrol-2-yl)--V-{4-[4-(4-methyl-pyridm-2-yl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-(l,5-Dimethyl-3-thiophen-2-yl-liϊ-pyrrol-2-yl)-iV-{4-[4-(5-methyl-pyridm-2-yl)- piperazin- 1 -yl] -phenyl} -2-oxo-acetamide, 2-(l,5-Dimethyl-3-thiophen-2-yl-lH"-pyrrol-2-yl)-N-{4-[4-(6-methyl-pyridin-2-yl)- piperazin- 1 -yl]-phenyl} -2-oxo-acetamide, iV-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l:>5-dimethyl-
3-thiophen-2-yl-l-E-r-pyrrol-2-yl)-2-oxo-acetamide:, iV-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl- 3-thiophen-2-yl-li-r-pyrrol-2-yl)-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lif-pyrrol-2-yl)-7V-[4-({2-[(4,6-dimethyl-pyridin-2-yl)- methyl-amino]-ethyl}-methyl-amino)-phenyl]-2-oxo-acetamide, T/GB2009/001058
N-[4-({2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-ainino]-ethyl}-methyl-aniino)-plienyl]-2-
[ 1 -(2-methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl]-2-oxo-acetamide,
N-[4-({2-[(4,6-Dime1hyl-pyridin-2-yl)-meώyl-ammo]-etliyl}-methyl-amino)-phenyl]-2- oxo-2-(7-phenyl-3 ,4-dihydro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide, N-[4-({2-[(4,6-Dimethyl-pyridin-2-yl)-me1iiyl-ainino]-eώyl}-methyl-amino)-phenyl]-2- oxo-2-(2-phenyl-6,7-dihydro-5H-pyrrolizin-3-yl)-acetamide,
N-[4-({2-[(4,6-Dimethyl-pyridin-2-yl)-meUiyl-amino]-ethyl}-methyl-amino)-phenyl]-2-
(l55-dimethyl-3-thiophen-2-yl-lH'-ρyrrol-2-yl)-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-l/f-pyrrol-2-yl)-iV-{4-[2-(4,6-dimethyl-pyridin-2-yloxy)- ethylamino]-phenyl}-2-oxo-acetamide,
N-{4-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethylamino]-phenyl}-2-[l-(2-methoxy-eth.yl)-
5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[2-(456-Dimethyl-pyridin-2-yloxy)-ethylamino]-phenyl}-2-oxo-2-(7-phenyl-3,4- dihy dro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide, N-{4-[2-(436-Dimethyl-pyridin-2-yloxy)-ethylamino]-phenyl}-2-oxo-2-(2-plienyl-6,7- dihydro-5H"-pyrrolizin-3-yl)-acetamide,
N-{4-[2-(4,6-Dime%l-pyridin-2-yloxy)-ethylamino]-ρhenyl}-2-(l,5-dimethyl-3- thiophen-2-yl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(4-{2-[(4,6-dimethyl-pyridin-2-yl)- methyl-amino]-ethoxy}-phenyl)-2-oxo-acetamide,
N-(4-{2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-ethoxy}-phenyl)-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl-l/f-pyrrol-2-yl]-2-oxo-acetamide,
N-(4-{2-[(456-Dimethyl-pyridin-2-yl)-methyl-aiϊiino]-ethoxy}-phenyl)-2-oxo-2-(7- phenyl-3 ,4-dihydro- liϊ-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide, N-(4-{2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-ethoxy}-phenyl)-2-oxo-2-(2- phenyl-6,7-dihydro-5H-pyrrolizin-3-yl)-acetamide,
N-(4-{2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-ainino]-ethoxy}-phenyl)-2-(l,5-dimethyl-
3 -thiophen-2-yl- 1 H-pyrrol-2-yl)-2-oxo-acetamide5
2-(l55-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-N-{4-[2-(4,6-dimethyl-ρyridin-2-yloxy)- ethoxy]-phenyl}-2-oxo-acetamide, iV-{4-[2-(456-Dimethyl-ρyridin-2-yloxy)-ethoxy]-phenyl}-2-[l-(2-methoxy-ethyl)-5- niethyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, iV-{4-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethoxy]-phenyl}-2-oxo-2-(7-phenyl-3,4- dihydro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide,
N-{4-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethoxy]-phenyl}-2-oxo-2-(2-ρhenyl-657- dihydro-5H-pyrrolizin-3-yl)-acetamide., N-{4-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethoxy]-phenyl}-2-(l55-dimethyl-3-thiophen-
2-yl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-iV-(4- { [2~(4,6-dimethyl-pyridin-2-ylarnino)- ethyl] -methyl-amino } -phenyl)-2-oxo-acetamide.
N-(4-{[2-(456-Dime%l-ρyridin-2-ylamino)-ethyl]-methyl-amino}-phenyl)-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, jV-(4-{[2-(456-Dimethyl-pyridin-2-ylamino)-ethyl]-methyl-ainino}-phenyl)-2-oxo-2-(7- phenyl-3 ,4-dihydro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-θ-yO-acetamide,
N-(4-{[2-(4,6-Dimethyl-pyridin-2-ylamino)-ethyl]-meth.yl-amino}-phenyl)-2-oxo-2-(2- phenyl-6,7-dihydro-5H"-pyrrolizin-3-yl)-acetamide, iV-(4-{[2-(4,6-Dimethyl-pyridin-2-ylamino)-ethyl]-methyl-amino}-phenyl)-2-(l55- dimethyl-3-thiophen-2-yl-lH-pyrrol-2-yl)-2-oxo-acetamide:>
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV'-{4-[2-(4,6-dimethyl-pyridin-2-ylamino)- ethylamino]-phenyl}-2-oxo-acetamide,
N- {4- [2-(4,6-Dimethyl-pyridin-2-ylamino)-ethylamino]-phenyl } -2-[ 1 -(2-methoxy- ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
7V"-{4-[2-(456-Dimethyl-pyridin-2-ylamino)-ethylammo]-phenyl}-2-oxo-2-(7-phenyl-
3 ,4-dihydro- 1 H-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide; jV-{4-[2-(4,6-Dimethyl-pyridin-2-ylamino)-ethylaniino]-phenyl}-2-oxo-2-(2-phenyl-
6,7-dihydro-5/i-pyrrolizin-3-yl)-acetamide, N- {4-[2-(4,6-Dimethyl-pyridin-2-ylamino)-ethylamino]-phen.yl} -2-(l ,5-dimethyl-3- thiophen-2-yl- 1 H-pyrrol-2-yl)-2-oxo-acetamide5
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(4-{2-[(4,6-dimethyl-ρyridin-2-yl)- methyl-amino]-ethylamino } -phenyl)-2-oxo-acetamide,
N-(4-{2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-ethylamino}-phenyl)-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl- lH-pyrrol-2-yl]-2-oxo~acetamide,
N-(4-{2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-ethylamino}-phenyl)-2-oxo-2-(7- phenyl-3,4-dihydro-lH-pyrrolo[25l-c][l,4]oxazin-6-yl)-acetamide, N-(4-{2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-ethylainino}-ph.enyl)-2-oxo-2-(2- phenyl-6,7-dihydro-5H-pyrrolizm-3-yl)-acetamide,
N-(4- {2-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-ethylaαiino } -phenyl)-2-( 1,5- dimethyl-3-iMophen-2-yl-lH~pyrrol-2-yl)-2-oxo-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-(4-{3-[(4,6-dimethyl-ρyridin-2-yl)- methyl-amino]-propyl}-phenyl)-2-oxo-acetamide,
N-(4-{3-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-propyl}-phenyl)-2-[l-(2-methoxy- ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
JV-(4- { 3 - [(4,6-Dimethyl-pyridin-2-yl)-meth.yl-amino] -propyl} -phenyl)-2-oxo-2-(7- phenyl-3 ,4-dihydro- l/f-pyrrolo[2, 1 -c] [l,4]oxazin-6-yl)-acetamide, iV-(4-{3-[(4,6-Dime1iiyl-pyridm-2-yl)-methyl-amino]-propyl}-phenyl)-2-oxo-2-(2- phenyl-657-dihydro-5Ji-pyrrolizin-3-yl)-acetamide,
N-(4-{3-[(456-Dimethyl-pyridin-2-yl)-methyl-amino]-propyl}-phenyl)-2-(l,5-dimethyl-
3-thiophen-2-yl-lJf/'-pyrrol-2-yl)-2-oxo-acetamide3 2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(436-dimethyl-pyridin-2-yl)-
[ 1 ,4]diazepan- 1 -yl] -phenyl} -2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)- [ 1 ,4] diazepan- 1 -yl] -phenyl } -2- [ 1 -(2-methoxy- ethyl)-5-methyl-3-phenyl-liZ"-pyrrol-2-yl]-2-oxo-acetamide,
A/-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-[l ,4]diazepan- 1 -yl]-ρhenyl}-2-oxo-2-(7-phenyl- 3,4-dihydro-lH-pyrrolo[2, 1 -c] [1 ,4]oxazin-6-yl)-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-[l,4]diazepan-l-yl]-ρhenyl}-2-oxo-2-(2-phenyl-
6,7-dihydro-5iϊ-pyrrolizin-3-yl)-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-[l,4]diazepan-l-yl]-ρhenyl}-2-(l,5-dimethyl-3- thiophen-2-y 1- 1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-(l,5-Dime%l-3-phenyl-lH-pyrrol-2-yl)-N-[4-({3-[(456-diniethyl-pyridm-2-yl)- methyl-amino]-propyl}-methyl-amino)-phenyl]-2-oxo-acetamide,
Λr-[4-({3-[(4,6-Dimethyl-pyridin-2-yl)-meώyl-amino]-propyl}-methyl-amino)-phenyl]-
2- [ 1 -(2-methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
Λr-[4-({3-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-propyl}-methyl-amino)-phenyl]- 2-oxo-2-(7-phenyl-354-dihydro-lH-pyrrolo[25l-c][l,4]oxazin-6-yl)-acetamide,
N-[4-({3-[(4,6-Dimethyl-pyridin-2-yl)-methyl-amino]-propyl}-methyl-amino)-phenyl]-
2-oxo-2-(2-phenyl-6,7-dihydro-5i?-pyrrolizin-3-yl)-acetamide, N- [4-( {3 - [(4,6-Dimethyl-pyridin-2-yl)-methyl-amino] -propyl } -methyl-amino)-phenyl] -
2-(l55-dimethyl-3-thiophen-2-yl-li?-pyrrol-2-yl)-2-oxo-acetamide,
2-(l,5-Dime%l-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(4-ethyl-pyridin-2-yl)-piperazin-l- yl] -phenyl} -2-oxo-acetamide, iV-{4-[4-(4-Ethyl-pyridin-2-yl)-ρiperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3-phenyl-li-7'-pyrrol-2-yl]-2-oxo-acetamide, jV-{4-[4-(4-Ethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3,4-dihydro- lH~pyrrolo[2,l-c][l,4]oxazin-6-yl)-acetamide,
7V-{4-[4-(4-Ethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-6,7-dihydro- 5H-pyrrolizin-3-yl)-acetamide, • ■
2-(l55-Dimethyl-3-thiophen-2-yl-lH-pyrrol-2-yl)-N-{4-[4-(4-ethyl-pyridin-2-yl)- piperazin- 1 -yl]-phenyl} -2-oxo-acetamide.,
2-(l55-Dimethyl-3-phenyl-l/f-pyrrol-2-yl)--V-{4-[4-(6-ethyl-pyridin-2-yl)-piperazm-l- yl] -phenyl } -2-oxo-acetamide, N-{4-[4-(6-Ethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl}-2-[l -(2-methoxy-ethyl)-5- methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, iV-{4-[4-(6-Ethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3,4-dihydro- l/f-pyrrolo[23l-c][l,4]oxazin-6-yl)-acetamide, iV-{4-[4-(6-Ethyl-ρyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-6,7-dihydro- 5H-pyrrolizin-3-yl)-acetamide, and
2-(l,5-Dimethyl-3-thiophen-2-yl-lH-pyrrol-2-yl)-iV-{4-[4-(6-ethyl-pyridin-2-yl)- piperazin-l-yl]-ρhenyl}-2-oxo-acetamide, and pharmaceutically and agriculturally acceptable salts thereof.
Preferred examples of compounds of formula (I) include: 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(456-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-2-( 1 -phenyl- 1 H- pyrrol-2-yl)-acetamide5
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-(5-methyl- 1 -phenyl- IH- pyrrol-2-yl)-2-oxo-acetamide:,
ΛL{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-lH-pyrrol-2- yl)-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(2-methyl-7-phenyl-
1 ,2,3 ,4-tetrahydro-pyrrolo [ 1 ,2-a]pyrazin-6-yl)-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-6,7- dihy dro-5H"-pyrrolizin-3 -yl)-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piρerazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3;>4- dihydro- 1 if-pyrrolo [2, 1 -c] [ 1 ,4] oxazin-6-yl)-acetamide,
N- {A- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-( 1 -isopropyl-5-methyl-
3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2-methoxy-ethyl)-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-( 1 ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-N- [4- [4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 -(3 -morpholin-4-yl-propoxymethyl)-phenyl] -2-oxo-acetamide,
N-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-
3 -phenyl- lH-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4,6-Diniethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-(3-furan-2-yl-l,5- dimethyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-3- thiophen-2-yl-l//"-pyiτol-2-yl)-2-oxo-acetaπiide,
N- {4-[4-(4;6-Dimethyl-pyridin-2-yl)-piperazm- 1 -yl] -phenyl} -2-(3 -isopropyl- 1 ,5- dimethyl- lH-pyrrol-2-yl)-2-oxo-acetamide,
N- { 4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazm- 1 -yl] -phenyl } -2- [ 1 ,5 -dimethyl-3 -
(tetrahydro-pyran-4-yl)-lH-pyrrol-2-yl]-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH"-pyiτol-2-yl)-N-naphthalen-l-yl-2-oxo-acetamide,
N-{3-(2-Dimethylamino-ethoxymethyl)-4-[4-(4:,6-dimethyl-pyridin-2-yl)-piperazm-l- yl]-phenyl}-2-(l,5-dimethyl-3-phenyl-li7-pyrrol-2-yl)-2-oxo-acetamide,
2-(l;4-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-li7-ρyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 - [3 -(4-methyl-piperazin- 1 -yl)-propoxymethyl] -phenyl} -2-oxo- acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-isopropyl-l-methyl-
3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N- {2-Chloro-4-[4-(456-dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-( 1 ,5-dimethyl-
3 -phenyl- 1 i/-pyrrol-2-yl)-2-oxo-acetamide5
2-(l,5-Dime%l-3-phenyl-lH-pyrrol-2-yl)-iV'-{4-[4-(456-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 -hydroxy-phenyl} -2-oxo-acetamide, N-(2,3-Dihydro-beiizofuran-4-yl)-2<l,5-dimethyl-3-phenyl-l//-ρyrrol-2-yl)-2-oxo- acetamide,
N- {3-Chloro-4- [4-(456-dimethyl-pyridin-2-yl)-piρerazin- 1 -yl]-phenyl} -2-[ 1 -(2- methoxy-ethyl)-5 -methyl -3 -phenyl- 1 /f-pyrrol-2 -yl] -2-oxo-acetamide,
N-[A- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2- [3 -isopropyl- 1 -(2- methoxy-ethyl)-5-methyl-li7-pyrrol-2-yl]-2-oxo-acetamide,
N- {2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-[ 1 -(2- methoxy-ethyl)-5-methyl-3-phenyl-lH"-pyrrol-2-yl]-2-oxo-acetamide, and
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piρerazin-l-yl]-ρhenyl}-2-[l-(2-ethoxy-ethyl)-5- methyl-3-phenyl-l//-pyrrol-2-yl]-2-oxo-acetamide, and pharmaceutically and agriculturally acceptable salts thereof.
Further preferred examples of compounds of formula (I) include:
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(3-methoxy-propyl)-
5 -methyl-3 -phenyl- 1 Η-pyrrol-2-yl] -2-oxo-acetamide,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N-quinolin-5-yl- acetamide,
N-Isoquinolin-5-yl-2- [1 -(2-methoxy-ethyl)-5-methyl-3 -phenyl- 1 H-pyrrol-2-yl]-2-oxo- acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-quinolin-8-yl-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-quinolin-5-yl-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-pyridin-4-yl-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-ethyl-5-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- propyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-(l -Butyl-5-methyl-3 -phenyl- 1 H-pyrroI-2-yI)-N- (4-[4-(456-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-quinolin-3-yl-acetamide, 2-(l,5-Dimethyl-3-phenyl-l/-r-pyrτol-2-yl)-2-oxo-Λr-[4-(4-pyridin-2-yl-piperazin-l-yl)- phenyl]-acetamide,
2-( 1 ,5-Dimethyl-3 -phenyl- 1 H"-pyrrol-2-yl)-jV- {4- [4-(6-methyl-pyridin-2-yl)-piperazin- l-yl]-phenyl}-2-oxo-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(4-methyl-pyridin-2-yl)-piperazin-
1 -yl]-phenyl} -2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-
657,8,9-tetrahydro-5H-pyrrolo[l ,2-a]azepin-3-yl)-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(l-phenyl- 6,7,8,9-tetrahydro-5H-pyrrolo[l ,2-a]azepin-3-yl)-acetamide,
N-Isoquinolin-8-yl-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo- acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-isoquinolin-8-yl-2-oxo-acetamide,
2-( 1 ,5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-N-naphthalen-2-yl-2-oxo-acetamide5 N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazm- 1 -yl] -phenyl} -2-( 1 -methyl-3 -phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-methyl-4-phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-ρyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-3- phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-(l-Benzyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[5-(4-methyl-piperazin-l-yl)-naphthalen-
1 -yl]-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l ,5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-N- {4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl]-3 -methyl-phenyl} -2-oxo-acetamide,
(2- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylaminooxalyl} -5 -methyl-3 - phenyl-pyrrol- 1 -yl)-acetic acid methyl ester,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-ethyl-l-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-[5-ethyl-l-(2-methoxy- ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-{4-[4-(4.6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxaryl}-5-methyl-3- phenyl-pyrrole-1-carboxylic acid ethyl ester, 2-{4-[4-(4,6-Dimetliyl-pyridin-2-yl)-piperazin-l-yl]-phenylaniinooxalyl}-5-methyl-3- phenyl-pyrrole-1-carboxylic acid methyl ester,
2-[3-(2-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-oxo-acetamide,
2-[4-(2-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-[3-(4-Chloro-ρhenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-oxo-acetamide,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N-phenyl-l- acetamide, (2- {4- [4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylaminooxalyl} -pyrrol- 1 -yl)- acetic acid methyl ester,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-methoxymethyl-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-methoxymethyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-hydroxy-ethyl)-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-[l-(2-Acetylamino-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-hydroxy-ethyl)-3- phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide.
N-{4-[4-(4.6-Dimethyl-pyridin-2-yl)-piperazine-l-yl]-phenyl}-2[l-(2-methoxy-ethyl)-
3-thiophen-2-yl-lH-pyrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-ρyridin-2-yl)piperazin-l-yl]-phenyl}-2-[3-isobutyl-l-(2- methoxy-ethyl)-lH-pyrrol-2-yl]-2-oxo-acetamide5
2-{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl}-5-methyl-3- phenyl-pyrrol-l-yl)-acetic acid ethyl ester, 2-[3-(3-CMoro-phenyl)-l-(2-methoxy-ethyl)-lH-ρyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-[4-(3-Chloro-ρhenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridm-2-yl)-piperazm4-yl]-phenyl} -2-oxo-acetamide, N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazine- 1 -yl] -phenyl} -2 [ 1 -(2-methoxy-ethyl)-
3 -thiophen-3 -yl- 1 H-pyrol-2-yl] -2-oxo-acetamide,
(2-{4-[4-(4, 6-Dimethyl pyridine-2-yl)-piperazin-l-yl]-phenylamino oxalyl} -3 -phenyl pyrrol- 1-yl) acetic acid ester,
(2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenylaminooxalyl}-3-phenyl- pyrrol- 1 -yl)-acetic acid methyl ester,
2-( 1 -Carbamoylmethyl-3 -phenyl- 1 H-pyrrol-2-yl)-N- {4- [4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl]-phenyl} -2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-(l -methyl carbamoyhnethyl-3 -phenyl- 1 -H-pyrrol-2-yl)-2-oxo-acetamide, 2{4-[4-(45 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl} -5-methyl-3- phenyl-pyrrol-1-yl) acetic acid isopropyl ester,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-[5-isopropyl-l -(2- methoxy-ethyl)-3-phenyl-lH"-pyrrol-2-yl]-2-oxo-acetamide,
2-( 1 , 5 -Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-iV-2-oxo-quinolin-5 -yl-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[3-(2-methoxy-ethyl)-5- methyl- 1 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2- [ 1 -(2-Methoxy-ethyl)-3 -phenyl- lH-pyrrol-2-yl] -2-oxo-iV-phenyl- 1 -acetamide,
2-[l-(2-Methoxy-ethyl)-3-phenyl-lH"-pyrrol-2-yl]-2-oxp-Λ''-propyl-acetamide,
Ν- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [3 -iso propyl- 1 -(2- methoxy-ethyl)-lΗ-pyrrol-2-yl]-2-oxo acetamide,
2-[l-(2-Dimethylamino-ethyl)-3-phenyl-lH-ρyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-[l-(2-Dimethylamino-ethyl)-4-phenyl-lF-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide, 2-[l-(2-Dimethylamino-ethyl)-5-methyl-3-phenyl-lH"-pyrrol-2-yl]-iV-{4-[4-(4,6- dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-oxo-acetamide, (2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl}-3-thiophen-
2-yl-pyrrol-l-yl)-acetic acid methyl ester,
(2-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaminooxalyl}-[3-iso propyl-pyrrol-l-yl)-acetic acid methyl ester, (2-{4-[4-(4,6-Dimethyl pyridine-2-yl) piperazine-l-yl]-phenylamino oxalyl}-3-isobutyl- pyrrol-l-yl)-acetic acid methyl ester, iV-{4-[4-(436-Dimethyl-pyridm-2-yl)-piperazm- 1 -yl]-phenyl} -2-(4-fluoro- 1 , 5-dimethyl-
3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl- lpyridin-2ylmethyl-liy-pyrrol-2-yl)-2-oxo-acetamide,
JV- {2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2- methoxy-ethyl)-5-methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- pyridin-3 -ylmethyl- 1 H"-pyrrol-2-yl)-2-oxo-acetamide, JV- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-[4-fluoro- 1 -(2- methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-( 1 , 5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-JV- [2-fluoro-4-(4-pyridin-2-yl-piperazin- 1 - yl)-phenyl] -2-oxo-acetamide,
JV-[2-Fluoro-4-(4-pyridin-2-yl-piperazin- 1 -yl)-phenyl]-2-[ 1 -(2-methoxy-ethyl-)-5- methyl-3-phenyl-lH-pyreol-2-yl]-2-oxo-acetamide,
JV- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [ 1 -(2-isopropoxy- ethyl)-5-methyl-3-phenyl-lH'-pyrrol-2-yl]-2-oxo-acetamide,
(2-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl amino oxalyl}-5- methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester, 2-(l , 5-Dimethyl-3 -phenyl- l/f-pyrrol-2-yl)-2-oxo-JV-(6-pyrrolidin-l -yl-pyridin-3-yl)- acetamide,
2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-JV-[2-fluoro-4-oxazole-2-yl-phenyl)-2-oxo- acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-JV-(2-fluoro-4-morpholin-4-yl-ρhenyl)-2- oxo-acetamide,
JV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- pyridin-4-ylmethyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrrol-2-yl]-iV'-{4-[4-(5-morpholin-4- ylmethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
2-[3-Cyclobutyl-l-(2-methoxy-ethyl)-lH-ρyrrol-2-yl]-N-{4-[4-(4,6-Dimethyl-ρyridin-
2-yl)-piperizin- 1 -yl] -phenyl} -2-oxo-acetamide, 2-(l ,5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-N-[2-fluoro-4-(4-isobutyl-piperazin- 1 -yl)- phenyl] -2-oxoacetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(2-fluoro-4-piperidin-l-yl-phenyl)-2-oxo- acetamide,
(3-Cyclobutyl-2-{4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl-]- phenylaminooxalyl } -pyrrol- 1 -yl)-acetic acid methyl ester,
2-(l,5-Dimethyl-3-phenyl-l/f-ρyrrol-2-yl)-N-{2-fluoro-4-[4-(2-methyl-allyl)-piperazin- l-yl]-phenyl}-2-oxo-acetamide,
N-{2-Fluoro-4-[4-(2-methyl-allyl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, N-[2-Fluoro-5-(4-isobutyl-piperazine-l -yl)-phenyl]-2-[l -(2-methoxy-ethyl)-5-methyl-3- phenyl- 1 H"-pyrrol-2-yl] -2-oxo-acetamide,
(2- {4- [4-(456-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -2-fluoro-phenylaminooxylyl } -5- methyl-3-phenyl-ρyrrol-l-yl)-acetic acid methyl ester,
2-( 1 ,5-Dimethyl-3 -phenyl- li7-pyrrol-2-yl)-iV- {4- [4-(2,2-dimethyl-propyl)-ρiperazin- 1 - yl]-2-fluoro-phenyl}-2-oxo-acetamide,
N-{4-[4-(2,2-Dimethyl-propyl)-piperazin-l-yl]-2-fluoro-phenyl}-2-[l-(2-methoxy- ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, iV-(2-Fluoro-4-piperidin-l-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH- pyrrol-2-yl]-2-oxo-acetamide, 2-(l, 5-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-N-(3-fluoro-4-ρiρeridm-l-yl-phenyl)-2-oxo- acetamide,
2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-[3-fluoro-4-(4-pyridin-2-yl-piperazin-l- yl)-phenyl]-2-oxo-acetamide,
N-(2-Fluoro-4-moφholin-4-yl-phenyl)-2-[l-(2-me1iioxy-ethyl)-5-methyl-3-phenyl-liϊ- pyrrol-2-yl] -2-oxo-acetamide,
2-( 1 , 5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-iV- [3 -fluoro-4(4-isobutyl-piperazin- 1 -yl)- phenyl]-2-oχo-acetamide, N-(3-Fluoro-4-piperdin-l-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH- pyrrol-2~yl]-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(5-morpholin-4-ylmethyl-pyridin-2- yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide, 2-[l-(2-Methoxy-ethyl)-4-phenyl-lH-pyrrol-2-yl]-2-oxo-N-propyl-acetamide,
(2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaminooxalyl}-4-phenyl- pyrrol- l-yl)-acetic acid methyl ester,
N-{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-ρiperazin-l -yl]-2-fluoro-phenyl}-2-[l -(2- methoxy-ethyl)-5-methyl-3-plienyl-lH-pyrrol-2-yl)-2-oxo-acetamide, N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperizin- 1 -yl]-phenyl} -2- [ 1 -methyl-3 -phenyl-5- propyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-ρiperazin- 1 -yl]-phenyl} -2-(5-ethyl- 1 - methoxymethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-(3 -Fluoro-4-morpholin-4-yl-phenyl)-2- [ 1 -(2-methoxy-ethyl)-5-methyl-3 -phenyl- 1 H- pyrrol-2-yl] -2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(5-fluoro-naphthalen-l-yl)-2-oxo- acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-(l-ethyl-4-fluoro-lH-indol-5-yl)-2-oxo- acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-(2-methoxy-ethyl)-l- methyl-3-phenyl-lH-ρyrrol-2-yl]-2-oxo-acetamide5
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methoxyinethyl-l- methyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
2-(l55-Bis-methoxymethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(456-dimethyl-pyridin-2- yl)-piperazine-l-yl]-phenyl}-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-( 1 -ethoxymethyl-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-methyl-l-(2- methylsulfanyl-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-[5-methyl- 1 -(2- phenoxy-ethyl)-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, 2-(l-Butoxymethyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4.6-dimethyl-pyridin-
2-yl)-piρerazin-l-yl]-phenyl}-2-oxo-acetamide5
N- {4- [4-(456-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-[ 1 -(3 -ethoxy-ρropyl)-5- methy-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-(5-methyl- 1 - methylsulfanylmethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy- ethoxymethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- propoxymethyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-methyl-3-phenyl-l-
(2-propoxy-ethyl)-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(4-methoxy-but-2- enyl)-5-methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(4-methoxy-butyl)-
5-methy-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
2-( 1 ,5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-N-(4-piperidin- 1 -yl-phenyl)- acetamide,
N-[4-(4-Benzyl-piperazin-l-yl)-phenyl]-2-(l,5-dimethyl-3-phenyl-lH-pyαol-2-yl)-2- oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[4-(4-isobutyryl-piperazin-l-yl)-phenyl]-
2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piρeraziri-l-yl]-phenyl}-2-[5-methyl-l-(2-rnethyl- oxazol-4-ylmethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(4-oxazol-2-yl-phenyl)-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[3-fluoro-4-oxazole-2-yl-phenyl)-2-oxo- acetamide,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-N-(4-oxazol-2-yl-ρhenyl)-
2-oxo-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(l,2-dimethyl-propyl)-piperazm-l- yl]-phenyl } -2-oxo-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-{4-[4-(2-methoxy-l-methyl-ethyl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-( 1 ,5 -Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-N- {4- [4-(2~furan-2-yl- 1 -methyl-ethyl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide, 2-( 1 ,5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo~N- [4-(5 -piperidin- 1 -ylmethyl-oxazol-
2-yl)-phenyl]-acetamide, and
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(4-morpholin-4-yl-phenyl)-2-oxo- acetamide, and pharmaceutically or agriculturally acceptable salts thereof. Particularly preferred compounds of the invention are
2-(l,5-Dimethyl-3-ρhenyl-l/f-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, iV-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-
3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide5 iV-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l55-dimethyl-
3 -phenyl- 1 i-r-pyrrol-2-yl)-2-oxo-acetamide,
N- {3 -Chloro-4- [4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2- methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-ethyl-5-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl}-2-(5-methyl-3-phenyl- 1 - propyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-(l-Butyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(456-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide;,
2-(l,5-Dimemyl-3-phenyl-li-r-pyrrol-2-yl)-2-oxo-iV-[4-(4-pyridin-2-yl-piperazin-l-yl)- phenyl] -acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV'-{4-[4-(6-methyl-pyridin-2-yl)-piperazin- 1-yl] -phenyl} -2-oxo-acetamide,
2-(l,5-DUBemyl-3-phenyl-li7-pyrrol-2-yl)-N-{4-[4-(4-methyl-pyridin-2-yl)-piperazin- l-yl]-phenyl}-2-oxo-acetamide5 N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-( 1 -methyl-3 -phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-(l55-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-{4-[4-(4,6-dimetliyl-ρyridin-2-yl)- piperazin- 1 -yl] -3 -methyl-phenyl } -2-oxo-acetamide.,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-ethyl-l-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-(l -methoxymethyl-5- methyl-3-ρhenyMH-pyrrol-2-yl)-2-oxo-acetamide,
2-(l, 5-Dimethyl-3-phenyl-lF-pyrrol-2-yl)-iV-[2-fluoro-4-(4-pyridm-2-yl-piperazin-l- yl)-phenyl]-2-oxo-acetamide,
(2-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl amino oxalyl}-5- methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[2-fluoro-4-(4-isobutyl-piperazin-l-yl)- phenyl] -2-oxoacetamide,
2-(l,5-Dimethyl-3-phenyl-li7-pyrrol-2-yl)-7V-{2-fluoro-4-[4-(2-methyl-allyl)-piperazin-
1 -yl] -phenyl } -2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-{4-[4-(2,2-dimethyl-proρyl)-piρerazin-l- yl]-2-fluoro-phenyl}-2-oxo-acetamide,
2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-[3-fluoro-4-(4-pyridin-2-yl-piperazm-l- yl)-phenyl] -2-oxo-acetamide,
2-(l , 5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-iV-[3 -fluoro-4(4-isobutyl-piperazin- 1 -yl)- phenyl] -2-oxo-acetamide, 2-(1.5-Dimemyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(5-moφholm-4-yhnethyl-pyridin-2- yl)-piperazin- 1 -yl]-phenyl} -2-oxo-acetamide,
N-{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-2-fluoro-phenyl}-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide5
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-ethoxymethyl-5- methyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide, and pharmaceutically and agriculturally acceptable salts thereof. 2-(l,5-Dimethyl-3-phenyl-lH-pyπ-ol-2-yl)-N-{4-[4-(456-dimethyl-ρyridin-2--yl)- piperazin-1-yl] -phenyl} -2-oxo-acetamide, and its pharmaceutically and agriculturally acceptable salts, is particularly preferred.
One embodiment of the invention relates to pyrrole derivatives of formula (IB), which are particularly active against fungi from both the Aspergillus and Candida genera and may therefore find use as broad spectrum anti-fungal agents. The pyrrole derivatives of this embodiment are of formula (IB):
Figure imgf000057_0001
wherein Al, Ll, n, Rl and R3 to R5 are as defined for formula (I) or (IA) above, and R2 is a group of formula -AIk1-X-R', wherein AIk1 is an unsubstituted or substituted C1-C6 alkylene group, X is a group -O-, -S-, -NR"-, -CO2-, -CONR"-, -OCO-, -OCONR"- or -SO2-, and R' and R" are independently selected from hydrogen and unsubstituted or substituted C1-C4 alkyl, for example unsubstituted or substituted C1-C4 alkyl.
AIk1 is typically an unsubstituted or substituted C1-C4 alkylene group, for example methylene or ethylene. Where AIk1 is substituted, it typically carries one or two, preferably one, substituent selected from halogen and further groups of formula -XR' as defined herein. Preferably AIk1 is unsubstituted. X is typically selected from -0-, -NR"-, -CO2- and -CONR"-. When X is
-CO2-, R' is typically a C1-C4 alkyl group.
R' and R" typically represent hydrogen or unsubtituted or substituted methyl or ethyl. R' is typically a methyl or ethyl group. R' and R" are independently unsubstituted or substituted, typically with one or two, preferably one, substituent. Suitable susbtituents are selected from unsubstituted substituents such as halogen (for example fluorine), hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino, -CO2H and -CO2(C1-C4 alkyl) and from C1-C4 alkoxy such as methoxy or ethoxy which are themselves unsubstituted or further substituted with unsubstituted methoxy or ethoxy.
Preferred substituerits are hydroxyl, amino, (C1-C4 alkyl)amino, di(Cl-C4 alkyl)amino and unsubstituted C1-C4 alkoxy. Preferably R' and R" are unsubstituted. Specific examples of compounds of formula (IB) include:
N-{4-[4-(4,6-Dimethyl-ρyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-ρyridin-2-yl)-piperazm-l-yl]-phenyl}-2-(l35-dimethyl-3- thiophen-2-yl-lH-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-[l-(2-methoxy-ethyl)-3- phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
(2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaminooxalyl}-5-methyl-3- phenyl-pyrrol-l-yl)-acetic acid methyl ester,
2- [3 -(2-Chloro-phenyl)- 1 -(2-methoxy-ethyl)- 1 H-pyrrol-2-yl]-N- {4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l -yl] -phenyl} -2-oxo-acetamide,
2-[3-(4-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2 -oxo-acetamide,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N-phenyl-l- acetamide, N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl}-2-(l -methoxymethyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-ρyridin-2-yl)ρiperazin-l-yl]-phenyl}-2-[3-isobutyl-l-(2- methoxy-ethyl)- 1 H-ρyrrol-2-yl]-2-oxo-acetamide,
2-{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl] -phenyl amino oxalyl}-5-methyl-3- phenyl-pyrrol-l-yl)-acetic acid ethyl ester,
2-[3-(3-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazine- 1 -yl]-phenyl} -2 [ 1 -(2-methoxy-ethyl)-
3 -thiophen-3 -yl- 1 H-pyrol-2-yl] -2-oxo-acetamide, (2-{4-[4-(4, 6-Dimethyl pyridine-2-yl)-piperazin-l-yl]-phenylamino oxalyl} -3 -phenyl pyrrol- 1-yl) acetic acid ester, (2- {4- [4-(4,6-Dimethyl-ρyridin-2-yl)-piperazin- 1 -yl] -phenylaminooxalyl } -3 -phenyl- pyrrol-l-yl)-acetic acid methyl ester,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-methyl carbamoylmethyl-3 -phenyl- 1 -H-pyrrol-2-yl)-2-oxo-acetamide, 2-[l-(2-Methoxy-ethyl)-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N-phenyl-l-acetamide,
2-[l-(2-Dime%lainino-ethyl)-3-ρhenyl-lH-ρyrrol-2-yl]-iV-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-[l-(2-Dimethylaniino-eώyl)-4-ρhenyl-liϊ-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-oxo-acetamide, 2-[l-(2-Dimethylamino-ethyl)-5-methyl-3--phenyl-lH-pyrrol-2-yl]-iV-{4-[4-(4:>6- dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide;
(2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl}-3-thiophen-
2-yl-pyrrol-l-yl)-acetic acid methyl ester,
(2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaminooxalyl}-[3-iso propyl-pyrrol- 1 -yl)-acetic acid methyl ester,
(2-{4-[4-(4,6-Dimethyl pyridine-2-yl) piperazine-l-yl]-phenylamino oxalyl}-3-isobutyl- pyrrol-l-yl)-acetic acid methyl ester,
2-[l-(2-Methoxy-eώyl)-5-methyl-3-pheny-lH-pyrrrol-2-yl]-Λ/'-{4-[-(5-morpholin-4- ylmethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide, 2-[3-Cyclobutyl-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-iV-{4-[4-(4,6-Dimethyl-pyridin-
2-yl)-piperizin-l-yl]-phenyl}-2-oxo-acetamide, iV-{2-Fluoro-4-[4-(2-methyl-allyl)-ρiperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, . .
N-{4-[4-(252-Dimethyl-propyl)-piperazin-l-yl]-2-fluoro-phenyl}-2-[l-(2-methoxy- ethyl)-5-methyl-3 -phenyl- lH-pyrrol-2-yl] -2-oxo-acetamide, and iV-(2-Fluoro-4-piperidin-l-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH- pyrrol-2-yl] -2-oxo-acetamide, and pharmaceutically and agriculturally acceptable salts thereof.
Compounds of the invention containing one or more chiral centre may be used in enantiomerically or diastereoisomerically pure form, or in the form of a mixture of isomers. For the avoidance of doubt, the compounds of the invention can, if desired, be used in the form of solvates. Further, for the avoidance of doubt, the compounds of the invention may be used in any tautomeric form.
As used herein, a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic, hydroiodic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic, p-toluenesulphonic acid, formic, acetic, propionic, glycolic, lactic, pyruvic, oxalic, salicylic, trichloroacetic, picric, trifluoroacetic, cinnamic, pamoic, malonic, mandelic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, p-aminobenzoic or glutamic acid, sulfates, nitrates, phosphates, perchlorates, borates, acetates, benzoates, hydroxynaphthoates, glycerophosphates or ketoglutarates. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are known to the skilled artisan. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines and heterocyclic amines, lysine, guanidine, diethanolamine and choline. Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form.
The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
The compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
The present invention also provides prodrugs of the compounds of the invention. A prodrug is an analogue of a compound of the invention which will be converted in vivo to the desired active compound. Examples of suitable prodrugs include compounds of formula (I) which have been modified at a carboxylic acid group to form an ester, or at hydroxy! group to form an ester or carbamate. Other suitable methods will be known to those skilled in the art. Further suitable prodrugs include those in which a nitrogen atom of a compound of formula (I) is quaternised by addition of an ester or alkyl ester group. For example, the nitrogen atom of an amine group or heterocyclyl ring on a substituent Rl or R5 may be quaternised by addition of a -CH2-O-COR group, wherein R is typically methyl or tert-butyl.
Suitable salts of the compounds of the invention include those mentioned herein as examples of pharmaceutically and agriculturally acceptable salts.
The compounds of the invention may be synthesised by reacting a compound of formula (II), wherein R2, R3, R4 and R5 are as hereinbefore defined, with a compound of formula (III), wherein R6, Al, n, Ll and Rl are as hereinbefore defined. Typically the reaction takes place in the presence of an organic solvent and a base. Preferably the solvent is dichloromethane or tetrahydrofuran and the base is triethylamine or pyridine. Typically the reaction is carried out at 0°C initially while the reagents are added and then stirred at room temperature until the reaction is complete. Compounds of formula (III) are typically available from commercial sources or can be prepared by known methods. Details of the synthesis of certain compounds of formula (III) are provided hereinafter.
Figure imgf000061_0001
(H) (Hi)
A compound of formula (II) may be prepared by reacting a compound of formula (IV)5 wherein R2, R3, R4 and R5 are as hereinbefore defined, with preferably oxalyl chloride. Typically the reaction takes place in an organic solvent. Preferably, the solvent is dichloromethane. Typically, the reaction is carried out at 0 °C initially while the reagents are added and then stirred at room temperature until the reaction is complete.
Figure imgf000062_0001
(IV)
The experimental section provides specific synthetic examples, and other compounds of the invention can be prepared by analogy with these specific synthetic examples and with reference to the general synthetic methodology discussed above. Some further general synthetic schemes and specific aniline-intermediate preparation summaries are as follows:
Preparation of β-ketoesters:
Figure imgf000062_0002
Solvent: acetonitrile
Base: triethylamine
Additional reagent: magnesium chloride
Preparation of oximes:
Figure imgf000062_0003
Reagent: sodium nitrite
Solvent: acetic acid
Preparation of pyrrole diesters:
Figure imgf000063_0001
Reagents: zinc powder, sodium acetate Solvent: acetic acid Temperature: 60-75 0C
Pyrrole N-alkylation:
Figure imgf000063_0002
Reagents/solvents: sodium hydride, THF, O °C to room temperature; sodium hydride, DMF, O 0C to 90 0C; potassium carbonate, acetonitrile, reflux.
Ester hydrolysis:
Figure imgf000063_0003
Reagents: sodium or potassium hydroxide, water/ethanol or water/methanol mixtures, reflux temperature.
Decarboxylation:
Figure imgf000063_0004
Solvent: ethanolamine Temperature: 175-180 °C
Primary amines:
There are a large number of ways of preparing primary alkyl amines and many examples are commercially available. Two of the most common examples of primary amine synthesis are:
1. The catalytic reduction of commercially available nitriles and nitro compounds to the corresponding amine:
Figure imgf000064_0001
N ^\/R
2. Gabriel synthesis
Figure imgf000064_0002
Exemplary anilines required for preparation of a number of preferred compounds of the invention could be prepared according to the following sequences of reactions:
4-(4-Pyridin-2-yl-piperazin-l-yl)-phenylamine:
From l-(4-nitro-phenyl)-piperazine and 2-chloropyridine5 by heating in DMSO to give l-(4-nitro-phenyl)-4-pyridin~2-yl-piperazine then catalytic hydro genation over Raney nickel in methanol. 4-[4-(4-Methyl-pyridin-2-yl)-piperazin-l-yl]-phenylamine:
From l-(4-nitro-phenyl)-piperazine and 2-cMoro-4-metihylpyridine, by heating in diglyme to give l-(4-methyl-pyridin-2-yl)-4-(4-nitro-phenyl)-piperazine then catalytic hydrogenation over Raney nickel in methanol.
4-[4-(6-Methyl-pyridin-2-yl)-piperazin-l-yl]-phenylamine:
From l-(4-nitro-phenyl)-piperazine and 2-chloro-6-methylpyridine, by heating in the presence of palladium (II) acetate, 2-dicyclohexylphospino-2-(i\yV -dimethyl amino)biphenyl and caesium carbonate in a mixture of toluene and THF to give l-(6- methyl-pyridin-2-yl)-4-(4-nitro-phenyl)-piperazine then catalytic hydrogenation over Raney nickel in methanol.
4- [4-(5 -Methyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylamine :
From l-(4-nitro-phenyl)-piperazine and 2-chloro-5-methylpyridine, in the same manner as the preparation of 4-[4-(6-methyl-pyridin-2-yl)-piρerazin-l-yl]-phenylamine.
4-[4-(4-Ethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylamine:
From 2-amino-4-ethylpyridine by treatment with sodium nitrite in hydrochloric acid in the presence of sodium chloride to afford 2-chloro-4-ethylpyridine, then in the same manner as 4-[4-(6-methyl-pyridin-2-yl)-ρiperazin-l-yl]-phenylamine.
4-[4-(6-Ethyl-pyridin-2-yl)-piperazin-l-yl]-phenylamine:
From 2-amino-6-ethylpyridine, in the same manner as 4-[4-(4-ethyl-pyridin-2- yl)-piperazin- 1 -yl] -phenylamine.
N-{2-[(4,6-Dimethyl-ρyridin-2-yl)-methyl-amino]-ethyl}-iV-methyl-benzene-l,4- diamine:
From l-chloro-4-nitrobenzene by heating in neat ethylene diamine to give iV*l*-
(4-nitro-phenyl)-ethane-l,2-diamine, followed by treatment with trifluoro- methanesulfonic acid 456-dimethyl-pyridin-2-yl ester (itself prepared according to J
Org. Chem., 63, 10048-51 (1998) using pyridine as base) in diglyme at reflux to afford iV-(4,6-dimethyl-pyridm-2-yl)-Λ/'-(4-nitro-phenyl)-ethane- 1 ,2-diamine. Dimethylation with methyl iodide in THF in the presence of sodium hydride followed by catalytic hydro genation over Raney nickel in methanol gives the required aniline.
iV-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethyl]-benzene-l,4-diamine: From 2-chloro-4,6-dimethylpyridine by treatment with ethanolamine and sodium hydroxide in a mixture of water and dioxane to afford 2-(4,6-dimethyl-pyridin- 2-yloxy)-ethylamine, followed by heating with l-fiuoro-4-nitrobenzene in ethanol to give [2-(4,6-dimethyl-pyridin-2-yloxy)-ethyl]-(4-nitro-phenyl)-amine. The free amine is protected as a trifluoroacetamide by treatment with trifluoroacetic anhydride and sodium hydride in THF then the nitro group is reduced with zinc powder in the presence of ammonium chloride in ethanol. Following coupling with the appropriately-selected acid chloride, a final treatment with lithium hydroxide in methanol removes the trifluoroacetamide to give the final compound described.
[2-(4-Ammo-phenoxy)-emyl]-(4,6-dimethyl-pyridin-2-yl)-methyl-amine:
From 4-nitrophenol by etherification with bromoacetic acid in the presence of sodium hydride in THF, acid chloride formation with thionyl chloride and catalytic DMF and amide formation with 2-amino-4,6-dimethylpyridine in triethylamine and chloroform to give iV-(4,6-dimethyl-pyridin-2-yl)-2-(4-nitro-phenoxy)-acetamide. The amide is the reduced with borane-dimethylsulfide in THF at reflux, the resulting amine methylated with methyl iodide in the presence of sodium hydride in THF, and finally catalytic hydrogenation over Raney nickel in methanol gives the required aniline.
4-[2-(4,6-Dimethyl-pyridin-2-yloxy)-ethoxy]-phenylamine: From 4-nitrophenol by etherification with 1 ,2-dibromoethane, with potassium carbonate as the base in 2-butanone to give l-(2-bromo-ethoxy)-4-nitro-benzene, followed by O-alkylation of 2-hydroxy-4,6-dimethylpyridine using potassium carbonate in DMF to give 2,4-Dimethyl-6-[2-(4-nitro-phenoxy)-ethoxy]-ρyridine. Reduction of the nitro group with tin (II) chloride in a mixture of ethanol and ethyl acetate gives the required aniline.
N-[2-(4,6-Dimemyl-pyrid^-2-ylamino)-emyl]-N-memyl-benzene-l,4-diamine: From l-fluoro-4-nitrobenzene by heating with glycine at reflux in a mixture of aqueous sodium bicarbonate and dioxane to give (4-rύ1ro-phenylamino)-acetic acid, followed by treatment with formaldehyde and formic acid at reflux to give [methyl-(4- nitro-phenyl)-amino] -acetic acid. Treatment with thionyl chloride and catalytic DMF to give the acid chloride followed by amide formation with 2-amino-4,6-dimethylpyridine in triethylamine and chloroform gives iV-(4,6-dimethyl-pyridin-2-yl)-2-(4-nitro- phenylamino)-acetamide. The amide is the reduced with borane-dimethylsulfide in THF at reflux then catalytic hydrogenation over Raney nickel in methanol gives the required aniline.
N- [2-(4,6-Dimethyl-pyridin-2-ylamino)-ethyl] -benzene- 1 ,4-diamine :
From 4-nitroaniline by treatment with ethyl oxalyl chloride in triethylamine and THF to give N-(4-nitro-phenyl)-oxalamic acid ethyl ester, followed by aminolysis with 2~amino-4,6-dimethylpyridine in triethylamine at reflux to afford iV-(4,6-dimethyl- pyridin-2-yl)-iV-(4-nitro-phenyl)-oxalamide. The amides are then reduced with borane- dimethylsulfide in THF at reflux, the free amine is protected as a trifluoroacetamide by treatment with trifluroacetic anhydride and sodium hydride in THF then the nitro group is reduced with zinc powder in the presence of ammonium chloride in ethanol. Following coupling with the appropriately- selected acid chloride, a final treatment with lithium hydroxide in methanol removes the trifluoroacetamide to give the final compound described.
iV-{2-[(4,6-Dimethyl-ρyridin-2-yl)-methyl-amino]-ethyl}-benzene-l,4-diamine: From (4-nitro-phenylamino)-acetic acid (prepared as described above) by treatment with trifluroacetic anhydride and sodium hydride in THF to give [(4-nitro- phenyl)-(2,252-trifluoro-acetyl)-amino]-acetic acid followed by acid chloride formation with thionyl chloride in chloroform and coupling with (4,6-dimethyl-pyridin-2-yl)- methyl-amine to yield iV-{[(4,6-dimethyl-pyridin-2-yl)-methyl-carbamoyl]-methyl}- 2;2,2-trifluoro-N-(4-nitro-phenyl)-acetamide. Treatment with lithium hydroxide in methanol removes the trifluoroacetamide, then the amide is reduced with borane- dimethylsulfide in THF at reflux to give iV-(4,6-Dimethyl-pyridin-2-yl)-7V-methyl-iV-(4- nitro-phenyl)-ethane-l,2-diamine. Catalytic hydrogenation over Raney nickel in methanol gives the required aniline.
[3-(4-Amino-phenyl)-propyl]-(4,6-dimethyl-pyridin-2-yl)-methyl-amine: Alkylation of diethyl malonate with 4-nitrobenzyl bromide using sodium hydride in THF, followed by ester hydrolysis with sodium hydroxide in water and ethanol, then heating the resulting diacid to its melting point causing decarboxylation gives 3-(4-nitro-phenyl)-propionic acid. Conversion to the acid chloride with thionyl chloride in DCM and coupling with 2-amino-4,6-dimethylpyridine affords N-(4,6- dimethyl-pyridin-2-yl)-3 -(4-nitro-phenyl)-propionamide. Amide reduction with borane- dimethylsulfide in THF at reflux, methylation of the resulting amine with methyl iodide and sodium hydride in THF and finally catalytic hydrogenation over Raney nickel in methanol gives the required aniline.
4-[4-(4,6-Dimethyl-pyridin-2-yl)-[l,4]diazepan-l-yl]-phenylamine:
From l-chloro-4-nitrobenzene and [l,4]diazepane (homopiperazine) by heating in n-butanol at reflux to give l-(4-nitro-phenyl)-[l,4]diazepane, followed by reaction with 2-chloro-4,6-dimethylpyridine by heating in the presence of palladium (II) acetate, 2-dicyclohexylphospino-2-(AζΛp-dimethyl aminojbiphenyl and caesium carbonate in a mixture of toluene and THF to give l-(4,6-dimethyl-pyridin-2-yl)-4-(4-nitro-phenyl)- [l,4]diazepane, and finally reduction with tin (II) chloride in a mixture of ethanol and ethyl acetate gives the required aniline.
N-{3-[(4,6-Dimethyl-pyridin-2-yl)-methyl-arnino]-propyl}-iV-methyl-benzene-l,4- diamine:
From methyl-(4-nitro-phenyl)-amine and acrylic acid by heating with catalytic sulfuric acid to give 3-[methyl-(4-nitro-phenyl)-amino]-propionic acid, acid chloride formation with thionyl chloride in DCM and coupling with (4,6-dimethyl-pyridin-2~yl)- methyl-amine to afford N-(4,6-dimethyl-pyridin-2-yl)-iV-methyl-3-[methyl-(4-nitro- phenyl)-amino]-propionamide. Amide reduction with borane-dimethylsulfide in THF at reflux and catalytic hydrogenation over Raney nickel in methanol gives the required aniline. All of the starting materials referred to in the reactions described above are available from commercial sources or can be prepared by analogy with known methods.
In one embodiment, the present invention provides combinations of the pyrrole derivative of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof, with a further antifungal agent. Thus, the pyrrole derivative of formula (I)5 (IA), (IB) or pharmaceutically acceptable salt thereof (also referred to herein as the first antifungal agent) is present in the combinations, compositions and products of the invention with a second antifungal agent The second antifungal agent used in the invention can be any suitable antifungal agent that the skilled person would judge to be useful in the circumstances. Particularly suitable classes of antifungal agents include azoles, polyenes, purine nucleotide inhibitors, pyrimidine nucleotide inhibitors, mannan inhibitors, protein elongation factor inhibitors, chitin synthase inhibitors, Beta-glucan synthase inhibitors, echinocandins, allylamines, anti-HSP90 antibodies, bactericidal/permeability inducing protein products and polyoxins. Other suitable antifungal agents which do not fall within the classes above include the compounds AN2690, AN2718 and icofungipen.
Preferred azoles are clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, fluconazole, isoconazole, itraconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, isavuconazole, ravuconazole, posaconazole, terconazole and voriconazole. Preferred echinocandins are anidulafungin, caspofungin and micafungin. Preferred allylamines are terbinafine, butenafine, amorolfine and naftifme. Preferred polyenes are amphotericin B and nystatin. A preferred example of a purine or pyrimidine nucleotide inhibitor is flucytosine. A preferred mannan inhibitor is pradamicin. A preferred protein elongation factor inhibitor is sordarin and analogues thereof. A preferred polyoxin is nikkomycin Z.
Particularly preferred second antifungal agents are caspofungin, micafungin, amphotericin B, voriconazole, posaconazole, fluconazole and itraconazole.
Examples of preferred combinations of the invention are compounds of formula (IA) and their pharmaceutically acceptable salts as defined above with a second antifungal agent selected from caspofungin, micafungin, amphotericin B, voriconazole, posaconazole, fluconazole and itraconazole. Further preferred combinations of the invention are combinations of (i) compounds of formula (Ia) and pharmaceutically acceptable salts thereof wherein:
Al represents phenyl, which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO2H and halogen, preferably Al is unsubstituted or substituted with one group selected from F, Cl and methyl, most preferably Al is unsubstituted; n represents one;
Ll represents an unsubstituted, saturated 5- to 7-membered heterocyclyl group containing two nitrogen atoms, the heterocycle being attached to Al and to Rl via a nitrogen atom, preferably Ll represents piperazinyl;
Rl represents unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or a group -A2, -CH2- A2 or -A2-CH2-A3;
A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF3, - OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group;
R5 represents unsubstituted phenyl;
R2 represents hydrogen, or C1-C4 alkyl or C2-C4 alkenyl, each of which may be unsubstituted or substituted with -OMe, -OEt, -OPr, -OBu3 -OCH2CH2OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C4 alkyl and C1-C4 alkoxy; and
R3 represents hydrogen or C1-C4 alkyl which is unsubstituted or substituted with -OMe or -OEt; with (ii) a second antifungal agent selected from caspofungin, micafungin, amphotericin B5 voriconazole, posaconazole, fluconazole and itraconazole.
In a preferred aspect of this embodiment, in the compounds of formula (IA)5 Al is a phenyl group which is unsubstituted or substituted with F, Cl or methyl, preferably Al is unsubstituted phenyl; Ll is piperazinyl and is linked to Al and Rl via a nitrogen atom; and Rl is unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or piperidinyl, wherein the piperidinyl group is unsubstituted or substituted with one, two or three substituents selected from unsubstituted C1-C4 alkyl groups. More preferably, Rl is piperidinyl which is substituted with two methyl groups. In a further preferred aspect of this embodiment, in the compounds of formula
(IA), R2 and R3 are independently selected from hydrogen and unsubstituted C1-C4 alkyl groups, preferably methyl.
In a further preferred as pect of this embodiment, the compound of formula (IA) is 2-(l,5-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3 -phenyl- lH-pyrrol-2-yl] -2-oxo-acetamide,
N-{3-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-
3-phenyl-l/f-pyrrol-2-yl)-2-oxo-acetamide, N-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-
3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N- { 3 -Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-[ 1 -(2- methoxy-ethyl)-5-methyl-3-phenyl-l//-pyrrol-2-yl]-2-oxo-acetamide,
Ν-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-ethyl-5-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- propyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l-Butyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl]-phenyl} -2-oxo-acetamide, 2-(l55-Dimethyl-3-phenyl-lH'-pyrrol-2-yl)-2-oxo-iV'-[4-(4-pyridin-2-yl-piperazin-l-yl)- phenyl] -acetamide. 2-( 1 ,5-Dimethyl-3 -phenyl- 1 J7-pyrrol-2-yl)-iV- {4- [4-(6-methyl-pyridin-2-yl)-piperazin-
1 -yl]-phenyl} -2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-l//-pyrrol-2-yl)-iVr-{4-[4-(4-methyl-pyridin-2-yl)-piperazin- l-yl]-phenyl}-2-oxo-acetarnide, N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl } -2-( 1 -methyl-3 -phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l,5-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl]-3 -methyl-phenyl} -2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-ethyl-l-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-(l -methoxymethyl-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV'-[2-fluoro-4-(4-pyridin-2-yl-piperazin-l- yl)-phenyl]-2-oxo-acetamide,
(2-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl amino oxalyl}-5- methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester,
2-(l,5-Dimetliyl-3-phenyl-lH-pyrrol-2-yl)-N-[2-fluoro-4-(4-isobutyl-piperazin-l-yl)- phenyl] -2-oxoacetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{2-fluoro-4-[4-(2-methyl-allyl)-piperazin-
1 -yl] -phenyl } -2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(2,2-dimethyl-propyl)-piperazin-l- yl]-2-fluoro-phenyl}-2-oxo-acetamide, 2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV'-[3-fluoro-4-(4-pyridin-2-yl-piperazin-l- yl)-phenyl]-2-oxo-acetamide,
2-( 1 , 5 -Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-N- [3 -fluoro-4(4-isobutyl-piperazin- 1 -yl)- phenyl]-2-oxo-acetamide;,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(5-morpholin-4-ylmethyl-pyridin-2- yl)-piperazin- 1 -yl]-phenyl} -2-oxo-acetamide,
N-{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-2-fluoro-phenyl}-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl-lΗ-pyrrol-2-yl)-2-oxo-acetamide, or N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-ethoxymethyl-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, or a pharmaceutically acceptable salt thereof.
The most preferred combinations of the invention include combinations of 2- (l,5-Dimethyl-3-phenyl-lH'-pyrrol-2-yl)-iV'-{4-[4-(456-dimethyl-pyridin-2-yl)-piperazm-
1-yl] -phenyl }-2-oxo-acetamide or a pharmaceutically acceptable salt thereof, with a second antifungal agent selected from caspofungin, micafungin, amphotericin B, voriconazole, posaconazole, fluconazole and itraconazole.
The compounds of the invention have antifungal activity. Accordingly, they may be used in a method of treating a subject suffering from or susceptible to a fungal disease, which method comprises administering to said subject an effective amount of a pyrrole derivative of formula (I), (IA) or (IB) or a pharmaceutically acceptable salt thereof. The compounds may be used in combination with a second antifungal agent, as desired. Preferably, the fungal disease comprises an infection by a fungus, for example an Ascomycete. Preferably, the fungal disease comprises an infection by an organism selected from the genera Absidia; Acremonium; Alternaria; Aspergillus; Bipolaήs;
Blastomyces; Blumeria; Candida; Cladosporium; Coccidioides; Colletotrichium;
Cryptococcus; Curvularia; Encephalitozoon; Epicoccum; Epidermophyton; Exophiala; Exserohilum; Fusarium; Histoplasma; Leptosphaeria; Microsporum; Mycosphaerella;
Neurospora, Paecilomyces; Penicillium; Phytophthora; Plasmopara; Pneumocystis;
Pyricularia; Pythium; Puccinia; Rhizoctonia; Rhizomucor; Scedosporium;
Scopulariopsis; Trichophyton; Trichosporon; and Ustilago.
Preferably, the fungal disease comprises an infection by an organism of the genus Aspergillus or Candida.
Preferably, the fungal disease comprises an infection by an organism selected from the species Absidia corymbifera; Acremonium spp; Alternaria alternata;
Aspergillus flavus; Aspergillus fumigatus; Aspergillus nidulans; Aspergillus niger;
Aspergillus parasiticus; Aspergillus terreus; Bipolar is spp; Blastomyces dermatitidis; Blumeria graminis; Candida albicans; Candida glabrata; Candida krusei; Candida parapsilosis; Candida ti'opicalis; Cladosporium cladosporoides; Cladosporium herbarium; Coccidioides immitis; Coccidioides posadasii; Curvularia lunata; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi; Epicoccum nigrum; Epidermophytonβoccosum; Exophiala spp; Exserohilum rostratum; Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Histoplasma capsulation; Leptosphaeria nodorum; Microsporum canis; Mycosphaerella graminicola; Paecilomyces lilanicus; Paecilomyces varioti;
Penicillium chrysogenum; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis proved; Puccinia coronata; Puccinia graminis; Pyricularia ory∑ae; Pythium ultimum; Rhizoctonia solani; Rhizomucor spp; Rhizopus spp; Scedosporium apiospermum; Scedosporium proϊificans; Scopulariopsis brevicaulis; Trichophyton mentagrophytes; Trichophyton inter digitale; Trichophyton rubrum; Trichosporon asahii; Trichosporon beigelii; and Ustilago maydis.
Preferably, the fungal disease comprises an infection by Aspergillus fumigatus. Examples of fungal diseases, which can be prevented or treated using the compounds of the invention, include both systemic and superficial infections. The fungal diseases include invasive fungal diseases caused by Aspergillus and Candida species such as aspergillosis or candidiasis, but also local forms of these infections. The compounds of the invention are particularly useful against diseases caused by Aspergillus species, for which a fungicidal drug is required which has lower toxicity than amphotericin. The invention also provides for the treatment of dermatological infections.
In one embodiment, the compounds of the invention are for use in the prevention or treatment of a disease caused by Aspergillus species. In a further embodiment of the invention, the compounds of the invention are pyrrole derivatives of formula (IB) or pharmaceutically acceptable salts thereof, these compounds being for use in preventing or treating diseases caused by Candida species. The compounds of formula (IB) or pharmaceutically acceptable salts thereof are therefore particularly useful in the prevention or treatment of diseases caused by Aspergillus species and diseases caused by Candida species.
The diseases caused by Aspergillus species include diseases caused by A. fumigatus, A. flavus, A. terreus and A. niger.
The diseases cause by Candida species include diseases caused by C. albicans, C. glabrata, C. krusei, C. tropicalis and C. parapsillosis. Examples of systemic infections which might be prevented or treated using the compounds of the invention include: systemic candidiasis; pulmonary aspergillosis, e.g. in immunosuppressed patients such as bone marrow recipients or AIDS patients; systemic aspergillosis; cryptococcal meningitis; rhinocerebral mucomycosis; blastomycosis; histoplasmosis; coccidiomycosis; paracoccidiomycosis; lobomycosis; sporotrichosis; chromoblastomycosis; phaeohyphomycosis; zygomycosis; cryptococcosis and disseminated sporotrichosis.
Examples of superficial infections, which can be prevented or treated using the compounds of the invention, include: ring worm; athlete's foot; tinea unguium (nail infection); candidiasis of skin, mouth or vagina; and chronic mucocutaneous candidiasis.
Examples of diseases or conditions which are caused by fungi or where fungi exacerbate an allergic response, and which can be prevented or treated using the compounds of the invention, include allergic bronchopulmonary asthma (ABPA); asthma, rhinosinusitis and sinusitis.
The present invention includes a pharmaceutical composition comprising a compound according to the invention and a pharmaceutically acceptable carrier or diluent. Said pharmaceutical composition typically contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention. Preferred pharmaceutical compositions are sterile and pyrogen free. Where a compound of the invention can exist as optical isomers, the pharmaceutical compositions provided by the invention typically contain a substantially pure optical isomer.
In one embodiment, the composition additionally comprises a second antifungal agent. In this embodiment, the pyrrole and second antifungal agent need not be present in admixture in a single composition. However, the pyrrole and second antifungal agent are preferably formulated for simultaneous or successive administration.
The compounds, combinations, compositions and products of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds, combinations, compositions and products of the invention may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds, combinations, compositions and products may also be administered as suppositories. The compounds, combinations, compositions and products may be administered by inhalation in the form of an aerosol via an inhaler or nebuliser. A compound of the invention, and optionally a second antifungal agent, is typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, solubilising agents, e.g. cyclodextrins or modified cyclodextrins; diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.
Liquid dispersions for oral administration may be solutions, syrups, emulsions and suspensions. The solutions may contain solubilising agents e.g. cyclodextrins or modified cyclodextrins. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol; solubilising agents, e.g. cyclodextrins or modified cyclodextrins, and if desired, a suitable amount of lidocaine hydrochloride.
Solutions for intravenous or infusions may contain as carrier, for example, sterile water and solubilising agents, e.g. cyclodextrins or modified cyclodextrins or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. Nanoformulations are also envisaged. A therapeutically effective amount of a compound of the invention is administered to a patient. A typical daily dose is up to 200 mg, e.g. up to 100 mg or up to 50 mg per kg of body weight, for example from 0.001 to 200 or 0.001 to 50 mg per kg of body weight, according to the activity of the specific compound or combination of specific antifungal agents used, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are up to 200mg, e.g. up to 150mg, up to lOOmg, up to 50 mg or up to 40mg per kg of body weight. Daily dosage levels are for example at least lmg, at least 2 mg or at least 5 mg per kg of body weight. In one embodiment the daily dosage level is from 0.05 mg to 2 g, preferably from 0.1 mg to 10 mg. Where a combination is administered, the compound of the invention is typically administered in an amount of at least 0.05 mg, preferably at least 0.1 mg, 2 mg or at least 5 mg. A preferred upper limit on the amount of compound of the invention administered is typically 200mg, e.g. 100 mg, 50 mg or 25 mg. The second antifungal agent is typically administered at or below the standard dose used for that drug. An advantage of the combinations of the present invention is that known antifungal agents may be administered in lower doses than are currently used, resulting in a reduction in toxic effects. The compound, combination or composition of the invention is typically administered to the patient in a non-toxic amount. The present invention also provides a method of controlling a fungal disease of a plant, which comprises applying to the locus of the plant a pyrrole derivative of formula (I), (IA) or (IB) or an agriculturally acceptable salt thereof, and optionally a second antifungal agent.
The compounds, combinations, compositions and products of the invention may, for example, be applied to the seeds of the plants, to the medium (e.g. soil or water) in which the plants are grown, or to the foliage of the plants.
The compounds, combinations, compositions and products of the invention are preferably used in the treatment or prevention of fungal diseases. Examples of fungal diseases of plants which can be controlled using the compounds of the invention include fungal diseases caused by the following plant pathogens: Blumeria graminis; Colletotrichium trifolii; Fusarium gramimarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Neurospora crassa; Phytophthora capsicϊ, Phytophthora infestans; Plasmopara viticola; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani; Trichophyton rubrum; and Ustilago maydis.
The present invention includes a composition comprising a compound of the invention, or an agriculturally acceptable salt thereof, and an agriculturally acceptable carrier or diluent. In one embodiment of the invention, the composition further comprises a second antifungal agent. Said agricultural composition typically contains up to 85 wt% of a compound of the invention. More typically, it contains up to 50 wt% of a compound of the invention. When used in an agricultural composition, the skilled person will readily be able to determine suitable levels of administration. As examples, the antifungal agent(s) can be used at a level of from 5g to 10kg per hectare, for example from 1Og to 5kg per hectare, for example from lOOg to 2kg per hectare.
Suitable agriculturally acceptable salts include salts with agriculturally acceptable acids, both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Salts may also be formed with agriculturally acceptable bases such as alkali metal (e.g. sodium or potassium) and alkaline earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines. A preferred agriculturally acceptable salt is the hydrochloride salt.
The compounds of the invention, and optional second antifungal agents, may be applied in combination with inert carriers or diluents, as in aqueous sprays, granules and dust formulations in accordance with established practice in the art. An aqueous spray is usually prepared by mixing a wettable powder or emulsifiable concentrate formulation of a compound of the invention with a relatively large amount of water to form a dispersion.
Wettable powders may comprise an intimate, finely divided mixture of a compound of the invention, an inert solid carrier and a surface-active agent. The inert solid carrier is usually chosen from among the attapulgite clays, the kaolin clays, the montmorillonite clays, the diatomaceous earths, finely divided silica and purified silicates. Effective surfactants, which have wetting, penetrating and dispersing ability are usually present in a wettable powder formulation in proportions of from 0.5 to 10 percent by weight. Among the surface active agents commonly used for this purpose are the sulfonated lignins, naphthalenesulfonates and condensed naphthalenesulfonates, alkylbenzenesulfonates, alkyl sulfates and non-ionic surfactants such as products of condensation of ethylene oxide with alkylphenols.
Emulsifiable concentrates may comprise a solution of a compound of the invention in a liquid carrier which is a mixture of a water-immiscible solvent and a surfactant, including an emulsifier. Useful solvents include aromatic hydrocarbon solvents such as the xylenes, alkylnaphthalenes, petroleum distillates, terpene solvents, ether-alcohols and organic ester solvents. Suitable emulsifiers, dispersing and wetting agents may be selected from the same classes of products which are employed in formulating wettable powders.
The fungicide formulations desirably contain from 0.1 percent to 95 percent by weight of the compound of the invention, or in the case of a combination of antifungal agents the total weight of antifungal agent, and from 0.1 to 75 percent of an inert carrier or surfactant. The direct application to plant seeds prior to planting may be accomplished in some instances by mixing either a powdered solid compound of the invention or a dust formulation with seed to obtain a substantially uniform coating which is very thin and represents only one or two percent by weight or less, based on the weight of the seed. In some instances, however, a non-phytotoxic solvent such as methanol is conveniently employed as a carrier to facilitate the uniform distribution of the compound of the invention on the surface of the seed.
When a compound of the invention, or in the case of a combination of antifungal agents one of the antifungal agents used, is to be applied to the soil, as for pre- emergence protection, granular formulations or dusts are sometimes more convenient than sprays. A typical granular formulation comprises a compound of the invention dispersed on an inert carrier such as coarsely ground clay, or clay which has been converted to granules by treatment of a rolling bed of the powdered material with a small amount of liquid in a granulating drum. In the usual process for preparing granular formulations, a solution of the active compound is sprayed on the granules while they are being agitated in a suitable mixing apparatus, after which the granules are dried with a current of air during continued agitation. Dust formulations customarily employ essentially the same inert diluents as wettable powders and granules, but are well-mixed in powder form and do not usually contain emulsifiers. Dusts may contain some surface active agents to facilitate uniform distribution of the active ingredient in the formulation and to improve the uniformity and adhesion of the dust coating on seeds and plants. The colloidal dispersion of dust formulations in the air is usually prevented by incorporation of a minor amount of an oily or waxy material in the formulation to cause agglomeration of colloidal size particles. In this way the dust may be applied to seeds or plants without generation of an air-polluting aerosol.
The following examples illustrate the invention but are not intended to limit the scope of the invention. In this regard, it is important to understand that the particular assays used in the Examples section are designed only to provide an indication of antifungal activity. There are many assays available to determine such activity, and a negative result in any one particular assay is therefore not determinative.
EXAMPLES
Reference Example 1; 3-MethoxypropionyI chloride
Thionyl chloride (7.48g, 64.46 mmol) was added to a solution of 2-methoxy- propionic acid (6.Og5 57.69 mmol) in chloroform (50 mL) and refluxed for 2 h.
Chloroform was then added and excess thionyl chloride removed in vacuo to afford (6.0 g, 82%) of 3-methoxypropionyl chloride as a colourless liquid.
Reference Example 2: Ethyl 3-(2-furyI)-3-oxo-propanoate
Triethylamine (11.7 mL, 84.3 mmol) was added drop wise to a suspension of potassium ethyl malonate (13.4 g, 78.5 mmol) in acetonitrile (80 mL) at 10 0C, followed by portionwise addition of anhydrous magnesium chloride (9.12 g, 95.8 mmol). The reaction mixture was warmed to room temperature and stirred for 2.5 h. The resulting white slurry was cooled to 0 0C and furan-2-carbonyl chloride (5.0 g, 38.3 mmol) in acetonitrile (20 mL) was added dropwise over a period of 20 min. The mixture was allowed to stir at ambient temperature overnight. The solvent was evaporated in vacuo and the residue was azeotroped with toluene (10 mL) then dissolved in toluene, cooled to between 0 and 5 0C and acidified with 13% aqueous hydrochloric acid (50 mL). After stirring for 15 min the aqueous phase was separated and the organic phase was washed with 13% aqueous hydrochloric acid (2 x 50 mL) followed by water (2 x 25 mL) and concentrated in vacuo to afford the crude compound. Purification by flash column chromatography over silica gel (100-200 mesh) using 5% ethyl acetate in petroleum ether as eluent afforded ethyl 3-(2-furyl)-3-oxo-propanoate (5.01 g, 72%) as a pale yellow liquid.
Reference Examples 3 to 8
The compounds set out below were prepared in a manner analogous to Reference Example 2:
Reference Compound Example
3 Ethyl 3-oxo-3-(2-thienyl)propanoate
4 Ethyl 4-methyl-3~oxo~pentanoate
5 Ethyl 3-oxo-3-tetrahydropyran-4-yl-propanoate
6 Ethyl 3-oxopentanoate
7 Ethyl 3-oxohexanoate
8 Ethyl 5-methoxy-3-oxo-pentanoate
Reference Example 9: Ethyl-2-hvdroxyimino-3-oxo-3-phenyI-propanoate
A solution of sodium nitrite (56.5 g, 0.815 mol) in water (400 mL) was added to a solution of ethyl benzoyl acetate (120 g, 0.625 mol) in glacial acetic acid (300 mL) at 0 - 10 0C over a period of 2 h. The product started precipitating during the course of addition and the reaction mixture was warmed to room temperature and stirred for 30 min. Water (2.5 L) was added and the mixture was stirred for a further 30 min and then filtered under suction. The solid was washed with water (20 mL), petroleum ether (200 mL) and then dissolved in chloroform (700 mL). The filtrate was extracted with chloroform (2 x 100 mL) and the combined organic phase was washed with water (2 x 200 mL), brine solution (2 * 250 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to afford ethyl-2-hydroxyimino-3-oxo-3-ρhenyl-propanoate (122.5 g, 88%).
Reference Example 10 to 14
The compounds set out below were prepared in a manner analogous to Reference Example 9:
Reference Compound Example
10 Ethyl 3 -(2-furyl)-2-hydroxyimino-3 -oxo-propanoate
11 Ethyl 2-hydroxyimmo-3-oxo~3-(2-thienyl)propanoate
12 Ethyl 2-hydroxyimino-4-methyl-3 -oxo-pentanoate
13 Ethyl 2-hydroxyimino-3-oxo-3-tetrahydropyran-4-yl-propanoate
14 Ethyl 2-hydroxyimino-5-methoxy-3 -oxo-pentanoate
Reference Example IS: Diethyl 5-methyl-3-phenyI-lH-pyrroIe-2,4-dicarboxγIate
A mixture of ethyl acetoacetate (72.5 g5 0.56 mol), zinc dust (98 g, 1.51 mol) and anhydrous sodium acetate (102 g, 1.21 mol) in glacial acetic acid (110 mL) was heated to 60 0C. Ethyl-2-hydroxyimino-3-oxo-3-phenyl-propanoate (110 g, 0.5 mol) was added as a solution (some precipitation on standing) in glacial acetic acid (550 mL) in 3 portions with vigorous stirring over a period of 1 h. The temperature increased to 90 0C during the addition and the reaction was then maintained at 60 - 75 0C for 3 h. Additional zinc dust (49 g, 0.75 mol) was added over 15 min, again causing a temperature rise, and then the reaction mixture was then stirred at 60 to 75 °C for 1 h. After cooling to room temperature the mixture was filtered and the filtrate was evaporated in vacuo to give a residue which was azeotroped with toluene (2 x 200 mL) to remove residual acetic acid. Water (2 L) and ethyl acetate (300 mL) were added to the residue and the mixture was stirred until two clear phases were obtained. The organic phase was separated and the aqueous phase extracted with ethyl acetate (2 x 200 mL). The combined organic phases were washed successively with water (2 x 250 mL), saturated bicarbonate solution (2 x 250 mL), water (2 x 100 mL), brine (2 x 100 mL), dried over anhydrous sodium sulfate and then concentrated to give a gummy residue. A mixture of dichloromethane and petroleum ether (175 mL; 1 :6) was added to the solid and it was stirred for 15 rnin. The resulting free-flowing solid was filtered off and washed with chilled petroleum ether (100 mL) to afford diethyl 5-methyl-3-phenyl- lH-pyrrole-254-dicarboxylate (85 g, 57%) as an off-white solid.
Reference Examples 16 to 24
The compounds set out below were prepared in a manner analogous to Reference Example 15:
Reference Compound Example
16 2-Ethyl 4-methyl 3-(2-furyl)-5-methyl-lH-pyrrole-254-dicarboxylate
17 Diethyl 5-methyl-3 -(2-thienyl)- 1 H-pyrrole-2,4-dicarboxylate
18 2-Ethyl 4-methyl 3 -isopropy 1-5 -methyl- lH-pyrrole-2,4-dicarboxy late
19 2-Ethyl 4-methyl 5-memyl-3-tetrahydropyran-4-yl-lH-pyrrole-2,4- dicarboxylate
20 Diethyl 5-isopropyl-3 -phenyl- 1 H-pyrrole-2,4-dicarboxylate
21 Diethyl 5-ethyl-3 -phenyl- 1 H-pyrrole-2,4-dicarboxylate
22 Diethyl 3-(2-methoxyethyl)-5-methyl-lH-pyrrole-2,4-dicarboxylate
23 Diethyl 3-phenyl-5-propyl-lH-pyrrole-2,4-dicarboxylate
24 Diethyl 5-(2-methoxyethyl)-3-phenyl-lH-pyrrole-2,4-dicarboxylate
Reference Example 25: Ethyl 4-methyl-3-phenyl-lH-pyrrole-2-carboxyIate
l,8-Diazabicyclo[5.4.0]undec-7-ene (3.70 g, 24.6 mmol) was added dropwise to a stirred solution of ethyl isocyanoacetate (1.50 g, 13.3 mmol) and 2-nitro-3-phenyl-2- propene (2.0 g, 12.3 mmol) in a mixture of tetrahydrofuran (15 mL) and wσ-propanol (5 mL) at between 10 and 20 °C. The reaction mixture was stirred at room temperature for 4 h. Excess tetrahydrofuran was removed in vacuo, water (15 mL) was added to the residue and the mixture was extracted with diethyl ether (3 x 25 mL). The combined organic phases were washed with brine (2 x 15 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford ethyl 4-methyl-3 -phenyl- IH- pyrrole-2-carboxylate (2.5 g, 90%) as an oil.
Reference Example 26: Diethyl l,5-dimethyI-3-phenvI-pyrroIe-2,4-dicarboxylate
A solution of diethyl 5-methyl-3 -phenyl- lH-pyrrole-2,4-dicarboxylate (85 g, 0.28 mol) in dry tetrahydrofuran (240 mL) was added to a suspension of sodium hydride (60% w/w; 17 g, 0.425 mol) in dry tetrahydrofuran (200 mL) at 0 0C over 45 min. The mixture was warmed to room temperature and stirred for 1 h before cooling back to 0 C. Methyl iodide (71 mL, 1.13 mol) was added dropwise over 30 min and the reaction mixture and then stirred at room temperature for 18 h. The mixture was quenched with ice- water (100 mL) and concentrated in vacuo to remove volatile organics. The aqueous phase was decanted off and the residual solid was extracted with dichloromethane (350 mL). The aqueous phase was extracted with dichloromethane (2 x 100 mL) and the combined extracts were washed successively with water (2 x 200 mL), brine (2 * 100 mL), dried over anhydrous sodium sulfate and concentrated to afford diethyl 1,5- dimethyl-3-phenyl-pyrrole-2,4-dicarboxylate (80 g, 90%) as a yellow solid.
Reference Examples 27 to 34
The compounds set out below were prepared in a manner analogous to Reference Example 26:
Reference Compound Example
27 2-Ethyl 4-methyl 3-(2-furyl)-l,5-dimethyl-pyrrole-254-dicarboxylate
28 Diethyl 1 ,5-dimethyl-3-(2-thienyl)pyrrole-2,4-dicarboxylate
29 2-Ethyl 4-methyl 3-isopropyl-l55-dimethyl-pyrrole-2,4-dicarboxylate
30 2-Ethyl 4-methyl l,5-dimethyl-3-tetrahydropyran-4-yl-pyiτole-2.,4- dicarboxylate
31 Ethyl 1 ,4-dimethyl-3 -phenyl-pyrrole-2-carboxylate
32 Diethyl 5 -isopropyl- 1 -methyl-3 -phenyl-pyrrole-2,4-dicarboxylate 33 Diethyl 1 -methyI-3 -pheny l-5-ρropyl-pyrrole-2,4~dicarboxylate
34 2-(Methoxymethyl)-l-methyl-4--phenyl-pyrrole
Reference Example 35: Diethyl 3-isopropyI-l-(2-methoxyethyI)-5-methyl-pyrrole- 2,4-diearboxyIate
Sodium hydride (55%; 555 mg, 12.7 mmol) was added to a solution of 2-ethyl
4-methyl 3-isopropyl-5-methyl-lH-pyrrole-2,4-dicarboxylate (1.8 g, 6.74 mmol) in dry dimethylformamide (10 mL) at 0-5 °C and stirred for 30 min. l-Bromo-2-methoxy- ethane (1.0 mL, 10.1 mmol) was added dropwise to the mixture which was stirred at 90 0C for 2 h. Additional sodium hydride (55%; 275 mg, 6.37 mmol) was added followed by l-bromo-2-methoxy-ethane (1.0 mL, 10.1 mmol) and stirring continued at 90 °C for 5 h. The reaction mixture was cooled to room temperature, quenched with ice water and extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with water (2 x 50 mL), brine (50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to afford diethyl 3-isopropyl-l-(2-methoxyethyl)-5-methyl- pyrrole-2,4-dicarboxylate (2.2 g, 100%).
Reference Examples 36 to 43
The compounds set out below were prepared in a manner analogous to Reference Example 35:
Reference Compound Example
36 Diethyl l-ethyl-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylate
37 Diethyl 5-methyl-3 -phenyl- 1 -propyl-pyrrole-2,4-dicarboxylate
38 Diethyl 1 -butyl-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylate
39 Ethyl 1 -methyl-4-phenyl-pyrrole-2-carboxylate
40 Diethyl l-benzyl-5-methyl-3-phenyl-pyrroIe-2,4-dicarboxylate
41 Methyl 2-(2-methyl-4-phenyl-pyrrol-l -yl)acetate
42 Diethyl 1 -(2-methoxyethyl)-5-methyl-3-phenyl-pyrrole-2,4- dicarboxylate 43 Diethyl 5-methyl-l -(2-ρhenoxyethyl)-3-phenyl-pyrrole-2,4- dicarboxylate
Reference Example 44: l-Ethoxy-2-iodo-ethane
Toluene-4-sulfonic acid 2-ethoxy-ethyl ester (prepared according to Crowley et. al, J. Chem. Soc, 1957, 2931-2934; 3.5 g, 14.3 mmol) was added to a solution of sodium iodide (4.30 g, 28.7 mmol) in acetone (30 mL) and heated at reflux overnight. Acetone was evaporated from the reaction mixture and ether was added. The mixture was filtered and the filtrate was concentrated in vacuo to afford l-ethoxy-2-iodo-ethane (1.5 g, 52%).
Reference Example 45: Diethyl l-(2-ethoxyethyI)-5-methyl-3-phenyl-pyrroIe-2,4- dicarboxylate
Potassium carbonate (1.82 g, 13.3 mmol) was added to a solution of diethyl 5- methyl-3-phenyl-lH-pyrrole-2,4-dicarboxylate (1.0 gs 3.32 mmol) and l-ethoxy-2-iodo- ethane (1.98 g, 9.96 mmol) in acetonitrile (20 mL) and the mixture heated at reflux for 72 h. The inorganic salts were filtered off and the filtrate was concentrated in vacuo to afford diethyl l-(2-ethoxyethyl)-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylate (1.25 g, quantitative).
Reference Examples 46 to 49
The compounds set out below were prepared in a manner analogous to Reference Example 45:
Reference Compound Example
46 Diethyl 1 -(3 -chloropropyl)-5 -methyl-3 -phenyl-pyrrole-2,4- dicarboxylate
47 Diethyl 5-isopropyl- 1 -(2-methoxyethyl)-3 -phenyl-pyrrole-2,4- dicarboxylate 48 1 -Benzyl-4-isobutyl-piperazine
49 tert-Butyl 4-(2-methylallyl)piperazine- 1 -carboxylate
Reference Example 50: Ethyl 2-cyano-4-methyl-pent-2-enoate
A solution of piperidine (0.3 mL, 3.04 nimol) in acetic acid (3 mL) was added to a solution of ethyl cyano acetate (10 g, 88.50 mmol) and isobutyraldehyde (9.35 g, 0.13 mol) in acetic acid at room temperature. The reaction mixture was allowed to stand for 24 h at room temperature, then diluted with water (50 mL) and extracted with ether (3 x 50 mL). The combined ether layers were washed with saturated bicarbonate solution, water, and brine and the organics were dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude compound. Purification by vaccum distillation (950C at 0.1mm Hg) afforded ethyl 2-cyano-4-methyl-pent-2-enoate (6.5 g, 30%) as a liquid.
Reference Example 51: 2-IsopropγlbutanedinitriIe
A solution of potassium cyanide (5.81 g, 89.52 mmol) in water (12 mL) was added to a solution of ethyl 2-cyano-4-methyl-pent-2-enoate (6.5 g, 38.92 mmol) in ethanol (20 mL) at room temperature and the reaction mixture was stirred overnight. The resulting mixture was refluxed for 2 h and then cooled to room temperature. The ethanol was evaporated and the residue dissolved in dichloromethane. The dichloromethane layer was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 2-isopropylbutanedinitrile (3.5 g, 74%) as a liquid.
Reference Example 52: 3-Isopropyl-lH-pyrrole
20% Diisobutyl aluminium hydride in toluene (62 mL, 74.59 mmol) was added to a solution of 2-isopropylbutanedinitrile (3.5 g, 28.69 mmol) in benzene (25 mL) at O0C. The reaction mixture was warmed to room temperature and stirred for 3 h. The reaction mixture was quenched with 2M sodium dihydrogen phosphate solution (200 mL), refluxed for 1 h then cooled to room temperature. Ether (50 mL) was added and the un-dissolved salts were filtered and 15% aq sodium chloride solution was added to the filtrate. The ether layer was separated, washed with water, brine solution and dried over anhydrous sodium sulfate. The organics were concentrated under reduced pressure to give the crude compound which was purified by vacuum distillation (100 0C at 0.15 mm Hg) to afford 3-isopropyl-lH-pyrrole (350 mg, 11%) as a liquid.
Reference Example 53: Ethyl l-(2-methoxyethyI)-4-phenvI-pyrrole-2-carboxyIate
Potassium fert-butoxide (780 mg, 6.96 mmol) was added in three portions over a period of 10 minto a stirred solution of ethyl 4-phenyl-lH'~pyrrole-2-carboxylate (1.0 g, 4.63 mmol) in dimethylsulfoxide (10 mL) at 10 0C and maintained at this temperature for 30 min. A solution of l-bromo-2-methoxy-ethane (770 mg, 5.50 mmol) in dimethylsulfoxide (2 mL) was added drop wise to the reaction mixture at 10 °C and then stirred for 2 h at room temperature. The reaction mixture was poured into ice water (25 mL) and the aqueous layer extracted with diethyl ether (3 x 20 mL). The combined organic layer was washed with water, brine (2 x 20 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford ethyl l-(2-methoxyethyl)-4- phenyl-ρyrrole-2-carboxylate (1.15 g, 91%) as an oil.
Reference Examples 54 to 77
The compounds set out below were prepared in a manner analogous to Reference Example 53:
Reference Compound Example
54 Diethyl 5 -ethyl- 1 -methyl-3 -phenyl-pyrrole-2,4-dicarboxylate
55 Diethyl 5-ethyl-l-(2-methoxyethyl)-3-ρhenyl-pyrrole-2,4-dicarboxylate
56 Ethyl 4-(2-chlorophenyl)- 1 -(2-methoxyethyl)pyrrole-2-carboxylate
57 4-(4-Chlorophenyl)- 1 -(2-methoxyethyl)pyrrole-2-carboxylic acid
58 Methyl 2-pyrrol-l-ylacetate
59 l-(2-Methoxyethyl)-3-(2-thienyl)pyrrole 60 Ethyl 4-isobutyl- l-(2-methoxyethyl)pyrrole-3-carboxylate
61 5-(3-Phenylpyrrol-l-yl)pentanenitrile
62 tert-Butyl 2-(2-methyl-4-phenyl-pyrrol- 1 -yl)acetate
63 Ethyl 4-(3-chlorophenyl)-l -(2-methoxyethyl)pyrrole-2-carboxylate
64 l-(2-Methoxyethyl)-3-(3-thienyl)pyrrole
65 tert-Butyl 2-(3-phenylpyrrol- 1 -yl)acetate
66 3 -Isopropyl- 1 -(2-methoxyethyl)pyrrole
67 N,N-dimethyl-2-(3 -phenylpyrrol- 1 -yl)ethanamine
68 N,N-dimethyl-2-(2-methyl-4-phenyl-pyrrol- 1 -yl)ethanamine
69 tert-Butyl 2-[3-(2-thienyl)pyrrol-l-yl]acetate
70 tert-Butyl 2-(3 -isobutylpyrrol- 1 -yl)acetate
71 Diethyl 5 -methyl-3 -phenyl- l-(2-pyridylmethyl)pyrrole-2,4- dicarboxylate
72 3-[(2-Methyl-4-phenyl-pyrrol-l-yl)niethyl]pyridine
73 3 -Bromo- 1 -(2-methoxyethyl)-2-methyl-4-phenyl-pyrrole
74 l-(2-Isopropoxyethyl)-2-methyl-4-phenyl-pyrrole
75 Diethyl 5-methyl-3 -phenyl- 1 -(4-pyridylmethyl)pyrrole-2,4- dicarboxylate
76 3-Cyclobutyl-l-(2-methoxyethyl)pyrrole
77 tert-Butyl 2-(3 -cyclobutylpyrrol- 1 -yl)acetate
Reference Example 78: Diethyl 5-methyl-l-(2-methyIsttlfanyIethyI)-3-phenyl- pyrrole-2,4-dicarboxylate
Potassium t-butoxide (224mg, 2.00mmol) was added to a solution of diethyl 5- methyl-3 -phenyl- lH-pyrrole-2,4-dicarboxylate (500 mg, 1.66 mmol) in dry dimethylsulfoxide (10 niL) at 10 0C over 5 min. The reaction mixture was allowed to warm to ambient temperature and stirred for 30 min before cooling again to 1O0C. 1- Chloro-2-methylsulfanyl-ethane (200 mg, 1.81 mmol) was added slowly and the reaction mixture then stirred at ambient temperature for 72 h. Saturated aqueous ammonium chloride was added and the mixture extracted with diethyl ether. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford the crude product. Purification by flash column chromatography over 100-200 mesh silica gel by eluting with 5%-7% ethyl acetate in petroleum ether afforded diethyl 5-methyl-l-(2-methylsulfanylethyl)-3-phenyl-pyrrole- 2,4-dicarboxylate (420 mg, 68%) as a liquid.
Reference Example 79
The compound set out below was prepared in a manner analogous to Reference Example 78:
Reference Compound Example
79 Diethyl 5-methyl- 1 -(methyIsulfanylmethyl)-3 -phenyl-pyrrole-2,4- dicarboxylate
Reference Example 80: Diethyl 5-ethyl-l-(methoxymethyl)-3-phenyl-pyrrole-2,4- dicarboxylate
Sodium hydride (50% in mineral oil; 220 mg, 4.76 mmol) was added to a solution of diethyl 5-methyl-3 -phenyl- 1 H-pyrrole-2,4-dicarboxylate (1 g, 3.18 mmol) in dimethylformamide (15 mL) at 0 0C and then the mixture stirred for 30 min at ambient temperature. The mixture was cooled to 0 0C and chloro-methoxy-methane (0.3 ml, 3.8 mmol) was added and the whole refluxed for 6 h. The reaction mixture was cooled, washed with water (2 x 25ml) and extracted with ethyl acetate (4 x 25ml). The combined ethyl acetate extracts were washed with water (2 x 25ml), brine (25 ml), dried over anhydrous sodium sulphate and concentrated to afford diethyl 5 -ethyl- 1- (methoxymethyl)-3-phenyl-pyrrole-2,4-dicarboxylate (1 g, 88%)as a pale yellow liquid.
Reference Examples 81 The compound set out below was prepared in a manner analogous to Reference
Example 80:
Reference Compound Example
81 Methyl 1 -(methoxymethyl)-4-phenyl-pyrrole-2-carboxylate
Reference Example 82: Diethyl 5-(2-methoxyethyl)-l-methyl-3-phenyl-pyrroIe-2,4- dicarboxylate
Potassium t-butoxide (0.51 g, 4.62 mmol) was added to a solution of diethyl 5-
(2-methoxyethyl)-3 -phenyl- lH-pyrrole-2,4-dicarboxylate (0.8 g, 2.31 mmol) in dry dimethylsulfoxide (15 niL) and stirred for 30 min at ambient temperature. To the reaction mixture was added methyl iodide (0.49 g, 3 Al mmol) and the reaction was stirred for a further 1 h. Saturated aqueous ammonium chloride was added and the mixture extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford diethyl 5-(2- methoxyethyl)-l-methyl-3-phenyl-pyrrole-2,4-dicarboxylate (0.6 g, 72%) as a solid.
Reference Example 83: l,2-Bis(methoxymethyl)-4-phenvI-pyrroIe
Sodium hydride (400 mg 1.83 mmol, 60%) was added to a solution of (1- methoxymethyl-4-phenyl-lH-pyrrol-2-yl)-methanol (420 mg, 2.08 mmol) in tetrahydrofuran (15 mL) at O0C and stirred for a further 15 min. Methyl iodide (517 mg, 3.66 mmol) was added and the reaction mixture stirred for 12 h. The mixture was poured into saturated aqueous ammonium chloride and extracted with ethyl acetate (2 x 5OmL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford l,2-bis(methoxymethyl)-4-phenyl- pyrrole (300 mg, 72%) as a brown liquid.
Reference Examples 84 to 85
The compounds set out below were prepared in a manner analogous to Reference Example 83:
Reference Compound Example
84 1 -(3 -Ethoxypropyl)-2-methyl-4-phenyl-pyrrole
85 2-Methyl-4-pheny 1- 1 -(2-propoxyethyl)pyrrole
Reference Example 86: 3-(2-ThienyDprop-2-enoic acid
Piperidine (2.45 g, 0.056 mol) was added drop wise over a period of 10 min to a stirred solution of thiophene-2-carbaldehyde (4.00 g, 0.036 mol) and malonic acid (1.00 g, 0.18 mol) in pyridine (40 mL) at 0 0C and the resulting reaction mixture was refluxed for 2 h. The reaction mixture was poured into 2N HCl (100 mL) and the precipitated solid filtered. The aqueous layer was extracted with ethyl acetate and the organic layer was washed with brine solution, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 3-(2-thienyl)prop-2-enoic acid (5.00 g, 92%) as a solid.
Reference Examples 87 to 89
The compounds set out below were prepared in a manner analogous to Reference Example 86:
Reference Compound Example
87 5-Methylhex-2-enoic acid
88 3-(3-Thienyl)prop-2-enoic acid
89 4-Methylpent-2-enoic acid
Reference Example 90: Ethyl (3-(2-thienyl)prop-2-enoate
A mixture of 3-(2-thienyl)prop-2-enoic acid (4.00 g, 25.94 mmol), thionyl chloride (6.20 mL, 77.90 mmol) and ethanol (45 mL) were refluxed for 3 h. Excess ethanol was removed in vacuo, then chloroform was added to the residue. The organic phase was washed with saturated sodium bicarbonate solution, water, brine and dried over anhydrous sodium sulfate. The organics were concentrated under reduced pressure to give the crude compound which was purified by column chromatography over silica gel (100-200 mesh) using 5% ethyl acetate in pet ether as eluent to afford ethyl (3-(2- thienyl)prop-2-enoate (2.70 g, 57%) as an oil.
Reference Examples 91 to 96
The compounds set out below were prepared in a manner analogous to Reference Example 90:
Reference Compound Example
91 Ethyl 5-methylhex-2-enoate
92 Ethyl 2-(2-methyl-4-phenyl-pyrrol- 1 -yl)acetate
93 Ethyl 3-(3-thienyl)prop-2-enoate
94 Methyl 2-(3 -phenylpyrrol- 1 -yl)acetate
95 Methyl 2-[3-(2-thienyl)pyrrol- 1 -yl]acetate
96 Methyl 4-methylpent-2-enoate
Reference Example 97: Ethyl 4-(2-thienyl)-lH-pyrroIe-3-carboxyIate
A solution of ethyl (3-(2-thienyl)prop-2-enoate (2.50 g, 13.70 mmol) and toluenesulfonylmethyl isocyanide (2.90 g, 14.90 mmol) in dimethylsulfoxide:diethyl ether (12.50 mL:20 mL) was added drop wise over a period of 15 min to a stirred solution of 60% sodium hydride in mineral oil (760 mg, 18.30 mmol) in diethyl ether (20 mL) at 10 0C. Stirring was continued for 3 h at room temperature and the reaction mixture was quenched with saturated ammonium chloride solution and extracted with diethyl ether. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give crude compound which was purified by column chromatography over silica gel (100-200 mesh) using 18% ethyl acetate in pet ether as eluent to afford 4-thiophene-2-yl-lH-pyrrole-3-carboxylic acid ethyl ester (100 mg, 42%) as a solid. Reference Examples 98 to 100
The compounds set out below were prepared in a manner analogous to Reference Example 97:
Reference Compound Example
98 Ethyl 4-isobutyl- 1 H-pyrrole-3 -carboxylate
99 Ethyl 4-(3 -thienyl)- 1 H-pyrrole-3 -carboxylate
100 Ethyl 4-isopropyl- 1 H-pyrrole-3 -carboxylate
Reference Example 101: Diethyl 3-(2-methoxyethyI)-5-methyl-l-phenyl-pyrrole- 2,4-dicarboxyIate
A mixture of diethyl 3-(2-methoxyethyl)-5-methyl-lH-pyrrole-2,4-dicarboxylate (100 mg,0.35 mmol), phenyl boronic acid (130 mg,1.06 mmol), copper acetate (130 mg,0.71 mmol), dry pyridine (110 mg,1.40 mmol), molecular sieves (400 mg) and dichloromethane (10 niL) was purged with argon gas for 30 min and stirred overnight. The mixture was filtered through a celite bed, washed with dichloromethane (15 mL) and concentrated under reduced pressure. The crude compound was purified by column chromatography over silica gel (100-200 mesh) using 20% ethyl acetate/pet ether as eluent to afford diethyl 3-(2-methoxyethyl)-5-methyl-l-phenyl-pyrrole-2J4- dicarboxylate (50 mg, 40%) as a colourless oil.
Reference Example 102: Ethyl 3-cyclobutylprop-2-enoate
A mixture of cyclobutyl-methanol (8.00 g, 93.02 mmol), ethoxycarbonylmethylene triphenylphosphorane (19.42 g, 55.81 mmol) and pyridine (3 mL) were dissolved in dry chloroform (100 mL) and heated at 70 0C. Manganese dioxide (97.11 g, 1.12 mol) was added portion wise over a period of 5 h (with 1 h gap between each addition) and refluxing was continued for 20 h. The reaction mixture was cooled to room temperature, filtered over celite and washed with chloroform. The filtrate was concentrated and the residue subjected to column chromatography over — i u u i u
silica gel (60-120 mesh) using 0% to 15% of ethyl acetate in pet ether as eluent to afford ethyl 3-cyclobutylprop-2-enoate (2.10 g, 15%) as a liquid.
Reference Example 103: Ethyl 4-cycIobutyl-lH-pyrrole-3-carboxylate
Toluenesulfonylmethyl isocyanide (3.04 g, 15.59 mmol) was added to the stirred solution of ethyl 3-cyclobutylprop-2-enoate (2.00 g, 12.99 mmol) in a mixture of dimethylsulfoxide (2 mL) and diethyl ether (30 mL) and stirred for 45 min. The resulting mixture was added to a slurry of sodium hydride (675 mg, 38.14 mmol, 60% in mineral oil) in diethyl ether (10 mL) over a period of 30 min then stirred for a further 1 h. The reaction mixture was quenched with saturated ammonium chloride solution, the organics were separated and the aqueous layer was extracted with diethyl ether (4 x 10 mL). The combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated. The residue was subjected to column chromatography over silica gel (100-200 mesh) using 0% to 15% of ethyl acetate in pet-ether as eluent, concentrated and dried under reduced pressure to afford ethyl 4-cyclobutyl-lH-pyrrole-3-carboxylate (1.70 g, 67%) as a liquid.
Reference Example 104: l,5-DimethyI-3-phenyl-pyrroIe-2,4-dicarboxyIic acid
A solution of sodium hydroxide (101 g, 2.53 mol) in water (340 mL) was added to a solution of diethyl l,5-dimethyl-3-phenyl-pyrrole-2,4-dicarboxylate (80 g, 0.25 mol) in ethanol (340 mL) and heated at reflux for 15 h. Ethanol was removed under reduced pressure and the residue diluted with water (200 mL) and chilled to 0 °C. Concentrated hydrochloric acid (~150 mL) was slowly added to adjust pH to ~25 while maintaining temperature below 10 °C and the mixture was stirred for 30 min. The precipitated solid was filtered, washed with water (100 mL) and petroleum ether (200 mL) and dried under vacuum at 60 0C to afford l,5-dimethyl-3-phenyl-pyrrole-2,4- dicarboxylic acid (60 g, 91%) as a white solid.
Reference Examples 105 to 145 The compounds set out below were prepared in a manner analogous to Reference Example 104:
Reference Compound Example
105 3-(2-Furyl)-l,5-dimethyl-pyrrole-2,4-dicarboxylic acid
106 1 ,5-Dimethyl-3 -(2-thienyl)pyrrole-2,4-dicarboxylic acid
107 3-Isopropyl-l,5-dimeώyl-pyrrole-2,4~dicarboxylic acid
108 155-Dimethyl-3 -tetrahydropyran-4-yl-pyrrole-254-dicarboxylic acid
109 1 ,4-Dimethyl-3 -phenyl-pyrrole-2-carboxylic acid
110 5-Isopropyl- 1 -methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
111 3 -Isopropyl- 1 -(2-methoxyethyl)-5-methyl-pyrrole-2,4-dicarboxylic acid
112 1 -(2-Ethoxyethyl)-5 -methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
113 1 -(3 -Methoxypropyl)-5-methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
114 l-Ethyl-S-memyl-S-phenyl-pyrrole^^-dicarboxylic acid
115 5 -Methyl-3 -phenyl- 1 -propyl-pyrrole-2,4-dicarboxylic acid
116 1 -Butyl-5-methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
117 1 -Methyl-4-phenyl-pyrrole-2-carboxylic acid
118 1 -Benzyl-5-methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
119 5-Methyl-3-phenyl-lH-pyrrole-2,4-dicarboxylic acid
120 5-Ethyl-l -methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
121 5-Ethyl- 1 -(2-methoxyethyl)-3 -phenyl-pyrrole-2,4-dicarboxylic acid
122 4-(2-Chlorophenyl)-l -(2-methoxyethyl)pyrrole-2-carboxylic acid
123 4-Isobutyl- 1 -(2-methoxy ethyl)pyrrole-3 -carboxylic acid
124 4-(3-Chloroρhenyl)- 1 -(2-methoxyethyl)pyrrole-2-carboxylic acid
125 5-Isopropyl-l-(2-methoxyethyl)-3-phenyl-pyrrole-2,4-dicarboxylic acid
126 3-(2-Methoxyethyl)-5-methyl- 1 -phenyI-pyrrole-2,4-dicarboxylic acid
127 4-Isopropyl- 1 H-pyrrole-3 -carboxylic acid
128 4-Isobutyl- 1 H-pyrrole-3 -carboxylic acid
129 5-methyl-3 -phenyl- 1 -(2-pyridyhnethyl)pyrrole-254-dicarboxylic acid
130 5-Methyl-3-phenyl-l-(4-pyridylmetliyl)pyrrole-2,4-dicarboxylic acid 131 4-Cyclobutyl- 1 H-pyrrole-3 -carboxylic acid
132 l-Methyl-S-phenyl-S-propyl-pyrrole^^-dicarboxylic acid
133 5-Ethyl- 1 -(methoxymethyl)-3 -phenyl-pyrrole-2,4-dicarboxylic acid
134 5-(2-methoxyethyl)-l-methyl-3-phenyl-pyrrole-2,4-dicarboxylic acid
135 l-(Ethoxymethyl)-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylic acid
136 5-Methyl-l-(2-methylsulfanylethyl)-3-phenyl-pyrrole-2,4-dicarboxylic acid
137 l-(3-Hydroxypropyl)-5-metb.yl-3-pb.enyl-pyrrole-2,4-dicarboxylic acid
138 5-Methyl- 1 -(methylsulfanylmethyl)-3 -phenyl-pyrrole-2,4-dicarboxylic acid
139 1 -(2-Methoxyethoxymethyl)-5 -methyl-3 -phenyl-pyrrole-2,4- dicarboxylic acid
140 5-Methyl-3 -phenyl- 1 -(propoxymethyl)pyrrole-2,4-dicarboxylic acid
141 1 -(2-Methoxyethyl)-5-methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
142 5-Methyl-l-(2-phenoxyethyl)-3-phenyl-pyrrole-2,4-dicarboxylic acid
143 l-(4-methoxybut-2-enyl)-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylic acid
144 5-Methyl- 1 - [(2-methyloxazol-4-yl)methyl]-3 -phenyl-pyrrole-2,4- dicarboxylic acid
145 1 -(Butoxymethyl)-5-methyl-3 -phenyl-pyrrole-2,4-dicarboxylic acid
Reference Example 146: 4-PhenyI-lH-pyrrole-2-carboxylic acid
A mixture of ethyl 4-phenyI-liT-pyrrole-2-carboxylate (700 mg, 3.25 mmol), aqueous sodium hydroxide (10% w/v, 10 mL) and ethanol (10 mL) were stirred at room temperature over night. The ethanol was evaporated in vacuo, then water (20 mL) was added and the organics were extracted with ethyl acetate (3 x 20 mL). The aqueous layer was acidified with 2N HCl (to pH 3) and extracted with ethyl acetate (3 x 20 mL). The combined organic layer was washed with water, brine (20 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford 4-phenyl- lJY-pyrrole-2-carboxylic acid (400 mg, 66%) as a solid. Reference Examples 147 to 150
The compounds set out below were prepared in a manner analogous to Reference Example 146:
Reference Compound Example
147 1 -(2-Methoxyethyl)-4-phenyl-pyrrole-2-carboxylic acid
148 1 -(Methoxymethyl)-4-phenyl-ρyrrole-2-carboxylic acid
149 4-(2-Thienyl)- 1 H-pyrrole-3 -carboxylic acid
150 4-(3-Thienyl)-lH-pyrrole-3-carboxylic acid
Reference Example 151 & 152: Dimethyl l-(3-methoxypropyD-5-methyI-3-phenyI- pyrroIe-2,4-dicarboxyIate (151) & 4-methoxycarbonvI-l-(3-methoxypropyI)-5- methyI-3-phenyi-pyrroIe-2-carboxyIic acid (152)
Sodium methoxide (190 rng, 3.50 mmol) was added to a solution of diethyl l-(3- chloropropyl)-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylate (1.1 g, 2.91 mmol) in methanol (10 mL) and stirred at reflux for 28 h. The reaction mixture was cooled to room temperature and concentrated to dryness. The residue was dissolved in water and the aqueous layer was extracted with dichloromethane. The organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford dimethyl l-(3-methoxypropyl)-5-methyl-3-phenyl-pyrrole-2;,4-dicarboxylate (330 mg, 33%) as a yellow oil. The aqueous layer was acidified with 2N hydrochloric acid to pH 2 and extracted with ethyl acetate. The combined organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated to afford 4- methoxycarbonyl-1 -(3-methoxypropyl)-5-methyl-3-phenyl-pyrrole-2-carboxylic acid (170 mg, 18%) as a pink oil.
Reference Example 153
The compound set out below was prepared in a manner analogous to Reference Example 151 & 152: Reference Compound Example
153 Diethyl 1 -(4-methoxybut-2-enyl)-5-methyl-3 -phenyl-pyrrole-2,4- dicarboxylate
Reference Example 154: Ethyl 4-bromo-5-methyl-3-phenyl-lH-pyrroIe-2- carboxylate
N-Bromo succinimide (1.40 g, 7.87 mmol) was added to a solution of ethyl 5- methyl-3 -phenyl- l//-pyrrole-2-carboxylate (1.5g, 6.55 mmol) in a mixture of dioxane (10 mL) and acetic acid (20 niL) at 0 0C. The reaction mixture was stirred at 0 0C for 15 min. The reaction mixture was warmed to room temperature and stirred for another 15 min. The mixture was quenched with 2N NaOH solution and the organic layer was separated, washed with water, brine solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give ethyl 4-bromo-5-methyl-3 -phenyl- IH- pyrrole-2-carboxylate (1.68 g, 84%) as a solid.
Reference Example 155: Ethyl 4-bromo-l,5-dimethyl-3-phenyl-pyrrole-2- carboxylate
60% Sodium hydride (320 mg, 8.03 mmol) in mineral oil was added to a solution of 4-bromo-5-methyl-3 -phenyl- lH-pyrrole-2-carboxylate (1.65 g, 5.36 mmol) in tetrahydrofuran (20 mL) at 0 0C. The reaction mixture was stirred at 0 0C for 15 min and then the methyl iodide (0.66 mL, 10.72 mmol) was added at 0 0C and then the reaction mixture was allowed to warm to room temperature overnight. The reaction mixture was quenched with ice and the solvent was evaporated. The organics were extracted with ethyl acetate and the organic layer was washed with water, brine and dried over anhydrous sodium sulfate. The ethyl acetate layer was concentrated under reduced pressure to afford ethyl 4-bromo-l ,5-dimethyl-3-phenyl-pyrrole-2-carboxylate (1.68 g, 98%) as a liquid. Reference Example 156: 4-Bromo-l,5-dimethyl-3-phenyl-pyrrole-2-earboxylie acid
A solution of potassium hydroxide (1.40 g, 25.0 mmol) in water (3 mL) was added to a solution of ethyl 4-bromo-l,5-dimemyl-3-phenyl-pyrrole-2-carboxylate (1.60 g, 4.97 mmol) in ethanol (5 mL) and the reaction mixture was refluxed overnight. The solvent was evaporated and the residue was washed with diethyl ether. The resultant filter cake was acidified with diluted HCl and extracted with ether. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 4-bromo-l,5-dimethyl-3-phenyl-pyrrole-2-carboxylic acid (1.0 g, 69%) as a solid.
Reference Examples 157
The compound set out below was prepared in a manner analogous to Reference Example 156:
Reference Compound Example
157 4-Bromo-5 -methyl-3 -phenyl- 1 H-pyrrole-2-carboxylic acid
Reference Example 158: l,2-Dimethyl-4-phenyl-pyrrole
A suspension of l,5-dimethyl-3-phenyl-pyrrole-2,4-dicarboxylic acid (60 g, 0.23 mol) and 2-aminoethanol (300 mL) was heated to 175 °C under a nitrogen atmosphere for 30 min. The mixture was allowed to cool to room temperature, diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed successively with water (3 * 100 mL) and brine (2 * 100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo at a temperature below 40 0C to afford the crude product. Flash column chromatography over neutral alumina using 5% ethyl acetate in petroleum ether as eluent afforded l,2-dimethyl-4-phenyl-pyrrole (30.5 g, 78%) as a white solid.
Reference Examples 159 to 207 The compounds set out below were prepared in a manner analogous to Reference Example 158:
Reference Compound Example
159 4-(2-Furyl> 1 ,2-dimethyl-pyrrole
160 152-Dimethyl-4-(2-thienyl)pyrrole
161 4-Isopropyl- 1 ,2-dimethyl-pyrrole
162 l,2-Dimethyl-4-tetrahydropyran-4-yl-pyrrole
163 1 ,3 -Dimethyl-4-phenyl-pyrrole
164 2-Isopropyl- 1 -methyl-4-phenyl-pyrrole
165 4-Isopropyl- 1 -(2-methoxyethyl)-2-methyl-pyrrole
166 l-(2-Ethoxyethyl)-2 -methyl-4-phenyl-pyrrole
167 l-(3-Methoxypropyl)-2-methyl-4-phenyl-pyrrole
168 1 -Ethyl-2-methyl-4-phenyl-pyrrole
169 2-Methyl-4-phenyl- 1 -propyl-pyrrole
170 1 -Butyl-2-methyl-4-phenyl-pyrrole
171 3 -Phenyl- 1 H-pyrrole
172 1 -Methyl-3 -phenyl-pyrrole
173 1 -(2-Methoxyethyl)-3 -phenyl-pyrrole
174 l-Benzyl-2-methyl-4-phenyl-pyrrole
175 2-Methyl-4-phenyl- 1 H-pyrrole
176 2-Ethyl- 1 -methyl-4-phenyl-pyrrole
177 2-Ethyl- 1 -(2-methoxyethyl)-4-phenyl-pyrrole
178 3-(2-Chlorophenyl)-l-(2-methoxyethyl)pyrrole
179 3 -(4-Chlorophenyl)- 1 -(2-methoxyethyl)pyrrole
180 1 -(Methoxymethyl)-3 -phenyl-pyrrole
181 3 -(2-Thienyl)- 1 H-pyrrole
182 3-Isobutyl-l-(2-methoxyethyl)pyrrole
183 3-(3-Chlorophenyl)-l-(2-methoxyethyl)pyrrole
184 3 -(3 -Thienyl)- 1 H-pyrrole 185 2-Isopropyl- 1 -(2-methoxyethyl)-4-phenyl-pyrrole
186 4-(2-Methoxyethyl)-2-methyl- 1 -phenyl-pyrrole
187 3 -Isopropyl- lH-pyrrole
188 3-Isobutyl-l.H-pyrrole
189 3 -Bromo- 1 ,2-dimethyl-4-phenyl-pyrrole
190 2-[(2-Methyl-4-phenyl-pyrrol- 1 -yl)methyl]pyridine
191 3 -Bromo^-methyM-phenyl- 1 H-pyrrole
192 4-[(2-Methyl-4-phenyl-pyrrol- 1 -yl)methyl]pyridine
193 3 -Cy clobutyl- 1 H-pyrrole
194 l-Methyl-4-phenyl-2-propyl-pyrrole
195 2-Ethyl- 1 -(methoxymethyl)-4-phenyl-pyrrole
196 2-(2-Methoxy ethyl)- 1 -methyl-4-phenyl-pyrrole
197 l-(Ethoxymethyl)-2-meth.yl-4-phenyl-pyrrole
198 2-Metliyl- 1 -(2-methylsulfanylethyl)-4-phenyl-pyrrole
199 3 -(2-Methyl-4-phenyl-pyrrol- 1 -yl)-propan- 1 -ol
200 2-Methyl- 1 -(methylsulfanylmethyl)-4-phenyl-pyrrole
201 l-(2-Methoxyethoxymethyl)-2-Methyl)-4-phenyl-pyrrole
202 2-Methyl-4-phenyl- 1 -(propoxymethyl)ρyrrole
203 l-(2-Methoxyethyl)-2-methyl-4-phenyl-pyrrole
204 2-Methyl- 1 -(2-phenoxyethyl)-4-phenyl-pyrrole
205 l-(4-Methoxybut-2-enyl)-2-methyl-4-phenyl-pyrrole
206 2-Methyl-4- [(2-methyl-4-ρhenyl-pyrrol- 1 -yl)methyl] oxazole
207 l-(Butoxymethyl)-2-methyl-4-phenyl-pyrrole
Reference Examples 208 and 209: 2-PhenvI-5,6,7,8-tetrahydropyrroIofl,2- aiazepin-9-one f208) & l-Phenyl-5,6,7,8-tetrahydropyrroIofl,2-a1azepm-9-one (209)
Dry hydrogen chloride gas was bubbled into a stirred solution of 5-(3-phenyl~ pyrrol- l-yl)pentanenitrile (1.45 g, 6.47 mmol) in dry diethyl ether (50 mL) and boron trifluoride etherate (2 mL) at -5 to 0 0C. When the mixture became saturated with the hydrogen chloride gas, it was allowed to stand for 24 h. Excess diethyl ether was removed in vacuo and the residue hydrolyzed by adding dilute ammonium hydroxide (20 mL) and chloroform (30 mL). The reaction mixture was refluxed for 12 h and the chloroform layer separated. The chloroform layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford a mixture of 2-phenyl- 5,6,7,8-tetrahydro-pyrrolo[l52-a]azepin-9-one & l-phenyl-5,6,7,8-tetrahydro- pyrrolo[l,2-a]azepin-9-one (1.50 g, 99%) as a gummy solid.
Reference Example 210 and 211; 2-PhenyI-6,7,8,9-tetrahvdro-5JHr-pyrrolori,2- alazepine (210) & l-phenyl-6,7,8,9-tetrahydro-5g-pyrroIofl,2-a1azepme (211)
80% Hydrazine hydrate (0.56 mL, 9.0 mmol) was added in one portion to a stirred solution of 2-phenyl-5,6,7,8-tetrahydro-pyrrolo[l,2~a]azepin-9-one & 1-phenyl- 5,6,7,8-tetrahydro-pyrrolo[l,2-a]azepin-9-one (50 mg, 2.22 mmol) and potassium hydroxide (500 mg, 8.90 mmol) in diethylene glycol (6 mL) and heated at 160-165 °C for 16 h. The reaction mixture was cooled, poured into ice-water (20 mL) and extracted with diethyl ether (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over anhydrous sodium sulphate, concentrated under reduced pressure to give the crude compound which was purified by column chromatography over neutral alumina using 20% ethyl acetate in petroleum ether as eluent to afford a mixture of 2- ρhenyl-6,7,8,9-tetrahydro-5#-pyrrolo[l,2-a]azepine & l-phenyl-6,7,8,9-tetrahydro-5H"- pyrrolo[l,2-a]azepine (170 mg, 36%) as an oil.
Reference Example 212: (3-Dimethylammo-2-phenyl-prop-2-envIidene)-dimethyl- ammonimn perchlorate
Phosphorus oxychloride (6.8 g, 44.4 mmol) was added to anhydrous dimethylformamide (16 g, 220 mmol) over a period of 15 min at 0-5 0C, then warmed to room temperature and stirred for 1 h. Phenylacetic acid (2.0 g, 14.7 mmol) was added and the reaction mixture stirred at 90-100 0C for 16 h. The reaction mixture was quenched by pouring into ice water with vigorous stirring. A solution of 70% perchloric acid (1.88 mL, 2.2 g, 22.0 mmol) in water (5 mL) was added dropwise with vigorous stirring. A solid precipitated which was filtered, washed with ice cold water and dried in vacuo to afford (3-dimethylamino--2-phenyl-prop-2-enylidene)-dimethyl--ammonium perchlorate (2.0 g, 66%) as a brown solid.
Reference Examples 213 to 215
The compounds set out below were prepared in a manner analogous to Reference Example 212:
Reference Compound Example
213 [2-(2-Chlorophenyl)-3-dimethylamino-prop-2- enylidene]-dimethyl-ammonium perchlorate
214 [2-(4-Chlorophenyl)-3-dimethylamino-prop-2- enylidene] -dimethyl-ammonium perchlorate
215 [2-(3 -Chloroρhenyl)-3 -dimethylamino-proρ-2- enylidene] -dimethyl-ammonium; oxalate
Reference Example 216: Ethyl 4-phenyl-lH-pyrroIe-2-carboxylate
Sodium metal (900 mg, 41.0 mmol) was added to dry ethanol (150 mL) and allowed to dissolve over 30 min. Glycine methyl ester hydrochloride (3.2 g, 25.0 mmol) and (3 -dimethylamino-2-phenyl-prop-2-enylidene)-dimethyl-ammonium perchlorate (5.0 g, 16.0 mmol) were added successively and the reaction mixture heated at reflux for 16 h. Ethanol was evaporated in vacuo, the residue diluted with water and extracted with chloroform. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product obtained was purified by column chromatography over neutral alumina using 10% ethyl acetate in petroleum ether as eluent to afford ethyl 4-phenyl-lH-pyrrole-2-carboxylate (2.0 g, 57%) as a solid.
Reference Examples 217 to 219
The compounds set out below were prepared in a manner analogous to Reference Example 219: Reference Compound Example
217 Ethyl 4-(2-chlorophenyl)- 1 H-pyrrole-2-carboxylate
218 Ethyl 4-(4-chlorophenyl)-lH-pyrrole-2-carboxylate
219 Ethyl 4-(3 -chlorophenyl)- 1 H-pyrrole-2-carboxylate
Reference Example 220: Ethyl l-(3-ethoxy-3-oxo-propyD-4-phenyl-pyrroIe-2- carboxylate
Potassium tert-butoxide (100 mg, 0.90 mmol), ethyl 4-phenyl-lH-pyrrole-2- carboxylate (1.0 g, 4.65 mmol) and ethyl acrylate (50 mL) were heated at reflux for 90 min. The reaction mixture was allowed to cool to room temperature and neutralized with acetic acid (1 mL). Excess ethyl acrylate was evaporated in vacuo, the residue diluted with water and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude compound. Purification by column chromatography over neutral alumina using 5% ethyl acetate in petroleum ether as eluent gave ethyl l-(3-ethoxy-3-oxo-propyl)-4- phenyl-pyrrole-2-carboxylate (1.0 g, 69%) as an oil.
Reference Example 221: Diethyl l-(ethoxymethylV5-methyl-3-phenyl-pyrrole-2,4- dicarboxylate
Potassium tert-butoxide (557 mg, 4.97 mmol) was added to a stirred solution of diethyl 5-methyl-3-phenyl-lH-pyrrole-2,4-dicarboxylate (600 mg, 1.99 mmol) in dimethylsulfoxide (15 mL) at 10 0C and stirred at ambient temperature for 1 h. Upon cooling to 10 0C, chloromethyl ethyl ether (377 mg, 3.99 mmol) was added and stirred at ambient temperature for 12 h. The mixture was poured onto ice- water and extracted with diethyl ether (5 x 1OmL). The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate and filtered. The filtrate was concentrated in vacuo and subjected to column chromatography over silica gel (100-200 mesh) using 8% ethyl acetate in petroleum ether as eluent to afford diethyl l-(ethoxymethyl)-5- methyl-3-phenyl-pyrrole-2,4-dicarboxylate (400 mg, 56%) as a liquid.
Reference Examples 222 to 227
The compounds set out below were prepared in a manner analogous to Reference Example 221 :
Reference Compound Example
222 Diethyl l-(2-methoxyethoxymethyl)-5-methyl-3-phenyl-pyrrole-2,4- dicarboxylate
223 Diethyl 5-methyl-3 -phenyl- 1 -(propoxymethyl)pyrrole-2,4-dicarboxylate
224 Diethyl l-(4-chlorobut-2-enyl)-5-methyl-3-phenyl-pyrrole-2,4- dicarboxylate
225 l-(4-Methoxybutyl)-2-methyl-4-phenyl-pyrrole
226 Diethyl 5 -methyl- 1 - [(2-methyloxazol-4-yl)methyl] -3 -phenyl- 1 H- pyrrole-2,4-dicarboxylate
227 Diethyl l-(butoxymethyl)-5-methyl-3-phenyl-pyrrole-2,4-dicarboxylate
Reference Example 228: Diethyl l-(3-hydroxypropylV5-methγl-3-phenyl-pyrrole- 2,4-dicarboxylate
Potassium tert-butoxide (744 mg, 6.64 mmol) was added to a stirred solution of diethyl 5 -methyl-3 -phenyl- lH-pyrrole-2,4 dicarboxylate (1.00 g, 1.99 mmol) in dimethylsulfoxide (15 mL) at 10 0C and stirred at ambient temperature for 1 h. The mixture was cooled to 10 0C, 3-bromo-l-propanol (738 mg, 5.31 mmol) added and stirring continued at ambient temperature for 12 h. The mixture was poured onto ice- water and extracted with diethyl ether (5 x 1OmL). The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate and filtered. The filtrate was concentrated in vacuo and subjected to column chromatography over silica gel (100-200 mesh) using 40% of ethyl acetate in petroleum ether as eluent to afford of diethyl l-(3-hydroxypropyl)-5-methyl-3-phenyl-pyrrole-2;>4-dicarboxylate (600 mg, 50%) as a liquid.
Reference Example 229: l-f2-CarboxyethyI)-4-phenyl-pyrrole-2-carboxylic acid
10% Aqueous sodium hydroxide solution (20 mL) was added to a stirred solution of ethyl l-(3-ethoxy-3-oxo-propyl)-4-ρhenyl-pyrrole-2-carboxylate (2.0 g, 6.35 mmol) in ethanol (20 mL). The reaction mixture was stirred for 2 h at 50-60 0C. The ethanol was evaporated in vacuo and then water added to the residue and acidified with 5N HCl to pH 4-5. The precipitated solid was filtered, washed with water and dried in vacuo to afford l-(2-carboxyethyl)-4-phenyl-pyrrole-2-carboxylic acid (900 mg, 56%) as a solid.
Reference Example 230: 6-Phenyl-2,3-dihydropyrrolizin-l-one
Anhydrous sodium acetate (200 mg, 2.5 mmol) was added to a stirred solution of l-(2-carboxyethyl)-4-phenyl-pyrrole-2-carboxylic acid (1.0 g, 3.90 mmol) in acetic anhydride (10 mL) and heated at reflux for 16 h. Excess acetic anhydride was evaporated in vacuo and water was added. The mixture was extracted with ethyl acetate and the separated organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the crude product. Purification by column chromatography over neutral alumina using 25% ethyl acetate in petroleum ether as eluent afforded 6-phenyl-2,3-dihydropyrrolizin-l-one (200 mg, 27%) as a brown solid.
Reference Example 231: (4-Phenyl-lH-pyrroI-2-yI)methanoI
A solution of ethyl 4-ρhenyl-lH-pyrrole-2-carboxylate (1 g, 5.58 mmol) in tetrahydrofuran (10 mL) was added to a suspension of lithium aluminum hydride (300 mg, 8.10 mmol) in tetrahydrofuran (20 mL) at 0 0C. The reaction mixture was slowly warmed to ambient temperature and stirred for 5 h. The mixture was slowly added to saturated sodium sulphate followed by extraction with ethyl acetate (2 x 25mL). The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford (4-phenyl-lH-pyrrol-2-yl)niethanol (800 mg, 84%) as a solid.
Reference Example 232: 2-MethyI-lH-pyrroIe
Lithium aluminium hydride (899 mg, 23.6 mmol) was added to the solution of lH-pyrrole-2-carbaldehyde (750 mg, 7.9 mmol) in tetrahydrofuran (10 mL) at 0 °C then the mixture was heated at reflux for 16 h. The mixture was quenched into ice water and extracted with ethyl acetate. The combined organic phases were washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a residue which was purified by washing with π-pentane. Drying afforded 2-methyl-lH-pyrrole (500 mg, 77%).
Reference Example 233: 4-Iodo-lH-pyrrole-2-carbaIdehyde
A solution of lH-pyrrole-2-carbaldehyde (7.0 g, 73.6 mmol) in tetrahydrofuran (45 mL) was cooled to -750C. N-iodosuccinimide (19.8 g, 88.3 mmol) was added portionwise over 20 min and the reaction mixture was then stirred for 2 h at -75 °C. Water and petroleum ether were added and the reaction mixture warmed to ambient temperature. The organic layer was separated and the aqueous phase extracted with petroleum ether. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford 4-iodo-lH- pyrrole-2-carbaldehyde (13.2 g, 81%) as a black solid.
Reference Example 234: Chloro(methoxy)methane
Dry HCl gas was passed through a suspension of paraformaldehyde (30.0 g, 1 mol) in methanol (32.0 g, 1 mol) at 0-5 °C for 6 h. The reaction mixture was filtered and the organic layer in the filtrate was separated and dried over anhydrous calcium chloride for 16 h. The organic layer was distilled using a Vigreux column to afford chloro(methoxy)methane (20 g, 25%) of 90% purity (by Gas Chromatography). Reference Example 235: Isopropyl 2-chloroacetate
Chloro acetyl chloride (5 g, 0.045 mmol) was added drop wise to isopropanol (2.7 g, 0.045 mmol) at O0C. The mixture was heated to 80 0C under a nitrogen atmosphere and maintained at this temperature for 3 h. The compound was purified by fractional distillation in vacuo to afford isopropyl 2-chloroacetate (5 g, 84%) as a liquid.
Reference Example 236: Ethyl 2-(2-formyl-4-iodo-pyrrol-l-yDacetate
Sodium hydride (1.62 g, 60% w/w dispersion in mineral oil, 67.9 mmol) was added to a solution of 4-iodo-lH-pyrrole-2-carbaldehyde (5.0 g, 22.6 mmol) in tetrahydrofuran (30 mL) over 10 min. The reaction mixture was stirred for 15 min, then ethyl bromoacetate (7.56 g, 45.2 mmol) was added and the mixture stirred for 2 h at ambient temperature. The reaction was quenched with methanol and concentrated in vacuo. The crude compound was then extracted into ethyl acetate. The organic layer washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated under in vacuo to afford the crude compound. Purification by column chromatography over silica gel (100-200 mesh) using 2% ethyl acetate in petroleum ether afforded ethyl 2-(2-formyl-4-iodo-pyrrol-l-yl)acetate (3.4 g, 49%).
Reference Examples 237 to 240
The compounds set out below were prepared in a manner analogous to Reference Example 236:
Reference Compound Example
237 l-(Methoxymethyl)-2-methyl-4-phenyl-pyrrole
238 Methyl 1 -(methoxymethyl)-4-phenyl-pyrrole-2-carboxylate
239 Isopropyl 2-(2-methyl-4-phenyl-pyrrol- 1 -yl)acetate
240 tert-Butyl 2-(3-isopropylpyrrol-l -yl)acetate Reference Example 241: Ethyl 2-(2-formvI-4-phenyI-pyrroI-l-vI)acetate
A solution of ethyl 2-(2-formyl-4-iodo-pyrrol-l-yl)acetate (3.0 g, 9.77 mmol) in dimethylformamide (25 mL) was purged with argon gas for 10 min. Bis- (triphenylphospnine)-palladium.(II)chloride (0.48 g, 0.68 mmol) was added and the mixture was purged with argon gas for 5 min. Anhydrous potassium phosphate (6.18 g, 29.3 mmol) and phenylboronic acid (1.43 g, 11.7 mmol) were added successively and the reaction mixture purged with argon gas for 10 min, then heated to 110 °C and maintained at that temperature for 4 h. The resulting mixture was allowed to cool to ambient temperature and diethyl ether added. The reaction mixture was filtered, the filtrate being washed with water and the separated aqueous phase being further extracted with diethyl ether. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the crude product. Purification by column chromatography over silica gel (100-200 mesh) using 8% ethyl acetate in petroleum ether as eluent afforded ethyl 2-(2-formyl-4-phenyl- pyrrol-l-yl)acetate (680 mg, 27%).
Reference Example 242: 2-MethyI-7-phenyl-l,2-dmydropyrrolo|l,2-a1pyrazin-3- one
Acetic acid was added to a solution of methylamine (0.45 mL, 5.30 mmol, 40% in water) in tetrahydrofuran (8 mL) to adjust the pH to 6. A solution of (2-formyl-4- phenyl-pyrrol-l-yl)-acetic acid ethyl ester (680 mg, 2.65 mmol) in tetrahydrofuran (4 mL) was added and the reaction mixture stirred at ambient temperature for 45 min. Sodium cyanoborohydride (0.33 g, 5.30 mmol) was added and the reaction mixture heated at 75 C for 18 h. Concentration in vacuo yielded a residue which was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford the crude product. Purification by column chromatography over silica gel (100-200 mesh) using 30% ethyl acetate in petroleum ether afforded 2-methyl-7-phenyl-l ,2- dihydropyrrolo[l52-a]pyrazin-3-one (180 mg, 30%) as a solid. Reference Example 243: 2-methyI-7-phenvI-3,4-dihydro-lH-pyrrolofl,2-a1pyrazine
Borane-dimethyl sulfide complex (0.25 mL, 2.6 mmol) was added to cold tetrahydrofuran (6 mL) and stirred for 10 min. 2-Methyl-7 -phenyl- 1,2- dihydropyrrolo[l52-a]pyrazin-3-one (180 mg, 0.8 mmol) was added, and the reaction mixture allowed to warm to room temperature and stirred for 3 h. The mixture was poured slowly into saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with water then brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude compound. Purification by column chromatography over silica gel (100-200 mesh) using 8% ethyl acetate in petroleum ether afforded 2-methyl-7-phenyl-3,4-dihydro-lH-pyrrolo[l,2- a]pyrazine (110 mg, 64%) as a solid.
Reference Example 244: 4-Iodo-l-isopropyl-pγrrole-2-carbaldehyde
Sodium hydride (860 mg, 55% in mineral oil, 19.7 mmol) was added to a solution of 4-iodo-pyrrole-2-carbaldehyde (3.0 g, 13.2 mmol) in dry dimethylformamide at ambient temperature under a nitrogen atmosphere. After stirring for 15 min 2-bromopropane (3.87 mL, 40.9 mmol) was added and the reaction mixture heated at reflux for 16 h. The mixture was allowed to cool to ambient temperature, quenched with water and extracted with diethyl ether. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude residue. Purification by column chromatography over silica gel (60-120 mesh) using 2% ethyl acetate in petroleum ether afforded 4-iodo-l-isopropyl- pyrrole-2-carbaldehyde (1.5 g, 43%) as a brown liquid.
Reference Example 245
The compound set out below was prepared in a manner analogous to Reference Example 245.
Reference Compound Example 245 4-Iodo- 1 -(2-methoxyethyl)~pyrrole-2-carbaldehyde
Reference Example 246: l-(2-HvdroxyethvI)-4-iodo-pyrroIe-2-carbaIdehyde
Potassium hydroxide (3.1 g, 54.3 mmol) was added to a stirred solution of 4- iodo-l/i-pyrrole-2-carbaldehyde (4.0 g, 18.1 mmol) in dioxane (20 mL). 2-Bromo- ethanol (2.56 mL, 36.2 mmol) was added to the reaction mixture and heated at 60 °C for 16 h. The reaction mixture was cooled to room temperature and the pH was adjusted to ~6 by the addition of acetic acid. The reaction mixture was then concentrated in vacuo to give a residue which was partitioned between water and ethyl acetate. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue which was purified by column chromatography over silica gel (100-200 mesh) using 10% ethyl acetate in petroleum ether as eluent to afford l-(2-hydroxyethyl)-4-iodo-pyrrole-2-carbaldehyde (2.4 g, 50%) as a colourless solid.
Reference Example 247: 2-(2-Formyl-4-iodo-pyrroI-l-yI)ethyI 4- methylbenzenesulfonate
Triethylamine (3.3 mL, 23.8 mmol) was added to a stirred solution of l-(2- hydroxyethyl)-4-iodo-pyrrole-2-carbaldehyde (2.1 g, 7.92 mmol) in dichloromethane (15 mL). The reaction mixture was chilled to 0 0C and 4-methyl-benzenesulfonyl chloride (1.82 g, 9.51 mmol) was added over 15 min. The reaction mixture was allowed to warm to ambient temperature and stirred overnight. Water was added, the organic phase separated and the aqueous phase extracted with dichloromethane. The combined organic layers were washed with saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue which was purified by washing with petroleum ether to afford 2-(2-formyl-4-iodo-ρyrrol-l-yl)ethyl 4-methylbenzenesulfonate (2.4 g, 72%) as a grey solid.
Reference Example 248: 2-f2-(HydroxymethyI)-4-iodo-pyrroI-l-vϊlethyI 4- methvlbenzenesulfonate 2-(2-Formyl-4-iodo-pyrrol-l-yl)ethyl 4-methylbenzenesulfonate (2.1 g, 5.01 mmol) in ethanol (25 mL) was cooled to 0 °C and sodium borohydride (95 mg, 2.50 mmol) was added. After 30 min, the reaction mixture was allowed to warm to ambient temperature and stirred for a further 1 h, after which time acetic acid was added and the mixture was concentrated in vacuo. The residue was partitioned between water and dichloromethane and the organic phase was washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2-[2-(hydroxymethyl)-4- iodo-pyrrol-l-yl]ethyl 4-methylbenzenesulfonate (2.0 g, 95%) as a brownish crystalline solid.
Reference Example 249: 7-Iodo-3,4-dihvdro-lff-pyrroIor2,l-c|[l,41oxazine
A solution of 2-[2-(hydroxymethyl)-4-iodo-pyrrol-l-yl]ethyl A- methylbenzenesulfonate (2.0 g, A .19 mmol) in tetrahydrofuran (15 mL) was slowly added to a suspension of sodium hydride (120 mg, 60% dispersion in mineral oil; 4.75 mmol) in tetrahydrofuran (5 mL) and stirred at room temperature for 36 h. The reaction was quenched with water and extracted with diethyl ether. The combined organic phases were washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give a residue which was purified by column chromatography over silica gel using 2% ethyl acetate in petroleum ether to afford 7- iodo-3,4-dihydro-lH-pyrrolo[2,l-c][l,4]oxazine (800 mg, 66%) as a colorless crystalline solid.
Reference Example 250: 7-Phenyl-34-dihydro4iy-pyrroIor24-ciri,41oxazine
A solution of 7-iodo-3,4-dihydro-lH-ρyrrolo[25l-c][l,4]oxazine (800 mg, 3.21 mmol) in dimethylformamide (8 mL) was purged with argon gas for 5 min. Caesium carbonate (3.14 g, 9.64 mmol) and phenylboronic acid (590 mg, 4.82 mmol) were added and the vessel was again purged with argon gas for 5 min.
Tetrakis(triphenylphosphine)palladium(0) (185 mg, 0.16 mmol) was added, the vessel was purged for a final time with argon gas for 5 min and then the mixture was heated at 75 °C for 3 h. The reaction mixture was allowed to cool to ambient temperature, filtered and then water was added and mixture extracted with diethyl ether. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) using 4% ethyl acetate in petroleum ether to afford 7-phenyl-3,4- dihydro-lH-pyrrolo[2,l-c][l,4]oxazine (90 mg, 14%) as a pale yellow solid.
Reference Examples 251 and 252
The compounds set out below were prepared in a manner analogous to Reference Example 250:
Reference Compound Example
251 1 -Isopropyl-4-phenyl- lH"-pyrrole-2-carbaldehyde
252 l-(2-Methoxyethyl)-4-phenyl-pyrrole-2-carbaldehyde
Reference Example 253: l-PhenyIpyrroIe~2-carbaIdehyde
Phosphorus oxychloride (0.7 mL, 7.68 mmol) was added slowly to ice-cold dimethylformamide (0.6 mL, 7.68 mmol). The mixture was warmed to room temperature and stirred for 15 min. A solution of 1-phenylpyrrole (1.0 g, 6.98 mmol) in ethylene dichloride (5 mL) was added and the reaction mixture heated at reflux for 1 h. The mixture was cooled to 10 0C and quenched into 10% sodium acetate solution (20 mL). The organic layer was separated and the aqueous phase was extracted with ether. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated under in vacuo to give a crude residue. Purification by column chromatography over silica gel (60-120 mesh) using 2% ethyl acetate in petroleum ether as eluent gave l-phenylpyrrole-2-carbaldehyde (700 mg, 59%) as a colourless oil.
Reference Example 254: 2-Methyl-l-phenyI-pyrrole A mixture of l-phenylpyrrole-2-carbaldehyde (700 mg, 4.1 nunol), potassium hydroxide (490 mg, 12.3 mmol) and hydrazine hydrate (0.8 mL, 12.3 mmol) in ethylene glycol (15 mL) was stirred at ambient temperature for 30 min and then slowly heated to 150 °C and maintained for 2 h. The reaction mixture was allowed to cool to ambient temperature, poured into ice- water and extracted with diethyl ether. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give the crude compound. Purification by column chromatography over silica gel (60-120 mesh) using petroleum ether as eluent to afford 2-methyl-l-phenyl-pyrrole (430 mg, 66%) as a yellow oil.
Reference Examples 255 to 256
The compounds set out below were prepared in a manner analogous to Reference Example 254.
Reference Compound Example
255 6-Phenyl-2,3 -dihydro- 1 H-pyrrolizine
256 l-Isopropyl-2-methyl-4-phenyl-pyrrole
Reference Example 257: Ethyl 2-methyI-4-phenyl-pyrroIe-l-carboxylate
«-Butyllithium (0.87 mL, 1.6M solution, 1.40 mmol) was added to a cold (below 0 0C) solution of 2-methyl-4-phenyl-lH-pyrrole (200 mg, 1.27 mmol) in tetrahydrofuran (6 mL) and stirred at below 0 °C for 20 min. Ethyl chloroformate (0.1 mL, 1.02 mmol) was added slowly to the reaction mixture and stirred at 0 to 10 °C for 90 min. The reaction mixture was quenched into saturated ammonium chloride solution and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford ethyl 2-methyl-4-phenyl-pyrrole-l- carboxylate (250 mg, 86%) as a brown solid.
Reference Examples 258 The compound set out below was prepared in a manner analogous to Reference Example 257.
Reference Compound Example
258 Methyl 2-methyl-4-phenyl-pyrrole- 1 -carboxylate
Reference Example 259: 3-FIuoro-l,2-dimethyl-4-phenyl-pγrrole
n-Butyllithium (2.06 mL, 1.6M solution, 3.30 mmol) was added to a solution of 3-bromo-l,2-dimethyl-4-phenyl-pyrrole (550 mg, 2.20 mmol) in tetrahydrofuran (10 mL) at -78 0C and the reaction mixture was stirred at -78 0C for 30 min. A solution of n- fluorodibenzene sulfonamide (901 mg, 2.86 mmol) in tetrahydrofuran (8 mL) was added to the reaction mixture at -78 0C and the reaction mixture was stirred at this temperature for another 1 h. The reaction mixture was allowed to warm to ambient temperature and stirred for 16 h after which time the reaction mixture was quenched with dilute HCl and evaporated to dryness. The residue was diluted with water and extracted with ethyl acetate. The ethyl acetate layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product. Purification by preparative HPLC afforded 3-fluoro-l,2-dimethyl-4- phenyl-pyrrole (160 mg, 39%) as a solid.
Reference Example 260
The compound set out below was prepared in a manner analogous to Reference Example 259.
Reference Compound Example
260 3-Fluoro-l-(2-methoxyethyl)-2-methyl-4-phenyl-pyrrole
Reference Example 261: 2-f2-Methyl-4-phenyl-pyrroI-l-vlkthanol Boron tribromide (0.3 mL5 3.07 mmol) was added drop wise to a solution of 1- (2-methoxyethyl)-2-methyl-4-phenyl-pyrrole (330 mg, 1.53 mmol) in dry dichloromethane (20 niL) at 0 to 5 0C and stirred for 1 h. The reaction mixture was quenched with a 10% sodium bicarbonate solution (20 mL) at 0 to 5 0C and extracted with ethyl acetate (2 x 25 mL). The organic layer was washed successively with water (2 x 25 mL), brine (2 x 25 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to yield 2-(2-methyl-4-phenyl-pyrrol-l-yl)-ethanol (270 mg, 88%) as a brown solid.
Reference Examples 262
The compound set out below was prepared in a manner analogous to Reference Example 261.
Reference Compound Example
262 2-(3 -Phenylpyrrol- 1 -yl)ethanol
Reference Example 263: 2-f2-methvI-4-phenyl-pyrrol-l-yi)ethyl 4- methylbenzenesulfonate
Triethylamine (2.1 mL, 15.22 mmol) was added to a solution of 2-(2-methyl-4- phenylpyrrol-l-yl)ethanol (1.53 g, 7.61 mmol) in dry dichloromethane (20 mL) at room temperature followed by the addition of p-toluene sulfonyl chloride (1.88 g, 9.89 mmol). The resulting reaction mixture was stirred for 16 h and then diluted with water (30 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with water (2 x 25 mL), brine (2 x 25 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to yield the crude compound. Purification by column chromatography over silica gel (100-200 mesh) with gradient elution with 10- 12% ethyl acetate in petroleum ether as eluent afforded 2-(2-methyl-4-phenyl-pyrrol-l- yl)ethyl 4-methylbenzenesulfonate (1.2 g, 44%) as a brownish white crystalline solid.
Reference Example 264 The compound set out below was prepared in a manner analogous to Reference Example 263:
Reference Compound Example
264 2-Isopropoxyethyl 4-methylbenzenesulfonate
Reference Example 265: l-(2-Azidoethyl)-2-methyI-4-phenyI-pyrroIe
Sodium azide (327 mg, 5.02 mmol) was added to a solution of 2-(2-methyl-4- phenyl-pyrrol-l-yl)ethyl 4-methylbenzenesulfonate (1.19 g, 3.35 mmol) in dry dimethylformamide (10 mL) and heated to 90 0C and stirred for 1 h. The reaction mixture was allowed to cool to ambient temperature and partitioned between water (20 mL) and ethyl acetate (25 mL). After stirring for 5 min, the organic layer was separated and washed successively with water (2 x 30 mL), brine (2 x 30 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to yield l-(2-azidoethyl)-2- methyl-4-phenyl-pyrrole (650 mg, 86%) as a brown liquid.
Reference Example 266: 2-(2-MethvI-4-phenvI-pyrroI-l-yI)ethanamine
10% Palladium-carbon (100 mg) was added to a solution of l-(2-azidoethyl)-2- methyl-4-phenyl-pyrrole (640 mg, 2.96 mmol) in methanol (20 mL) at room temperature and hydrogenated at atmospheric pressure for 27 h. The catalyst was filtered and washed with methanol (20 mL). The combined filtrate and washings were concentrated in vacuo to afford 2-(2-methyl-4-phenyl-pyrrol-l-yl)ethanamine (490 mg, 83%) as a brown syrup.
Reference Example 267
The compound set out below was prepared in a manner analogous to Reference Example 266:
Reference Compound Example
267 1 -Isobutyl-piperazine
Reference Example 268: 2-(2-Methyl-4-phenyI-pyrroI-l-yI)ethvI acetate
Triethylamine (0.5 mL, 3.59 mmol) was added dropwise to a solution of 2-(2- methyl-4-phenyl-pyrrol-l-yl)ethanol (260 mg, 1.29 mmol) in dry dichloromethane (20 mL) at 0 to 5 °C followed by the addition of acetyl chloride (0.2 mL, 2.81 mmol). The reaction mixture was stirred for 30 min and then quenched into ice water (30 mL) and ethyl acetate (20 mL) and stirred for 15 min. The organic layer was separated and washed with water (2 x 25 mL), brine (2 x 25 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to afford 2-(2-methyl-4-phenyl-pyrrol-l-yl)ethyl acetate (300 mg, 96%) as a brown liquid.
Reference Examples 269 to 270
The compounds set out below were prepared in a manner analogous to Reference Example 268:
Reference Compound Example
269 N- [2-(2-Methyl-4-phenyl-pyrrol- 1 -yl)-ethyl] acetamide
270 2-(3 -Phenyl-pyrrol- 1 -yl)-ethyl acetate
Reference Example 271: Ethyl 2-(3-PhenylpyrroI-l-yl)acetate
Glycine ethyl ester hydrochloride (0.44 g, 3.17 mmol), sodium acetate (0.47 g,
5.76 mmol) were dissolved in minimum amount of water (5 mL) and added to glacial acetic acid (5 mL). The mixture was heated to 80 0C and then added to a solution of 2,5- dimethoxy-3-phenyl-tetrahydrofuran (0.6 g, 2.88 mmol) in glacial acetic acid (5 mL). The reaction was stirred at 80 0C for 2 h and then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with copious amount of water, dried over anhydrous sodium sulfate and concentrated in vacuo to afford ethyl 2-(3- phenylpyrrol-l-yl)acetate (0.55 g, 83%).
Reference Example 272: 2-(3-IsopropyIpyrrol-l-yI)acetic acid
Trifluoroacetic acid (1.20 mL, 15.70 mmol) was added to a solution of tert-butyl 2-(3-isopropyl-pyrrol-l-yl)acetate (350 mg, 1.57 mmol) in dichloromethane at 0 0C and the reaction mixture was stirred at ambient temperature for 16 h. The solvent was evaporated in vacuo and the residue was basified with saturated sodium bicarbonate solution. The solution was washed with diethyl ether and the alkaline solution was then acidified with concentrated aqueous HCl and extracted with diethyl ether. The organic layer was washed with water, brine solution, dried over anhydrous sodium sulfate and concentrated in vacuo to give 2-(3-isopropylpyrrol-l-yl)acetic acid (180 mg, 69%) as a semi-solid.
Reference Examples 273 to 275
The compounds set out below were prepared in a manner analogous to Reference Example 272:
Reference Compound Example
273 2-(3 -Isobutyl-pyrrole- 1 -yl)acetic acid
274 2-(3 -Cyclobutylpyrrol- 1 -yl)acetic acid
275 1 -(2-Methylallyl)piperazine
Reference Example 276: Methyl 2-(3-Isopropylpyrrol-l-yl)acetate
Potassium carbonate (298 mg, 2.15 mmol) was added to a solution of 2-(3- isopropylpyrrol-l-yl)acetic acid (180 mg, 1.07 mmol) in acetone at 0 0C and the reaction was stirred at 0 0C for 15 min. Methyl iodide (0.13 mL, 2.15 mmol) was added at 0 0C and the mixture refluxed for 16 h. The reaction mixture was concentrated in vacuo and the residue was diluted with water and extracted with diethyl ether. The organic layer was washed with water, brine solution, dried over anhydrous sodium sulphate, filtered and concentrated in vacuo to give the crude compound. Purification by column chromatography over neutral alumina by using 1-2% ethyl acetate in petroleum ether as eluent afforded methyl 2-(3-Isopropylρyrrol-l-yl)acetate (135 mg, 69%) as a liquid.
Reference Examples 277 to 278
The compounds set out below were prepared in a manner analogous to Reference Example 276:
Reference Compound Example
277 Methyl 2-(3 -Isobutylpyrrol- 1 -yl)acetate
278 Methyl 2-(3 -Cyclobutyl-pyrrol- 1 -yl)acetate
Reference Example 279: Ethyl 2-f5-(methoxymethylVl-methyl-3-phenyl-pyrrol-2- yn-2-oxo-acetate
Ethyl chloro oxoacetate (760 mg, 5.59 mmol) was added to a solution of 2- methoxymethyl-l-methyl-4-phenyl-pyrrole (750mg 3.73mmol) and triethylamine (490mg 4.85 mmol) in dichloromethane (1OmL) at 0 0C. The mixture was stirred for 4 h then concentrated in vacuo. The resulting residue was dissolved in dichloromethane and washed with saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford the crude product. Purification by column chromatography over neutral alumina using 5-10% ethyl acetate in petroleum ether as eluent afforded ethyl 2-[5-(methoxymethyl)-l-methyl-3-phenyl-pyrrol-2-yl]-2-oxo- acetate (600 mg, 53%) as a liquid.
Reference Example 280
The compound set out below was prepared in a manner analogous to Reference Example 279: Reference Compound Example
280 Ethyl 2-[l,5-bis(memoxymethyl)-3-phenyl-pyrrol-2-yl]~2-oxo-acetate
Reference Example 281; 2-f5-(methoxymethylVl-methyl-3-phenvI-pyrroI-2-yII-2- oxo-acetic acid
Lithium hydroxide (170 mg, 4.04 mmol) was added to a solution of ethyl 2-[5-
(methoxymethyl)-l-methyl-3-phenyl-pyrrol-2-yl]-2-oxo-acetate (600 mg, 1.90 mmol) in methanol (20 niL) and stirred for 3 h at ambient temperature. The mixture was concentrated in vacuo and the residue dissolved in water and acidified with acetic acid. The mixture was extracted with ethyl acetate, the organic layer washed with brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford 2- [5-
(methoxymethyl)-l-methyl-3-phenyl-pyrrol-2-yl]-2-oxo-acetic acid (350 mg, 64%) as a solid.
Reference Examples 282 to 283 The compounds set out below were prepared in a manner analogous to
Reference Example 281:
Reference Compound Example
282 2-[l,5-Bis(methoxymethyl)-3-phenyl-pyrrol-2-yl]-2-oxo-acetic acid
283 2- [ 1 -(2-Methoxy ethyl)-3 -(3 -thienyl)pyrrol-2-yl] -2-oxo-acetic acid
Reference Example 284: 2-(l,5-Dimethyl-3-phenyl-pyrroI-2-yr)-2-oxo-acetyl chloride
Oxalyl chloride (19.5 mL, 0.21 mol) was added slowly to a 0 0C solution of 1,2- dimethyl-4-phenyl-pyrrole (30.5 g, 0.178 mol) in dry dichloromethane (150 mL). The reaction mixture was warmed to room temperature and stirred for 1 h. The solvent was removed in vacuo to afford 2-(l,5-dimethyl-3-phenyl-pyrrol-2-yl)-2-oxo-acetyl chloride (46 g, 99%) as a brown oil.
Reference Examples 285 to 348 The compounds set out below were prepared in a manner analogous to
Reference Example 284:
Reference Compound Example
285 2-Oxo-( 1 -phenylpyrrol-2-yl)acetyl chloride
286 2-(5 -Methyl- 1 -ρhenylpyrrol-2-yl)-2-oxo-acetyl chloride
287 2-(5-Methyl- l//-pyrrol-2-yl)-2-oxo-acetyl chloride
288 2-(2-Methyl-7-ρhenyl-3,4-dihydro-lH-pyrrolo[l,2- a]pyrazin-6-yl)-2-oxo-acetyl chloride
289 2-Oxo-2-(2-phenyl-6,7-dihydro-5H-ρyrrolizin-3- yl)acetyl chloride
290 2-Oxo-2-(7-phenyl-3,4-dihydro-lH-pyrrolo[2,l- c][l,4]oxazin-6-yl)acetyl chloride
291 2-(l-Isoproρyl-5-methyl-3-phenyl-pyrrol-2-yl)-2-oxo- acetyl chloride
292 2-[l-(2-Methoxyethyl)-5-methyl-3-phenyl-pyrrol-2-yl]- 2-oxo-acetyl chloride
293 2-[3-(2-Furyl)- 155-dimethyl-pyrrol-2-yl]-2-oxo-acetyl chloride
294 2-[l,5-Dimethyl-3-(2-thienyl)pyrrol-2-yl]-2-oxo-acetyl chloride
295 2-(3-Isopropyl- 155-dimethyl-pyrrol-2-yl)-2-oxo-acetyl chloride
296 2-( 1 ,5-Dimethyl-3 -tetrahydropyran-4-yl-pyrrol-2-yl)-2- oxo-acetyl chloride
297 2-(l,4-Dimethyl-3-phenyl-pyrrol-2-yl)-2-oxo-acetyl chloride (obtained as a mixture with the regioisomer 2- (l,3-dimethyl-4-phenyl-lH"-pyrrol-2-yl)-2-oxo-acetyl chloride)
298 2-(5-Isopropyl-l-methyl-3-phenyl-pyrrol-2-yl)~oxo- acetyl chloride
299 2- [3 -Isopropyl- 1 -(2-methoxyethyl)-5 -methyl-pyrrol-2- yl]-2-oxo-acetyl chloride
300 2-[l-(2-Ethoxyethyl)-5-methyl-3-phenyl-pyrrol-2-yl]-2- oxo-acetyl chloride
301 2-[ 1 -(3 -Methoxypropyl)-5-methyl-3 -phenyl-ρyrrol-2- yl]-2-oxo-acetyl chloride
302 2-(5-Ethyl-l-methyl-3-ρhenyl-pyrrol-2-yl)-2-oxo-acetyl chloride
303 2- [5-Ethyl- 1 ~(2-methoxyethyl)-3 -phenyl-pyrrol-2-yl]-2- oxo-acetyl chloride
304 Ethyl 2-(2-chloro-2-oxo-acetyl)-5-methyl-3-phenyl- pyrrole-1 -carboxylate
305 Methyl 2-(2-chloro-2-oxo-acetyl)-5-methyl-3-phenyl- pyrrole- 1 -carboxylate
306 2-[3-(2-Chloroρhenyl)-l-(2-methoxyethyl)ρyrrol-2-yl]- 2-oxo-acetyl chloride
307 2-[4-(2-Chloroρhenyl)-l-(2-methoxyethyl)pyrrol-2-yl]- 2-oxo-acetyl chloride
308 2-[3-(4-Chlorophenyl)-l-(2-methoxyethyl)pyrrol-2-yl]- 2-oxo-acetyl chloride
309 Methyl 2- [2-(2-chloro-2-oxo-acetyl)pyrrol- 1 -yl] acetate
310 2- [ 1 -(Methoxymethyl)-3 -phenyl-pyrrol-2-yl] -2-oxo- acetyl chloride & 2-[l-(Methoxymethyl)-4-phenyl-li-r- pyrrol-2-yl)-2-oxo-acetyl chloride
311 2-[2-(2-Chloro-2-oxo~acetyl)-5-methyl-3-phenyl-pyrrol- l-yl]acetate
312 2-[l-(2-Acetamidoethyl)-5-methyl-3-phen.yl-pyrrol-2- yl]-2-oxo-acetyl chloride 313 2-[l-(2-Methoxyethyl)-3-(2-thienyl)pyrrol-2-yl]-2-oxo- acetyl chloride
314 2- [3 -Isobutyl- 1 -(2-methoxyethyl)pyrrol-2-ylJ-2-oxo- acetyl chloride
315 2-[3-(3-Chlorophenyl)- 1 -(2-methoxyethyl)pyrrol-2-ylJ- 2-oxo-acetyl chloride & 2-[4-(3-Chlorophenyl)-l-(2- methoxyethyl)pyrrol-2-yl] -2-oxo-acetyl chloride
316 Ethyl 2-[2-(2-chloro-2-oxo-acetyl)-3-phenyl-pyrrol-l - yl] acetate
317 Methyl 2-[2-(2-chloro-2-oxo-acetyl)-3-phenyl-pyrrol-l- yl] acetate & methyl 2-[2-(2-chloro-2-oxo-acetyl)-4- phenyl-pyrrol- 1 -yljacetate
318 Isopropyl 2-[2-(2-clϋoro-2-oxo-acetyl)-5-methyl-3- phenyl-pyrrol- 1 -yl] acetate
319 2-[5-Isopropyl- 1 -(2-methoxyethyl)-3-phenyl-pyrrol-2- yl]-2-oxo-acetyl chloride
320 2-[3-(2-Methoxyethyl)-5-methyl-l-phenyl-pyrrol-2-yl]- 2-oxo-acetyl chloride
321 2-[l-(2-Methoxyethyl)-3-phenyl-pyrrol-2-ylJ-2-oxo- acetyl chloride
322 2- [3 -Isopropyl- 1 -(2-methoxyethyl)pyrrol-2-yl] -2-oxo- acetyl chloride
323 2-[l-(2-Dimethylaminoethyl)-3-phenyl-pyrrol-2-yl]-2- oxo-acetyl chloride
324 2-[l-(2-Dimethylaminoethyl)-4-phenyl-pyrrol-2-yl]-2- oxo-acetyl chloride
325 2- [ 1 -(2-Dimethylaminoethyl)-5 -methyl-3 -phenyl-pyrrol- 2-yl]-2-oxo-acetyl chloride
326 Methyl 2-[2-(2-chloro-2-oxo-acetyl)-3-(2-thienyl)pyrrol- 1 -yljacetate
327 Methyl 2-[2-(2-chloro-2-oxo-acetyl)-3-isopropyl-pyrrol- 1 -yljacetate 328 Methyl 2- [2-(2-chloro-2-oxo-acetyl)-3 -isobutyl-pyrrol- 1 - yl] acetate
329 2-(4-Fluoro-l,5-dimethyl-3-phenyl-pyrrol-2-yl)~2-oxo~ acetyl chloride
330 2-[5-Methyl-3-phenyl-l-(2-pyridyhnethyl)pyrrol-2-yl]- 2-oxo-acetyl chloride
331 2- [5 -Methyl-3 -phenyl- 1 -(3 -pyridylmethyl)pyrrol-2-yl] - 2-oxo-acetyl chloride
332 2-[4-Fluoro- 1 -(2-methoxyethyl)-5-methyl-3 -phenyl- pyrrol-2-yl]-2-oxo-acetyl chloride
333 2- [ 1 -(2-Isopropoxyethyl)-5 -methyl-3 -phenyl-pyrrol-2- yl] -2-oxo-acetyl chloride
334 2-[5-Methyl-3-phenyl-l-(4-pyridylmethyl)pyrrol-2-yl]- 2-oxo-acetyl chloride
335 2-[3-Cyclobutyl-l-(2-methoxyethyl)pyrrol-2-yl]-2-oxo- acetyl chloride
336 Methyl 2- [2-(2-chloro-2-oxo-acetyl)-3 -cyclobutyl- pyrrol- 1 -yl] acetate
337 2-(l-Methyl-3-phenyl-5-propyl-pyrrol-2-yl)-2-oxo- acetyl chloride
338 2-[5-Ethyl-l-(methoxymethyl)-3-phenyl-pyrrol-2-yl]-2- oxo-acetyl chloride
339 2-[l-(Ethoxymethyl)-5-methyl-3-phenyl-pyrrol-2-yl]-2- oxo-acetyl chloride
340 2-[5-Methyl-l-(2-methylsulfanylethyl)-3-phenyl-pyrrol- 2-yl] -2-oxo-acetyl chloride
341 2-[l-(3-Ethoxypropyl)-5-methyl-3-phenyl-pyrrol-2-yl]- 2-oxo-acetyl chloride
342 2-[l-(2-Methoxyethoxymethyl)-5-methyl-3-phenyl- pyrrol-2-yl] -2-oxo-acetyl chloride
343 2-[5-Methyl-3-phenyl-l-(propoxymethyl)pyrrol-2-yl]-2- oxo-acetyl chloride 344 2-[5-Methyl-l-(2-phenoxyethyl)-3-phenyl-pyrrol-2-yl]- 2-oxo-acetyl chloride
345 2-[5-Methyl-3 -phenyl- 1 -(2-propoxyethyl)pyrrol-2-yl] -2- oxo-acetyl chloride
346 2-[l-(4-Methoxybut-2-enyl)-5-methyl-3-phenyl-pyrrol- 2-yl]-2-oxo-acetyl chloride
347 2-[l-(4-Methoxybutyl)-5-methyl-3-phenyl-pyrrol-2-yl]- 2-oxo-acetyl chloride
348 2-[l-(Butoxymethyl)-5-methyl-3-phenyl-ρyrrol-2-yl]-2- oxo-acetyl chloride
Reference Example 349: Ethyl 2-fl-f2-methoxyethvIV3-(3-thienyl)pyrrol-2-yll-2- oxo-acetate
Chloroethyl oxalate (0.13 mL, 1.18 mmol) was added slowly to a cooled solution of l-(2-methoxy-ethyl)-3-thiophen-2-yl-lH-pyrrole (300 mg, 1.55 mmol) and triethylamine (0.28 mL) in dry dichloromethane (15 mL) at 0 0C. The reaction mixture was allowed to warm to ambient temperature and stirred for 16 h. The solvent was removed in vacuo to afford ethyl 2-[l-(2-methoxyethyl)-3-(3-thienyl)pyrrol-2-yl]-2- oxo-acetate (250 mg, 85%) as a brown oily liquid.
Reference Example 350: 2-Chloro-4,6-dimethyI-pyridine
A mixture of 2-amino-456-dimethylpyridine (90 g, 0.736 mol) and sodium chloride (216 g, 3.69 mol) in concentrated hydrochloric acid (720 mL) was cooled to between -15 and -20 0C. A solution of sodium nitrite (71.2g, 1.03 mol) in water (135 mL) was added over 30 min. More sodium chloride (216 g, 3.69 mol) was added and the reaction mixture was allowed to warm to ambient temperature and stirred for 1 h. The reaction mixture was basified with solid bicarbonate (700 g) and extracted with dichloromethane (1 L), filtered and the two phases separated. The organic layer was concentrated in vacuo and the crude purified by flash column chromatography over silica gel (100-200 mesh) with 20% dichloromethane in petroleum ether as eluent to afford 2-chloro-4,6-dimethylpyridine (40 g, 38%) as a solid.
Reference Example 351: l-(4,6-dimethvI-2-pyridyI)piperazine
A solution of piperazine (195 g, 2.26 mol) in diglyme (250 mL) was heated to 160 °C and a solution of 2-chloro-4,6-dimethyl pyridine (40 g, 0.283 mol) in diglyme (150 mL) was added over a period of 30 min. The mixture was maintained at this temperature for 36 hand then the reaction mixture was allowed to cool to ambient temperature, diluted with brine and extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with brine (2 x 100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the crude compound. Vacuum distillation to remove diglyme afforded l-(4,6-dimethyl-2-pyridyl)piperazine (50 g, 92%) as an oil.
Reference Examples 352 to 354
The compounds set out below were prepared in a manner analogous to Reference Example 351:
Reference Compound Example
352 1 -(2-Pyridyl)piperazine
353 1 -(6-Methyl-2-pyridyl)piperazine
354 1 -(4-Methyl-2-pyridyl)piperazine
Reference Example 355: l-(4,6-dimethyI-2-pyridyI)-4-(4-nitrophenyI)piperazine
A solution of l-(4,6-dimethyl-2-pyridyl)piperazine (52 g, equivalent to 50.0 g after correcting for residual diglyme determined by GC analysis, 265 mmol) and potassium carbonate (72.4 g, 523 mmol) in diglyme (150 mL) was stirred at room temperature for 15 min and then heated to 150 °C. A solution of l-chloro-4-nitro- benzene (62 g, 392 mmol) in diglyme (150 mL) was added over 15 min and the mixture heated at reflux for 46 h. The reaction mixture was allowed to cool to ambient temperature and filtered to remove insoluble salts and the filter cake was washed with ethyl acetate (2 x 250 mL). The filtrate was concentrated in vacuo to give a viscous oil, to which was added 3N hydrochloric acid (650 mL). After stirring for 1 h the precipitated solid was filtered off and washed with water (100 mL). This solid was stirred in ethyl acetate (500 mL) for 30 min and filtered. The process was repeated once more yielding the crude product as its hydrochloride salt (85 g). The salt was suspended in water (1.0 L), basified to pH ~9 with ammonium hydroxide (100 mL) and extracted with dichloromethane (2 x 750 mL). The combined organic layers were washed with brine (2 x 250 mL), dried and evaporated to dryness to afford l-(4,6-dimethyl-2- pyridyl)-4-(4-nitrophenyl)piperazine (49 g, 60%) as a solid.
Reference Examples 356 to 360
The compounds set out below were prepared in a manner analogous to Reference Example 355:
Reference Compound Example
356 [2-[4-(4,6-Dimethyl-2-pyridyl)piperazin-l-yl]-5-nitro-phenyl]methanol
357 l-(2-Chloro-4-nitro-phenyl)-4-(4,6-dimethyl-2-pyridyl)piperazine
358 5-[4-(456-Dimethyl-2-pyridyl)piperazin-l-yl]-2-nitro-aniline
359 1 -Methyl-4-(5-nitro- 1 -naphthyl)piperazine
360 l-(456-Dimethyl-2-pyridyl)-4-(2-methyl-4-nitro-phenyl)piperazine
Reference Example 361: 2-ChIoro-5-nitro-phenol
A saturated solution of sodium nitrite (1.8 g, 26.0 mmol) in water (12 mL) was added dropwise to a suspension of 2-amino-5-nitro-phenol (2.0 g, 13.0 mmol) in concentrated hydrochloric acid (10 mL) at 0 0C and stirred for 30 min. A solution of Copper (I) chloride (5.15 g, 52.0 mmol) and concentrated hydrochloric acid (20 mL) heated to between 60 and 70 0C was added dropwise over a period of 30 min. The resultant reaction mixture was heated to 80 °C and stirred for 15 min and then allowed to cool to ambient temperature. Ethyl acetate (50 mL) was added and after stirring for 5 min the organic phase was separated and the aqueous phase was re-extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with water (4 x 50 mL), brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue which was purified by column chromatography over silica gel (100-200 mesh) using 5% ethyl acetate in petroleum ether as eluent to afford 2-chloro-5-nitro-phenol (2.08 g, 92%) as a crystalline yellow solid.
Reference Example 362: l-Fluoro-5-nitro-naphthalene
Sodium nitrite (660 mg, 9.57 mmol) was added portionwise to a suspension of 5-nitronaphthalen-l -amine (1.2 g, 6.38 mmol) in a 1:1 mixture of water/concentrated hydrochloric acid (10 mL) at -50C. The mixture was stirred for 15 min at -50C and a 60% w/w hexafluoro phosphoric acid solution (6 mL) was added. The brown precipitate was filtered and washed with cold water and diethyl ether and then allowed to dry in vacuo. The resulting solid was suspended in toluene and heated to 110 0C for 2 h before the mixture was then allowed to cool to ambient temperature and the solvent removed in vacuo to afford the crude product. Purification by column chromatography over silica gel (100-200 mesh) using petroleum ether as eluent afforded l-fluoro-5-nitro- naphthalene (450 mg, 37%) as a yellow solid.
Reference Example 363: 2-BenzyIoxy-l-chIoro-4-nitro-benzene
Benzyl bromide (0.6 mL, 5.04 mmol) was added dropwise to a mixture of 2- chloro-5-nitro-phenol (800 mg, 4.61 mmol) and potassium carbonate (1.27 g, 9.22 mmol) in acetone (20 mL) at ambient temperature and then heated at reflux for 2 h. The inorganic residue was filtered off and washed with acetone (20 mL). The combined filtrate and washings were concentrated in vacuo and the resulting residue was then dissolved in ethyl acetate (25 mL) and washed successively with water (2 x 20 mL), brine (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to yield 2-benzyloxy-l-chloro-4-nitro-benzene (1.20 g, 99%) as a cream solid. Reference Example 364: l-(2-Benzvϊoxy-4-nitro-phenyI)-4-(4,6-dimethvI-2- pyridyDpiperazine
A mixture of 2-benzyloxy-l-chloro-4-nitro-benzene (700 mg, 2.66 mmol), 1- (456-dimethyl-pyridin-2-yl)-piperazine (457 mg, 2.39 mmol) and caesium carbonate (2.58 g, 7.97 mmol) in toluene (30 mL) was purged with argon gas. Palladium acetate (24 mg, 0.106 mmol) and 2-(dicyclohexylphosphino)-2'-iV,iV-dimethylamino)-biphenyl (42 mg, 0.106 mmol) were added. After purging again with argon gas the reaction mixture was heated at reflux for 20 h. The reaction mixture was cooled, filtered and the filter cake was washed with ethyl acetate (30 mL). The combined filtrate and washings were washed successively with water (2 x 50 mL), brine (2 x 50 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to yield a residue which was purified by flash column chromatography over silica gel (100-200 mesh) using 8-10% ethyl acetate in petroleum ether as eluent to afford l-(2-benzyloxy-4-nitro-phenyl)-4- (4,6-dimethyl-2-pyridyl)piperazine (510 mg, 46%) as a pale yellow solid.
Reference Example 365: 4-r3-fr2-r4-(4,6-Dimethyl-2-pyridyl)piperazin-l-yll-5- nitro-phenylimethoxylpropyllmorpholine
Aqueous sodium hydroxide (50% w/w, 1O g, 125 mmol) and tetrabutylammonium hydrogen sulfate (0.20 g) were added successively to a solution of [2-[4-(4,6-dimethyl-2-pyridyl)piperazin-l-yl]-5-nitro-phenyl]methanol (0.50 g, 1.46 mmol) in toluene (5 mL). The mixture was heated to reflux with vigorous stirring for 45 min then 4-(3-chloro-propyl)-morpholine (0.50 g, 3.00 mmol) was added and reflux continued for 28 h. The reaction mixture was cooled and the organic phase separated. The aqueous phase was extracted with ethyl acetate (3 x 5 mL). The organic phases were combined, washed with water and brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to give a residue which was purified by preparative TLC eluting with 2% methanol in chloroform to afford 4-[3-[[2-[4-(4,6- dimethyl-2-pyridyl)piperazin-l-yl]-5-nitro-phenyl]methoxy]propyl]morpholine (550 mg, 80%) as a solid. Reference Examples 366 and 367
The compounds set out below were prepared in a manner analogous to Reference Example 365.
Reference Compound Example
366 2-[[2-[4-(4,6-Dimethyl-2-pyridyl)ρiperazin-l-yl]-5-nitro- phenyl]methoxy]-N,N-dimethyl-ethanamine
367 l-(4,6-Dimethyl-2-pyridyl)-4-[2-[3-(4-methylpiperazin-l- yl)propoxymethyl]-4-nitro-phenyl]piperazine
Reference Example 368: l-(3-chIoro-4-nitro-phenγl)-4-(4,6-dimethyI-2- pyridvDpiperazine
50% Aqueous hydrochloric acid (30 niL) was cooled to -20 0C, 5-[4-(4,6- dimethyl-2-pyridyl)piperazm-l-yl]-2-nitro-aniline (1.4 g, 4.28 mmol) was added and the reaction mixture stirred for 15 min. A solution of sodium nitrite (350 mg, 5.14 mmol) in water (8 mL) was added and the reaction mixture stirred for 15 min. This solution was added drop wise to a cooled solution of copper (I) chloride (635 mg, 6.42 mmol) in 50% hydrochloric acid (20 mL) over a period of 20 min and stirred for a further 10 min before basifying with saturated sodium carbonate solution. The mixture was extracted with ethyl acetate and the organic phase was washed with water, brine, dried over anhydrous sodium sulfate and concentrated under vacuum to give a crude residue. Purification by column chromatography over silica gel (100-200 mesh) using 8% ethyl acetate in petroleum ether as eluent afforded l-(3-chloro-4-nitro-phenyl)-4-(4,6- dimethyl-pyridin-2-yl)-piperazine 1 -(3 -chloro-4-nitro-phenyl)-4-(4,6-dimethyl-2- pyridyl)piperazine (800 mg, 54%) as a yellow solid.
Reference Example 369: 2-f4-(4,6-dimethvI-2-pyridyl)piperazin-l-vπ-5-nitro- phenol Trifluoroacetic acid (5 mL) was added to l-(2-benzyloxy-4-nitro-phenyl)-4-(4,6- dimethyl-2-pyridyl)piperazine (720 mg, 1.72 mmol) at between 0 and 5 0C followed by concentrated hydrochloric acid (2 mL). The mixture was heated at reflux for 16 h then cooled to between 0 and 5 0C and quenched with saturated sodium bicarbonate solution (30 mL). Chloroform (30 mL) was added and the mixture was stirred for 15 min. The organic phase was separated and the aqueous phase was extracted with chloroform (30 mL). The combined organic phases were washed with water (2 x 30 mL), brine (30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a crude residue. Trituration with petroleum ether afforded 2-[4-(4,6-dimethyl-2- pyridyl)piperazin~l-yl]-5-nitro-phenol (510 mg, 90%) as a brownish-yellow solid.
Reference Example 370: [244-(4,6-dimethyl-2-pyridγl)piperazm-l-vI]-5-nitro- phenyli acetate
Triethylamine (1.0 mL, 7.17 mmol) was added to a solution of 2-[4-(456- dimethyl-pyridin-2-yl)-piperazin-l-yl]-5-nitro-phenol (500 mg, 1.52 mmol) in dry dichloromethane (20 mL) followed by the dropwise addition of acetyl chloride (0.2 mL, 2.80 mmol). After stirring for 15 min, water was added and the mixture warmed to room temperature. The organic phase was separated and the aqueous phase was extracted with dichloromethane (2 x 30 mL). The combined organic phases were washed with water (2 x 30 mL), brine (2 x 30 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was triturated with 5% dichloromethane in petroleum ether (2 x 20 mL) to afford [2-[4-(4,6-dimethyl-2-pyridyl)piperazin-l-yl]-5- nitro-phenyl] acetate (365 mg, 65%) as a pale brownish-yellow solid.
Reference Example 371
The compound set out below was prepared in a manner analogous to Reference Example 370.
Reference Compound Example
371 iV-[2-(2-Methyl-4-phenyl-pyrrol-l-yl)ethyl]acetamide Reference Example 372: 2-fl3romomethyIVl-methoxy-3-nitro-benzene
iV-bromosuccinimide (590 mg, 3.30 mmol) was added to a solution of 1- methoxy-2-niethyl-3-nitro-benzene (500 mg, 3.0 mmol) in carbon tetrachloride (5 mL) followed by a catalytic amount of dibenzoyl peroxide (25 mg). The reaction mixture was heated at reflux for 3 h then cooled to room temperature and poured into water. The organic phase was separated, washed with water (2 x 20 mL), dried over the anhydrous sodium sulfate and concentrated in vacuo to afford 2-(bromomethyi)-l-methoxy-3~ nitro-benzene (640 mg, 86%) as a solid.
Reference Example 373: 2-(2-Methoxy-6-nitro-phenyl)acetonitrile
Sodium cyanide (165 mg, 3.36 mmol) was added to a solution of 2- (bromomethyl)-l-methoxy-3 -nitro-benzene (680 mg, 2.56 mmol) in ethanol (5 mL) and the mixture was heated at reflux for 16 h. The solvent was removed in vacuo, water (30 mL) was added and the mixture was extracted with dichloromethane (25 mL). The organic phase was washed with water (2 x 20 mL), brine (20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The crude compound was purified by column chromatography over silica gel (100-200 mesh) using 8% ethyl acetate in petroleum ether to afford 2-(2-methoxy-6-nitro-phenyl)acetonitrile (300 mg, 61%).
Reference Example 374: Ethyl 2-(2-methoxy-6-nitro-phenyI)acetate
Concentrated sulfuric acid (1 mL) was slowly added to a solution of 2-(2- methoxy-6-nitro-phenyl)acetonitrile (200 mg, 1.04 mmol) in 95% ethanol (2 mL). The mixture was heated at reflux overnight then quenched into ice cold water and extracted with diethyl ether (10 mL). The organic phase was washed with water (2 x 10 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to afford ethyl 2-(2- methoxy-6-nitro-phenyl)acetate (180 mg, 72%). Reference Example 375: 2-(2-Methoxy-6-nitro-phenyl)ethanol
Diisobutylaluminium hydride (20 wt %; 2.38 g, 16.8 mmol) in toluene was added to a solution of 2-(2-methoxy-6-nitro-phenyl)acetate (1.0 g, 4.18 mmol) in tetrahydrofuran (8 mL) at -5 0C. The reaction mixture was stirred at 0 0C for 1 h and then poured into IN hydrochloric acid. The mixture was extracted with ethyl acetate (30 mL) and the separated organic phase was washed with water (2 x 30 mL), brine (25 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to afford 2-(2- methoxy-6-nitro-phenyl)ethanol (780 mg, 94%).
Reference Example 376: [l-(methoxymethyl)-4-phenyl-pyrrol-2-yll methanol
Lithium aluminum hydride (113 mg, 3.06 mmol) was added portionwise to a stirred solution of methyl l-(methoxymethyl)-4-phenyl-pyrrole-2-carboxylate (500 mg, 2.04 mmol) in tetrahydrofuran (10 mL) over a period of 15min at 0 0C. The resulting mixture stirred for 12 h and then quenched with ice and the mixture extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to yield [l-(methoxymethyl)-4-phenyl-pyrrol- 2-yl]methanol (400 mg, 91%) as a brown liquid.
Reference Example 377: 4-Nitro-2,3-dihydropenzofιiran
2-(2-Methoxy-6-nitro-phenyl)ethanol (700 mg, 3.55 mmol) was dissolved in polyphosphoric acid (3 mL) and heated at 120 °C for 1 h. After cooling to ambient temperature, ice- water water was added and the mixture was extracted with ethyl acetate. The organic phase was washed with water (2 x 20 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to afford 4-nitro-2,3-dihydrobenzofuran (400 mg, 68%).
Reference Example 378: l-(4-nitrophenyI)-4-(2-pyridvDpiperazine A mixture of l-chloro-4-nitro-benzene (4.34 g, 27.6 mmol) and anhydrous potassium carbonate (5.08 g, 36.8 mmol) was added to a solution of l-(2- pyridyl)piperazine (3.0 g, 18.4 mmol) in diglyme (10 mL) and heated at reflux for 24 h. The reaction mixture was cooled to ambient temperature, filtered and the filtrate was concentrated in vacuo. The residue was diluted with chloroform and the organic layer was washed with water (5 x 40 mL), brine (3 x 30 mL), dried over anhydrous sodium sulphate and concentrated to yield a crude compound. This was purified by washing with hexane (5 x 5 mL) and then pentane (2 x 5 mL) to afford l-(4-nitrophenyl)-4-(2- pyridyl)piperazine (4.0 g, 77%) as a yellow solid.
Reference Examples 379 to 381
The compounds set out below were prepared in a manner analogous to Reference Example 378:
Reference Compound Example
379 l-(6-Methyl-2-pyridyl)-4-(4-nitrophenyl)piperazine
380 l-(4-Methyl-2-pyridyl)-4-(4-nitrophenyl)piperazine
381 6-[4-(4-Nitrophenyl)piperazin-l-yl]pyridine-3-carbaldehyde
Reference Example 382: 4-ir6-r4-(4-nitrophenyDpiperazin-l-yI|-3- pyridyll methyl] morpholine
Morpholine (250 mg, 2.87 mmol) was added to a suspension of 6-[4-(4- nitrophenyl)piperazin-l-yl]pyridine-3-carbaldehyde (750 mg, 2.41 mmol) and sodium cyanoborohydride (454 mg, 7.23 mmol) in a mixture of tetrahydrofuran (10 mL) and acetic acid (0.5 mL) at ambient temperature then heated at reflux for 3 h. The mixture was then concentrated in vacuo to give a gummy solid which was dissolved in chloroform (40 mL), washed with water (2 x 20 mL), brine (2 x 15 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give the crude compound. Purification by column chromatography over neutral alumina using 20-30% of ethyl acetate in petroleum ether afforded 4-[[6-[4-(4-nitrophenyl)piperazin-l-yl]-3- pyridyl]methyl]morpholine (550 mg, 59%).
Reference Example 383: l-(2-fluoro-4-nitro-phenyI)piperidine
Piperidine (0.80 g, 9.42 mmol) was added to a solution of 3,4-difluoro-nitro benzene (1.0 g, 6.28 mmol) in acetonitrile (15 mL) and diisopropyl ethylamine (1.62 g, 12.57 mmol) and the mixture was refluxed for 3 h. The acetonitrile was removed in vacuo and the residue was diluted with water and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford l-(2-fluoro-4-nitro-phenyl)piperidine (1.3 g, 92%) as a yellow liquid.
Reference Examples 384 to 388 The compounds set out below were prepared in a manner analogous to
Reference Example 383:
Reference Compound Example
384 l-(2-Fluoro-4-nitro-phenyl)-4-(2-pyridyl)piperazine
385 l-(2-Fluoro-4-nitro-phenyl)-4-isobutyl-piperazine
386 4-(2-Fluoro-4-nitro-phenyl)morpholine
387 1 -(4-Nitroρhenyl)piperidine
388 4-(4-Nitrophenyl)morpholine
Reference Example 389: l-Benzyl-4-(4-nitrophenγI)piperazine
Benzyl bromide (1.42 mL, 11.6 mmol) was added to a solution of l-(4- nitrophenyl)piρerazine (2.0 g, 11.6 mmol) in acetonitrile (30 mL) with triethylamine (2.68mL, 19.32 mmol) and refluxed for 12 h. The mixture was concentrated in vacuo and the residue partitioned between water and ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford l-benzyl-4-(4-nitrophenyl)piperazine (2.2 g, 77%).
Reference Example 390: l-fl,2-DimethylpropyI)-4-(4-nitrophenyI)piperazme
3-Methyl-2-butanone (0.76 mL, 7.24 mmol) was added to a solution of l-(4- nitrophenyl)piperazine (1.0 g, 4.83 mmol) in methanol (10 mL) and acetic acid (1 mL) and stirred for 30 min at ambient temperature. Sodium cyanoborohydride (1.81 g, 28.98 mmol) was added and the mixture refluxed for 12 h, cooled and then poured into water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford the crude product. Purification by column chromatography over silica gel (100-200 mesh) using 5-10% ethyl acetate/petroleum ether as eluent afforded l-(l,2-Dimethylpropyl)-4- (4-nitrophenyl)piperazine (0.46g, 34%).
Reference Examples 391 to 392
The compounds set out below were prepared in a manner analogous to Reference Example 390:
Reference Compound Example
391 1 -(2-Methoxy- 1 -methyl-ethyl)-4-(4-nitrophenyl)piperazine
392 l-[2-(2-Furyl)-l-methyl-ethyl]-4-(4-nitrophenyl)piperazine
Reference Example 393: 2-(4-NitrophenyI)-5-(l-piperidyImethyl)oxazole
5-(Bromomethyl)-2-(4-nitrophenyl)oxazole (800 mg, 2.82 mmol) was heated with piperidine (10 mL) in a sealed tube at 100-110 0C for 12 h. The resulting mixture was allowed to cool ambient temperature and then poured into water (30 OmL) and stirred for 30 min. The resultant solid was filtered and washed with water to remove excess piperidine. The residue was dried to give 2-(4-nitrophenyl)-5-(l- piperidylmethyl)oxazole (700 mg, 86%) as light orange colour solid. Reference Example 394: 4-Nitro-N-prop-2-vnyI-benzamide
To a stirred solution of propargylamine hydrochloride (5.0 g, 54.6mmol) and pyridine (7.8 g, 99.1 mmol) in tetrahydrofuran (3OmL) was added 4-nitro- benzoylchloride (9.2 g, 49.6 mmol) in tetrahydrofuran (20 mL) and the mixture was heated at reflux for 16 h. The mixture was allowed to cool to ambient temperature and concentrated in vacuo. The crude residue was dissolved in ethyl acetate and washed with saturated aqueous sodium bicarbonate solution, water, brine, dried over anhydrous sodium sulphate, filtered and concentrated in vacuo to afford 4-nitro-N-prop-2-ynyl- benzamide (7.74 g, 77%) as a solid.
Reference Example 395: 5-Methyl-2-(4-nitrophenyI)oxazoIe
To a stirred solution of 4-nitro-N-prop-2-ynyl-benzamide (7.5 g, 36.7 mmol) in ethanol (150 mL) was added a solution of potassium hydroxide (4.1 g, 73.4 mmol) in ethanol (100 mL) and the mixture was stirred at 50-55 0C for 12 h. The mixture was acidified with acetic acid and concentrated to dryness in vacuo at 45-50 C. The resultant residue was extracted into ethyl acetate and the separated organic phase was washed with water; aqueous sodium bicarbonate, brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford 5-methyl-2-(4-nitrophenyl)oxazole (3.47 g, 46%) as an oil.
Reference Example 396: Preparation of 5-(BromomethyI)-2-(4-nitrophenvI')oxazoIe
To a stirred solution of 5-methyl-2-(4-nitrophenyl)oxazole (3.2 g, 15.68 mmol) and benzoyl peroxide (10 mg, catalytic) in carbon tetrachloride (20 mL), was added N- bromo succinamide (2.77 g, 15.68 mmol). The mixture was heated to reflux for 9 h, filtered and the residue was washed with carbon tetrachloride. The combined filtrates were washed with water, sodium bicarbonate solution, brine, dried over anhydrous sodium sulphate and concentrated in vacuo. The crude product was purified over silica gel (60-120 mesh) with 30% ethyl acetate/hexane as eluent to afford 5-(bromometliyl)- 2-(4-nitro-ρhenyl)-oxazole (2.9 g, 65%) as a solid.
Reference Example 397: 2-Methyl-l-[4-(4-nitrophenyI)piperazin-l-yllpropan-l- one
Triethylamine (976 nag, 9.66 mmol) was added to a solution of l-(4- nitrophenyl)piperazine (1.00 g, 4.83 mmol) in dichloromethane (20 mL) at 0 0C and stirred for 30 min. Isobutyryl chloride (617 mg, 5.79 mmol) was then added and the mixture was warmed to ambient temperature and stirred for 4 h. the reaction mixture was quenched with ice-water and the organic layer separated. The aqueous layer was extracted with dichloromethane (5 x 5mL) and the combined organic layers were washed water, saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford 2-methyl-l-[4-(4- nitrophenyl)piperazin-l-yl]propan-l-one (1.20 g, 90%) as a yellow solid.
Reference Example 398: 4-[4-(4,6-dimethyl-2-pyridyl)piperazin-l-yrianiline
A solution of l-(456-dimethyl-2-pyridyl)-4-(4-nitrophenyl)piperazine (49 g, 157 mmol) in methanol was hydrogenated over Raney Nickel (15 g) at 90 psi pressure for 36 h. The mixture was filtered through Celite and the filtrate was concentrated in vacuo giving a crude product which was washed with petroleum ether (100 mL) to afford 4-[4- (4,6-dimethyl-2-pyridyl)piperazin-l-yl]aniline (43.5 g, 98%).
Reference Examples 399 to 417
The compounds set out below were prepared in a manner analogous to Reference Example 398 at a suitable pressure:
Reference Compound Example
399 4- [4-(4,6-Dimethyl-2-pyridyl)piperazin- 1 -yl] -3 -(3 - morpholinopropoxymethyl)aniline 09 001058
400 3 -Chloro-4- [4-(4,6-dimethyl-2-pyridyl)piperazin- 1 -yl] aniline
401 3-(2-Dimethylaminoetnoxymethyl)-4-[4-(4,6-dimethyl-2- pyridyl)piperazin- 1 -yl]aniline
402 4-[4-(456-Dimethyl-2-pyridyl)piperazin-l-yl]-3-[3-(4-metliylpiperazin- 1 -yl)propoxymethyl] aniline
403 5-Amήio-2-[4-(4,6-dimethyl-2-pyridyl)piperaziii-l-yl]phenol
404 2,3-Dihydrobenzoftιran-4-amine ,
405 4- [4-(2-Pyridyl)piperazin- 1 -yl] aniline
406 4- [4-(6-Methyl-2-pyridyl)piperazin- 1 -yl] aniline
407 4- [4-(4-Methyl-2-pyridyl)piperazin- 1 -yl] aniline
408 5 -(4-Methylpiperazin- 1 -yl)naphthalen- 1 -amine
409 4- [4-(4,6-Dimethyl-2-pyridyl)piperazin- 1 -yl] -3 -methyl-aniline
410 4- [4- [5 -(Morpholinomethyl)-2-pyridyl]piperazin- 1 -yl] aniline
411 3 -Fluoro-4-( 1 -piperidyl)aniline
412 3 -Fluoro-4-(4-isobutylpiperazin- 1 -yl)aniline
413 3 -Fluoro-4-moφholino-aniline
414 5-Fluoro-naphthalen-l -amine
415 4-(l -Piρeridyl)aniline
416 4-Morpholinoaniline
417 4- [4-(2-Methoxy- 1 -methyl-ethyl)piperazin- 1 -yl] aniline
Reference Example 418: 5-Nitro-2-pyrroIidin-l-yl-pyridine
A mixture of 2-bromo-5-nitro pyridine (300 mg, 1.48 mmol) and pyrrolidine (313 mg, 4.41 mmol) in toluene (5 mL) was heated at HO0C for 2 h. The reaction mixture was allowed to cool to ambient temperature, poured onto ice- water, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate, filtered and concentrated in vacuo to afford 5-nitro-2-pyrrolidin-l-yl- pyridine (250 mg, 88%) as a solid. Reference Example 419: 2-ChIoro-4-[4-(4,6-dimethyI-2-pyridvI)piperaziii-l- yli aniline
Stannous chloride dihydrate (2.6 g, 11.5 mmol) was added to a solution of l-(3- chloro-4-nitro-phenyl)-4-(4,6-dimethyl-pyridin-2-yl)-piperazine (800 mg, 2.31 mmol) in a mixture of ethyl acetate (20 mL) and ethanol (5 mL). The reaction mixture was heated at reflux for 2 h, allowed to cool to ambient temperature and basified with triethylamine. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography over neutral alumina with 10% ethyl acetate in petroleum ether as eluent to afford 2-chloro-4-[4-(4,6-dimethyl-2- pyridyl)piperazin-l-yl] aniline (470 mg, 64%) as a viscous light brown oil.
Reference Examples 420 to 428:
The compounds set out below were prepared in a manner analogous to Reference Example 419:
Example Compound
420 6-Pyrrolidin- 1 -yl-pyridin-3 -amine
421 1 -Ethyl-4-fluoro-indol-5-amine
422 4-(4-Benzylpiperazin- 1 -yl)aniline
423 4-Oxazol-2-ylaniline
424 3 -Fluoro-4-oxazol-2-yl-aniline
425 4-[4-(l,2-Dimethylpropyl)piperazin-l-yl]aniline
426 1 - [4-(4- Aminophenyl)piperazin- 1 -yl] -2-methyl-propan- 1 -one
427 4-[4-[2-(2-Furyl)-l-methyl-ethyl]piperazin-l-yl]aniline
428 4-[(5-Piperidylmethyl)oxazol-2-yl]aniline
Reference Example 429: 5-Nitronaphthalen-l-amine
A 70 0C solution of sodium sulfide (3.17 g, 32.97 mmol) and sodium bicarbonate in water (7 mL) was added dropwise to suspension of 1,5-dinitro naphthalene (2.0 g, 9.16 mmol) in methanol (30 mL) at reflux and the resultant mixture was stirred for 5 min. The mixture was cooled to O0C, quenched with ice and stirred for a further 10 min followed by acidification with concentrated hydrochloric acid. The resulting mixture was stirred for 30 min then washed with ethyl acetate (2 x 50 mL). The aqueous layer was basified with aqueous ammonia and extracted with ethyl acetate (2 x 100 mL).The combined organic layers were washed with water (2 x 50 mL), brine (2 x 50 mL), dried over anhydrous sodium sulphate, filtrated and concentration in vacuo afforded of 5-nitronaphthalen-l-amine (710 mg, 42%) as a brown solid.
Reference Example 430: 5-Bromoisoquinoline
A solution of sodium nitrite (2.15 g, 31.21 mmol) in water (2 mL) was added to a solution of isoquinolin-5-ylamine (3.0 g, 20.80 mmol) in aqueous 46% hydrogen bromide (9.98 g, 124.84 mmol) at 0 °C. The mixture was stirred at 0 0C for 30 min then a solution of cuprous bromide (3.58 g, 24.96 mmol) in aqueous 46% hydrogen bromide (9.98 g, 124.84 mmol) was added and the reaction was allowed to warm to ambient temperature and stirred for 2 h. The resulting mixture was basified with aqueous ammonium and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulphate and concentrated to afford the crude compound. Purification by column chromatography over silica gel (100-200 mesh) with 20% ethyl acetate in petroleum ether as eluent afforded 5-bromoisoquinoline (2.3 g, 53%) as a pale yellow solid.
Reference Example 431: 5-Bromo-8-nitro-isoquinoline
Potassium nitrate (1.17 g, 11.59 mmol) was added portion- wise to a solution of
5-bromo-isoquinoline (2.0 g, 9.66 mmol) in concentrated sulphuric acid (10 mL) and stirred at ambient temperature for 1 h. The reaction mixture was quenched with water and basified with aqueous ammonia. The aqueous layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated in vacuo to afford 5-bromo-8- nitro-isoquinoline (2.0 g, 82%) as a yellow solid.
Reference Example 432: 3-Phenylfuran Furan-3-boronic acid (1.0 g, 8.93 mmol), bromo benzene (1.26 g, 8.04 mmol) and sodium carbonate (1.89 g, 17.86 mmol) were dissolved in a mixture of toluene (15 mL) and methanol (5 mL) and purged with argon for 15 min. Tetrakis palladium (0) (20 mg) was added and the mixture again degassed for 15 min. The reaction was heated at 80 0C for 4 h and the resultant solids which formed were filtered and the filtrate was concentrated in vacuo to give a crude residue. Purification by flash chromatography over silica gel (100-200 mesh) using 2% ethyl acetate/petroleum ether as eluent afforded 3-phenylfuran (0.9 g, 70%).
Reference Example 433: 2,5-Dimethoxy-3-phenyl-2,5-dihydrofuran
Bromine (0.83 g, 5.31 mmol) dissolved in methanol (5 mL) was added drop wise to a solution of 3-phenylfuran (0.85 g, 5.90 mmol) in methanol (5 mL) and diethyl ether (3 mL) at -400C. The resultant mixture was allowed to warm to -250C and stirred for a further 2 h. The reaction the mixture was quenched with ice cold water and extracted with diethyl ether. The combined organic extracts were washed with saturated bicarbonate solution, dried over anhydrous sodium sulfate and concentrated in vacuo to give the crude compound. Purification by flash chromatography over silica gel (100-200 mesh) with 2% ethyl acetate/petroleum ether as eluent afforded 2,5-dimethoxy-3- ρhenyl-2,5-dihydrofuran (0.65 g5 54%).
Reference Example 434; Isoquinolin-8-amine
A suspension of 5-bromo-8-nitro-isoquinoline (2.0 g, 7.93 mmol), triethylamine
(1.2 g, 11.90 mmol) and PdVC (10%; 200 mg) in dimethylformamide (10 mL) was hydrogenated at atmospheric pressure for 2 h. The reaction mixture was filtered through Celite and washed with ethyl acetate. The filtrate was concentrated in vacuo to afford isoquinolin-8-amine (700 mg, 66%) as a pale yellow solid.
Reference Examples 435 and 436: The compounds set out below were prepared in a manner analogous to Reference Example 434:
Example Compound
435 2,5-Dimeώoxy-3-phenyl-tetrahydrofuran
436 3-Fluoro-4-[4-(2-pyridyl)piperazin-l-yl]aniline
Reference Example 437: Naphthalen-2-amine
Polyphosphoric acid (7.5 g) was added to a mixture of 2-naphthoic acid (600 mg, 3.48 mmol) and hydroxylamine hydrochloride (254 mg, 3.66 mmol) at room temperature and heated slowly to 160 0C. The reaction mixture was stirred for 90 min and then allowed to cool to ambient temperature and quenched with crushed ice (50 g). The resultant solid was filtered and washed with water (2 x 20 mL). The combined filtrate and washings were basified with 10% potassium hydroxide solution (100 mL). The precipitated solid was filtered, washed with water (2 x 25 mL), petroleum ether (2 x 20 mL), diethyl ether (2 x 20 mL) and dried in vacuo to afford naphthalen-2-amine (165 mg, 34%) as a light pink solid.
Reference Example 438: 2-FIuoro-4-F4-(2-pyridyDpiperazm-l-yπ aniline
2-Fluoro-4-iodoaniline (750 mg, 3.16 mmol) was added to a suspension of 2- pyridyl-piperazine (568 mg, 3.48 mmol), 8-hydroxyquinoline (68 mg, 0.47 mmol) and potassium carbonate (660 mg, 4.74 mmol) in dimethylsulfoxide (5 mL) under an inert atmosphere. Cuprous iodide (94 mg, 0.47 mmol) was added and the reaction mixture was heated at 140-145 0C for 16 h. The reaction mixture was allowed to cool to ambient temperature and poured into a mixture of ammonium hydroxide, ethyl acetate and charcoal and stirred for 30 min. The organic layer was separated and the aqueous layer extracted with ethyl acetate (2 x 75 mL). The combined organic layers were washed with brine (100 mL), dried over sodium sulphate and concentrated to dryness in vacuo. The crude product was purified by column chromatography with silica gel (100-200 mesh) using 13% ethyl acetate in petroleum ether as eluent to afford 2-fluoro-4-[4-(2- pyridyl)piperazin-l-yl] aniline (220 mg, 26%) as an orange semi-solid.
Examples 439 to 444:
The compounds set out below were prepared in a manner analogous to Reference Example 438:
Reference Compound Example
439 2-Fluoro-4-morpholino-aniline
440 2-Fluoro-4-(4-isobutylpiperazin- 1 -yl)aniline
441 2-Fluoro-4-(l -piperidyl)aniline
442 2-Fluoro-4-[4-(2-methylallyl)piperazin-l-yl]aniline
443 4- [4-(2,2-Dimethylpropyl)piperazin- 1 -yl] -2-fluoro-aniline
444 4-[4-(4,6-Dimethyl-2-pyridyl)piperazin-l-yl]-2-fluoro-aniline
Reference Example 445: 3-FIuoro-4-nitro-benzoic acid
2-Fluoro-4-methyl-l-nitro-benzene (1.0 g, 12.9 mmol) was added portion- wise to a suspension of potassium dichromate (5.04 g, 17.16 mmol) in glacial acetic acid (8 mL) follow by concentrated sulfuric acid (3.6 mL). The reaction mixture was heated to 1200C for 2 h and then allowed to cool to ambient temperature. The reaction was quenched with crushed ice and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford 3-fluoro-4-nitro-benzoic acid (1.9 g, 83%) as a white solid.
Reference Example 446: 3-FIuoro-4-nitro-benzoyl chloride
A stirred solution of 3-fluoro-4-nitro-benzoic acid (1.65 g, 8.91 mmol) in tbionyl chloride (10 mL) was heated at reflux for 2 h. Excess thionyl chloride was evaporated in vacuo and the residue azeotroped with toluene to afford 3-fluoro-4-nitro-benzoyl chloride (1.7 g, 99%) as a brown oil. Reference Example 447:
The compound set out below was prepared in a manner analogous to Reference Example 446:
Reference Compound Example
447 2-Fluoro-4-nitro-benzoyl chloride
Reference Example 448: N-(2,2-Dimethoxyethyl)-3-fluoro-4-nitro-benzamide
To a cooled solution of amino acetaldehyde dimethyl acetal (0.91 mL, 8.30 mmol) in dry tetrahydrofuran (15 mL) was added sodium bicarbonate (769 mg, 9.16 mmol) and then a solution of 3-fluoro-4-nitro-benzoyl chloride (1.7 g, 8.30 mmol) in dry tetrahydrofuran (15 mL) was added dropwise at 0 0C over a period of 30 min. The reaction mixture was stirred overnight at ambient temperature, the solvent was removed in vacuo, and the residue was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated to yield iV-(2,2-dimethoxyethyl)-3-fluro-4-nitro-benzamide (2.0 g, 90%) as a brown liquid.
Reference Example 449 to 450: The compounds set out below were prepared in a manner analogous to
Reference Example 448:
Reference Compound Example
449 N-(2,2-Dimethoxyethyl)-4-nitro-benzamide
450 N-(252-Dimethoxyethyl)-2-fluoro-4-nitro-benzamide
Reference Example 451: 2-(3-Fluoro-4-nitrophenyl)oxazole Phosphorous pentoxide (4.14 g, 29.41 mmol) was added portion- wise to a solution of Λ/-(2,2-dimethoxyethyl)-3-fluoro-4-nitro-benzainide (2.0 g, 7.35 mmol) in methane sulphonic acid (3 mL) at 0 0C over a period of 30 min. The mixture was heated to 145 0C for 5 h. The reaction mixture was allowed to cool to ambient temperature and quenched with crushed ice and then extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulfate and concentrated to afford the crude residue. Purification by flash chromatography with silica (60-120 mesh) using 15% ethyl acetate-petroleum ether as eluent to afforded 2-(3- fiuoro-4-nitrophenyl)oxazole (500 mg, 33%) as a white solid.
Examples 452 to 453:
The compounds set out below were prepared in a manner analogous to Reference Example 451 :
Reference Compound Example
452 2-(4-Nitrophenyl)oxazole
453 2-(2-Fluoro-4-nitrophenyl)oxazole
Reference Example 454: l-Ethyl-4-fluoro-5-nitro-indole
2,3-Dicliloro-5,6-dicyanohydroquinone (1.02 g, 4.50 mmol) was added to the solution of 4-fluoro-5-nitro-2,3-dihydro-indole (0.47 g, 2.25 mmol) in benzene (30 mL) and the mixture was refiuxed for 7 h. The solvent was removed in vacuo and the residue partitioned between ethyl acetate (100 mL) and water (100 mL). The organic phase was washed with water (3 x 1OmL), brine (3 x 1OmL)5 dried over anhydrous sodium sulphate and concentration in vacuo afforded the crude product. Purification by column chromatography over neutral alumina using 5% ethyl acetate in hexane as eluent afforded 1 -ethyl-4-fluoro-5-nitro-indole (0.33 g, 72%) as yellow solid.
Reference Example 455: l-ethvl-4-fluoro-5-nitro-indoIine Anhydrous potassium carbonate (0.83 g, 6 mmol) was added to a solution of 4- fluoro-5-nitro-indoline (0.54 g, 3 mmol) in acetone (20 mL). The mixture was stirred at 60 0C for 10 min and ethyl bromide (0.33 mL, 4.50 mmol) added dropwise and the mixture was refluxed for a further 12 h. The mixture was concentrated in vacuo and the residue partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was separated and the aqueous layer extracted with ethyl acetate (5 x 1OmL). The combined organic layers were washed with water (3 x 1OmL), brine (3 x 1OmL) and then dried over anhydrous sodium sulphate. Concentration of the organic layer afforded the crude product which was purified by column chromatography over silica gel neutral alumina mesh using 5-8% ethyl acetate in hexane as eluent to afford l-ethyl-4-fluoro-5- nitro-indoline (0.47 g, 75%) as a yellow solid.
Reference Example 456: 4-FIuoro-5-nitro-indoϋne
A mixture of l-(4-fluoro-5-nitro-indolin-l-yl)ethanone (0.56 g, 2.51 mmol) and concentrated hydrochloric acid (10 mL) was refluxed for 16 h. The reaction mixture was cooled to ambient temperature and partitioned between chloroform (100 mL) and water (100 mL). The organic layer was separated and the aqueous layer extracted with chloroform (5 x 30 mL). The combined organic layers were washed with water (3 x 20 mL), brine (3 x 20 mL) and dried over anhydrous sodium sulphate. Concentration in vacuo afforded 4-fluoro-5-nitro-indoline (0.35g, 76%) as a yellow solid.
Reference Example 457: l-(4-FIuoro-5-nitro-indoIin-l-yI)ethanone
Fuming nitric acid (0.22 mL) was added dropwise to a solution of l-(4-fluoro- indolin-l-yl)ethanone (1 g, 5.58 mmol) in concentrated sulfuric acid (10 mL) at -15 0C to 0 0C. The reaction mixture was stirred at 0 0C for 2 h and then the resulting mixture was basifϊed with sodium bicarbonate solution (100 mL). The reaction mixture was partitioned between chloroform (100 mL) and water (100 mL). The organic layer was separated and the aqueous layer was extracted with chloroform (5 x 30 mL). The combined organic layers were washed with water (3 x 20 mL), brine (3 x 20 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to give the crude product. Purification by column chromatography over neutral alumina using 10-12% ethyl acetate inhexane as eluent afforded l-(4-fluoro-5-nitro-indolin-l-yl)ethanone (0.56 g, 45%) as a yellow solid.
Reference Example 458: l-(4-FIuoro-indoIin-l-yI)ethanone
A mixture of 4-fluoro-indoline (1 g, 7.30 mmol) and acetic anhydride (10 mL) was stirred at ambient temperature for 1 h. The resulting mixture was partitioned between ethyl acetate (100 mL) and water (100 mL).The organic layer was separated and the aqueous layer was extracted with ethyl acetate (5 x 30 mL). The combined organic layers were washed with water (3 x 20 mL), sodium bicarbonate solution (3 x 20 mL), brine (3 x 20 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to afford l-(4-fiuoro-indolin-l-yl)ethanone (1 g, 77%) as a white solid.
Reference Example 459: 4-Fluoroindoline
Sodium cyanoborohydride (1.86 g, 29.62 mmol) was added portion wise to a solution of 4-fluoro-lH-indole (2 g, 14.81 mmol) in acetic acid (20 mL) at 0 0C and stirred at ambient temperature for 2 h. The resulting mixture was concentrated in vacuo and partitioned between ethyl acetate (100 mL) and water (100 mL).The organic layer was separated and the aqueous layer was extracted with ethyl acetate (5 x 30 mL). The combined organic layers were then washed with water (5 x 20 mL), sodium bicarbonate solution (3 x 30 mL), brine (3 x 20 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to give the crude product. Purification by column chromatography over neutral alumina using 5% ethyl acetate in hexane as eluent to afforded 4-fluoroindoline (1 g, 45%) as a brown liquid.
Reference Example 460: 4-Fluoro-lH-indole
Raney Nickel (500 mg) was added to a suspension of l-[2-(2-fiuoro-6-nitro- phenyl)vinyl]pyrrolidine (6 g, 25.42 mmol) in methanol (50 mL) and hydrogenated under atmospheric pressure at ambient temperature for 20 h. The mixture was filtered through a pad of Celite and the filtrate was concentrated in vacuo to afford 4-fluoro-lH- indole (2.05 g, 60%) as a brown liquid.
Reference Example 461: l-f2-(2-Fluoro-6-nitro-phenvI)vinyll pyrrolidine
Pyrrolidine (0.26 mL, 3.22 mmol) was added to a solution of 2-fluoro-6- nitrotoluene (5 g, 32.23 mmol) in N, N-dimethyl formamide dimethyl acetal (50 mL) and refluxed for 48 h. The resulting mixture was cooled to ambient temperature and partitioned between ethyl acetate (150 mL) and water (150 mL). The organic layer was separated and the aqueous layer extracted with ethyl acetate (5 x 30 mL). The combined organic layers were washed with water (3 x 30 mL). brine (3 x 20 mL), dried over anhydrous sodium sulphate and concentrated in vacuo to give l-[2-(2-fluoro-6-nitro- phenyl)vinyl]pyrrolidine (6.08 g, 80%) as brown liquid.
Reference Example 462: 2-Fluoro-4-oxazol-2-yl-aniline
A stirred solution of 2-(3-fluoro-4-nitro-phenyl)oxazole (500 mg, 2.40 mmol) in methanol (10 mL) was added to stannous chloride (2.7 g, 12.01 mmol) under nitrogen atmosphere and stirred for 16 h. The reaction mixture was diluted with water and filtered through Celite. The filtrate was basified with bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford 2-fluoro-4-oxazol-2-yl aniline (350 mg, 83%) as a yellow colour solid.
Reference Example 463: l-(CMoromethoxy)butane
Hydrogen chloride was continuously passed through a suspension of n-butanol (10 g, 135.13 mmol) and paraformaldehyde (4.06 g, 135.33 mmol) until the mixture appeared transparent with two separate layers. The upper layer was separated and fractionally distilled to afford 1-Chloromethoxy-butane (8 g, 48%).
Reference Example 464: 4-MethoxvbutyI-4-methyIbenzenesttIfonate Triethylamine (2.91 g, 28.86 mmol) was added to the stirred solution of 4- methoxy-1-butanol (1.00 g, 9.62 mmol) in dichloromethane (15 mL) at 0 0C and stirred for 15 min. p-Toluene sulfonyl chloride (1.83 g, 9.62 mmol) was added and the mixture was warmed to ambient temperature and stirred for 2 h. The reaction mixture was quenched with ice- water and the organic layer was separated. The aqueous layer was extracted with dichloromethane (3 x 5 mL) and the combined organic layers were washed with saturated sodium bicarbonate, water, and brine; dried over anhydrous sodium sulphate and concentrated in vacuo. The crude product was purified by column chromatography over silica gel (60-120 mesh) with 0% to 20% ethyl acetate in petroleum ether as eluent to afford 4-methoxybutyl-4-methylbenzenesulfonate (800 mg, 32%) as a liquid.
Reference Example 465: 4-(Bromomethyl)-2-methyI-oxazoIe
Carbon tetrabromide (1.58 g 4.77 mmol) and triphenylphosphme (1.25 g 4.77 mmol) were added to a solution of (2-methyloxazol-4-yl)methanol (450 mg 3.98 mmol) in dry acetonitrile (8 mL) and the mixture was stirred for 12 h at ambient temperature. The volatiles were removed in vacuo to afford the crude product which was used without further purification.
Reference Example 466: (2-Methyloxazol-4-yI)methanoI
IM Diisobutyl aluminum hydride (23.23 mL; 23.23 mmol) was added to a solution of methyl 2-methyloxazol-4-caboxylate (1.1 g, 7.80 mmol) in dry tetrahydrofuran (25 mL) at -600C. The resulting mixture was allowed to warm to ambient temperature and was stirred for 3 h. Saturated aqueous ammonium chloride was added and the resultant suspension was filtered and the organic layer separated. The aqueous layer was extracted with ethyl acetate (2 x 25 mL) and the combined organic layers washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford (2-methyloxazol-4-yl)methanol (450 mg, 51%) as a semi-solid. Reference Example 467: Methyl 2-methyloxazol-4-caboxyIate
Hexamethylenetetramine (11.7 g, 5.00 mmol) and l,8-diazabicyclo(5,4,0)undec- 7-ene were added to a stirred suspension of copper bromide (18.7 g, 83.85 mmol) in dichloromethane (50 mL) at 0 0C and purged with argon gas for 20 min. To the mixture was added methyl 2-methyl-4,5-dihydrooxazole-4-caboxylate (3 g, 20.97 mmol) at 0 0C. The mixture was allowed to warm to ambient temperature and stirred for a further 12 h. The solvent was removed in vacuo and the resulting residue partitioned between ethyl acetate and 1 : 1 saturated aqueous ammonium chloride and ammonium hydroxide. The organic layer was separated and the aqueous layer extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with 1:1 saturated aqueous ammonium chloride and ammonium hydroxide, 10% aqueous citric acid, saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford methyl 2-methyloxazol-4-caboxylate (1.1 g, 34%) as a solid.
Reference Example 468: Methyl 2-methyl-4, 5-dihydrooxazoIe-4-caboxγIate
Triethylamine (5.86 g, 58.01 mmol) was added to a suspension of L-serine methyl hydrochloride (4.5 g, 29.03 mmol) and ethylacetimidate hydrochloride (4.3 g, 34.95 mmol) in dichloromethane (40 mL) at 0 0C over a period of 20 min. The mixture was then stirred at ambient temperature for 18 h. The suspension was filtered and washed with diethyl ether. The solid which precipitated from the filtrate was again filtered and washed with diethyl ether. The resulting filtrate was dried over anhydrous sodium sulfate and concentrated in vacuo to afford methyl 2-methyl-4,5- dihydrooxazole-4-caboxylate (3 g, 72%) as a liquid. Example l: 2-α,5-DimethvI-3-phenγI-l.ar-pyrrol-2-yl)-JV-(4-r4-(4,6-dimethyl- PVridm-2-vIVpiperazin-l-vI1-phenyl}-2-oxo-acetamide
A solution of (l,5-dimethyl-3-phenyl-lH-pyrrol-2-yl)-oxo-acetyl chloride (46 g, 0.176 mol) in dry dichloromethane (300 mL) was added to a solution of 4-[4-(4,6- dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylamine (40 g, 0.140 mol) and triethylamine (14.2 g, 0.140 mol) in dry dichloromethane (300 mL) over 15 min. After stirring for 1 h the reaction mixture was quenched into water (200 mL) and the organic phase separated. The aqueous layer was extracted with dichloromethane (2 x 50 mL) and the combined organic layers were washed successively with water (2 x 200 mL), brine (2 x 100 mL), dried over anhydrous sodium sulfate and concentrated to give a solid. This was dissolved in acetone (580 mL) and silica gel was added (72.5g, 100-200 mesh). The mixture was stirred at room temperature for 1 h, filtered and the solids washed with acetone (75 mL). The silica treatment was repeated a second time. The filtrate was concentrated to ~300 mL (~ 4 vols), activated carbon (8 g) was added and heated at reflux for 15 min. The mixture was cooled to 45—50 0C and filtered over celite, washing with acetone (75 mL). The solution was again concentrated to ~300 mL and petroleum ether (725 mL, 10 vols) was added, slowly, at reflux. The resulting suspension was cooled to room temperature, stirred for 15 min, then cooled to 0 °C and stirred for 1 h. The solid was filtered off, washed with petroleum ether (150 mL) and dried under vacuum to afford 2-(l,5-dimethyl-3-phenyl-l//-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl] -phenyl }-2-oxo-acetamide (53.5 g, 74%) as a yellow solid.
The compounds set out below were prepared in a manner analogous to Example 1:
Example Compound
2 JV- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-2- ( 1 -phenyl- 1 H-pyrrol-2-yl)-acetamide
3 JV- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl } -2-(5- memyl-l-phenyl-lJY-pyrrol-2-yl)-2-oxo-acetamide
4 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methyl-l/f-pyrrol-2-yl)-2-oxo-acetamide
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(2- methyl-7-phenyl- 1,2,3 ,4-tetrahydro-pyrrolo [ 1 ,2-a]pyrazin-6-yl)-2-oxo- acetamide iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2- (2-phenyl-6,7-dihydro-5H-pyrrolizin-3-yl)-acetarαide
N-{4-[4-(456-Dim.ethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2- (7-phenyl-3,4-dihydro-lH-pyrrolo[2,l-c][l,4]oxazin-6-yl)-acetamide
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-(l - isopropyl-5-methyl-3 -phenyl- 1 H"-pyrrol-2-yl)-2-oxo-acetamide
JV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-5 -methy 1-3 -phenyl- 1 if-pyrrol-2-yl]-2-oxo-acetamide
2-( 1 ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-iV-[4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-3-(3-morpholin-4-yl-propoxymethyl)- phenyl]-2-oxo-acetamide
N- {3 -Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} - 2-(l ,5-dimethyl-3-phenyl- lH-pyrrol-2-yl)-2-oxo-acetamide
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-(3 - furan-2-yl-l,5-dimethyl-lH'-pyrrol-2-yl)-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridm-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5- dimethyl-3 -thiophen-2-yl- 1 H-pyrrol-2-yl)-2-oxo-acetamide jV-{4-[4-(436-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}r2-(3- isopropyl- 1 ,5 -dimethyl- 1 H"-pyrrol-2-yl)-2-oxo-acetaraide
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2- [1,5- dimethyl-3-(tetrahydro-pyran-4-yl)-li/-'pyrrol-2-yl]-2-oxo-acetamide
2-(l55-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-iV-naphthalen-l-yl-2-oxo- acetamide
N-{3-(2-Dimethylamino-ethoxymethyl)-4-[4-(456-diπiethyl-pyridm-2- yl)-piperazin- 1 -yl]-phenyl} -2-(l ,5-dimethyl-3-phenyl- li7-pyrrol-2-yl)- 2-oxo-acetamide
2-(l54-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide 2-(l55-Dimethyl-3-phenyl-lif-pyrrol-2-yl)-N'-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -3 - [3 -(4-methyl-piperazin- 1 -yl)- propoxymethyl]-phenyl}-2-oxo-acetamide jV_{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-(5- isopropyl- 1 -methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide
N-{2-Chloro-4-[4-(456-dimethyl-pyridin-2-yl)-piρerazin-l-yl]-phenyl}- 2-(l ,5-dimethyl-3-phenyl- lH-pyrrol~2-yl)-2-oxo-acetamide
2-(l,5-Dimethyl-3-phenyl-lH-pynrol-2-yl)-N'-{4-[4-(456-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -3 -hydroxy-phenyl } -2-oxo-acetamide iV-(2,3-Dihydro-benzofuran-4-yl)-2-(l,5-dimethyl-3-phenyl-17f-pyrrol- 2-yl)-2-oxo-acetamide iV-{3-Chloro-4-[4-(456-dimethyl-pyridm-2-yl)-ρiρerazin-l-yl]-phenyl}- 2- [ 1 -(2-methoxy-ethyl)-5 -methyl-3 -phenyUH-pyrrol-2-yl] -2-oxo- acetamide
N-{4-[4-(436-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[3- isopropyl-l-(2-methoxy-ethyl)-5-memyl-lH-pyrrol-2-yl]-2-oxo- acetamide
N-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piρerazin-l-yl]-phenyl}- 2- [ 1 -(2-methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo- acetamide
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2- ethoxy-ethyl)-5-methyl-3-phenyl-lif-pyrrol-2-yl]-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piρerazin-l-yl]-phenyl}-2-[l-(3- methoxy-propyl)-5-methyl-3-phenyl-li/-pyrrol-2-yl]-2-oxo-acetamide
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-iV- quinolin-5-yl-acetamide iV-Isoquinolin-5 -yl-2- [ 1 -(2-methoxy-ethyl)-5-methyl-3 -phenyl- IH- pyrrol-2-yl] -2-oxo-acetamide
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-quinolin-8-yl- acetamide
2-( 1 ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-2-oxo-N-quinolin-5-yl- acetamide 2-(l,5-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-2-oxo-iV-pyridin-4-yl- acetamide
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l- ethyl-5 -methyl-3 -phenyl- 1 if-pyrrol-2-yl)-2-oxo-acetamide
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-(5- methyl-3 -phenyl- 1 -propyl- lH"-pyrrol-2-yl)-2-oxo-acetamide
2-(l-Butyl-5-m.ethyl-3-phenyl-lH-ρyrrol-2-yl)-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piρerazin- 1 -yl] -phenyl } -2-oxo-acetamide
2-(l,5-Dimethyl-3-phenyl-lH'-pyrrol-2-yl)-2-oxo-iV-qumolin-3-yl- acetamide
2-(l,5-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-2-oxo-iV-[4-(4-pyridin-2-yl- piperazin- 1 -yl)-phenyl] -acetamide
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(6-methyl-pyridm- 2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide
2-(l ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-JV- {4- [4-(4-methyl-ρyridin- 2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide a N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2- (2-phenyl-657,8,9-tetrahydro-5i7-pyrrolo[l,2-a]azepin-3-yl)-acetamideb N-{4-[4-(456-Dimethyl-pyridm-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2- (l-phenyl-6,7,8,9-tetrahydro-5H-pyrrolo[l,2-a]azepin-3-yl)-acetamide
N-Isoquhiolin-8-yl-2-[l-(2-methoxy-ethyl)-5-m.etliyl-3-phenyl-liϊ- pyrrol-2-yl] -2-oxo-acetamide
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)--V-isoquinolin-8-yl-2-oxo- acetamide
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-Λr-naphthalen-2-yl-2-oxo- acetamide
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l- methyl-3-phenyl-l/i'-pyrrol-2-yl)-2-oxo-acetamide
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-(l - methyl-4-phenyl-li-r-pyrrol-2-yl)-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide 2-(l-Beii2yl-5-methyl-3-phenyl-lH-pyπ-ol-2-yl)-N-{4-[4-(4,6-dimethyl- pyridm-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide
2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-iV-[5-(4-methyl-ρiρerazin-l- yl)-naphthalen-l-yl]~2-oxo-acetamide
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methyl-3-phenyl-lH"-pyrrol-2-yl)-2-oxo-acetamide
2-(1.5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(456-dimethyl- ρyridin-2-yl)-piperazin-l-yl]-3-methyl-phenyl}-2-oxo-acetamide
(2- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] - phenylaminooxalyl}-5-methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester jV-{4-[4-(4,6-Dimeth.yl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- ethyl- 1 -methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridm-2-yl)-piperazin-l-yl]-phenyl}-2-[5~ ethyl-l-(2-methoxy-ethyl)-3-phenyl-lH'-pyrrol-2-yl]-2-oxo-acetamide
2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl}-5-methyl-3-phenyl-pyrrole-l-carboxylic acid ethyl ester
2- {4- [4-(4,6-Dimethy l-pyridin-2-yl)-piperazin- 1 -yl] - phenylaminooxalyl} -5-methyl-3 -phenyl-pyrrole- 1 -carboxylic acid methyl ester
2-[3-(2-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-iV-{4-[4- (4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide
2-[4-(2-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4- (4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide
2-[3-(4-Chloro-phenyl)-l-(2-methoxy-ethyl)-l/f-pyrrol-2-yl]-iV-{4-[4- (456-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N- phenyl- 1 -acetamide
(2- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] - phenylaminooxalyl} -pyrrol- 1- yl)-acetic acid methyl ester iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l- methoxymethyl-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l- methoxymethyl-3-phenyl-l/f-pyrrol-2-yl)-2-oxo-acetamide
2-[l-(2-Acetylamino-ethyl)-5-methyl-3-ρhenyl-lH-ρyrrol-2-yl]-iV-{4- [4-(456-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-[l-(2- hydroxy-ethyl)-3-phenyl-lH"-pyrrol-2-yl]-2-oxo-acetamide iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-ρiperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-3 -thiophen-2-yl- 1 i7-pyrrol-2-yl] -2-oxo-acetamide iV-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-[3- isobutyl- 1 -(2-methoxy-ethyl)- 1 H-pyrrol-2-yl] -2-oxo-acetamide
(2- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]- phenylaminooxalyl}-5-methyl-3-phenyl-pyrrol-l-yl)-acetic acid ethyl ester
2-[3-(3-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH"-pyrrol-2-yl]-iV-{4-[4- (4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide
2-[4-(3-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-iV-{4-[4- (4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide
(2-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl}-3-phenyl-pyrrol-l-yl)-acetic acid ethyl ester
(2- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]- phenylaminooxalyl}-3-phenylpyrrol-l-yl)-acetic acid methyl ester
(2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl} -5-methyl-3 -phenyl-pyrrol- 1 -yl)-acetic acid isopropyl ester iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperizin-l-yl]-phenyl}-2-[5- isopropyl- 1 -(2-methoxy-ethyl)-3 -phenyl- 1 /f-pyrrol-2-yl] -2-oxo- acetamide
79 2-(l,5-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-2-oxo-iV-quinolin-5-yl- acetamide
80 JV- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-[3 -(2- methoxy-ethyl)-5 -methyl- 1 -phenyl- 1 ϋT-pyrrol-2-yl] -2-oxo-acetamide
81 2-[l-(2-Methoxy-ethyl)-3-phenyl-l/f-pyrrol-2-yl]-2-oxo-iV-ρhenyl- acetamide
82 2-[l-(2-Methoxy-ethyl)-3-phenyl-lH-ρyrrol-2-yl]-2-oxo-N-ρroρyl- acetamide
83 /Y- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-[3 - isopropyl- 1 -(2-methoxy-ethyl)- 1 H-pyrrol-2-yl] -2-oxo-acetamide
84 2-[l-(2-Dimethylamino-ethyl)-3-phenyl-lH-pyrrol-2-yl]-iV-{4-[4-(4,6- dimethyl-pyridin-2-yl)-piρerazin- 1 -yl]-phenyl} -2-oxo-acetamide
85 2-[l-(2-Dimethylamino-ethyl)-4-ρhenyl-lH"-pyrrol-2-yl]-7V-{4-[4-(4,6- dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl} -2-oxo-acetamide
86 2-[l-(2-Dime1iiylarndno-ethyl)-5-methyl-3-phenyl-lH'-pyrrol-2-yl]-N- {4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo- acetamide
87 (2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl}-3-thiophen-2-yl-pyrrol-l-yl)-acetic acid methyl ester
88 (2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl}-[3-isopropyl-pyrrol-l-yl)-acetic acid methyl ester
89 (2- {4- [4-(4,6-Dimethyl-pyridm-2-yl)-piperazin- 1 -yl] - phenylaminooxalyl}-3-isobutyl-pyrrol-l-yl)-acetic acid methyl ester
90 iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(4- fluoro-l,5-dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide
91 N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methyl-3-phenyl- 1 -pyridin-2-ylmethyl-l H-pyrrol-2-yl)-2-oxo- acetamide
92 N-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}- 2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH"-pyrrol-2-yl]-2-oxo- acetamide
93 ΛL{4-[4-(4,6-Dimethyl-pyridin-2-yl)-ρiperazin-l-yl]-phenyl}-2-(5- methyl-3 -phenyl- 1 -pyridin-3 -ylmethyl- 1 H~pyrrol-2-yl)-2-oxo- acetamide
94 iV-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[4- fluoro-l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo- acetamide
95 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[2-fluoro-4-(4-pyridin-2- yl-piperazin- 1 -yl)-phenyl] -2-oxo-acetamide
96 N- [2-Fluoro-4-(4-pyridin-2-yl-piperazin- 1 -yl)-phenyl] -2- [ 1 -(2-methoxy- ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide
97 N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2- isopropoxy-ethyl)-5 -methyl-3 -phenyl- l/f-pyrrol-2-yl] -2-oxo-acetamide
98 (2-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl}-5-methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester
99 2-(l,5-Dimethyl-3-phenyl-l/."-ρyrrol-2-yl)-2-oxo-N-(6-pyrrolidin-l-yl- pyridin-3 -yl)-acetamide
100 2-(l,5-Dimethyl-3-phenyl-lH'-pyrrol-2-yl)-iV-[2-fl.uoro-4-oxazol-2-yl- phenyl)-2-oxo-acetamide
101 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-Λ'-(2-fluoro-4-morpholin-4- yl-phenyl)-2-oxo-acetamide
102 Λ/-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methy 1-3 -phenyl- 1 -pyridin-4-ylmethyl- 1 i7-pyrrol-2-yl)-2-oxo- acetamide
103 2-[l-(2-Methoxy-ethyl)-5-methyl-3-pheny-lH-pyrrol-2-yl]-JV-{4-[4-(5- morpholin-4-ylmethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo- acetamide
104 2-[3-Cyclobutyl-l-(2-methoxy-ethyl)-17f-pyrrol-2-yl]-N-{4-[4-(4,6- dimethyl-pyridin-2-yl)-piperizin- 1 -yl] -phenyl} -2-oxo-acetamide
105 2-(l,5-Dimethyl-3-phenyl-lΗ-pyrrol-2-yl)-N-[2-fluoro-4-(4-isobutyl- piperazin- 1 -yl)-phenyl] -2-oxo-acetamide 106 2-(l,5-Dimethyl-3-phenyl-lH'-pyrrol-2-yl)-iV-(2-fluoro-4-piperidin-l-yl- phenyl)-2-oxo-acetamide
107 (3-Cyclobutyl-2-{4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl} -pyrrol- l-yl)-acetic acid methyl ester
108 2-(l55-Dimethyl-3-phenyl-liϊ-pyrrol-2-yl)-iV-{2-fluoro-4-[4-(2-rnethyl- allyl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide
109 iV-{2-Fluoro-4-[4-(2-methyl-allyl)-ρiperazin-l-yl]-ρhenyl}-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl-li7-pyrrol-2-yl]-2-oxo-acetamide
110 N- [2-Fluoro-4-(4-isobutyl-piperazin- 1 -yl)-phenyl] -2- [ 1 -(2-methoxy- ethyl)-5-methyl-3 -phenyl- 1 H-ρyrrol-2-yl]-2-oxo-acetamide
111 (2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-2-fluoro- phenylaminooxalyl}-5-methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester
112 2-(l,5-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-N-{4-[4-(2,2-dimethyl- propyl)-piperazin-l-yl]-2-fluoro-phenyl}-2-oxo-acetamide
113 iV-{4-[4-(2,2-Dimethyl-propyl)-piperazin-l-yl]-2-fluoro-phenyl}-2-[l- (2-methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide
114 JV-(2-Fluoro-4-piperidin-l-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl- 3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide
115 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(3-fluoro-4-piperidin-l-yl- phenyl)-2-oxo-acetamide
116 2-(l55-Dimethyl-3-phenyl-li7-pyrrol-2-yl)-iV-[3-fluoro-4-(4-pyridin-2- yl-piperazin-l-yl)-phenyl]-2-oxo-acetamide
117 iV-(2-Fluoro-4-morpholin-4-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide
118 2-(l,5-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-iV-[3-fluoro-4-(4-isobutyl- piperazin- 1 -yl)-phenyl] -2-oxo-acetamide
119 iV-(3-Fluoro-4-piperdin-l-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl- 3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide 20 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(5-morpholin-4- ylmethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide 121 2-[l-(2-Methoxy-ethyl)-4-ρhenyl-lH-ρyrrol-2-yl]-2-oxo-N-propyl- acetamide
122 (2- {4- [4-(4,6-Dimethyl-ρyridin-2-yl)-piperazin- 1 -yl] - phenylaminooxalyl}-4-phenyl-pyrrol-l-yl)-acetic acid methyl ester
123 N- {4- [4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-2-fluoro-phenyl} - 2- [ 1 -(2-methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-ρyrrol-2-yl)-2-oxo- acetamide
124 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperizin-l-yl]-phenyl}-2-[l- methyl-3-phenyl-5-propyl-lH-pyrrol-2-yl)-2-oxo-acetaniide
125 N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- ethyl- 1 -methoxymethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide
127 2-(l55-Dimethyl-3-ρhenyl-lH-ρyrrol-2-yl)-N-(5-fluoro-naρhthalen-l- yl)-2-oxo-acetamide
132 N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-( 1 - ethoxymethyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide
133 N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [5 - methyl- 1 -(2-methylsulfanyl-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl]-2-oxo- acetamide
134 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5- methyl- 1 -(2-ρhenoxy-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide
135 2-(l-Butoxymethyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6- dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide
136 N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(3- ethoxy-ρropyl)-5-methy-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide
138 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethoxymethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo- acetamide
139 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methyl-3-phenyl- 1 -propoxymethyl- 1 H-pyrrol-2-yl)-2-oxo-acetarnide
140 N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-[5- methyl-3-phenyl-l-(2-propoxy-ethyl)-lH-pyrrol-2-yl]-2-oxo-acetamide 141 N-{4-[4-(456-Dimethyl-ρyridin-2-yl)-ρipera2;in-l-yl]-phenyl}-2-[l-(4- methoxy-but-2-enyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo- acetamide
142 N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-[l -(4- methoxy-butyl)-5-methy-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide
143 2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-2-oxo-N-(4-piperidin-l-yl- phenyl)-acetamide
148 2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-[3-fluoro-4-oxazole-2-yl- phenyl)-2-oxo-acetamide
154 2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-(4-morpholin-4-yl- phenyl)-2-oxo-acetamide
Example 126: N-(3-FIuoro-4-morpholin-4-vI-phenvI)-2-fl-f2-methoxy-ethyl)-5- methyl-3-phenyl-lH-pyrrol-2-vIl-2-oxo-acetamide
Oxalyl chloride (0.19 g, 1.53 mmol) was added to a solution of l-(2-methoxy- ethyl)-2-methyl-4-phenyl-lH-ρyrrole (0.30 g, 1.39 mmol) in chloroform (5 niL) at 0 0C and slowly warmed the ambient temperature to RT over 30 min. Completion of reaction and removal of excess oxalyl chloride in vacuo afforded the intermediate acid chloride, [1 -(2-methoxy-ethyl)-5-methyl-3 -phenyl- lH-pyrrol-2-yl]-oxo-acetyl chloride which was taken in chloroform (5 mL). This was then added to a solution of 3-fluoro-4- morpholin-4-yl-phenylamine (0.19 g, 0.97 mmol) in chloroform (5 mL) with triethyl amine (0.28 g, 2.78 mmol). The reaction was stirred for 30 min at ambient temperature and then diluted with water and extracted into chloroform. Combined organic extracts were washed with saturated bicarbonate solution, dried over anhydrous sodium sulfate and stirred over neutral alumina for 10 min. The mixture was filtered and concentrated in vacuo to afford N-(3-fluoro-4-morpholin-4-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5- methyl-3 -phenyl- lH-pyrrol-2-yl]-2-oxo-acetamide (0.26 g, 40%) as pale yellow solid.
The compounds set out below were prepared in a manner analogous to Example 126: Example Compound
128 2-(l,5-Dimethyl-3-phenyl-lH-ρyrrol-2-yl)-N-(l-ethyl-4-fluoro-lH- indol-5-yl)-2-oxo-acetamide
129 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-(2- methoxy-ethyl)- 1 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide
137 N-{4-[4-(4;6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methyl- 1 -methylsulfanylmethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo- acetamide
144 N-[4-(4-Benzyl-piperazin-l-yl)-phenyl]-2-(l,5-dimethyl-3-phenyl-lH- pyrrol-2-yl)-2-oxo-acetamide
145 2-(l,5-Dimethyl-3-ρhenyl-lH-ρyrrol-2-yl)-N-[4-(4-isobutyryl- piperazin- 1 -yl)-phenyl]-2-oxo-acetamide
146 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5- methyl- 1 -(2-methyl-oxazol-4-ylmethyl)-3 -phenyl- 1 H-pyrrol-2-yl]-2- oxo-acetamide
147 2-(l55-Dimethyl-3-phenyl-lH-pyrrol--2-yl)-N-(4-oxazol-2-yl-phenyl)-2- oxo-acetamide
149 2-[l-(2-Methoxy-ethyl)-5-methyl-3-ρhenyl-lH-ρyrrol-2-yl]-N-(4- oxazol-2-yl-phenyl)-2-oxo-acetamide
150 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(l;,2-dimethyl- propyl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide
151 2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(2-methoxy-l- methyl-ethyl)-piperazin-l -yl]-phenyl} -2-oxo-acetamide
152 2-(l55-Dimethyl-3-phenyl-lH-pyiτol-2-yl)-N-{4-[4-(2-furan-2-yl-l- methyl-ethyl)-piperazin- 1 -yl]-phenyl} -2-oxo-acetamide
153 2-(l55-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-2-oxo-N-[4-(5-piperdin-l- ylmethyl-oxazol-2-yl)-phenyl]-acetamide
Example 64: JV-f4-r4-(4,6-DimethvI-pyridin-2-yl)-piperazin-l-yll-phenγU-2-ri-(2- hydroxy-ethγl)-5-methyl-3-phenyl-ljHr-pyrrol-2-yI1~2-oxo-acetamide Lithium hydroxide monohydrate (30 mg, 0.70 mmol) was added to a suspension of acetic acid 2-(2-{4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]- phenylaminooxalyl}-5-methyl-3-phenyl-pyrrol-l-yl)-ethyl ester (340 mg, 0.59 mmol) in methanol (10 mL) at room temperature and stirred for 60 min. The solvent was evaporated in vacuo and the resulting residue dissolved in water (20 mL). The solution was acidified with IN acetic acid to adjust the pH to ~6 to 7 and the aqueous layer was extracted with ethyl acetate (2 x 25 mL). The combined organic layer was washed with water (2 x 30 mL), brine (2 x 30 mL). dried over anhydrous sodium sulphate and concentrated in vacuo to yield the crude compound. Purification by preparative TLC using 2.5% of methanol in chloroform as eluent afforded 7V-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2-hy droxy-ethyl)-5 -methyl-3 -phenyl- 1 H- pyrrol-2-yl]-2-oxo-acetamide (230 mg, 73%) as an orange solid.
Example 72: JV-{4-r4-(4,6-DimethyI-pyridin-2-yI)-piperazin-l-yn-phenyl}-2-fl-(2- methoxy-ethyl)-3-thiophen-3-vI-ljHr-pyrrol-2-vn-2-oxo-acetamide
Diisopropylethylamine (0.40 mL, 2.17 mmol), (2-(7-Aza-lH-benzotriazole-l- yl)-l,l,3,3-tetramethyluronium hexafiuorophosphate) (0.28 mg, 0.72 mmol) was added to a solution of [l-(2-methoxy-ethyl)-3-thiophen-3-yl-lJf-r-pyrrol-2-yl]-oxo-acetic acid (200 mg, 0.72 mmol) in dry dichloromethane at room temperature and the reaction mixture stirred for 1 h. 4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylamine (160 mg, 0.56 mmol) was added and the mixture was then heated in a sealed tube at 90 °C for 18 h. The reaction mixture was cooled to room temperature, washed with water and brine. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure to give crude compound which was purified by preparative HPLC to afford J¥-{4-[4-(4,6-dimethyl-pyridin-2-yl)ρiperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-3-thiophen-3-yl-liJ-pyrrol-2-yl]-2-oxo-acetamide (80 mg, 20%) as a solid.
The compounds set out below were prepared in a manner analogous to Example
72: Example Compound
130 N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5- methoxymethyl- 1 -methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide
131 2-(l,5-Bis-methoxymethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6- dimethyl-pyridin-2-yl)-piperazme-l-yl]-phenyl}-2-oxo-acetamide
Example 75 : 2-(l-Carbamoylmethyl-3-phenyl-lfr-pyrroI-2-vπ-A^{4- f4-(4,6- dimethyl-pyridin-2-yl)-piperaziπ-l-yl]-phenyI}-2-oxo-acetamide
(2- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylaminooxalyl } -3 - phenyl-pyrrol-1-yl) acetic ethyl acid ester (100 mg, 0.17 mmol) and niethanolic ammonia (5 mL) were heated at 60 0C in a sealed tube for 2 h. On completion of the reaction the volatiles were removed in vacuo to give the crude compound, which was purified by preparative HPLC to afford 2-(l-carbamoylmethyl-3-phenyl-li?-pyrrol-2- yl)-iV-{4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide (70 mg, 74%) as a yellow powder.
The compound set out below was prepared in a manner analogous to Example
75:
Example Compound
76 N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-( 1 - methylcarbamoylmethyl-3-phenyl-lif-pyrrol-2-yl)-2-oxo-acetamide
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Activity Example: Measurement of minimum inhibitory concentrations (MICs)
Between 1 and 5 mgs of compound were accurately weighed out into a sterile Eppendorf tube. The compound was dissolved in DMSO to give a solution containing 5 mg/mL. Tubes were stored at -20 0C until required.
On the day of testing thawed solutions were vortex mixed to ensure homogeneity. 30 μL of solution was removed and added to 570 μL of sterile water in a separate sterile Eppendorf. The thoroughly mixed solution was used to prepare a series of doubling dilutions in water, in a deep well plate. Thirteen replicate plates were prepared using a Minitrak by aspirating 20 μL from each well into eleven clear polystyrene 96 well plates.
Spores of Aspergillus spp. (Aspergillus fumigatus [two strains], Aspergillus terreus [two strains], Aspergillus niger and Aspergillus flavus) were harvested from cultures grown on Sabarauds agar for 5 days, and resuspended in PBS/Tween 80 to approx 1x107 cfu/mL. Each organism suspension was diluted in YAG medium (1% glucose, 1% ammonium chloride and 0.5% yeast extract) to 0.5-2x104 cfu/mL. 80 μL of an organism suspension was added to each well of the plate containing drug dilutions.
This produced MIC plates with a drug range 50-0.05 mg/L and organism inocula of l-2xlθ4 cfu/mL for Aspergillus spp.. All plates were incubated for 24 h at 35 0C. Growth was assessed by monitoring the optical density at 485 nm for each well. The MIC of a compound is the lowest drug concentration that inhibits growth of an organism by >70% compared with a drug free control. MICs are recorded as mg/L. In cases where the MIC of an organism is >=0.05 mg/L the MIC is repeated using a concentration range of 0.5 - 0.0005 mg/L. Assays were also performed in RPMI medium for both Aspergillus spp. (strains described above) and Candida spp. (Candida albicans, Candida glabrata, Candida h-usei, Candida par apsϊlosis and Candida tropicalis). To perform MIC tests in this medium, dilutions of compounds are prepared in microtitre plates as described above. Fungal strains to be tested are grown and harvested in an identical manner to that described above, and each organism suspension was diluted in RPMI medium, containing 2% glucose and 0.135 M MOPS buffer (pH 7.0) to 0.5-2x104 cfu/mL, rather than in YAG medium. 80 μL of an organism suspension was added to each well of the plate containing drag dilutions.
This produced MIC plates with a drug range 50-0.05 mg/L and organism inocula of 1-2x104 CfUZmL. All plates were incubated for 24-48 h at 35 0C. Growth was assessed by monitoring the optical density at 485 nm for each well. The MIC of a compound is the lowest drug concentration that inhibits growth of an organism by >80% compared with a drug free control.
The following organisms were tested: Aspergillus flavus, Aspergillus fumigatus AF293 and AF210, Aspergillus niger, Aspergillus terreus AT4 and AT49, Candida albicans, Candida glabrata, Candida krusei, Candida par apsϊlosis and Candida tropicalis.
Other fungi including Absidia corymbifera; Acremonium spp; Alternaria alternata; Aspergillus nidulans; Aspergillus parasiticus; Bipolaris spp; Blastomyces dermatitidis; Blumeria graminis; Cladosporium cladosporoides; Cladosporiwn herbarium; Coccidioides immitis; Coccidioides posadasii; Colletotrichium trifolii;
Curvularia lunata; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi; Epicoccum nigrum; Epidermophytonfloccosum; Exophiala spp; Exserohilum rostratum; Fusarium graminearium; Fusarium solani; Fusarium sporotrichoides; Histoplasma capsulatum; Leptosphaeria nodorum; Magnaporthe grisea; Microsporum canis; Mycosphaerella graminicola; Neurospora crassa; Paecilomyces lilanicus;
Paecilomyces varioti; Penicillium chrysogenum; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizomucor sp.; Rhizoctonia solani', Rhizomucor spp.; Rhizopus spp.; Scedosporium apiospermum; Scedosporium prolificans; Scopulariopsis brevicaulis; Trichophyton interdigitάle; Trichophyton mentagrophytes; Trichophyton rubrum; Trichosporon asahii; Trichosporon beigelii; and Ustilago maydis may also be used in the above assay. Fungi are cultured by standard methods known to those skilled in the art, and MICs determined as above.
Aspergillus MIC results in mg/L CYAG medium): The following MIC results have been banded into grades. Thus, a grade of 1 represents an MIC of greater than 10 mg/L. A grade of 2 represents an MIC of from 1 to 10 mg/L. A grade of 3 represents an MIC of less than 1 mg/L.
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Figure imgf000196_0001
Aspergillus MIC results in mg/L (RPMI medium):
The following MIC results have been banded into grades as defined above.
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Candida MIC results in mg/L (RPMI medium):
The following MIC results have been banded into grades as defined above.
Figure imgf000202_0002
Figure imgf000203_0001
In vivo testing Example
2-(l,5-Dimethyl-3-phenyl-l//-ρyrrol-2-yl)-iV-{4-[4-(456-dimethyl-pyridin-2-yl)- piperazin-l~yl] -phenyl }-2-oxo-acetamide has excellent activity in vifro against Aspergillus and other filamentous fungi and shows good oral bio-availability and tissue distribution. The efficacy of oral dosed 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV- {4- [4-(456-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide has been tested in murine survival models of disseminated aspergillosis.
Methods: Temporary (TI) or persistently (PI) neutropenic CD-I mouse models of disseminated aspergillus were used. 3 days post immunosuppression with cyclophosphamide (200mg/kg ip) mice were infected IV with an LD90 challenge of A. fumigatus Al 163. Treatment commenced 5 h post infection and animals were treated for 9 days and observed for either 2 days or 7 days following cessation of treatment. In PI models animals had a further dose of cyclophosphamide one day after infection. 2- (l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin- l-yl]-phenyl} -2-oxo-acetamide was dosed orally as a suspension in HPMC/Tween 80 once or twice daily. Caspofungin dosed IP was used as a comparator. Results: A dose dependent response was seen in the TI survival model with doses of 1.25 and 2.5mg/kg per day showing little benefit, 5mg/kg per day showing 80% survival, 10mg/kg/day being highly effective (90% survival) and doses of 20, 30 and 40mg/kg/day giving 100% survival. In a severe PI model 20mg/kg BD gave 70% survival at day 12, untreated animals were all dead at day 7. A comparison of once and twice daily dosing in a TI model with prolonged observation showed that 1 Omg/kg BD (80% survival at day 18) was superior to 20mg/kg OD (70% survival at day 18). Conclusions: 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-oxo-acetamide demonstrated dose dependent survival improvement following a lethal A. fumigatus infection and efficacy in persistently neutropenic models and in models where animals were observed for 7 days following cessation of treatment. 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4- (4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl} -2-oxo-acetamide was at least as effective as CAS in these models.
Combination therapy example 1: Determination of combined effect of two antifungal agents In order to determine the combined effect of an antifungal pyrrole compound and a second antifungal agent as described above a checkerboard titration can be carried out. These are relatively simple tests to determine if an additive or synergistic effect between two compounds is present. The description which follows describes an exemplary checkerboard titration; the skilled person would readily identify which aspects of the method can be changed, for example using different organisms, different growth media, different concentrations of stock solutions and so forth.
In the checkerboard titration doubling dilutions of compound A (e.g. an antifungal pyrrole compound as defined earlier) are prepared in every row across a microtitre plate and doubling dilutions of compound B (e.g. a second antifungal agent as defined earlier) are prepared in every column down a microtitre plate. The activity of the two compounds in combination can be compared with the activity of each compound alone. In such experiments a narrow range of dilutions can be tested for each compound around the minimum inhibitory concentration (MIC). As an example, a stock solution of compound A (e.g. 5 mg/ml) can be prepared in a suitable solvent such as DMSO. A stock solution of compound B (e.g. caspofungin) is also prepared (e.g. 2mg/ml). The stock solution of compound A is diluted (e.g. at a concentration of 1:2000 in water) to 2.5 μg/ml. From this stock, aqueous solutions containing the following concentrations of compound A can be prepared: 0.9, 0,8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05, 0.025, 0.0125 μg/ml. 20 μl volumes of each stock solution can then be added to the first eleven wells in a column of a microtitre plate, with the remaining column being given 20 μl of water. Each row of the plate contains 20 μl of a series of dilutions of compound A and one free control well containing no antifungal agent. The compound B stock solution can be diluted in water by adding 5.5 μl of stock solution to 10 ml water. From this stock aqueous dilutions of compound B containing the following concentrations can be prepared: 0.55, 0.45, 0.35, 0.25, 0.15, 0.05, 0.025 ug/ml. Each of these stocks can then be added to every row in the microtitre plate containing the compound A dilutions. The bottom row of the plate can be given 20 μl of water.
Thus each well contains 40 μl of liquid comprising 20 μl of compound A or water and 20 μl of compound B or water. Spores of a relevant organism (e.g. Aspergillus fumigatus AF210) are harvested, for example from a 5-10 day old culture grown on a Sabourad agar plates. A suspension is made in PBS/Tween80 and the number of spores estimated using a spectrophotometer at A495 using a previously constructed calibration curve. Appropriate growth media can be used, for example RPMI or YAG media.
These can be prepared in line with the following example: 10.1 g of RPMI powder (Gibco) are added to a 1 L Duran bottle, along with 34.5 g MOPS buffer and 18 g Glucose. Approximately 500 ml of deionised water is added and the bottle placed on a magnetic stirrer to assist solution. When completely dissolved the solution is adjusted to pH 7.0 using 5N NaOH. The solution is then made up to 600 ml total volume using deionised water and then filter sterilised through a 0.2 μm membrane and stored at 4 0C. For the test the spores of the chosen organism are diluted in the relevant medium (e.g. RPMI) to give a concentration of 1-3 xl O4 cfu/ml. The media is vortex mixed and the 60 μl of spore suspension is added to each well of the plate, to give a final spore concentration of 0.5-2.5 xlO4 cfu/ml. The final concentrations of compound A and compound B in the medium is:
Compound A: 0.18, 0.16, 0.14, 0.12, 0.1, 0.08, 0.06, 0.04, 0.03, 0.02, 0.01 μg/ml Compound B: 0.11, 0.09,0.07,0.05.0.03, 0.01, 0.005 μg/ml
The plate is incubated in a moist chamber for 48 hrs and then examined for growth. The row containing dilutions of compound A without compound B provides the MIC of compound A. Similarly, the column which contains dilutions of compound B with no compound A provides the MIC of compound B.
To determine the combined effect of the compounds the Fractional inhibitory concentration FIC is determined, where FIC is defined as:
FIC = FICA + FIC5 = CA comb/MICA alone + CB comb/MICBalone
where MICA alone and MICB310"6 are the MICs of compounds A and B when acting alone and CA Comb and CB COmb are concentrations of compounds A and B at the isoeffective combinations, respectively. The interpretation of the FIC is as follows: a FIC value of ≤ 0.5 reveals synergy, a value of 1 to 4 reveals indifference, and a value of >4 represents antagonism. In accordance with the description above, a study was carried out with Aspergillus fumigatus AF210 in RPMI media with 2-(l,5-Dimethyl-3-phenyl-lH- pyrrol-2-yl)-N- {4-[4-(4,6-dimethyl-pyridin-2-yl)-ρiperazin- 1 -yl]-ρhenyl} -2-oxo- acetamide (i.e. the compound of Example 1) as compound A and caspofungin as compound B. In this experiment an FIC of 0.67 was obtained.
Combination therapy example 2: Determination of synergy between two antifungal compounds in vivo
Antifungal drugs are often used in combination to treat systemic infections in ill patients. When drugs are used together in combination various interactions may occur, these actions may be synergistic, antagonistic or indifferent (also known as an additive effect). For patient care antagonistic combinations should be avoided as they may be associated with a worse outcome, synergistic effects are desirable however indifferent or additive combinations can be of benefit.
Interactions between two antifungal drugs can be studied in vitro using checkerboard synergy tests, or kill curve type studies, however it is also useful to be able to asses the interaction between a combination of drugs in in vivo models which are more realistic as the pharmacokinetics effects of each drug are taken into account. There are several models that can be used to assess the efficacy of a combination of antifungal drugs, the models typically being tissue burden models or survival models.
In the first model groups of mice (typically 6-7 although larger groups can be used) are immunosuppressed with cyclophosphamide 200mg/kg on day 1, on day 4 they are then infected with the infecting organism eg Aspergilli. or Candida spp. Infection may be through the lateral tail vein, intranasal, pulmonary or GI. The inoculum is sufficient to establish infection in different body organs. Four to 24 hours after infection animals are treated with each of the test drugs individually at appropriate doses and with both drugs in combination. Typical doses could be from 5 to 150 mg/kg of the pyrrole agent in combination with the approved dose of other marketed agents. Different routes of administration may be used for the different drugs, and different frequencies of dosing may be appropriate for each drug. The animals are treated for up to 14 days and then remain untreated for 12-18hr following the last dose of drug. A group of animals which are infected but untreated are used as controls for comparison purposes. The animals are then humanely euthanized, and the kidneys are removed. Both kidneys from each mouse are pooled, weighed and then homogenised in ImI of PBS/ Tween. The homogenate is then diluted in PBS and aliquots of the homogenates are plated onto Sabourauds agar and incubated for 24-48hrs. Colonies are counted and the actual colony count per gram (cfu/gm) of tissue calculated taking into account dilution factors and tissue weight.
The cfu/gm of each mouse in each treatment group is plotted graphically. This allows comparison of the untreated animals with the treatment groups, and also a comparison of each drug used singly and in combination. Statistical analyses can be carried out on each treatment group compared with the control group and between the individual drugs and the combination of drugs.
Other in vivo studies that are used for assessing the efficacy of combinations in comparison with single drugs are survival studies. In these models groups of mice (typically 10 per group) are immunosuppressed with cyclophosphamide and infected with A. fumigatus in the same manner as the tissue burden study. Animals are treated with drug for 10 days using relevant dosages, routes and frequencies and then observed for 2-7 days after treatment has ceased. The number of mice surviving in each group is assessed on a daily basis. Infected but untreated animals serve as controls and usually succumb to infection and die by day 5-7. The efficacy of compounds is assessed by comparing survival rates at the end of the study. Although such studies are useful for comparing different single agents unless individual agents have poor survival rates then it will be difficult to identify additive or synergistic effects between two agents. More severe models can be employed to reduce the survival rates for single agents such as using a persistently neutropenic survival model, in which animals are given additional doses of immunosuppressive agents or delayed treatment models in which the first dose of drug is given 24hrs or later following infection.
The models described previously are disseminated models of A. fumigatus infection in which infection is established in numerous body organs following intravenous injection of spores. Alternative models of infection for conducting synergy studies include survival studies using pulmonary models of infection. In such models Aspergillus spores are introduced into the lung either through inhalation of aerosols or spore suspensions. Infection develops in the lung, the most common site of infection in humans. These infections are perhaps a better mimic of human infection. Such infection models can be used to examine synergy between compounds. These models are typically severe as the animals are persistently immunosuppressed and untreated animals rapidly succumb to infection. Further modifications to these models can be made by delaying treatment and continuing observation of animals following cessation of treatment.
Synergy studies are carried out by comparing the effect of each individual drug and the drugs in combination. If drugs are highly potent and give good survival rates when used singly despite increasing the severity of the infection then a suitable approach is to lower the dose of each drug either by reducing the dose or dosing frequency. In this way survival rates below 50% may be achieved which will allow synergy to be demonstrated when both drugs are used in combination.
In another example of combination therapy, dosing of the novel pyrrole agent may allow the reduced dosing of other more toxic antifungal agents. This would result in a reduction of the toxic effects or drug-drug interaction profiles ordinarily seen with the established agent.
Examples of this would be with the azole class of antifungals where toxicities and drug drug interactions are well known. By using members of this class, specifically itraconazole, voriconazole and posaconazole, in combination with the novel pyrrole agent described , increased efficacy could be expected with reduced azole dosing and result in reduced toxicities.

Claims

1. A compound which is a pyrrole derivative of formula (I), or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of a fungal disease:
Figure imgf000210_0001
(Q wherein:
Rl represents hydrogen, unsubstituted or substituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -COR' or -SO2(C 1-C4 alkyl), or a group -A2, -L2-A2, -L3-A2, -A2-L3-A3 or -A4; Al represents a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-
ClO aryl or 5- to 12-membered heterocyclyl group;
A2 and A3 are the same or different and represent C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group; A4 is an unsubstituted or substituted 5- to 12-membered heterocyclyl group wherein 1 or 2 ring carbon atoms are replaced with a group selected from >C(=O), >S(=O)2, >C(=N0R7) where R7 is hydrogen or a C1-C4 alkyl group, >C=CH2 or >C(-OCH2CH2O-);
Ll represents a bond, a C1-C6 alkylene group in which none, one, two or three -CH2- groups are independently replaced by -O-, -S- or -NR'-, or a 5- to 12-membered heterocyclyl group;
L2 represents -NR'-, -O~, -CO-, -OCO-, -OCONR'R"-, -CONR'R"- or -SO2-; L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH2- groups are independently replaced by -O-, -S- or -NR'-; n is 1 or 2; R6 represents hydrogen or C 1 -C4 alkyl; R5 represents an unsubstituted or substituted group selected from C6-C10 aryl, a 5- to 12-membered heterocyclyl group, C1-C8 alkyl and C3-C6 cycloalkyl, hydrogen, halogen or a group of formula -B1-B2 or -B3;
Bl represents an unsubstituted or substituted C6-C10 aryl group; B2 represents an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group;
B3 is an unsubstituted or substituted 5- to 12-membered heterocyclyl group where 1 or 2 ring carbon atoms are replaced with a group selected from >C(=O), >S(=O)2, >C(=NOR11) where Rl 1 is hydrogen or a C1-C4 alkyl group, >C=CH2 or >C(-OCH2CH2O-);
R2 and R3 independently represent C6-C10 aryl, a 5- to 12-membered heterocyclyl group, C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', -SO2NR5R", -SO3H, -NR'R", -NR5COR5, -CO2R', -CONR'R", -COR', -OCOR5, -CF3, -NSO2R' or -OCONR'R", or a group (Cl-4) alkyl-A5, wherein none, one or two -CH2- groups are independently replaced by -0-5-S- or -NR'- and wherein A5 represents C6-10 aryl or a 5- to 12-membered heterocyclyl group; or R2 and R3 together with the ring atoms to which they are bonded form a 5- to 7-membered, at least partially saturated ring containing a nitrogen atom from the adjacent pyrrole ring, and optionally one or two further heteroatoms selected from N, O and S, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring;
R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -OR', -CO2R', -CONR'R", -COR', -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12-membered heterocyclyl group, or a group of formula -Alk6-L5-A12, where AIk6 is a C1-C4 alkylene group, L5 is a group of formula -0-C(=0)-, -C(=0)- or -NRl 3 -C(O)- and Rl 3 is hydrogen or C1-C4 alkyl, and Al 2 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group;
Y represents C1-C8 alkylene, C2-C8 alkenylene or C2-C8 alkynylene; Z represents halogen, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', -
SO2NR5R", -SO3H, -NR5R", -NR5COR', - NO2, -CO2R', -CONR'R", -COR', - OCOR5, -CN5 -CF3, -NSO2R', -OCONR5R" or -CR'=N0R"; and R' and R" independently represent hydrogen, C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl.
2. A compound according to claim 1, wherein Ll is represents a bond, a 5 -to 7- membered heterocyclyl group or a C1-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced by -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group; and Al represents a bond, phenyl, napthyl, a 5- or 6-membered heterocyclyl group or an 8- 10-membered bicyclic heterocyclyl group.
3. A compound according to any one of the preceding claims, wherein n is 1 ; Rl is hydrogen, an unsubstituted group selected from C 1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -CO(C 1-C4 alkyl) and -SO2(C 1-C4 alkyl), or a group -A2, -L2-
A2, -L3-A2,
-A2-L3-A3 or A4;
A2 and A3 are the same or different and represent phenyl or a 5- or 6-membered heterocyclic group; and
L3 represents a bond or a C1-C4 alkylene group in which none, one or two -CH2- moieties are independently replaced with -O- or -NR'-, wherein R' represents hydrogen or unsubstituted C1-C4 alkyl.
4. A compound according to any one of the preceding claims, wherein R5 is hydrogen, phenyl, a monocyclic 5- to 8-membered heterocyclyl ring, an unsubstituted C3-C6 cycloalkyl group, an unsubstituted C1-C8 alkyl or a C1-C8 alkyl substituted with a C1-C4 alkoxy group.
5. A compound according to any one of the preceding claims, wherein either (i) R2 represents unsubstituted or substituted phenyl, hydrogen, -COO(C 1-C4 alkyl), halogen, unsubstituted C3-C6 cycloalkyl, or a C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkoxy group which is unsubstituted or substituted with -SMe, -SEt, hydroxyl, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R", -NR'CO(C1-C4 alkyl), unsubstituted C1-C4 alkoxy or C1-C4 alkoxy substituted with -OMe or -OEt, where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -0-, -S- or -NR'- and wherein A5 represents phenyl, pyridinyl or oxazolyl; and R3 represents hydrogen, halogen, unsubstituted C2-C4 alkenyl, or a C1-C4 alkyl or C1-C4 alkoxy group which is unsubstituted or substituted with -OMe or -OEt; or (ii) R2 and R3 together with the ring atoms to which they are bonded form an at least partially saturated 5- or 6-membered ring containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O, with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring.
6. A compound according to any one of the preceding claims which is a pyrrole derivative of formula (Ia) or a pharmaceutically acceptable salt thereof:
Figure imgf000213_0001
(IA) wherein:
Al represents a bond, phenyl, naphthyl, pyridyl, piperidinyl, benzofuranyl, isoquinolinyl or quinolinyl, each of which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO2H and halogen, or from a group of formula -(Cl -C2 alkyl)-0-(Cl-C4 alkyl)-NR'R" where R' and R" are the same or different and represent hydrogen or C1-C4 alkyl, or R' and R", together with the nitrogen atom to which they are bonded, form a piperazinyl or morpholinyl group which is unsubstituted or substituted with 1 or 2 C1-C4 alkyl groups; n represents one or two; Ll represents a bond, a saturated 5- to 7-membered heterocyclyl group containing one or two nitrogen atoms, or an unsubstituted C1-C6 alkylene group wherein none, one or two -CH2- groups are independently replaced with -O- or -NR'-, wherein R' is hydrogen, unsubstituted C1-C4 alkyl or C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, and wherein the heterocyclyl group is unsubstituted or substituted with an unsubstituted group selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy and halogen; when Ll is a bond, Rl represents hydrogen, -A2, -SO2- A2, A2-L3-A3 or A4; and when Ll is other than a bond, Rl represents hydrogen or an unsubstituted group selected from C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and -SO2(C1-C4 alkyl), or a group -A2, -SC-2-A2, -L3-A2 or -A2-L3-A3; A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF3, -OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -O(C1-C4 alkyl)-0(Cl-C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group;
L3 represents a bond or unsubstituted methylene or ethylene;
A4 represents unsubstituted dioxothiomorpholinyl, methoxyiminopiperidinyl, methoxyiminopyrrolidinyl, methylenepiperidinyl, dioxoazaspirodecyl or oxadihydropyrazolyl;
R5 represents hydrogen, unsubstituted or substituted phenyl, unsubstituted C3- C6 cycloalkyl, unsubstituted or substituted pyridinyl or piperidinyl, or unsubstituted thiophenyl, furanyl or tetrahydropyranyl, the substituents being selected from halogen, unsubstituted C1-C4 alkyl, unsubstituted C1-C4 alkoxy or R5 is a C1-C8 alkyl group substituted with a C1-C4 alkoxy group; and either (i) R2 represents unsubstituted phenyl, hydrogen, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C2-C4 alkenyl, unsubstituted C1-C4 alkyl, or C1-C4 alkyl or C2-C4 alkenyl substituted with -OMe, -OEt, -OPr, -OBu, -OCH2CH2OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl- A5, wherein none or one -CH2- groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C4 alkyl and C1-C4 alkoxy; and R3 represents hydrogen, halogen, unsubstituted phenyl, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 alkyl, or C1-C4 alkyl substituted with -OMe or -OEt; or (ii) R2 and R3 together with the ring atoms to which they are bonded form a substituted or unsubstituted at least partially saturated 5- or 6-membered ring containing a nitrogen atom from the adjacent pyrrole ring and none or one further heteroatom selected from N and O5 the substituents being selected from unsubstituted C1-C4 alkyl and unsubstituted C1-C4 alkoxy groups.
7. A compound according to claim 6, wherein Al represents phenyl, which may be unsubstituted or substituted with one or more substituents selected from unsubstituted C1-C4 alkyl, C1-C4 alkyl substituted with an unsubstituted C1-C4 alkoxy group, unsubstituted C1-C4 alkoxy, -CO2H and halogen; n represents one;
Ll represents an unsubstituted, saturated 5- to 7-membered heterocyclyl group containing two nitrogen atoms, the heterocycle being attached to Al and to Rl via a nitrogen atom;
Rl represents unsubstituted C1-C6 alkyl, unsubstituted C2-C6 alkenyl, or a group -A2, -CH2- A2 or -A2-CH2-A3 ;
A2 and A3 independently represent phenyl or a 5- or 6-membered heterocyclyl group, wherein A2 and A3 are unsubstituted or substituted with one, two or three substituents selected from the unsubstituted substituents halogen, -COCF3, - OCONR'R" and -NR'R", and from C1-C4 alkyl and C1-C4 alkoxy groups which are unsubstituted or substituted with -OH, -OMe, -OEt or -0(C 1 -C4 alkyl)-O(C 1 -C2 alkyl), wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group;
R5 represents unsubstituted phenyl; R2 represents hydrogen, or C1-C4 alkyl or C2-C4 alkenyl, each of which may be unsubstituted or substituted with -OMe, -OEt, -OPr, -OBu5 -OCH2CH2OMe, -SMe, hydroxy, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R" or -NR'CO(C1-C4 alkyl) where R' and R" are the same or different and represent hydrogen or unsubstituted C1-C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -O- and wherein A5 represents phenyl, pyridinyl or oxazolyl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C1-C4 alkyl and C1-C4 alkoxy; and R3 represents hydrogen or C1-C4 alkyl which is unsubstituted or substituted with -OMe or -OEt.
8. A compound according to any one of the preceding claims wherein the pyrrole derivative is of formula (IB):
Figure imgf000216_0001
(IB)
wherein Al5 Ll, n, Rl and R3 to R5 are as defined in any one of the preceding claims, and R2 is a group of formula -AIk1-X-R', wherein AIk1 is an unsubstituted or substituted C1-C6 alkylene group, X is a group -O-, -S-, -NR"-, -CO2-, -CONR"-5 -OCO-, -OCONR' '- or -SO2-, and R' and R' ' are independently selected from hydrogen and unsubstituted or substituted C1-C4 alkyl.
9. A compound according to claim 1 , which is
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-{4-[4-(4,6-dimethyl-pyridm-2-yl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-oxo-2-(l-phenyl-lH- pyrrol-2-yl)-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridm-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-l-phenyl-liϊ"- pyrrol-2-yl)-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-(5-methyl- lH-pyrrol-2- yl)-2-oxo-acetamide, iV-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(2-methyl-7-phenyl-
1 ,2,3 ,4-tetrahydro-pyrrolo [ 1 ,2-a]pyrazin-6-yl)-2-oxo-acetarnide,
-¥-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-657- dihydro-5H-pyrrolizin-3-yl)-acetamide, N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(7-phenyl-3,4- dihydro-lH-pyrrolo[2,l-c][l,4]oxazin-6-yl)-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-isopropyl-5-methyl-
3 -phenyl- lH-pyrrol-2-yl)-2-oxo-acetarnide,
N-{4-[4-(456-Dime1±ιyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-niethoxy-ethyl)-5- methyl-3-phenyl-l/f-pyrrol-2-yl]-2-oxo-acetamide:> 2-(l,5-Dime%l-3-phenyl-lH-pyrrol-2-yl)-iV'-[4-[4-(456-dimethyl-pyridin-2-yl)- piperazin-l-yl]-3-(3-moφholin-4-yl-propoxymethyl)-phenyl]-2-oxo-acetamide5
N- {3-Chloro-4- [4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-( 1 ,5-dimethyl-
3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-(3 -furan-2-yl- 1,5- dimeώyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l,5-dimethyl-3- tliiophen-2-yl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(3-isopropyl-l,5- dimethyl-lH-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l,5-dimethyl-3-
(tetrahydro-pyran-4-yl)-lH"-pyrrol-2-yl]-2-oxo-acetamide5
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-naphthalen-l-yl-2-oxo-acetamide,
N-{3-(2-Dimethylamino-ethoxymethyl)-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l- yl]-phenyl}-2-(l55-dimethyl-3-phenyl-li7-pyrrol-2-yl)-2-oxo-acetamide, 2-( 1 ,4-Dimethyl-3 -phenyl- lH-ρyrrol-2-yl)-N- {4- [4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl]-phenyl} -2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-l/f-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 - [3 -(4-methyl-piperazin- 1 -yl)-propoxymethyl] -phenyl } -2-oxo- acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-isopropyl-l-methyl-
3 -phenyl- lH-pyrrol-2-yl)-2-oxo-acetamide,
N- {2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-(l ,5-dimethyl-
3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-( 1 ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-N- {4- [4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 -hydroxy-phenyl } -2-oxo-acetamide,
N-(2,3-Dihydro-benzofuran-4-yl)-2-(l,5-dimethyl-3-phenyl-lH"-pyrrol-2-yl)-2-oxo- acetamide, iV-{3-Chloro-4-[4-(4,6-dimethyl-pyridiB-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [3 -isopropyl- 1 -(2- methoxy-ethyl)-5-methyl-lH-pyrrol-2-yl]-2-oxo-acetamide, iV-{2-Chloro-4-[4-(456-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-5-methyl-3-phenyl-l/f-pyrrol-2-yl]-2-oxo-acetamide5
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [ 1 -(2~ethoxy-ethyl)-5- methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(436-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(3-methoxy-propyl)- 5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide;,
2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N-quinolin-5-yl- acetamide,
N-Isoquinolin-5-yl-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo- acetamide, 2-(l ,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-quinolin-8-yl-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-quinolin-5-yl-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-N-pyridin-4-yl-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2τ(l-ethyl-5-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl} -2-(5-methyl-3-phenyl- 1 - propyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l-Butyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-(l ,5-Dimethyl-3-phenyl- 1 H-pyrrol-2-yl)-2-oxo-N-quinolin-3-yl-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-iV'-[4-(4-pyridin-2-yl-piperazin-l-yl)- phenyl] -acetamide,
2-(l,5-Dimethyl-3-phenyl-li7-pyrrol-2-yl)-iV-{4-[4-(6-methyl-pyridin-2-yl)-piperazin- l-yl]-phenyl}-2-oxo-acetamide,
2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4-methyl-pyridin-2-yl)-piperazm- l-yl]-phenyl} -2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(2-phenyl-
6,7,859-tetrahydro-5H-pyrrolo[l,2-a]azepin-3-yl)-acetaniide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-2-(l-phenyl-
6,7, 8 ,9-tetrahydro-5H-pyrrolo [ 1 ,2-a] azepin-3 -yl)-acetamide,
N-Isoquinolin-8-yl-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo- acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-isoquinolin-8-yl-2-oxo-acetamide,
2-( 1 ,5 -Dimethy 1-3 -phenyl- 1 H-pyrrol-2-yl)-N-naphthalen-2-yl-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-( 1 -methyl-3 -phenyl- lH-pyrrol-2-yl)-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-y l)-piperazin- 1 -yl] -phenyl } -2-( 1 -methyl-4-phenyl- 1 H-ρyrrol-2-yl)-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [ 1 -(2-methoxy-ethyl)-3 - phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-(l -Benzyl-5 -methyl-3 -phenyl- 1 H-pyrrol-2-yl)-N- {4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide, 2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[5-(4-methyl-piperazin-l-yl)-naphthalen-
1 -yl] -2-oxo-acetamide5
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-
1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2-yl)- piperazin- 1 -yl] -3 -methyl-phenyl } -2-oxo-acetamide,
(2- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylaminooxalyl} -5-methyl-3 - phenyl-pyrrol-l-yl)-acetic acid methyl ester,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-ρiperazin-l-yl]-phenyl}-2-(5-etliyl-l-methyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-ethyl-l-(2-methoxy- ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl}-5-methyl-3- phenyl-pyrrole-1-carboxylic acid ethyl ester,
2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaminooxalyl}-5-methyl-3- phenyl-pyrrole-1-carboxylic acid methyl ester,
2-[3-(2-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimetliyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide, 2-[4-(2-Chloro-ρhenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
2-[3-(4-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(456-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide, 2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-N-phenyl-l- acetamide,
(2- {4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenylaminooxalyl} -pyrrol- 1 -yl)- acetic acid methyl ester,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl}-2-(l -methoxymethyl-5- methyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-(l -methoxymethyl-3- phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2-hydroxy-ethyl)-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, 2-[l-(2-Acetylamino-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2- [ 1 -(2-hydroxy-ethyl)-3 - phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazine-l-yl]-phenyl}-2[l-(2-methoxy-ethyl)- 3 -thiophen-2-yl- 1 H-pyrol-2-yl]-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)piperazin- 1 -yl] -phenyl } -2- [3 -isobutyl- 1 -(2- methoxy-ethyl)-lH-pyrrol-2-yl]-2-oxo-acetamide,
2-{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl] -phenyl amino oxalyl}-5-methyl-3- phenyl-pyrrol-l-yl)-acetic acid ethyl ester, 2-[3-(3-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
2-[4-(3-Chloro-phenyl)-l-(2-methoxy-ethyl)-lH-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazine- 1 -yl] -phenyl} -2 [ 1 -(2-methoxy-ethyl)- 3 -thiophen-3 -yl- 1 H-pyrol-2-yl] -2-oxo-acetamide,
(2-{4-[4-(4, 6-Dimethyl pyridine-2-yl)-piperazin-l-yl]-phenylamino oxalyl} -3 -phenyl pyrrol- 1-yl) acetic acid ester, (2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaininooxalyl}-3-phenyl- pyrrol- l-yl)-acetic acid methyl ester,
2-(l-Carbamoylmethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(456-dimethyl-pyridin-2-yl)- piperazin-l-yl]-phenyl}-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-methyl carbamoylmethyl-3 -phenyl- 1 -H-pyrrol-2-yl)-2-oxo-acetamide,
2{4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl}-5-methyl-3- phenyl-pyrrol-1-yl) acetic acid isopropyl ester, iV-{4-[4-(4,6-Dimethyl-pyridm-2-yl)-piperazin-l-yl]-phenyl}-2-[5-isopropyl-l-(2- methoxy-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-iV-2-oxo-quinolin-5-yl-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [3 -(2-methoxy-ethyl)-5 - methyl- 1 -phenyl- 1 H"-pyrrol-2-yl] -2-oxo-acetamide,
2-[l-(2-Methoxy-ethyl)-3-phenyl-lH-pyrrol-2-yl]-2-oxo-iV-phenyl-l-acetamide, 2- [ 1 -(2-Methoxy-ethyl)-3 -phenyl- 1 i7-pyrrol-2-yl] -2-oxo-JV-propyl-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [3 -iso propyl- 1 -(2- methoxy-ethyl)-lH-pyrrol-2-yl]-2-oxo acetamide,
2-[ 1 -(2-Dimethylamino-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl]-JV- {4- [4-(4,6-dimethyl- pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide5 2-[l-(2-Dimethylaimno-emyl)-4-phenyl-l/f-pyrrol-2-yl]-N-{4-[4-(4,6-dimethyl- pyridin-2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-[l-(2-Dimethylamino-ethyl)-5-methyl-3-phenyl-li7-pyrrol-2-yl]-iV-{4-[4-(456- dimethyl-pyridin-2-yl)-piperazin-l -yl]-phenyl} -2-oxo-acetamide5
(2- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl]-phenyl amino oxalyl} -3 -thiophen- 2-yl-pyrrol-l-yl)-acetic acid methyl ester,
(2- {4- [4-(456-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenylaminooxalyl } - [3 -iso propyl-pyrrol-l-yl)-acetic acid methyl ester,
(2-{4-[4-(4,6-Dimethyl pyridine-2-yl) piperazine-l-yl]-phenyϊamino oxalyl } -3 -isobutyl- pyrrol-l-yl)-acetic acid methyl ester, N-{4-[4-(4,6-Drmethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(4-fluoro-l, 5-dimethyl-
3-phenyl-l/f-pyrrol-2-yl)-2-oxo-acetamide, N- {4- [4-(4,6-Dimethyl-pyridm-2-yl)-piperazin- 1 -yl]-phenyl} -2-(5-methyl-3 -phenyl-
1 pyridin-2ylmethyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, iV-{2-Chloro-4-[4-(456-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(2- methoxy-ethyl)-5-methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piρerazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- pyridin-3 -ylmethyl- 1 i7-pyrrol~2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[4-fluoro-l-(2- methoxy-ethyl)-5-methyl-3-phenyl-lϋf-pyrrol-2-yl]-2-oxo-acetamide5
2-(l, 5-Dimetitiyl-3-phenyl-lH"-pyrrol-2-yl)-iV-[2-fluoro-4-(4-pyridm-2-yl-piperazm-l- yl)-phenyl]-2-oxo-acetamide,
N-[2-Fluoro-4-(4-pyridin-2-yl-piperazin-l-yl)-phenyl]-2-[l-(2-methoxy-ethyl-)-5- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
N- { 4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2- [ 1 -(2-isopropoxy- ethyl)-5 -methyl-3 -phenyl- 1 Jf-pyrrol-2-yl] -2-oxo-acetamide, (2-{2-Chloro-4-[4-(4,6-dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl amino oxalyl}-5- methyl-3-phenyl-pyrrol-l-yl)-acetic acid methyl ester,
2-( 1 , 5 -Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-2-oxo-N-(6-pyrrolidin- 1 -yl-pyridin-3 -yl)- acetamide,
2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[2-fluoro-4-oxazole-2-yl-phenyl)-2-oxo- acetamide,
2-(l,5-Dimethyl-3-phenyl-l/f-pyrrol-2-yl)-N-(2-fluoro-4-morpholin-4-yl-phenyl)-2- oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-methyl-3-phenyl-l- pyridin-4-ylmethyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 2-[l-(2-Metiioxy-ethyl)-5-me%l-3-phenyl-lHr-ρyrrrol-2-yl]-N-{4-[4-(5-morpholin-4- ylmethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-oxo-acetamide,
2-[3-Cyclobutyl-l-(2-methoxy-ethyl)-li7-pyrrol-2-yl]-N-{4-[4-(4,6-Dimethyl-pyridin-
2-yl)-piperizin-l-yl]-phenyl}-2-oxo-acetamide,
2-(l 55-Dimethyl-3-phenyl- 1 H-pyrrol-2-yl)-Ν-[2-fluoro-4-(4-isobutyl-piperazin- 1 -yl)- phenyl]-2-oxoacetamide5
2-(l,5-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-N-(2-fluoro-4-piperidin-l-yl-phenyl)-2-oxo- acetamide, (3 -Cyclobutyl-2- {4- [4-(4,6-dimethyl-pyridin-2-yl)-piperazin- 1 -yl-] - phenylaminooxalyl} -pyrrol- l-yl)-acetic acid methyl ester,
2-( 1 ,5-Dimethyl-3-phenyl- lH-pyrrol-2-yl)-iV- {2-fluoro-4- [4-(2-methyl-allyl)-piperazin-
1 -yl] -phenyl } -2-oxo-acetamide, iV-{2rFluoro-4-[4-(2-methyl-allyl)-piperazin-l-yl]-phenyl}-2-[l-(2-methoxy-ethyl)-5- methyl-3 -phenyl- 1 H~~pyrrol-2-yl] -2-oxo-acetamide, iV-[2-Fluoro-5-(4-isobutyl-piperazine-l-yl)-phenyl]-2-[l-(2-methoxy-ethyl)-5-methyl-3- phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
(2-{4-[4-(456-Dimethyl-pyridm-2-yl)-piperazin-l-yl]-2-fluoro-phenylaminooxylyl}-5- methyl-3 -phenyl-pyrrol- 1 -yl)-acetic acid methyl ester,
2-(l55-Dimethyl-3-phenyl-lH"-pyrrol-2-yl)-iV-{4-[4-(2,2-dimethyl-propyl)-ρiρeraziii-l- yl]-2-fluoro-phenyl}-2-oxo-acetamide,
N-{4-[4-(2,2-Dimethyl-propyl)-piperazin-l-yl]-2-fluoro-phenyl}-2-[l-(2-methoxy- ethyl)-5 -methyl-3 -phenyl- 1 Η-pyrrol-2-yl] -2-oxo-acetamide, iV-(2-Fluoro-4-piperidin- 1 -yl-phenyl)-2-[ 1 -(2-methoxy-ethyl)-5-methyl-3 -phenyl- 1 H- pyrrol-2-yl] -2-oxo-acetamide,
2-(I5 5-Dimethyl-3-phenyl-li-r-pyrrol-2-yl)-iV-(3-fluoro-4-piperidin-l-yl-phenyl)-2-oxo- acetamide,
2-(l, 5-Dimethyl-3-phenyl-liZ'-pyrrol-2-yl)-N-[3-fluoro-4-(4-pyridin-2-yl-piperazin-l- yl)-phenyl]-2-oxo-acetamide, iV-(2-Fluoro-4-morpholin-4-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH- pyrrol-2-yl] -2-oxo-acetamide,
2-(l, 5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-7Vr-[3-fluoro-4(4-isobutyl-piperazin-l-yl)- phenyl] -2-oxo-acetamide, N-Q -Fluoro-4-piperdin- 1 -yl-phenyl)-2- [ 1 -(2-methoxy-ethyl)-5 -methyl-3 -phenyl- 1 H- pyrrol-2-yl] -2-oxo-acetamide,
2-(l,5-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-iV'-{4-[4-(5-morpholin-4-ylmethyl-pyridin-2- yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2- [ 1 -(2-Methoxy-ethyl)-4-phenyl- 1 Η-pyrrol-2-yl] -2-oxo-N-propyl-acetamide, (2-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenylaminooxalyl}-4-phenyl- pyrrol-l-yl)-acetic acid methyl ester, N- {4-[4-(4, 6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -2-fluoro-phenyl} -2- [1 -(2- methoxy-ethyl)-5-methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide5
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperizin- 1 -yl] -phenyl } -2- [ 1 -methyl-3 -phenyl-5 - propyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-{4-[4-(4.6-Dimethyl-pyridin-2-yl)-pipera2;m-l-yl]-phenyl}-2-(5-ethyl-l- methoxymethyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N-(3-Fluoro-4-morpholin-4-yl-phenyl)-2-[l-(2-methoxy-ethyl)-5-methyl-3-phenyl-lH- pyrrol-2-yl] -2-oxo-acetamide,
2-(l ,5-Dimethyl-3 -phenyl- lH-pyrrol-2-yl)-N-(5-fluoro-naphthalen- 1 -yl)-2-oxo- acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(l-ethyl-4-fluoro-lH-indol-5-yl)-2-oxo- acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-(2-methoxy-ethyl)-l- methyl-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide., N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-(5 -methoxymethyl- 1 - methyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
2-(l,5-Bis-methoxymethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-2- yl)-piperazine- 1 -yl] -phenyl} -2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(l-ethoxymethyl-5- methyl-3-phenyl-lH-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-methyl-l-(2- methylsulfanyl-ethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-methyl-l-(2- phenoxy-ethy l)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide, 2-(l-Butoxymethyl-5-methyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(4,6-dimethyl-pyridin-
2-yl)-piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
N- {4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-[l -(3 -ethoxy-propyl)-5- methy-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-(5 -methyl- 1 - methylsulfanylmethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N- {4- [4-(4,6-Dimethyl-pyridin-2-yl)-piperazin- 1 -yl] -phenyl} -2-[l -(2-methoxy- ethoxymethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-(5-metliyl-3-plienyl-l- propoxymethyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[5-methyl-3-phenyl-l-
(2-propoxy-ethyl)- 1 H-pyrrol-2-yl] -2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-ρhenyl}-2-[l-(4-methoxy-but-2- enyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-2-oxo-acetamide,
N-{4-[4-(456-Dimethyl-pyridin-2-yl)-piperazin-l-yl]-phenyl}-2-[l-(4-methoxy-butyl)-
5 -methy-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide,
2-(l ,5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-N-(4-piperidin- 1 -yl-phenyl)- acetamide,
N-[4-(4-Benzyl-piperazin-l-yl)-phenyl]-2-(l,5-dimethyl-3-phenyl-lH-pyrrol-2-yl)-2- oxo-acetamide,
2-( 1 ,5 -Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-N- [4-(4-isobutyryl-piperazin- 1 -yl)-phenyl] -
2-oxo-acetamide, N-{4-[4-(4,6-Dimethyl-pyridin-2-yl)-piperazm-l-yl]-phenyl}-2-[5-methyl-l-(2-methyl- oxazol-4-ylmethyl)-3 -phenyl- 1 H-pyrrol-2-yl] -2-oxo-acetamide
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(4-oxazol-2-yl-phenyl)-2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-[3-fluoro-4-oxazole-2-yl-phenyl)-2-oxo- acetamide, 2-[l-(2-Methoxy-ethyl)-5-methyl-3-phenyl-lH-pyrrol-2-yl]-N-(4-oxazol-2-yl-phenyl)-
2-oxo-acetamide,
2-(l,5-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-{4-[4-(l52-dimethyl-propyl)-piperazin-l- yl] -phenyl } -2-oxo-acetamide,
2-(l,5-Dimethyl-3-ρhenyl-lH-ρyrrol-2-yl)-N-{4-[4-(2-methoxy-l-methyl-ethyl)- piperazin- 1 -yl] -phenyl} -2-oxo-acetamide,
2-(l,5-Dimethyl-3-ρhenyl-lH-pyrrol-2-yl)-N-{4-[4-(2-furan-2-yl-l-methyl-ethyl)- piperazin- 1 -yl] -phenyl } -2-oxo-acetamide,
2-( 1 , 5-Dimethyl-3 -phenyl- 1 H-pyrrol-2-yl)-2-oxo-N- [4-(5 -piperidin- 1 -y lmethyl-oxazol-
2-yl)-phenyl] -acetamide, or 2-(l55-Dimethyl-3-phenyl-lH-pyrrol-2-yl)-N-(4-morpholin-4-yl-phenyl)-2-oxo- acetamide, or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical combination comprising a combination of a pyrrole derivative of formula (I) or a pharmaceutically acceptable salt thereof as defined in any one of the preceding claims, with a second antifungal agent.
11. A combination according to claim 10, wherein the pyrrole derivative of formula (I) or pharmaceutically acceptable salt thereof and the second antifungal agent are formulated for simultaneous or successive administration.
12. A combination according to claim 10 or claim 11 , wherein the second antifungal agent is selected from the group consisting of azoles, polyenes, purine nucleotide inhibitors, pyrimidine nucleotide inhibitors, mannan inhibitors, protein elongation factor inhibitors, echinocandins, allylamines, anti-HSP90 antibodies, bactericidal/permeability inducing protein products or polyoxins, or one of the compounds AN2690, AN2718 or icofungipen.
13. A combination according to claim 12, wherein the second antifungal agent is (i) an azole selected from clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, fluconazole, isoconazole, itraconazole, ketoconazole, miconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, isavuconazole, ravuconazole, posaconazole, terconazole and voriconazole; (ii) an echinocandin selected from anidulafungin, caspofungin and micafungin; (iii) an allylamine selected from terbinafϊne, butenafine, amorolfine and naftifine; (iv) a polyene selected from amphotericin B and nystatin; (v) a purine or pyrimidine nucleotide inhibitor which is flucytosine; (vi) a mannan inhibitor which is pradamicin; (vii) a protein elongation factor inhibitor selected from sordarin and analogues thereof; or (viii) a polyoxin which is nikkomycin Z.
14. A product comprising a pyrrole derivative of formula (I) as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof and a second antifungal agent for separate, simultaneous or sequential use in the prevention or treatment of a fungal disease.
15. A pharmaceutical composition comprising (i) a pyrrole derivative of formula (I) as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, (ii) a second antifungal agent as defined in any one of claims 10 to 13, and (iii) a pharmaceutically acceptable carrier or diluent.
16. A combination, product or pharmaceutical composition as claimed in any one of claims 10 to 15 for use in the treatment or prevention of fungal disease.
17. A compound, combination, product or pharmaceutical composition according to any one of the claims 1 to 9 or 16, wherein the disease is caused by an Aspergillus species, or a compound according to claim 8, wherein the disease is caused by an Aspergillus or Candida species.
18. A compound, combination, product or pharmaceutical composition according to any one of claims 1 to 9 or 16, wherein the disease is caused by a fungal dermatophyte, or wherein the disease is Allergic Bronchopulmonary Aspergillosis (ABPA) or asthma.
19. A kit comprising, in admixture or in separate containers, a pyrrole derivative of formula (I) as defined in any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof and a second antifungal agent.
20. A method of controlling a fungal disease in a plant, which method comprises applying to the locus of the plant a pyrrole derivative as defined in any one of claims 1 to 9 or an agriculturally acceptable salt thereof, and optionally a second antifungal agent.
21. Use of a pyrrole derivative as defined in any one of claims 1 to 9 or an agriculturally acceptable salt thereof, optionally together with a second antifungal agent, as an agricultural fungicide.
22. A compound which is a pyrrole derivative of formula (I) or a pharmaceutically or agriculturally acceptable salt thereof:
Figure imgf000227_0001
(I) wherein Rl, Ll, n, R3 and R5 are as defined in any one of claims 1 to 9;
Al is a bond, a C3-C6 cycloalkyl or an unsubstituted or substituted C6-C10 aryl, 5- or 6-membered heterocyclyl or 8- to 10-membered bicyclic heterocyclyl group; R6 represents hydrogen;
R2 represents C6-C10 aryl, a 5- to 12-membered heterocyclyl group other than benzothiophene, unsubstituted C3-C6 cycloalkyl, hydrogen, halogen, C1-C8 alkyl, C2- C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, -OR', -SR', -SOR', -SO2R', - SO2NR5R", -SO3H5 -NR'R", -NR'COR', -CO2R', -CONR'R", -COR', -OCOR', -CF3, -NSO2R' or -OCONR'R", or a group (Cl-4) alkyl-A5, wherein none, one or two -CH2- groups are independently replaced by -0-,-S- or -NR'- and wherein A5 represents C6- 10 aryl or a 5- to 12-membered heterocyclyl group; or R2 together with R3 and the ring atoms to which they are bonded form a 5- to 7-membered, at least partially saturated ring containing a nitrogen atom from the adjacent pyrrole ring, and optionally one or two further heteroatoms selected from N5 O and S5 with the proviso that R2 and R3 do not form, together with the pyrrole ring to which they are bonded, an indolizine or tetrahydroindolizine ring; wherein when R2 represents aryl or heterocyclyl it is unsubstituted or substituted with one or more unsubstituted substiruents selected from halogen, -NR'R", -CO2R', - CONR'R", -OCONR'R", -OCOR', -COCF3 and hydroxyl, or C1-C6 alkyl or C1-C4 alkoxy which are unsubstituted or substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group; wherein R' and R" are independently selected from hydrogen, unsubstituted C1-C4 alkyl and C1-C4 alkyl substituted with a hydroxyl or unsubstituted C1-C4 alkoxy group
R4 represents hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, -OR', -CO2R', -CONR'R", -CN, -NO2, -NR'R", CF3, -Y-Z, C6-C10 aryl, or 5- to 12- membered heterocyclyl group, or a group of formula -Alk6-L5-A12, where AIk6 is a Cl- C4 alkylene group, L5 is a group of formula -0-C(=0)-, -C(=0)- or -NR13-C(=0)- and R13 is hydrogen or C1-C4 alkyl, and A12 is an unsubstituted or substituted C6-C10 aryl or 5- to 12-membered heterocyclyl group; wherein Y, Z, and unless otherwise specified R' and R" are as defined in any one of claims 1 to 9; with the provisos that
- when Al is a bond, Ll-Rl is not hydrogen;
- when Al is a bond, R2 is unsubstituted or substituted phenyl and R3 to R5 are all hydrogen, -Ll-Rl is not unsubstituted or substituted benzyl or substituted phenethyl; - when Al is a bond, R2 is hydrogen and R3 to R5 are all hydrogen or chlorine, then none of Ll, L3 and Ll-Rl represents an unsubstituted or substituted C1-C4 alkyl group; and the compound is not N-(4-Bromo-phenyl)-2-[l-(2-chloro-4-nitro-phenyl)-lH-pyrrol-2-yl]-2-oxo-acetamide, 2-[l-(2-chloro-4-nitro-phenyl)-lH-pyrrol-2-yl-N-(4-chloro-phenyl)-2-oxo-acetamide, 3 - [2-(4-Fluoro-phenylaminooxalyl)-pyrrol- 1 -yl] -propionic acid, N-Benzo [1,3] dioxol-5-yl-2- [ 1 -(2-cyano-ethyl)- 1 H-pyrrol-2-yl] -2-oxo-acetamide, 2-[l-(2-Cyano-ethyl)-lH-pyrrol-2-yl]-N-(4-fluoro-phenyl)-2-oxo-acetamide, N-(2,4-Difluoro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, N-(2,3-Difluoro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 2-(l -Methyl- 1 H-pyrrol-2-yl)-2-oxo-N-(4-phenoxy-phenyl)-acetamide3 N-(2-Methoxy-4-nitro-phenyl)-2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, N-(2,3-Dichloro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, 4-[2-(l -Methyl-lH-pyrrol-2-yl)-2-oxo-acetylamino]-benzoic acid methyl ester, 2-(l-Methyl-lH-pyrrol-2-yl)-2-oxo-N-(2-trifluoromethyl-phenyl)-acetamide5 2-(l-Methyl-lH-pyrrol-2-yl)-2-oxo-N-(3-trifluoromethyl-phenyl)-acetamide, N-(3,5-Dichloro-phenyl)-2-(l-methyl-lH-pyrrol-2-yl)-2-oxo-acetamide, N-(2,4-Dichloro-phenyl)-2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide, 2-( 1 -Methyl- 1 H-pyrrol-2-yl)-2-oxo-N-phenyl-acetamide,
N-(4-Chloro-phenyl)-2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetamide,
3-[2-(4-Bromo-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
3 - [2-(4-Chloro-phenylaminooxalyl)-pyrrol- 1 -yl] -thiophene-2-carboxylic acid methyl ester,
3-[2-(2-trifluoromethyl-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
3 _[2-(4-trifluoromethyl-phenylaminooxalyl)-pyrrol- 1 -yl] -thiophene-2-carboxylic acid methyl ester, 3 - [2-(3 -trifluoromethyl-phenylaminooxalyl)-pyrrol- 1 -yl] -thiophene-2-carboxylic acid methyl ester, 3-[2-(4-Fluoro-phenylaminooxalyl)-pyrrol-l-yl]-thiophene-2-carboxylic acid methyl ester,
N-[l-(4-methyl-3-penten-l-yl)-4-piperidinyl]-lH-pyrrole-2-acetamide,
3-(2-Allylaminooxalyl-pyrrol-l-yl)-thiophene-2-carboxylic acid methyl ester, 3 -(2-Propylaminooxalyl-pyrrol- 1 -yl)-thiophene-2-carboxylic acid methyl ester,
5 -Thia-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 3 -(hydroxymethyl)- 8 -oxo-7- [2-(2- pyrrolyl)glyoxylamido]-, acetate ester
3-{2-[2-(3,4-Dimethoxy-phenyl)-ethylaminooxalyl]-pyrrol-l-yl}-propionic acid
2- [ 1 -(2-Cyano-ethyl)- 1 H-pyrrol-2-yl] -N-foran-2-y lmethyl-2-oxo-acetamide 2-[l-(2-Cyano-ethyl)-lH-pyrrol-2-yl]-N-[2-(3,4-dimethoxy-phenyl)-ethyl]-2-oxo- acetamide
2-Oxo-N-[2-(5-piperidin-l-ylmethyl-lH-pyrrol-2-yl)-ethyl]-2-[5-(lH-pyrrol-2- ylmethyl)-lH-pyrrol-2-yl]-acetamide
2-Oxo-N-[2-(lH-pyrrol-2-yl)-ethyl]-2-[5-(lH-pyrrol-2-ylmethyl)-lH-pyrrol-2-yl]- acetamide
5 -Aminooxalyl-3 -(2-methoxycarbonyl-ethyl)-4-methoxycarbonylmethyl- 1 H-pyrrole-2- carboxylic acid tert-butyl ester
N-(3-Nitro-biphenyl-4-yl)-2-oxo-2-(lH-pyrrol-2-yl)-acetamide
(2S,5R,6R)-3 ,3-Dimethyl-6- [2-( 1 -methyl- 1 H-pyrrol-2-yl)-2-oxo-acetylamino] -7-oxo-4- thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-3,3-Dme%l-7-oxo-6-[2-oxo-2-(l-phenyl-lH-pyπ'θl-2-yl)-acetylamino]-4- thia- 1 -aza-bicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[2-oxo-2-(lH-pyrrol-2-yl)-acetylamino]-4-thia-l- aza-bicyclo[3.2.0]heptane-2-carboxylic acid Potassium; (2S,5R,6R)-3 ,3 -dimethyl-7-oxo-6- [2-oxo-2-( 1 -phenyl- 1 H-pyrrol-2-yl)- acetylamino] -4-thia- 1 -aza-bicyclo [3.2.0]heptane-2-carboxylate
Potassium; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[2-oxo-2-(lH-ρyrrol-2-yl)-acetylamino]-
4-thia- 1 -aza-bicyclo [3.2.0] heptane-2-carboxylate or
Potassium; (2S,5R,6R)-3,3-dimethyl-6-[2-(l-methyl-lH-pyrrol-2-yl)-2-oxo- acetylamino]-7-oxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate.
23. A compound according to claim 22, wherein R2 represents phenyl, hydrogen,
-COO(C1-C4 alkyl), halogen, unsubstituted C3-C6 cycloalkyl, or a C1-C4 alkyl, C2-C4 alkenyl or C1-C4 alkoxy group which is unsubstituted or substituted with -SMe, -SEt, hydroxyl, di(Cl-C4 alkyl)amino, -COO(C1-C4 alkyl), -CONR'R", -NR'CO(C1-C4 alkyl), unsubstituted C1-C4 alkoxy or C1-C4 alkoxy substituted with -OMe or -OEt, where R' and R" are the same or different and represent hydrogen or unsubstituted Cl- C4 alkyl; or R2 represents a group (C1-C4) alkyl-A5, wherein none or one -CH2- groups are independently replaced by -O-, -S- or -NR'- and wherein A5 represents phenyl, pyridinyl or oxazolyl.
24. A compound which is a pyrrole derivative of formula (IB) or a pharmaceutically or agriculturally acceptable salt thereof:
Figure imgf000231_0001
wherein Al, Ll, n and Rl to R5 are as defined in claim 8, wherein the compound is not 3-[2-(4-fluoro-phenylaminooxalyl)-pyrrol-l-yl]-propionic acid or 3- {2- [2-(3 ,4-Dimethoxy-phenyl)-ethylaminooxalyl] -pyrrol- 1 -yl } -propionic acid.
25. A composition comprising a compound or pharmaceutically acceptable salt as defined in any one of claims 22 to 24 and a pharmaceutically acceptable carrier or diluent, or comprising a compound or agriculturally acceptable salt as defined in any one of claims 22 to 24 and an agriculturally acceptable carrier or diluent.
PCT/GB2009/001058 2008-04-24 2009-04-23 Pyrrole antifungal agents WO2009130481A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL09734928T PL2283006T3 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
EP09734928.6A EP2283006B1 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
DK09734928.6T DK2283006T3 (en) 2008-04-24 2009-04-23 Pyrrole-based antifungal agents
AU2009239778A AU2009239778B2 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
JP2011505591A JP5657524B2 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agent
US12/989,410 US8993574B2 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
ES09734928.6T ES2535516T3 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
NZ589010A NZ589010A (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
CA2721944A CA2721944C (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
US14/625,532 US9452168B2 (en) 2008-04-24 2015-02-18 Pyrrole antifungal agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0807532.7 2008-04-24
GB0807532A GB0807532D0 (en) 2008-04-24 2008-04-24 Antifungal agents
GB0819696A GB0819696D0 (en) 2008-10-27 2008-10-27 Antifungal combination therapy
GB0819696.6 2008-10-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/989,410 A-371-Of-International US8993574B2 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents
US14/625,532 Division US9452168B2 (en) 2008-04-24 2015-02-18 Pyrrole antifungal agents

Publications (1)

Publication Number Publication Date
WO2009130481A1 true WO2009130481A1 (en) 2009-10-29

Family

ID=40749825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001058 WO2009130481A1 (en) 2008-04-24 2009-04-23 Pyrrole antifungal agents

Country Status (11)

Country Link
US (2) US8993574B2 (en)
EP (2) EP2283006B1 (en)
JP (2) JP5657524B2 (en)
AU (1) AU2009239778B2 (en)
CA (1) CA2721944C (en)
DK (2) DK2626361T3 (en)
ES (2) ES2535516T3 (en)
NZ (1) NZ589010A (en)
PL (1) PL2283006T3 (en)
PT (1) PT2283006E (en)
WO (1) WO2009130481A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060448A1 (en) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combined pharmaceutical composition as antifungal agent
US8841327B2 (en) 2005-10-31 2014-09-23 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
WO2016079536A1 (en) * 2014-11-21 2016-05-26 F2G Limited Antifungal agents
US9452168B2 (en) 2008-04-24 2016-09-27 F2G Ltd Pyrrole antifungal agents
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9688662B2 (en) 2013-04-04 2017-06-27 Janssen Pharmaceutica Nv N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
WO2017203270A1 (en) * 2016-05-25 2017-11-30 F2G Limited Pharmaceutical formulation
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US9850262B2 (en) 2013-11-12 2017-12-26 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10351568B2 (en) 2010-01-28 2019-07-16 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2020043866A1 (en) * 2018-08-31 2020-03-05 Ucl Business Ltd Compounds
CN111393349A (en) * 2020-05-15 2020-07-10 上海毕得医药科技有限公司 Synthetic method of 4-iodine-1H-pyrrole-2-formaldehyde
US10765117B2 (en) 2013-01-30 2020-09-08 Agrofresh Inc. Volatile applications against pathogens
US10966429B2 (en) 2016-03-07 2021-04-06 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
WO2021110010A1 (en) 2019-12-03 2021-06-10 微境生物医药科技(上海)有限公司 Novel pyrrole compound
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CN113429396A (en) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 Five-membered heteroaromatic ring derivative and preparation method and application thereof
CN114644634A (en) * 2020-12-21 2022-06-21 深圳市祥根生物医药有限公司 Pyrrole derivative and preparation method and application thereof
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6570301B2 (en) * 2015-04-23 2019-09-04 キヤノン株式会社 Method for producing 4-fluoroisatin derivative
TW201841890A (en) * 2017-04-05 2018-12-01 日商阿格諾卡那休股份有限公司 Novel 1-phenylpiperidine derivative and agricultural/horticultural drug agent including same as effective component

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
FR1556822A (en) 1967-03-23 1969-02-07
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
WO1996033973A1 (en) 1995-04-28 1996-10-31 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
US20050090541A1 (en) 2003-10-24 2005-04-28 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
WO2006123145A1 (en) 2005-05-18 2006-11-23 F2G Ltd Antifungal agents
WO2008062182A1 (en) 2006-11-21 2008-05-29 F2G Ltd 2- [ (2-substituted) -ind0lizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents
WO2008106860A1 (en) 2007-03-06 2008-09-12 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof
WO2008145963A1 (en) 2007-05-25 2008-12-04 F2G Limited 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1051723A (en) 1962-04-27
US3252970A (en) * 1963-02-27 1966-05-24 Ciba Geigy Corp Aromatization
BE631632A (en) 1963-04-26
US3268558A (en) * 1964-11-05 1966-08-23 Ortho Pharma Corp 1-r-2, 4-dinitropyrroles
JPS5549575B2 (en) * 1971-10-30 1980-12-12
BE790747A (en) 1971-10-30 1973-02-15 Whitefin Holding Sa 1- (1 '- (0-CHLORO-BENZYL) -PYRROL-2'-YL) -2-DIBUTYL SEC.-AMINO-ETHANOL STEREO-ISOMERS AND PROCESS FOR THEIR PREPARATION
GB1476503A (en) 1973-06-21 1977-06-16 Sterling Drug Inc 1-arylamino-and 1-arylimino-pyrroles and preparation thereof
BE848465A (en) * 1976-11-18 1977-03-16 1- (1'-BENZYL-2 'PYRRYL) -2-DISEC.BUTYLAMINOETHANOLS STEREO-ISOMERS WITH ANALGESIC ACTIVITY AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4316900A (en) * 1977-10-05 1982-02-23 Ciba-Geigy Corporation Piperazinopyrrolobenzodiazepines
JPS57142966A (en) 1981-02-27 1982-09-03 Sagami Chem Res Center (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative
JPS57144255A (en) 1981-03-03 1982-09-06 Sagami Chem Res Center Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative
US4761424A (en) 1985-10-01 1988-08-02 Warner-Lambert Company Enolamides, pharmaceutical compositions and methods for treating inflammation
FR2601368B1 (en) * 1986-07-08 1989-04-07 Synthelabo NITROFURAN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
ATE251158T1 (en) 1994-07-21 2003-10-15 Lilly Co Eli INDOLIZIN SPAL2 INHIBITORS
DE69517160T2 (en) 1995-06-06 2000-11-16 Agfa-Gevaert N.V., Mortsel Photographic materials
JPH09249669A (en) 1996-03-13 1997-09-22 Ono Pharmaceut Co Ltd Condensed pyrrole derivatives, and medicines containing the derivatives as active ingredients
PL194262B1 (en) 1998-06-03 2007-05-31 Amgen Inc Aza-heterocyclic compounds used to treat neurological disorders and hair loss
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
EP1399442B1 (en) 2001-06-06 2006-08-09 Vertex Pharmaceuticals Incorporated Cak inhibitors and uses thereof
IL159438A0 (en) 2001-06-20 2004-06-01 Daiichi Seiyaku Co Diamine derivatives
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2003072028A2 (en) 2002-02-23 2003-09-04 Bristol-Myers Squibb Company Method of treating hiv infection by preventing interaction of cd4 and gp120
TW200505915A (en) 2003-03-13 2005-02-16 Synta Pharmaceuticals Corp Fused pyrrole compounds
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
CA2603322C (en) 2005-03-31 2014-12-16 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
AR053713A1 (en) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc HETEROCICLICAL COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2009130481A1 (en) 2008-04-24 2009-10-29 F2G Ltd Pyrrole antifungal agents

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202654A (en) 1962-04-27 1965-08-24 Bristol Myers Co 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
FR1556822A (en) 1967-03-23 1969-02-07
US3573294A (en) 1968-03-14 1971-03-30 Glaxo Lab Ltd 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives
WO1996033973A1 (en) 1995-04-28 1996-10-31 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
US20050090541A1 (en) 2003-10-24 2005-04-28 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
WO2006123145A1 (en) 2005-05-18 2006-11-23 F2G Ltd Antifungal agents
WO2008062182A1 (en) 2006-11-21 2008-05-29 F2G Ltd 2- [ (2-substituted) -ind0lizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents
WO2008106860A1 (en) 2007-03-06 2008-09-12 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Protein tyrosine phosphatase 1b inhibitor, preparation methods and uses thereof
WO2008145963A1 (en) 2007-05-25 2008-12-04 F2G Limited 2-oxo-2- (2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl) -acetamide derivatives and related compounds as antifungal agents

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 14, 2007, pages 3814 - 3818
CANADIAN JOURNAL OF CHEMISTRY, vol. 49, no. 6, 1971, pages 919 - 22
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 3, 1998, pages 201 - 207
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 4, no. 3, 1967, pages 335 - 8
JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999, vol. 17, 1992, pages 2175 - 87
LIEBIGS ANNALEN DER CHEMIE, vol. 1, 1991, pages 67 - 70
ORGANIC LETTERS, vol. 4, no. 7, 2002, pages 1103 - 1105
PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 177, no. 3, 2002, pages 545 - 553
TETRAHEDRON LETTERS, vol. 41, no. 25, 2000, pages 4991 - 4995
TETRAHEDRON, vol. 34, no. 2, 1978, pages 241 - 5
TETRAHEDRON, vol. 57, no. 27, 2001, pages 5873 - 5878

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841327B2 (en) 2005-10-31 2014-09-23 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US9452168B2 (en) 2008-04-24 2016-09-27 F2G Ltd Pyrrole antifungal agents
US10351568B2 (en) 2010-01-28 2019-07-16 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2012060448A1 (en) 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Combined pharmaceutical composition as antifungal agent
AU2016203895B2 (en) * 2011-05-12 2017-12-07 Proteostasis Therapeutics, Inc. Proteostasis regulators
US10532996B2 (en) 2011-05-12 2020-01-14 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
US11917997B2 (en) 2013-01-30 2024-03-05 Agrofresh Inc. Volatile applications against pathogens
US11771089B2 (en) 2013-01-30 2023-10-03 Agrofresh Inc. Large-scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US11202448B2 (en) 2013-01-30 2021-12-21 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10765117B2 (en) 2013-01-30 2020-09-08 Agrofresh Inc. Volatile applications against pathogens
US9688662B2 (en) 2013-04-04 2017-06-27 Janssen Pharmaceutica Nv N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
US9850262B2 (en) 2013-11-12 2017-12-26 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US11242361B2 (en) 2013-11-12 2022-02-08 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US11958873B2 (en) 2013-11-12 2024-04-16 Kineta, Inc. Proteasome activity enhancing compounds
EP3415511A1 (en) * 2014-11-21 2018-12-19 F2G Limited Antifungal agents
US11065228B2 (en) 2014-11-21 2021-07-20 F2G Limited Antifungal agents
WO2016079536A1 (en) * 2014-11-21 2016-05-26 F2G Limited Antifungal agents
US10596150B2 (en) 2014-11-21 2020-03-24 F2G Limited Antifungal agents
CN111096967A (en) * 2014-11-21 2020-05-05 F2G有限公司 Antifungal agent
CN107207470A (en) * 2014-11-21 2017-09-26 F2G有限公司 Antifungal agent
RU2727520C2 (en) * 2014-11-21 2020-07-22 Ф2Г Лимитед Antifungal agents
AU2015348043B2 (en) * 2014-11-21 2019-08-22 F2G Limited Antifungal agents
CN107207470B (en) * 2014-11-21 2019-12-03 F2G有限公司 Antifungal agent
CN111096967B (en) * 2014-11-21 2023-03-10 F2G有限公司 Antifungal agent
US10201524B2 (en) 2014-11-21 2019-02-12 F2G Limited Antifungal agents
US10966429B2 (en) 2016-03-07 2021-04-06 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
KR102464150B1 (en) 2016-05-25 2022-11-07 에프2지 리미티드 pharmaceutical formulation
WO2017203270A1 (en) * 2016-05-25 2017-11-30 F2G Limited Pharmaceutical formulation
US10973821B2 (en) 2016-05-25 2021-04-13 F2G Limited Pharmaceutical formulation
KR20190013865A (en) * 2016-05-25 2019-02-11 에프2지 리미티드 Pharmaceutical formulation
CN109982704A (en) * 2016-05-25 2019-07-05 F2G有限公司 Pharmaceutical preparation
CN109982704B (en) * 2016-05-25 2023-10-24 F2G有限公司 Pharmaceutical preparation
AU2017270942B2 (en) * 2016-05-25 2022-07-21 F2G Limited Pharmaceutical formulation
RU2760681C2 (en) * 2016-05-25 2021-11-29 Ф2Г Лимитед Pharmaceutical preparation
US11634391B2 (en) 2018-08-31 2023-04-25 Ucl Business Ltd Compounds which are inhibitors of Notum
WO2020043866A1 (en) * 2018-08-31 2020-03-05 Ucl Business Ltd Compounds
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2021110010A1 (en) 2019-12-03 2021-06-10 微境生物医药科技(上海)有限公司 Novel pyrrole compound
EP4071137A4 (en) * 2019-12-03 2024-02-14 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Novel pyrrole compound
CN111393349A (en) * 2020-05-15 2020-07-10 上海毕得医药科技有限公司 Synthetic method of 4-iodine-1H-pyrrole-2-formaldehyde
WO2022134837A1 (en) * 2020-12-21 2022-06-30 深圳市祥根生物医药有限公司 Pyrrole derivative, and preparation method and use therefor
AU2021407690B2 (en) * 2020-12-21 2024-03-14 Shenzhen Sungening Biological Co., Ltd A pyrrole derivative, its preparation method and use
CN114644634A (en) * 2020-12-21 2022-06-21 深圳市祥根生物医药有限公司 Pyrrole derivative and preparation method and application thereof
CN113429396A (en) * 2021-06-08 2021-09-24 深圳市祥根生物医药有限公司 Five-membered heteroaromatic ring derivative and preparation method and application thereof

Also Published As

Publication number Publication date
US8993574B2 (en) 2015-03-31
NZ589010A (en) 2012-11-30
EP2283006A1 (en) 2011-02-16
ES2535516T3 (en) 2015-05-12
US20150238500A1 (en) 2015-08-27
EP2626361A1 (en) 2013-08-14
US9452168B2 (en) 2016-09-27
PT2283006E (en) 2015-06-29
ES2526083T3 (en) 2015-01-05
AU2009239778A1 (en) 2009-10-29
CA2721944A1 (en) 2009-10-29
DK2283006T3 (en) 2015-05-26
CA2721944C (en) 2016-06-07
JP2015051984A (en) 2015-03-19
JP5657524B2 (en) 2015-01-21
JP2011518818A (en) 2011-06-30
AU2009239778B2 (en) 2014-03-13
PL2283006T3 (en) 2015-08-31
EP2626361B1 (en) 2014-10-15
EP2283006B1 (en) 2015-02-25
DK2626361T3 (en) 2015-01-19
US20110152285A1 (en) 2011-06-23
JP5903475B2 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
EP2283006B1 (en) Pyrrole antifungal agents
US20200179340A1 (en) Antifungal agents
CN110015977B (en) Malononitrile oxime ether compound and its use
JP5712263B2 (en) 2-[(2-Substituted) -indolizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents
JP2011523948A (en) Antifungal combination therapy
EP3720846A1 (en) Microbiocidal phenylamidine derivatives
US8524705B2 (en) 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents
KR20090084502A (en) Antibacterial composition containing 2-iminobenzoimidazole derivatives
CN107616174B (en) Composition containing ZJ10520 and amide bactericide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734928

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2721944

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011505591

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009239778

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 589010

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2009734928

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009239778

Country of ref document: AU

Date of ref document: 20090423

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12989410

Country of ref document: US